

**Gregg W. Stone MD, FACC, FSCAI**

**Curriculum Vitae**

**Personal Information:**

Present positions:

8/04 - present

Professor of Medicine  
Columbia University  
Director of Cardiovascular Research and Education  
Center for Interventional Vascular Therapy  
Columbia University Medical Center  
Herbert Irving Pavilion, 5th Floor  
161 Fort Washington Avenue  
New York, NY 10032  
212 305-7060 (tel)  
212 342-3550 (fax)

7/98 - present

Chairman (since 2006)  
The Cardiovascular Research Foundation  
11 E. 59<sup>th</sup> St.  
11<sup>th</sup> Floor  
New York City, NY 10022  
212-851-9302 (tel)  
212-851-9396 (fax)  
[gstone@crf.org](mailto:gstone@crf.org) (e-mail)

Past positions:

10/99 – 7/04

Interventional Cardiology  
Lenox Hill Hospital  
130 E. 77<sup>th</sup> St.  
9<sup>th</sup> Floor, Black Hall  
New York City, NY 10021

7/98 – 10/99

Interventional Cardiology  
Director of the Cardiovascular Training and Education Center  
Washington Hospital Center  
Washington DC

7/89 - 7/98

Director of Interventional Cardiology  
The Cardiovascular Institute  
Mountain View, CA

Interventional Cardiology  
El Camino Hospital  
Mountain View, CA

Interventional Cardiology  
Stanford University Medical Center  
Palo Alto, CA

Home address: 21 Wyckham Hill Lane  
Greenwich, CT 06831

Home phone: 203-422-0334  
Home fax: 203-422-0329

Date of birth: February 22nd, 1957

Place of birth: Cleveland, Ohio

Family: Married (Dr. Amy E. Stone MD, FCCP, ACP -  
Pulmonary and Sleep Disorders Medicine)  
Daughter Samantha Gabrielle Stone

**Education:**

College (9/75-6/78):  
The University of Michigan  
Ann Arbor, MI 48104  
Graduated in 3 years  
Degree: B.S., Magna Cum Laude (High Distinction)  
Major/Minor: Zoology/Theoretical Mathematics

Medical School (9/78-6/82):  
The Johns Hopkins School of Medicine  
Baltimore, MD 21205  
Degree: M.D.  
Graduated 1st decile

Internship and Residency (7/82-6/85):  
Internal Medicine  
Dr. R. Gordon Douglass, Chairman  
The New York Hospital-Cornell Medical Center  
New York City, NY 10021

Fellowship (7/85-6/88):  
Cardiology  
Dr. Jeremy H. Swan, Director  
Cedars-Sinai Medical Center  
Los Angeles, CA 90048

Fellowship (7/88-7/89):  
Advanced Coronary Angioplasty (4th year)  
Dr. Geoffrey O. Hartzler, Preceptor  
Mid America Heart Institute  
St. Luke's Hospital  
44th and Wornall Rds.  
Kansas City, MO 64111

**Licensure:**

New York – 156307  
Connecticut - 042683  
Washington DC - MD31096  
California - C41818  
Missouri - R4H67  
Licensed, Nuclear Cardiology, California #4944-43

**Board Certification:**

American Board of Internal Medicine, 9/85, 95th percentile  
American Board of Cardiovascular Diseases, 3/88, 98th percentile  
American Board of Interventional Cardiology – 11/99, top decile

**Professional Associations, Honors and Awards (past and present):**

Phi Beta Kappa  
Honor's College, University of Michigan  
James B. Angell Scholar, University of Michigan  
NIH Medical Student Research Training Award (national grant)  
President, Academy of Transcatheter Cardiovascular Therapeutics, 2003, 2004  
Fellow, American College of Cardiology  
Fellow, Society for Cardiac Angiography and Interventions  
Member, American Medical Association  
Member, International Society of Cardiovascular Interventionists  
Member, AHA Council on Clinical Cardiology  
Member, AHA Laennec Society  
Consultant, American Medical Foundation for Peer Review and Education  
European Society of Cardiology Guidelines for Percutaneous Intervention 2002-2005  
Invited participant, NHLBI Strategic Plan, 2006  
America's Best Doctors, selected by Castle Connolly Medical Ltd., 2004-2007

**Course Director (ongoing yearly symposia - partial list)**

Director, Transcatheter Cardiovascular Therapeutics, 1998 – present  
Director, Transcatheter Valve Therapies, 2008 - present  
Director, National Interventional Cardiology Fellow's Course, 1994 – present  
Director, Enter the Drug-eluting Stent Revolution – A Critical Appraisal, 2002-present  
Director, Advanced Endovascular Therapies, 2000 – 2002  
Director, Harmonizing Interventional and Pharmacologic Strategies in ACS and AMI, 2000  
Director, Standards in ACS: From Diagnosis to Discharge, 2003  
Director, International Chronic Total Occlusion Summit, 2004 - present  
Director, TCT Course at EuroPCR, 2002 - present  
Director, TCT Course at SOLACI, 2002 – present  
Director, TCT Course at China Interventional Therapeutics, 2003 - present  
Director, Cardiovascular Management Strategies, 2006 – present  
Co-Director, Complex Catheter Course in Japan, 2004 – present  
Co-Director, Asia Pacific Interventional Cardiology of Korea, 2005 - present  
Co-Director, China Course on Interventional Therapies (CIT), 2004 – present  
Co-Director, Pediatric & Adult Interventional Therapies for Congenital & Valvular Heart Disease (PICS/ENTICHS), 2006 - 2007

**Editorial Positions:**

Editorial Board, Circulation: Cardiovascular Interventions  
Editorial Boards, Journal of the American College of Cardiology and JACC Interventions  
Editorial Board, The Journal of Invasive Cardiology  
Editorial Board, The Journal of Interventional Cardiology  
Editorial Board, Current Interventional Cardiology Reports  
Editorial Board, Catheterization and Cardiovascular Interventions  
Editorial Board, Critical Pathways in Cardiology  
Editorial Board, International Journal of Cardiovascular Interventions  
Editorial Advisory Panel, Future Cardiology  
Editorial Board, Acute Cardiac Care  
Reviewer, New England Journal of Medicine  
Reviewer, Journal of the American Medical Association  
Reviewer, Lancet  
Reviewer, Circulation  
Reviewer, American Journal of Cardiology  
Reviewer, American Heart Journal  
Reviewer, European Heart Journal  
Reviewer, American Journal of Medicine  
Associate Editor, Reviews in Cardiovascular Medicine  
Past Physician Editor, Cardio Intervention  
Abstract grader, AHA, ACC and TCT Annual Scientific Sessions

**Board of Directors or Trustees**

Board of Directors (Chairman), The Cardiovascular Research Foundation, NYC, NY  
Board of Trustees, Society for Cardiac Interventions and Angiography (2003-2006)  
Board of Directors, Devax Medical Corp.  
Board of Directors, Endosonics Corp., Sacramento, CA (past)

**Advisory Boards (past and present):**

Coronary Artery Disease and Atherosclerosis NHLBI Level 1 Working Group.  
Member, Medical Advisory Board, Guidant Vascular Intervention  
Member, Medical Advisory Board, Boston Scientific Corp.  
Member, Physician Advisory Board, Devices for Vascular Intervention  
Member, Stent Physician Advisory Board, Johnson & Johnson/Cordis  
Member, Physician Advisory Board, Medtronic AVE  
Member, U.S. Cardiology Opinion Leader Board, Cordis Corp.  
Chairman, Scientific Advisory Board, Endosonics Corp.  
Member, Physician Advisory Board, Cardiovascular Dynamics, Inc.  
Member, Investigational Advisory Board, Eclipse Corp.  
Member, Scientific Advisory Board, Danforth Biomedical Inc.  
Member, Cardiology Advisory Council, Mallinkrodt Inc.  
Member, New Product Advisory Board, Guidant Vascular Intervention  
Member, Stent Research and Development Advisory Board, Guidant VI  
Member, Scientific Advisory Panel, Intella Interventional Systems, Inc.  
Member, Scientific Advisory Boards, Biocompatibles Limited  
Chairman, National Acute Myocardial Infarction Strategies Council  
Member, Coronary Radiation Applications Advisory Board, Guidant  
Member, Scientific Advisory Board, Radiance Corp.  
Member, Scientific Advisory Board, Intraluminal Therapeutics

Member, Scientific Advisory Board, X-Site, Inc.  
 Member, Scientific Advisory Board, Emboli Protection Inc.  
 Member, Scientific Advisory Board, Endicor Medical, Inc.  
 Member, Clinical Advisory Board, Centocor/Lilly Cardiovascular  
 Member, Scientific Advisory Board, Quanam Medical  
 Co-Chairman, Bracco Diagnostics Advisory Board  
 Member, Medical and Scientific Advisory Board, Abbott Laboratories  
 Member, Medical Advisory Board, PercuSurge Inc.  
 Member, Medical Advisory Board, Magna Labs  
 Member, Scientific Advisory Board, Savacor, Inc.  
 Member, Scientific Advisory Board, Devax Medical  
 Member, Scientific Advisory Board, Radiant Medical, Inc.  
 Member, Scientific Advisory Board, Volcano Therapeutics  
 Chairman, Vulnerable Plaque Advisory Board, Guidant Corp.  
 Member, Scientific Advisory Board, Cardiac Dimensions  
 Member, Scientific Advisory Board, Confluent Medical  
 Chairman, Scientific Advisory Board, Thermocore Inc.  
 Member, Medical Advisory Board, A-Med Systems  
 Member, Scientific Advisory Board, FlowCardia Inc.  
 Member, Medical Advisory Board, InfraReDx  
 Member, Endovascular Heart Valve Therapy Clinical Council, Edwards Life Sciences  
 Chairman, Scientific Advisory Board, Guided Delivery Systems  
 Member, Scientific Advisory Board, CoreValve  
 Member, Scientific Advisory Board, MediGuide  
 Member, Scientific Advisory Board, Bioabsorbable Vascular Solutions  
 Member, Scientific Advisory Board, AorTx  
 Member, Scientific Advisory Board, Setagon  
 Member, Scientific Advisory Board, ParinGenix  
 Member, Scientific Advisory Board, Cardium  
 Member, Scientific Advisory Board, Prescient Medical  
 Member, Scientific Advisory Board, Reva  
 Member, Scientific Advisory Board, Bioabsorbable Therapeutics Inc.  
 Member, Scientific Advisory Board, Edwards Life Sciences  
 Member, Scientific Advisory Board, Edwards St. Jude Medical

### **Selected Research:**

#### National/international Principal Investigator /Steering Committee

The INFUSE Trial – Principal Investigator  
 The ADAPT-DES Trial – Principal Investigator  
 The PROSPECT Trial – Principal Investigator  
 The TAXUS IV trial - Principal Investigator  
 The TAXUS V de novo trial - Principal Investigator  
 The TAXUS V ISR trial - Principal Investigator  
 The PROGRESS in CTO trial - Principal Investigator  
 The SPIRIT-III Everolimus Drug-eluting Stent Trial – Principal Investigator  
 The SPIRIT-IV Everolimus Drug-eluting Stent Trial – Principal Investigator  
 The PLATNIMUM Trial – principal Investigator  
 The ZOMAXX-II Trial – Steering Committee Chair and Executive Committee member  
 The VIP-1 and VIP-2 Trials (BMS Imaging and Thermocore) – Executive Steering Committee

The VIKING mitral valve sinoplasty system – Principal Investigator  
 The ACUITY Trial - Principal Investigator  
 The HORIZONS-AMI Trial - Principal Investigator  
 The AMIHOT-II Trial - Principal Investigator  
 The CADILLAC Trial - Principal Investigator  
 The ADEST Trial – Study Chairman  
 The TEMPO Trial - Principal Investigator  
 The X-SIZER Atherectomy in Acute Myocardial Infarction – Study chairman  
 The X-TRACTION Trial - Principal Investigator  
 X-Sizer Atherectomy in Acute Ischemic Syndromes (X-TRACT) - Principal Investigator  
 The EMERALD Trial – PercuSurge in AMI - Principal Investigator  
 The RDX Brachytherapy Catheter for SVG Lesions (SVG BRITE) - Principal Investigator  
 The BSC/EPI distal protection in SVG Intervention (SPARK) Trial - Principal Investigator  
 The BSC/EPI distal protection in SVG Intervention (FIRE) Trial - Principal Investigator  
 The JOMED Stent-Graft to Prevent Restenosis in SVGs (BARRICADE) – PI  
 The JOMED Stent-Graft Coronary Aneurysm and AV Fistula Study – PI  
 The CONTRAST Study (Corlopam for contrast nephropathy) – Principal Investigator  
 The PAMI Stent Pilot (International) - Principal Investigator  
 The PAMI Heparin-Coated Stent Trial, North American Chairman  
 The PAMI Heparin-Coated Stent IVUS Substudy - Principal Investigator  
 Senior PAMI – Steering Committee  
 Percutaneous Myocardial Revascularization (PTMR) in Chronic Occlusions- PI  
 PTMR as an Adjunct to PTCA - Principal Investigator  
 The EXCITE randomized trial (Xemilofiban) - Leadership Committee  
 Clinical Outcomes with Ultrasound Trial (CLOUT) - Principal Investigator  
 Optimal Stent Implantation Study (The OSTI Trial) - Phase I - Principal Investigator  
 Optimal Stent Implantation Study Phase IIA, IIB - Principal Investigator  
 Laser Angioplasty vs. Angioplasty (LAVA) Trial - Principal Investigator  
 Holmium Angioplasty Randomized Trial in Unstable Angina (HART-USA) - PI  
 The DANAMI-2 Trial - International Advisory Board/DSMB  
 The Benchmark IntraAortic Balloon Counterpulsation registry - Steering Committee  
 The AMISTAD-2 Study - Steering Committee  
 The Hedgehog Rotablator Burr - Steering Committee  
 Abciximab/Tirofiban Comparative Pharmacodynamic Trial (ATHENS) – Co-PI  
 Abciximab/Tirofiban Comparative PCI (TARGET) Trial - Executive Committee  
 The SYNERGY Study – Angiographic substudy chairman  
 The Temperature Outcomes (TEMPO) Trial - Principal Investigator  
 Matrix VSG vascular closure system trial - Steering Committee  
 Devax Bifurcation Stent Steering Committee  
 ORAR II (oral rapamycin) Steering Committee  
 The A-MED Systems temporary left ventricular assist device- Principal Investigator  
 The COOL RCN Pilot Study (hypothermia for contrast nephropathy prevention) - PI  
 The COOL RCN Randomized Trial - PI  
 The FREEDOM Trial – Executive and Steering Committee  
 The PREMAIR Trial – Executive Committee  
 The COMBAT Trial – Executive Committee

Local Principal Investigator for the following studies (partial list):

The ASCENT Trial (ACS OTW Multi-Link Stent randomized trial)  
 The ACS HP RX MultiLink Stent  
 The Primary Angioplasty in Myocardial Infarction Trials - I, II, III, Stent

The Cardiovascular Dynamics Drug infusion angioplasty system  
 The B. Braun "E" Cath Randomized Angioplasty Trial  
 The PAS Paragon stent randomized trial and registry  
 The Cordis/JJIS Crown Stent with PowerGrip Delivery System  
 6F Angio-Seal Wound Closure Device  
 The ACCESS randomized trial (Atorvastatin)  
 CONVINCe randomized trial (Coer-Verapamil)  
 Orbofiban (oral GP IIb-IIIa receptor antagonist) in Acute Ischemic Syndromes  
 The EXCITE Randomized study (xemilofiban)  
 The TECBEST II randomized trial  
 The Symphony Trial (Sibrafiban)  
 The AVE GFX 2.5 mm stent study  
 The AMIGO study (Multi-Link stenting  $\pm$  atherectomy Randomized trial)  
 The Guidant Soni-Cross system for total occlusions  
 The PRESTO Trial (Tranilast) after coronary intervention  
 The Radiance RDX Intravascular Brachytherapy system (BRITE-II and SVG BRITE)  
 The Guidant Galileo Intravascular Brachytherapy system (SUPPRESS)  
 Astra Pharmaceuticals SC-931-5129 P2T inhibitor in PCI, Phase I and II  
 The Guidant Duet Stent Registries  
 The Guidant TriStar Stent  
 The Guidant ULTRA-REVIVE registry  
 The Intraluminal Therapeutics CTO OCT System (CATS)  
 The Intraluminal Therapeutics OCT Guided Radiofrequency Ablation System (GREAT)  
 The Boston Scientific VICTORY Stent  
 The Guidant VISION Stent  
 The Guidant DELIVER Trial (Randomized Taxol Coated PharmaLink Stent)  
 The X-Site RACE Trial  
 The Innercool ICE-IT study  
 The FACTOR trial (Flow Cardia Ultrasonic recanalization of chronic total occlusions)  
 The Cardiac Dimensions Carrillon mitral valve sinoplasty system  
 The Boston Scientific ATLAS long lesion and small vessel study

### Books and Book Chapters

1. **Stone GW**, Grines CL, Topol EJ. "Update on Percutaneous Transluminal Coronary Angioplasty for Acute Myocardial Infarction". In: Current Review of Interventional Cardiology, 2nd edition, Edited by Eric Topol and Patrick Serruys. Current Medicine, Philadelphia, PA, 1-56:1995.
2. **Stone GW**, Grines CL. "Interventional strategies for the management of acute myocardial infarction". In: International Update on Interventional Cardiology, ed. by Patrick Serruys and Amar Kapoor. 1995.
3. St. Goar F and **Stone GW**. "Percutaneous management of acute myocardial infarction". In: Cardiology Clinics, 1994;12:559-571.
4. Grines CL, **Stone GW**, and O'Neill WW. PTCA in Unstable Ischemic Syndromes. In: Manual of Interventional Cardiology, 1st ed., edited by Freed M, Grines CL and Safian RD, *Physicians' Press*, Birmingham, MI, 1996, pp 105-153.
5. **Stone GW**. Primary Angioplasty in Acute Myocardial Infarction. In: Acute Ischemic Syndromes, edited by Eric J. Topol. Marcel Dekker, Inc., New York City, NY. 1997, pp 233-268.
6. Brodie BR and **Stone GW**. Primary PTCA - The Preferred Therapy for Acute Myocardial Infarction: A Handbook for Cardiologists, Interventionalists, and Hospital Administrators. Health Management Publications, Inc., Wayne, PA, 1998.
7. **Stone GW**, Ed. Applications in Imaging: Cardiac Interventions. Anderson Publishing, Ltd. Ocean, NJ, 1997.
8. Grines CL, **Stone GW**, and O'Neill WW. PTCA in Unstable Ischemic Syndromes. In: The New Manual of Interventional Cardiology, 2nd ed., edited by Freed M, Grines C and Safian RD, *Physicians' Press*, Birmingham, MI, 1998, pp 107-154.
9. DeGeare VS, **Stone GW** and Grines CL. Primary Catheter-Based Reperfusion in Acute Myocardial Infarction – A Protagonist's View. In Press "Heart Disease: Clinical Update", Eugene Braunwald, Ed., Saunders, 1999.
10. Linnemeier TJ, and **Stone GW**, Eds. Applications in Imaging: Cardiac Interventions. Anderson Publishing, Ltd. Ocean, NJ, 1998.
11. **Stone GW**. Percutaneous Transluminal Myocardial Revascularization (PTMR) – The Eclipse System and Studies. In: Handbook of Myocardial Revascularization and Angiogenesis, Kornowski R, Epstein SE and Leon MB, Eds, Martin Dunitz, London, 1999.
12. Lansky AJ, **Stone GW**. Percutaneous Intervention for Acute Coronary Syndromes. In: The Manual of Interventional Cardiology, 3rd ed., edited by Safian RD and Freed MS, *Physicians' Press*, Birmingham, MI, 2001, pp 85 - 140.



13. Dangas G, DeGeare VS Grines CL **Stone GW**. Interventional Procedures in Acute Myocardial Infarction. Cardiovascular Therapeutics, A Companion to Braunwald's Heart Disease, 2<sup>nd</sup> edition, edited by Elliott Antman, W. B. Saunders, Phila, PA, 2002, pp 919-936.
14. Dangas G, **Stone GW**. Stenting in Acute Myocardial Infarction. In press in: Coronary Stenting, ed. by Igor Palacios and Sheldon Goldberg.
15. **Stone GW**. The Primary Angioplasty in Myocardial Infarction Studies: An Overview. In press in: Thrombolytic Therapy, ed. by Gerald C. Timmis, Futura Publishing Co., Armonk, NY, 2000.
16. **Stone GW**, Grines CL. Primary Angioplasty in Acute Myocardial Infarction: Comparative Analysis with Thrombolytic Therapy. Interventional Cardiovascular Medicine: Principles and Practice, 2nd ed. Edited by Richard S. Stack, Gary S. Roubin, and William W. O'Neill. Churchill Livingstone, Philadelphia, PA, 2001, pp 227-300.
17. **Stone GW**, Grines CL. Beyond Primary PTCA: New Devices in Acute Myocardial Infarction. Interventional Cardiovascular Medicine: Principles and Practice, 2nd ed. Edited by Richard S. Stack, Gary S. Roubin, and William W. O'Neill. Churchill Livingstone, Philadelphia, PA, 2001, pp 301-379.
18. **Stone GW**, Kandzari DE, Grines CL. Integrating Coronary Stents and Glycoprotein IIb/III Inhibitors into a Mechanical Reperfusion Strategy: The CADILLAC and ADMIRAL Trials. In: Primary Angioplasty in Acute Myocardial Infarction. Edited by Tchong JE. Humana Press, Inc., Totawa, NJ, 2002, pp 139-168.
19. Dangas G and **Stone GW**. Stenting in Acute Myocardial Infarction. In press in: New Device Angioplasty. Edited by Palacios I and Goldberg S. 2002
20. Colombo A and **Stone GW**. The Boston Scientific TAXUS Trials. In press in: Handbook of Drug Eluting Stents. Edited by Patrick Serruys and Anthony Gershlick. Martin Dunitz, London, 2002.
21. **Stone GW**, Associate Editor. The Encyclopedia of Clinical Trials, John Wiley and Sons, In Press.
22. Colombo A and **Stone GW**. The Boston Scientific TAXUS Trials. In press in: Handbook of Drug Eluting Stents. Edited by Patrick Serruys and Anthony Gershlick. Martin Dunitz, London, 2005.
23. **Stone GW**. Coated Stents-Overview – Paclitaxel. In press in: Strategic Approaches in Coronary Intervention. Edited by Stephen G. Ellis and David R. Holmes. Lippincott Williams & Wilkins, Philadelphia, PA, 2005.
24. **Stone GW**. Coronary Stenting. In Cardiac Catheterization, Angiography and Intervention. 7<sup>th</sup> Edition. Edited by Donald S. Baim, Lippincott Williams & Wilkins, Philadelphia, PA, 2006; pp 492-542.
25. Crouch ED, Ohman ME, **Stone GW**. Intravenous direct thrombin inhibition: acute coronary syndromes and heparin-induced thrombocytopenia. In press in: Therapeutic Strategies in

Thrombosis, Ed. By S De Caterina, RD Kristensen, and DJ Moliterno, 2006. Atlas Medical Publishing, Oxford, UK, pp 77-106.

26. Kodali S and **Stone GW**. Tips and Tricks in Acute Myocardial Infarction. In press in: Problem-oriented Approach in Interventional Cardiology. Ed. By Antonio Colombo, 2006.

## Publications

1. Lands WEM, Sauter J, **Stone GW**. Oxygen requirement for prostaglandin biosynthesis. *Prostaglandin Medicine* 1(2):117-120, 1978.
2. Platia EW, Berdoff R, **Stone GW**, Reid PR. Comparison of acebutolol and propranolol therapy for ventricular arrhythmias. *J Clin Pharm* 25:130-137, 1985.
3. Ryman KS, Kubo SH, Lystash J, **Stone GW**, Cody RJ. Effect of nicardipine on rest and exercise hemodynamics in chronic congestive heart failure. *Am J Cardiol* 58:583-588, 1986.
4. **Stone GW**, Kubo SH, Cody RJ. Adverse influence of baroreceptor dysfunction on upright exercise in congestive heart failure. *Am J Med* 80:799-802, 1986.
5. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. *Cath and Cardiovasc Diagn* 18:227-31, 1989.
6. **Stone GW**, Hartzler GO. Spontaneous reversible spasm in an internal mammary artery graft causing acute myocardial infarction. *Am J Cardiol* 64:822-23, 1989.
7. **Stone GW**, Spaude S, Ligon RW, Hartzler GO. Usefulness of percutaneous transluminal coronary angioplasty in alleviating silent ischemia in patients with absent or minimal painful myocardial ischemia. *Am J Cardiol* 64:560-564, 1989.
8. **Stone GW**, Ligon RW, Rutherford BD, McConahay DR, Hartzler GO. Acute outcome and long term follow-up following coronary angioplasty in the young patient: an 8 year experience. *Am Heart J* 118:873-877, 1989.
9. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Direct coronary angioplasty in patients with acute myocardial infarction: Outcome in patients with single vessel disease. *J Am Coll Cardiol* 15:534-543, 1990.
10. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Procedural outcome of angioplasty for total coronary artery occlusion: an analysis of 971 lesions. *J Am Coll Cardiol* 15:849-856, 1990.
11. **Stone GW**, O'Kell R, Good TH, Hartzler GO. Lipomatous hypertrophy of the interatrial septum: diagnosis by percutaneous transvenous biopsy. *Am Heart J* 119:406-8, 1990.
12. **Stone GW**, Griffin B, Shah PK, Berman DS, Siegal RJ, Cook SL, Maurer G. Prevalence of unsuspected mitral regurgitation and left ventricular diastolic dysfunction in coronary artery disease and acute pulmonary edema associated with normal or depressed left ventricular systolic function. *Am J Cardiol* 67:37-41, 1991.
13. Grines CL, Browne KF, Marco J, Rothbaum D, **Stone GW**, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vliestra R, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. *New England Journal of Medicine* 1993;328:673-9.

14. Wilson WSW and **Stone GW**. Late Results of Percutaneous Transluminal Coronary Angioplasty of Two or More Major Native Coronary Arteries. *American Journal of Cardiology*: 1994;73:1041-6.
15. **Stone GW**. Primary angioplasty in myocardial infarction. *Cardio Intervention* 1993;3:11-20.
16. **Stone GW**, Grines CL. Is there a role for percutaneous transluminal coronary angioplasty without antecedent thrombolysis in the treatment of acute myocardial infarction? *Cardiol Rev* 1994;2:2, 98-111.
17. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Predictors of in-hospital and 6 month outcome after acute myocardial infarction in the reperfusion era: The Primary Angioplasty in Myocardial Infarction (PAMI) Trial. *J Am Coll Cardiol* 1995;25:370-7.
18. **Stone GW**. The PTCA-CABG Trials - what have we learned? *Cardio Intervention* 1994;4-1:2-5.
19. **Stone GW**. What should have been taught in your angioplasty fellowship (Part 1). *Cardio Intervention* 1994;4-3:2-3.
20. **Stone GW**. What should have been taught in your angioplasty fellowship (Part 2). *Cardio Intervention* 1994;4-4:3-4.
21. **Stone GW**. Intracoronary Ultrasound Imaging. *Therapeutic Research* 1994;15:53-71.
22. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Implications of Recurrent Ischemia After Reperfusion Therapy in Acute Myocardial Infarction: A Comparison Of Thrombolytic Therapy and Primary Coronary Angioplasty. *J Am Coll Cardiol* 1995;26:66-72.
23. **Stone GW**. Intravascular Ultrasound Imaging During Coronary Intervention: Indispensable Adjunct or Unnecessary Expense? *Cardio Intervention* 1994;4-2:2-3.
24. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Comparison of In-Hospital Outcome in Men Versus Women Treated by Either Thrombolytic Therapy or Primary Coronary Angioplasty for Acute Myocardial Infarction. *Am J Cardiol* 1995;75:987-992.
25. **Stone GW**. Spontaneous Coronary Dissection Resulting in Acute Myocardial Infarction: Successful Treatment by Primary Angioplasty. *Cathet & Cardiovasc Diagn* 1996;38:62-66.
26. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Influence of Acute Myocardial Infarction Location on In-Hospital and Late Outcome After Primary Percutaneous Transluminal Coronary Angioplasty versus Tissue Plasminogen Activator. *Am J Cardiol* 1996;78:19-25.

27. **Stone GW**, St. Goar F, Linnemeier TJ. Initial Clinical Experience with a Novel Low-Profile Integrated Ultrasound-Angioplasty Catheter. *Cath & Cardiovasc Diag* 1996;38:303-307.
28. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Outcome of Different Reperfusion Strategies in Patients with Former Contraindications to Thrombolytic Therapy: A Comparison of Primary Angioplasty and Tissue Plasminogen Activator. *Cath & Cardiovasc Diag* 1996;39:333-339.
29. **Stone GW**. Primary Coronary Angioplasty in High Risk Patients with Acute Myocardial Infarction. *J Interv Cardiol* 1995;7:12F-21F.
30. **Stone GW**. Rotational Atherectomy for Stent Restenosis - Role of Intracoronary Ultrasound Guidance. *Cath & Cardiovasc Diag* 1996;3:73-77.
31. O'Keefe J, **Stone GW**, McCallister BD., Maddex C, Ligon R, Kacich RL, Kahn J, Caverio PG, Hartzler GO, McCallister BD. Combination Lovastatin and Probucol for the Prevention of Restenosis After Coronary Angioplasty. *Am J Cardiology* 1996;77:649-653.
32. **Stone GW**, Hodgson JMcB, St. Goar FG, Frey A, Mudra H, Sheehan H, and Linnemeier TJ. Improved Procedural Results of Coronary Angioplasty with Intravascular Ultrasound Guided Balloon Sizing: The CLOUT Pilot Trial. *Circulation* 1997;95:2044-2052.
33. **Stone GW**, Brodie BR, Morice MC, Griffin JJ, St. Goar FG, O'Neill WW and Grines CL. Primary Stenting in Acute Myocardial Infarction: Design and Interim Results of the PAMI Stent Pilot Trial. *J Interv Cardiol* 1997;9(suppl B):21B-30B.
34. Grines CL, **Stone GW**, O'Neill WW. Establishing a Program and Performance of Primary PTCA - The PAMI Way. *J Interv Cardiol* 1997;;9(suppl B):44B-52B.
35. **Stone GW**, Grines CL, Rothbaum D, Browne KF, O'Keefe J, Overlie P, Donohue B, Chelliah N, Vlietstra R, Catlin T, and O'Neill WW. Analysis of the relative costs and effectiveness of primary angioplasty compared to tissue plasminogen activator: The Primary Angioplasty in Myocardial Infarction Trial. *J Am Coll Cardiol* 1997;29:901-907.
36. **Stone GW**, Marsalese D, Brodie BR, Griffin JJ, Donohue B, Costantini C, Balestrini C, Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Sachs D, Grines L, O'Neill WW, Grines CL. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. *J Am Coll Cardiol* 1997;29:1459-1467.
37. **Stone GW**, St. Goar FG, Hodgson JMcB, Fitzgerald PJ, Alderman A, Yock PY, Coverdale J and Linnemeier TJ. Analysis of the relation between stent implantation pressure and expansion. *Am J Cardiol* 1999;83:1397-1400.
38. **Stone GW**, Grines CL, O'Neill WW. Primary coronary angioplasty versus thrombolysis. *N Engl J Med* 1997;337:1168-1170.
39. **Stone GW**. Primary Angioplasty in Acute Myocardial Infarction. *Interventional Cardiology Newsletter* 1997;5(1):1-10. Elsevier Science Inc., 1997.

40. **Stone GW**, de Marchena E, Dageforde D, Foschi A, Muhlestein JB, McIvor M, Rizik D, Vanderlaan R, McDonnell J. A prospective, randomized, multicenter comparison of laser facilitated balloon angioplasty versus stand alone balloon angioplasty in patients with obstructive coronary artery disease. *J Am Coll Cardiol* 1997;30:1714-1721.
41. Moses J, Moussa I, **Stone GW**. Clinical trials of coronary stenting in acute myocardial infarction. *J Intervent Cardiol* 1997;10:225-229.
42. Topaz O, McIvor M, **Stone GW**, Krucoff MW, Perin EC, Foschi AE, Sutton J, Nair R, DeMarchena E. Acute results, complications and effect of lesion characteristics on outcome with the solid-state, mid-infrared laser angioplasty system: final multi-center registry report. *Lasers in Surgery and Medicine* 1998;22:228-239.
43. Grines CL, Marsalese D, Brodie B, Griffin J, Donohue B, Costantini C, Balestrini C, **Stone GW**, Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Sachs D, Grines LL, O'Neill W. Safety and cost effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. *J Am Coll Cardiol* 1998;31:967-972.
44. **Stone GW**, Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, Overlie PA, Popma JJ, McDonnell J, Jones D, O'Neill WW, Grines CL. A prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30 day results of the PAMI Stent Pilot Trial. *J Am Coll Cardiol* 1998;31:23-30.
45. **Stone GW**. Stenting in Acute Myocardial Infarction: Observational Studies and Randomized Trials - 1998. *J Inv Cardiol* 1998;10:16A-26A.
46. **Stone GW**. Stenting and Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction: An Introduction to the CADILLAC Trial. *J Inv Cardiol* 1998;10:36B-47B.
47. Grines CL, **Stone GW**, O'Neill WW. The PAMI (Primary Angioplasty in Myocardial Infarction) Studies: An overview. *J Intervent Cardiol* 1998;11:87-99.
48. **Stone GW**, Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, Overlie PA, Popma JJ, McDonnell J, Jones D, O'Neill WW, Grines CL. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: The Primary Angioplasty in Myocardial Infarction (PAMI) Stent Pilot Trial. *Circulation* 1999;99:1548-1554.
49. **Stone GW**. Primary stenting in acute myocardial infarction. The promise and the proof. *Circulation* 1998;97:2482-2485.
50. Serruys PW, Grines CL, **Stone GW**, et al. Stent implantation in acute myocardial infarction using a heparin-coated stent: A pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting. *J Intervent Cardiovasc Interventions* 1998;1:19-27.
51. **Stone GW**. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes. *Am J Cardiol* 1999;83:16E-20E.
52. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Kornowski R, Hong MK, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Angiographic patterns of in-stent

- restenosis. Classification and implications for long-term outcome. *Circulation* 1999;100(18):1872-8.
53. Fuchs S, Kornowski R, Mehran R, Satler LF, Pichard AD, Kent KM, **Stone GW**, Leon MB. Prognostic value of cardiac troponin I levels following catheter-based coronary interventions. *J Am Coll Cardiol* 1999;34(6):1704-10.
  54. Grines CL, Cox D, **Stone GW**, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC. A randomized trial of primary angioplasty compared to heparin-coated stent implantation for acute myocardial infarction. *N Engl J Med*. 1999;341(26):1949-56.
  55. Dangas G and **Stone GW**. Primary Angioplasty in Acute Myocardial Infarction – The United States Experience. *Seminars in Interventional Cardiology* 1999;4:21-34.
  56. Gruberg L, Lansky AJ, Dangas G, **Stone GW**. IIb/IIIa Receptor Inhibitors During Primary Angioplasty for Acute Myocardial Infarction. *Current Interventional Cardiology Reports* 1999 Dec;1(4):359-367.
  57. Nunn C, O'Neill WW, Rothbaum D, **Stone GW**, O'Keefe J, Overlie P, Donohue B, Grines L, Browne K, Vlietstra R, Catlin T, Grines CL. Long-term outcome following primary angioplasty: Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. *J Am Coll Cardiol* 1999;33:640-646.
  58. **Stone GW**, Grines CL, Brodie BR, Griffin JJ, Morice MC, Costantini C, Overlie PA, Linnemeier TJ, Moses J, and O'Neill WW. Improved short-term outcomes of primary coronary stenting compared to primary balloon angioplasty at experienced centers: The PAMI study group experience. *J Intervent Cardiol* 1999;12:101-107.
  59. Gruberg L, Mehran R, Dangas G, Hong MK, Mintz GS, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, **Stone GW**, Leon MB. Effect of plaque debulking and stenting on short- and long-term outcomes after revascularization of chronic total occlusions. *J Am Coll Cardiol* 2000;35(1):151-6.
  60. Gruberg L, Hong MK, Mehran R, Mintz GS, Kent KM, Pichard AD, Satler LF, Wu H, Greenberg A, **Stone GW**, Leon MB. Optimally deployed stents in the treatment of restenotic versus de novo lesions. *Am J Cardiol* 2000 Feb 1;85(3):333-7.
  61. **Stone GW**, Brodie BR, Griffin JJ, et al. The role of cardiac surgery in the hospital phase management of patients treated with primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2000;85(11):1292-1296.
  62. Kornowski R, Bhargava B, Fuchs S, Lansky AJ, Satler LF, Pichard AD, Kent KM, Mehran R, **Stone GW**, Leon MB. Procedural results and late clinical outcomes following percutaneous interventions using long ( $\geq 25$ mm) versus short ( $< 20$ mm) stents. *J Am Coll Cardiol*. 2000;35(3):612-8.
  63. DeGeare VS, **Stone GW**, Grines L, Brodie BR, Cox DA, Garcia E, Wharton TP, Boura JA, O'Neill WW, Grines CL. Angiographic and clinical predictors of increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing primary angioplasty: A pooled analysis of the PAMI Trials. *Am J Cardiol* 2000;86:30-34.

64. Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions. An intravascular ultrasound study of 2,256 patients. *Circulation* 2000 Feb 15;101(6):604-10.
65. Dangas G, Mintz GS, Mehran R, Lansky AJ, Kornowski R, Pichard AD, Satler LF, Kent KM, **Stone GS**, and Leon MB. Preintervention Arterial Remodeling as an Independent Predictor of Target-Lesion Revascularization After Nonstent Coronary Intervention : An Analysis of 777 Lesions With Intravascular Ultrasound Imaging. *Circulation* 1999;99:3149-3154.
66. Kornowski R, Bhargava B, Fuchs S, Lansky AJ, Satler LF, Pichard AD, Hong MK, Kent KM, Mehran R, **Stone GW**, Leon MB. Procedural results and late clinical outcomes after percutaneous interventions using long (> or = 25mm) versus short (< 20mm) stents. *J Am Coll Cardiol*. 2000;35(3):612-8.
67. **Stone GW**, Brodie BR, Griffin JJ, Grines L, Boura J, O'Neill WW, Grines CL. Clinical and angiographic outcomes in patients with previous coronary artery bypass graft surgery treated with primary balloon angioplasty for acute myocardial infarction. Second Primary Angioplasty in Myocardial Infarction Trial (PAMI-2) Investigators. *J Am Coll Cardiol*. 2000;35(3):605-11.
68. Gruberg L, Hong MK, Mehran R, Mintz GS, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, Dangas G, Wu H, **Stone GW**, Leon MB. In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site. *Am J Cardiol*. 1999;84(12):1381-4.
69. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Kent KM, Satler LF, **Stone GW**, Leon MB. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. *Circulation*. 1999;100(24):2400-5.
70. Gruberg L, Dangas G, Mehran R, Hong MK, Waksman R, Mintz GS, Kent KM, Pichard AD, Satler LF, Lansky AJ, **Stone GW**, Leon MB. Percutaneous revascularization of the internal mammary artery graft: Short- and Long-Term Outcomes. *J Am Coll Cardiol* 2000;35:944-8.
71. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Kent KM, Satler LF, **Stone GW**, Leon MB. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. *Circulation*. 1999 Dec 14;100(24):2400-5.
72. Saucedo JF, Mehran R, Dangas G, Hong MK, Lansky A, Kent KM, Satler LF, Pichard AD, **Stone GW**, Leon MB. Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting. *J Am Coll Cardiol*. 2000;35:1134-41.



73. Mehran R, Dangas G, Mintz GS, Waksman R, Abizaid A, Satler LF, Pichard AD, Kent KM, Lansky AJ, **Stone GW**, Leon MB. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: Comparative mechanisms and results. *Circulation*. 2000;101(21):2484-2489.
74. Ahmed JM, Hong MK, Mehran R, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, Wu H, **Stone GW**, Leon MB. Comparison of debulking followed by stenting versus stenting alone for saphenous vein graft aortoostial lesions: immediate and one-year clinical outcomes. *J Am Coll Cardiol*. 2000;35(6):1560-8.
75. Ahmed JA, Dangas G, Lansky AJ, Mehran R, Hong MK, Mintz GS, Waksman R, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Influence of gender on early and late clinical outcomes after saphenous vein graft stenting. *Am J Cardiol* 2001;87:401-405.
76. DeGeare VS, **Stone GW**, Grines CL. Interventional procedures in acute myocardial infarction. *Am Heart J* 2001;141:15-25.
77. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky A, Kent KM, Pichard AD, Satler LF, **Stone GW**, Leon MB. Comparison of time course of target lesion revascularization following successful saphenous vein graft angioplasty versus successful native coronary angioplasty. *Am J Cardiol* 2000 Jan 15;85(2):256-8.
78. Dangas G, Mintz GS, Mehran R, Ahmed JM, Lansky AJ, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Stent implantation neutralizes the impact of preintervention arterial remodeling on subsequent target lesion revascularization. *Am J Cardiol*. 2000 Aug 15;86(4):452-5.
79. Mehran R, Dangas G, Abizaid A, Lansky AJ, Mintz GS, Pichard AD, Satler LF, Kent KM, Waksman R, **Stone GW**, Leon MB. Treatment of focal in-stent restenosis with balloon angioplasty alone vs. stenting: acute and long-term results. *Am Heart J* 2001;141:610-614.
80. Gruberg L, Dangas G, Leon MB, **Stone GW**. Platelet glycoprotein IIb/IIIa receptor antagonists during primary angioplasty and stenting for acute myocardial infarction. *Cardiol Int* 2000;1:30-36.
81. Ahmed JM, Hong MK, Mehran R, Dangas G, Mintz GS, Pichard AD, Satler LF, Kent KM, Wu H, **Stone GW**, Leon MB. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. *J Am Coll Cardiol*. 2000;36(4):1186-93.
82. Kornowski R, Fuchs S, Hong MK, Mehran R, Satler LF, Pichard AD, Kent KM, **Stone GW**, Leon MB. Prognostic value of recurrent episodes of creatine kinase-MB elevation following repeated catheter-based coronary interventions. *Catheter Cardiovasc Interv*. 2000 Oct;51(2):131-7.
83. Fuchs S, Kornowski R, Mehran R, Gruberg L, Satler LF, Pichard AD, Kent KM, **Stone GW**, Leon MB. Clinical outcomes following rescue administration of abciximab in patients undergoing percutaneous coronary angioplasty. *J Inv Cardiol*. 2000 Oct;12(10):497-501.

84. Dangas G, Mehran R, Lansky AJ, Waksman R, Satler LF, Pichard AD, Kent KM, Mintz GS, **Stone GW**, Leon MB. Acute and long-term results of treatment of diffuse in-stent restenosis in aortocoronary saphenous vein grafts. *Am J Cardiol*. 2000 Oct 1;86(7):777-9.
85. Mattos LA, Grines CL, Cox D, Sousa JE, Costantini C, **Stone GW**, Morice MC, O'Neill W, Garcia E, Boura J. A comparative analysis of primary stenting and optimal balloon coronary angioplasty in acute myocardial infarction. Six month results from the STENT PAMI trial. *Arq Bras Cardiol* 2000;75:508-514.
86. Dangas G, Mehran R, Abizaid AS, Curry BH, Lansky AJ, Kent KM, Pichard AD, Satler LF, Paliou M, **Stone GW**, Leon MB. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. *Am J Cardiol*. 2001;87:470-472.
87. Kobayashi Y, Teirstein PS, Linnemeier TJ, **Stone GW**, Leon MB, Moses JW. Rotational atherectomy (stentablation) in a lesion with stent underexpansion due to heavily calcified plaque. *Catheter Cardiovasc Interv* 2001;52:208-211.
88. Anderson KM, Califf RM, **Stone GW**, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol*. 2001;37(8):2059-65.
89. **Stone GW**, Tumlin JE, Mathur VS, Madyoon H, Lepor NS, McCollough P, Gupta S, O'Neill WW. Design and Rationale of CONTRAST - A Prospective, Randomized Placebo-Controlled Trial of Fenoldopam Mesylate for the Prevention of Radiocontrast Nephropathy. *Reviews in Cardiovascular Medicine* 2001;2 (Suppl 1):S31-S36.
90. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Kent KM, Pichard AD, Satler LF, **Stone GW**, Leon MB. Are we making progress with percutaneous saphenous vein graft treatment? Comparison of 1990-94 and 1995-98 results. *J Am Coll Cardiol* 2001 Jul;38(1):150-4.
91. **Stone GW**. Glycoprotein IIb/IIIa inhibitors: More different than alike? *Cathet Cardiovasc Interv* 2001 Jul;53(3):304-7.
92. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, **Stone GW**, DiBattiste PM, Demopoulos L. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. *N Engl J Med*. 2001 Jun 21;344(25):1888-94.
93. Gruberg L, Mehran R, Waksman R, Dangas G, Fuchs S, Wu H, Kent KM, Pichard AD, Satler LF, **Stone GW**, Leon MB. Creatine kinase-MB fraction elevation after percutaneous coronary intervention in patients with chronic renal failure. *Am J Cardiol*. 2001 Jun 15;87(12):1356-60.
94. Dangas G, Mehran R, Abizaid AS, Curry BH, Lansky AJ, Kent KM, Pichard AD, Satler LF, Paliou M, **Stone GW**, Leon MB. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. *Am J Cardiol*. 2001 Feb 15;87(4):470-2.

95. **Stone GW**, St. Goar FSG, Taussig A, Power JA, Kosinski E, Shawl F. Safety and efficacy of hybrid percutaneous transmyocardial laser revascularization and angioplasty in patients with lesions at high risk for restenosis – results of a phase I feasibility study. *In Am Heart J* 2001;142(4):679-83.
96. **Stone GW**, Cox D, Garcia E, Brodie BR, Morice MC, Griffin MD, Matos MD, Lansky AJ, O'Neill WW, Grines CL. TIMI-3 flow prior to mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: Analysis from the PAMI Trials. *Circulation* 2001;104(6):636-41.
97. **Stone GW**, Mehran R, Dangas G, Lansky AJ, Konowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. *Circulation* 2001;104(6):642-7.
98. Ferguson JL, Cohen M, Freedman RJ, **Stone GW**, Miller MF, Joseph DL, Ohman M. A The current practice of intra-aortic balloon counterpulsation: Results from the Benchmark Registry: *J Am Coll Cardiol* 2001;38:1456-62.
99. Lansky AJ, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, Fahy M, **Stone GW**, Waksman R, Leon MB. Quantitative angiographic methods for appropriate endpoint analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. *J Am Coll Cardiol* 2002;39(2):274-80.
100. Cohen M, Ferguson JJ, Freedman RJ, Miller MF, Reddy RC, Graeber GM, Ohman EM, **Stone GW**, Joseph DL. Comparison of Outcomes After 8 versus 9.5 French Size Intra-Aortic Balloon Counterpulsation Catheters Based on 9332 Patients in the Prospective Benchmark<sup>™</sup> Registry. *Cath Cardiovasc Interv* 2002;56:200-6.
101. Cohen DJ, Taira DA, Berezin R, Eigelshoven M, Cox DA, Brodie BR, **Stone GW**, Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: Results from the Stent PAMI trial. *Circulation* 2001;104(25):3039-45.
102. Angeja BG, Gibson CM, Chin R, Frederick PD, Every NR, Ross AM, **Stone GW**, Barron HV. Predictors of door-to-balloon delay in primary angioplasty. *Am J Cardiol* 2002;89:1156-61.
103. Rinfret S, Grines CL, Cosgrove RS, Ho KK, Cox DA, Brodie BR, Morice MC, **Stone GW**, Cohen DJ. Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One year results from the STENT-PAMI trial. *J Am Coll Cardiol* 2001;38:1614-21.
104. Mattos LA, Grines CL, Sousa JE, Sousa AG, **Stone GW**, Cox D, Garcia E, Morice MC, O'Neill W, Grines L, Boura J. One-year follow-up after primary coronary intervention for acute myocardial infarction in diabetic patients. A substudy of the STENT PAMI trial. *Arq Bras Cardiol.* 2001 Dec;77(6):556-61.
105. **Stone GW**, Cox DA, Low R, et al. Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts. Results of the phase-I multicenter X-TRACT feasibility study. *Catheter Cardiovasc Interv.* 2003;58:419-27.

106. **Stone GW**, Peterson M, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in AMI. *J Am Coll Cardiol* 2002;39:591-7.
107. Grube E, Schofer J, Webb J, Schuler G, Colombo A, Sievert H, Gerckens U, and **Stone GW**. Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. *Am J Cardiol* 2002;89:941-5.
108. Dangas G, Mehran R, Kokolis S, Feldman D, Satler LF, Pichard AD, Kent KM, Lansky AJ, **Stone GW**, Leon MB. Vascular complications after percutaneous interventions following hemostasis with manual compression versus arteriotomy closure devices. *J Am Coll Cardiol* 2001;38:638-41.
109. El-Omar MM, Dangas G, and **Stone GW**. A comparison of tirofiban and abciximab in patients undergoing coronary stent implantation: rationale, design and results of the TARGET trial. *Curr Interv Cardiol Rep* 2001;3:336-348.
110. Ashby DT, Dangas G, Mehran R, Lansky AJ, Fahy MP, Iakovou I, Satler LF, Pichard AD, Kent KM, **Stone GW**, Leon MB. Comparison of 1-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers and non-smokers. *Am J Cardiol* 2002 Jan 15;89(2):221-4.
111. **Stone GW**, Teirstein PS, Rubenstein P, et al. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonre canalizable chronic total occlusions. *J Am Coll Cardiol* 2002;39:1686-91.
112. Dangas G, Mehran R, Fahy M, Leon MB, **Stone GW**. Complications of vascular closure devices—not yet evidence based. Reply. *J Am Coll Cardiol* 2002;39:1706-1708.
113. Brodie BR, **Stone GW**, Morice MC, Cox DA, Garcia E, Mattos LA, Boura J, O'Neill WW, Stuckey TD, Milks S, Lansky AJ, Grines CL. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). *Am J Cardiol* 2001;88:1085-90.
114. Kobayashi Y, Moussa I, Dangas G, Mehran R, Desai K, Adamian M, Collins M, Kreps E, **Stone GW**, Leon MB, Moses JW. Acute angiographic and clinical results of the NIR w/SOX stent. *J Invasive Cardiol*. 2002 Jan;14(1):14-8.
115. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, **Stone GW**, Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. *Circulation*. 2001 Dec 18;104(25):3039-45.
116. **Stone GW**. The Bent Stent [commentary]. *J Inv Cardiol* 2001;14: 54-56.
117. **Stone GW**, Ohman ME, Miller MF, Joseph DJ, Christenson JT, Cohen M, Urban PM, Reddy RC, Freedman RJ, Staman KL, Ferguson JJ. Contemporary Utilization and Outcomes of Intra-aortic Balloon Counterpulsation in Acute Myocardial Infarction: The Benchmark Registry. *J Am Coll Cardiol* 2003;41:1940-5.

118. Gruberg L, Dangas G, Mehran R, Mintz GS, Kent KM, Pichard AD, Satler LF, Lansky AJ, **Stone GW**, Leon MB. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. *Catheter Cardiovasc Interv* 2002 Jan;55(1):66-72.
119. Ashby DT, Dangas G, Mehran R, Lansky AJ, Fahy MP, Iakovou I, Satler LF, Pichard AD, Kent KM, **Stone GW**, Leon MB. Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers. *Am J Cardiol*. 2002 Jan 15;89(2):221-4.
120. Lansky AJ, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, Fahy M, **Stone GW**, Waksman R, Leon MB. Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. *J Am Coll Cardiol*. 2002;39:274-80.
121. **Stone GW**, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, for the Controlled Abciximab in Device Investigation to Lower Late Angioplasty Complications (CADILLAC) investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *N Engl J Med* 2002;346:957-66.
122. Dangas G, Mehran R, Feldman D, Stoyioglou A, Pichard AD, Kent KM, Satler LF, Fahy M, Lansky AJ, **Stone GW**, Leon MB. Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. *Am J Cardiol* 2002;89(5):586-9.
123. **Stone GW**, Moliterno DJ, Bertrand M, et al. Impact of clinical syndrome acuity on the differential response to two glycoprotein IIb/IIIa Inhibitors in patients undergoing coronary stenting: The TARGET trial. *Circulation* 2002;105:2347-54.
124. Iakovou I, Dangas G, Mehran R, Lansky AJ, Kobayashi Y, Adamian M, Polena S, Collins MB, Roubin GS, **Stone GW**, Leon MB, Moses JW. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. *Am J Cardiol*. 2002;89:976-9.
125. Ashby DT, Dangas G, Mehran R, Lansky AJ, Narasimaiah R, Iakovou I, Polena S, Satler LF, Pichard AD, Kent KM, **Stone GW**, Leon MB. Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries. *Am J Cardiol*. 2002;89:1162-6.
126. Kipshidze NN, Kim HS, Iversen P, Yazdi HA, Bhargava B, New G, Mehran R, Tio F, Haudenschild C, Dangas G, **Stone GW**, Iyer S, Roubin GS, Leon MB, Moses JW. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. *J Am Coll Cardiol* 2002;39:1686-91.
127. Grube E, Colombo A, Hauptmann A, Londero H, Reifart N, Gerckens U, and **Stone GW**. Multicenter experience with a novel distal protection filter during carotid artery stent implantation. *Catheter Cardiovasc Interv* 2003;58:139-46.

128. Lansky AJ, Mehran R, Dangas G, Desai K, Costantini-Ortiz C, Cristea E, New G, Negoita M, **Stone GW**, Leon MB. New-device angioplasty in women: clinical outcome and predictors in a 7,372-patient registry. *Epidemiology* 2002;13:S46-S51.
129. **Stone GW**. Anticipating the Era of Drug-Eluting Stents. *Cath Lab Digest* 2002;10:1-12.
130. **Stone GW**, Rogers C, Ramee S, White C, Kuntz RE, Popma JJ, George J, Almany S, Bailey S. Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. *J Am Coll Cardiol* 2002;40:1882-8.
131. Ashby DT, **Stone GW**, Moses JW. Acute myocardial infarction and cardiogenic shock. *Cath Cardiovasc Interv* 2003;59:34-43.
132. **Stone GW**, Grines CL and Tchong JE. Comparison of angioplasty with stenting in acute myocardial infarction (letter). *N Engl J Med* 2002;347:367-368.
133. **Stone GW**. Primary Angioplasty vs. "Earlier" Thrombolytic Therapy – Time for a Wake Up Call. *The Lancet* 2002;360:814-6.
134. Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, **Stone GW**, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. *Lancet* 2002;360:355–60.
135. Christenson JT, Cohen M, Ferguson JJ 3rd, Freedman RJ, Miller MF, Ohman EM, Reddy RC, **Stone GW**, Urban PM. Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery. *Ann Thorac Surg*. 2002 Oct;74(4):1086-90.
136. E. Magnus Ohman, Michael F. Miller, Debra L. Joseph, Marc Cohen, Robert J. Freedman, **Gregg W. Stone**, Philip M. Urban, Ramachandra C. Reddy, Jan T. Christenson, James J. Ferguson. Validation of a Multicenter Registry Database of Intra-Aortic Balloon Pumping in a Variety of Clinical Settings. *HeartDrug* 2003;3:8-13.
137. Harjai KJ, Boura J, Grines L, Goldstein J, **Stone GW**, Brodie B, Cox D, O'Neill WW, Grines C. Comparison of effectiveness of primary angioplasty for proximal versus distal right coronary artery culprit lesion during acute myocardial infarction. *Am J Cardiol* 2002 Dec 1;90(11):1193-7.
138. **Stone GW** and Teirstein PS. Percutaneous Laser Revascularization in Patients With Chronic Total Occlusions. *J Am Coll Cardiol* 2002 Dec 4;40(11):2062-3.
139. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, Mintz GS, Kent KM, Pichard AD, Satler LF, **Stone GW**, Leon MB. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. *J Invasive Cardiol* 2003 Jan;15(1):18-22
140. **Stone GW**, Mehran R, Midei M, et al. Beta Radiation for De Novo and In-Stent Restenotic Lesions in Saphenous Vein Grafts. *Am J Cardiol* 2003;92:312-314.
141. **Stone GW**. Primary angioplasty or thrombolysis for acute myocardial infarction? *Lancet*. 2003;361:78-9.

142. El-Omar MM, Dangas G, Mehran R, Lansky AJ, Kipshidze NN, Polena S, Fahy M, Moussa I, Glasser L, Moses JW, **Stone GW**, Leon MB. Usefulness of atrial fibrillation as a marker of outcome after percutaneous coronary intervention. *Am J Cardiol*. 2003;91:232-4.
143. Ashby DT, Dangas G, Aymong E, Farkouh MF, Mehran R, Moses JW, Leon MB, and **Stone GW**. Relationship between the degree of procedural anticoagulation and complications after coronary stent implantation. *Am J Cardiol* 2003;92:319-322.
144. Pellizon GG, Dixon SR, **Stone GW**, et al. Relation of admission white-blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (the Stent-PAMI trial). *Am J Cardiol* 2003;91:729-31.
145. Harjai KJ, **Stone GW**, Boura J, et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 2003;91:655-90.
146. Ashby DT, Dangas G, Aymong EA, Iakovou I, Kuepper F, Mehran R, **Stone GW**, Leon MB, and Moses JW. Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. *J Am Coll Cardiol* 2003;41:749-52.
147. Ashby DT, Mehran R, Aymong EA, Lansky AJ, Iakovou I, Weisz G, New G, Moussa I, Dangas G, Moses JW, **Stone GW**, Leon MB. Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries. *Am J Cardiol* 2003;91:979-81.
148. Harjai KJ, **Stone GW**, Boura J, et al. Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2003;91:1041-5.
149. Nguyen TT, O'Neill WW, Grines CL, **Stone GW**, Brodie BR, Cox DA, Grines LL, Boura JA, Dixon SR. One-year survival in patients with acute myocardial infarction and a saphenous vein graft culprit treated with primary angioplasty. *Am J Cardiol* 2003;91:1250-4.
150. Dixon SR, O'Neill WW, Sadeghi HM, **Stone GW**, et al. Usefulness of creatinine clearance in predicting early and late death after primary angioplasty for acute myocardial infarction. *Am J Cardiol*. 2003;91:1454-7.
151. Fujii K, Kobayashi Y, Mintz GS, Hirose M, Moussa I, Mehran R, Dangas G, Lansky AJ, Kreps E, Collins M, Colombo A, **Stone GW**, Leon MB, Moses JW. Dominant contribution of negative remodeling to development of significant coronary bifurcation narrowing. *Am J Cardiol*. 2003 Jul 1;92(1):59-61.
152. Schoenhagen P, **Stone GW**, Nissen SE, et al. Coronary Plaque Morphology and Frequency of Ulceration Distant From Culprit Lesions In Patients With Unstable and Stable Presentation. *Arterioscler Thromb Vasc Biol*. 2003;23:1895-900.
153. Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, **Stone GW**, Cohen DJ, Moliterno DJ. Effect of abciximab versus tirofiban on activated

- clotting time during percutaneous intervention and its relation to clinical outcomes-observations from the TARGET trial. *Am J Cardiol*. 2003 Jul 15;92(2):125-9.
154. Hirose M, Kobayashi Y, Mintz GS, Moussa I, Mehran R, Lansky AJ, Dangas G, Kreps EM, Collins MB, **Stone GW**, Colombo A, Leon MB, Moses JW. Correlation of coronary arterial remodeling determined by intravascular ultrasound with angiographic diameter reduction of 20% to 60%. *Am J Cardiol*. 2003 Jul 15;92(2):141-5.
  155. **Stone GW**, Rogers C, Hermiller J, et al. Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts. *Circulation*. 2003;108:548-553.
  156. Limpijankit T, Mehran R, Mintz GS, Dangas G, Lansky AJ, Kao J, Ashby DT, Moussa I, **Stone GW**, Moses JW, Leon MB, Teirstein PS. Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III). *Am J Cardiol* 2003;92:315-8.
  157. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Teirstein PS, **Stone G**, Vandertie L, Proctor B, Fahy M, Yeung A, Raizner AE, Waksman R, Leon MB; INHIBIT trial. Implications of the presence and length of "geographic miss" on restenosis and the edge phenomenon in the INHIBIT trial. *Am J Cardiol* 2003;91:1261-5.
  158. Harjai KJ, Grines C, **Stone GW**, et al. Frequency, determinants, and clinical implications of residual intracoronary thrombus following primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2003;92:377-82.
  159. Kobayashi Y, Mehran R, Mintz GS, Dangas G, Moussa I, Lansky AJ, **Stone GW**, Moses JW, Leon MB. Comparison of in-hospital and one-year outcomes after multiple coronary arterial stenting in patients > or =80 years old versus those <80 years old. *Am J Cardiol* 2003 Aug 15;92:443-6.
  160. Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, **Stone GW**. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2003;108:1316-23.
  161. Cox DA, **Stone GW**, Grines CL, et al. Outcomes of optimal or "stent-like" balloon angioplasty in acute myocardial infarction: The CADILLAC trial. *J Am Coll Cardiol* 2003;42:971-7.
  162. Kandzari DE, Tcheng JE, Cohen DJ, Bakhai A, Grines CL, Cox DA, Effron M, Stuckey T, Griffin JJ, Turco M, Carroll JD, Fahy M, Mehran R, **Stone GW**. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). *Am J Cardiol*. 2003;92:779-84.
  163. Bartholomew BA, Harjai KJ, Grines CL, Boura JA, Grines LL, **Stone GW**, Cox DA, Brodie BR, O'Neill WW. Variation in hospital length of stay in patients with acute myocardial infarction undergoing primary angioplasty and the need to change the diagnostic-related group system. *Am J Cardiol*. 2003;92:830-3.



164. Kernis SJ, Harjai KJ, **Stone GW**, et al. The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol.* 2003;42:1173-7.
165. Chan AW, Moliterno DJ, Berger PB, **Stone GW**, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival. Results from the do Tirofiban and ReoPro give similar efficacy outcome trial (TARGET). *J Am Coll Cardiol.* 2003;42:1188-95.
166. Cohen M, Urban P, Christenson JT, Joseph DL, Freedman RJ Jr, Miller MF, Ohman EM, Reddy RC, **Stone GW**, Ferguson JJ. Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark((R)) Registry. *Eur Heart J.* 2003;24:1763-70.
167. Ashby DT, Aymong EA, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Carroll JD, Turco M, Lansky AJ, **Stone GW**. Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). *Am J Cardiol.* 2003;92(9):1095-8.
168. Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, Mehran R, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Lansky AJ, **Stone GW**. Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). *Am J Cardiol.* 2003;92(9):1091-4.
169. Iakovou I, Dangas G, Mehran R, Mintz GS, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, **Stone GW**, Leon MB, Moses JW. Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients  $\geq 75$  years of age versus those  $< 75$  years of age. *Am J Cardiol.* 2003 Nov 1;92(9):1083-6.
170. **Stone GW**, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. *JAMA.* 2003;290(17):2284-91.
171. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Dangas G, Mehran R, **Stone GW**, Leon MB. Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy. *Am J Cardiol.* 2003;92:1214-7.
172. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Dangas G, Mehran R, Fahy M, Slack S, Coral M, Teirstein PS, Waksman R, **Stone GW**, Moses J, Leon MB. Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions. *J Am Coll Cardiol.* 2003 May 21;41(10):1725-31.
173. Iakovou I, Mintz GS, Dangas G, Abizaid A, Mehran R, Lansky AJ, Kobayashi Y, Hirose M, Ashby DT, **Stone GW**, Moses JW, Leon MB. Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries. *Am J Cardiol.* 2003;92:1171-6.
174. Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Dangas G, Moussa I, Mehran R, Lansky AJ, Kreps E, Collins M, Colombo A, **Stone GW**, Leon MB, Moses JW. Intravascular ultrasound assessment of ulcerated ruptured plaques. A comparison of culprit and

nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. *Circulation*. 2003;108:2473-8.

175. Takebayashi H, Kobayashi Y, Dangas G, Fujii K, Mintz GS, **Stone GW**, Moses JW, Leon MB. Restenosis due to underexpansion of sirolimus-eluting stent in a bifurcation lesion. *Catheter Cardiovasc Interv*. 2003;60:496-9.
176. Halkin A, Keren G, **Stone GW**, Holmes DR, Rosenschein U. Coronary intervention in thrombus-rich lesions: beyond stents and glycoprotein IIb/IIIa inhibitors. *Isr Med Assoc J*. 2003;5:795-800.
177. Mehta RH, Harjai KJ, Cox D, **Stone GW**, Brodie B, Boura J, O'Neill W, Grines CL. Clinical and angiographic correlates and outcomes of suboptimal coronary flow in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. *J Am Coll Cardiol* 2003;42:1739-46.
178. Sadeghi HM, **Stone GW**, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. *Circulation*. 2003;108:2769-75.
179. Kobayashi Y, Mehran R, Mintz GS, Dangas G, Moussa I, Collins M, Brara P, Moussavian M, Lansky AJ, **Stone GW**, Leon MB, Moses JW, Teirstein PS. Acute and long-term outcomes of cutting balloon angioplasty followed by gamma brachytherapy for in-stent restenosis. *Am J Cardiol*. 2003;92:1329-31.
180. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Teirstein PS, **Stone GW**, Vandertie L, Proctor B, Fahy M, Yeung A, Raizner AE, Waksman R, Leon MB. Implications of the presence and length of "geographic miss" on restenosis and the edge phenomenon in the INHIBIT trial. *Am J Cardiol*. 2003;91(10):1261-5.
181. **Stone GW**, Cox DA, Babb J, et al. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus containing coronary arteries. *J Am Coll Cardiol* 2003;42:2007-2013.
182. Bakhai A, **Stone GW**, Grines CL, et al. Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction: Results From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. *Circulation* 2003;108:2857-2863.
183. Iakovou I, Mintz GS, Dangas G, Abizaid A, Mehran R, Kobayashi Y, Lansky AJ, Aymong ED, Nikolsky E, **Stone GW**, Moses JW, Leon MB. Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study. *J Am Coll Cardiol* 2003;42:1900-5.
184. Shirai K, Lansky AJ, Mintz GS, Costantini CO, Fahy M, Mehran R, Dangas G, Moses JW, **Stone GW**, Waksman R, Leon MB. Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. *Am J Cardiol* 2003;92:1409-13.

185. Mehta RH, Harjai KJ, Boura J, Cox D, **Stone GW**, O'Neill W, Grines CL. Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. *Am J Cardiol* 2003;92:1445-7.
186. **Stone GW**, Ellis SG, Cox DA, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med* 2004;350:221-231.
187. Nikolsky E, Mehran R, Mintz GS, Dangas GD, Lansky AJ, Aymong ED, Negoita M, Fahy M, Moussa I, Roubin GS, Moses JW, **Stone GW**, Leon MB. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. *J Endovasc Ther* 2004;11:60-70.
188. Iakovou I, Dangas G, Mintz GS, Mehran R, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, **Stone GW**, Leon MB, Moses JW. Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. *Am J Cardiol* 2004;93:346-9.
189. Halkin A, Aymong E, Cox DA, Mehran R, Lansky AJ, Fahy M, Weisz G, Garcia E, Tchong JE, Grines CL, **Stone GW**. Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). *Am J Cardiol* 2004;93:349-53.
190. Sanborn TA, Ogilby JD, Ritter JM, **Stone GW**, Klugherz BD, Fields RH, White CC, Wilensky RL. Reduced vascular complications after percutaneous coronary interventions with a nonmechanical suture device: Results from the randomized RACE study. *Catheter Cardiovasc Interv* 2004;61:327-32.
191. Mehran R, Iakovou I, Dangas G, Lansky AJ, **Stone GW**, Mintz GS, Kent KM, Pichard AD, Satler LF, Fahy M, Leon MB, Waksman R. Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. *Catheter Cardiovasc Interv* 2004;61:354-9.
192. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, Colombo A, **Stone GW**, Teirstein PS, Leon MB, Moses JW. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. *Circulation* 2004;109:1085-8.
193. Addala S, Grines CL, Dixon SR, **Stone GW**, Boura JA, Ochoa AB, Pellizzon G, O'Neill WW, Kahn JK. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). *Am J Cardiol* 2004;93:629-32.
194. Kandzari DE, Hasselblad V, Tchong JE, **Stone GW**, Califf RM, Kastrati A, Neumann FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. *Am Heart J* 2004;147:457-62.
195. Kipshidze NN, Iversen P, Kim HS, Yiazdi H, Dangas G, Seaborn R, New G, Tio F, Waksman R, Mehran R, Tsapenko M, **Stone GW**, Roubin GS, Iyer S, Leon MB, Moses JW. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent

implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. *Catheter Cardiovasc Interv* 2004;61:518-27.

196. Prasad A, **Stone GW**, Aymong E, et al. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: An analysis from the CADILLAC trial. *Am Heart J* 2004;147:669-75.
197. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, **Stone GW**, Leon MB, Knopf WD, O'Neill WW. Non-Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions. Angiographic Follow-Up of the DELIVER Clinical Trial. *Circulation* 2004;109:1948-1954.
198. **Stone GW**, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. *Circulation* 2004;109:1942-1947.
199. Shirai K, Lansky AJ, Mehran R, Dangas GD, Costantini CO, Fahy M, Slack S, Mintz GS, **Stone GW**, Leon MB. Minimally invasive coronary artery bypass grafting versus stenting for patients with proximal left anterior descending coronary artery disease. *Am J Cardiol*. 2004 ;93:959-62.
200. Iakovou I, Dangas G, Mintz GS, Mehran R, Kobayashi Y, D Aymong E, Hirose M, Ashby DT, Lansky AJ, **Stone GW**, Leon MB, Moses JW. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. *Am J Cardiol*. 2004;93:963-8.
201. Mehran R, Dangas GD, Kobayashi Y, Lansky AJ, Mintz GS, Aymong ED, Fahy M, Moses JW, **Stone GW**, Leon MB. Short- and long-term results after multivessel stenting in diabetic patients. *J Am Coll Cardiol* 2004;43:1348-54.
202. Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tchong JE, Garcia E, Guagliumi G, Turco M, Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, **Stone GW**. Importance of mitral regurgitation in patients undergoing percutaneous coronary intervention for acute myocardial infarction; The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. *J Am Coll Cardiol*. 2004;43:1368-74.
203. Hodgson JM, Bottner RK, Klein LW, Walpole HT Jr, Cohen DJ, Cutlip DE, Fenninger RB, Firth BG, Greenberg D, Kalisky I, Meskan T, Powell W, **Stone GW**, Zito JP, Clark MA. Drug-eluting stent task force: Final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. *Catheter Cardiovasc Interv*. 2004;62:1-17.
204. Mehta RH, Harjai KJ, Grines L, **Stone GW**, Boura J, Cox D, O'Neill W, Grines CL. Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention; Incidence, predictors, and outcomes. *J Am Coll Cardiol*. 2004;43(10):1765-72.

205. Kernis SJ, Harjai KJ, **Stone GW**, Grines LL, Boura JA, O'Neill WW, Grines CL. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? *J Am Coll Cardiol*. 2004;43(10):1773-9.
206. Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tchong JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, Lansky AJ, **Stone GW**. Impact of intravenous Beta-Blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. *J Am Coll Cardiol*. 2004;43:1780-7.
207. Cox DA, **Stone GW**. Composite confusion: Reply. *J Am Coll Cardiol*. 2004;43(10):1927.
208. Nikolsky E, Mehran R, Dangas GD, Lasic Z, Mintz GS, Negoita M, Lansky AJ, **Stone GW**, Moussa I, Iyer S, Na Y, Moses JW, Leon MB. Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions. *Am J Cardiol*. 2004;93:1536-9.
209. Iakovou I, Mehran R, Dangas G, Lansky AJ, **Stone GW**, Mintz GS, Aymong E, Ashby DT, Pichard AD, Satler LF, Kent K, Leon MB, Waksman R. Favorable effect of gamma-radiation for in-stent restenosis: Effect of diabetes on angiographic and clinical outcomes. *Catheter Cardiovasc Interv*. 2004;62:303-7.
210. Urban PM, Freedman RJ, Ohman EM, **Stone GW**, Christenson JT, Cohen M, Miller MF, Joseph DL, Bynum DZ, Ferguson JJ. In-hospital mortality associated with the use of intra-aortic balloon counterpulsation. *Am J Cardiol*. 2004;94:181-5.
211. Costantini CO, **Stone GW**, Mehran R, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. *J Am Coll Cardiol*. 2004;44:305-12.
212. Hirose M, Kobayashi Y, Kreps EM, **Stone GW**, Moussa I, Leon MB, Moses JW. Luminal narrowing due to intramural hematoma shift from left anterior descending coronary artery to left circumflex artery. *Catheter Cardiovasc Interv*. 2004;62:461-5.
213. Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E, Moses JW, **Stone GW**, Leon MB, Dangas GD. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. *Am J Cardiol*. 2004;94:300-5.
214. Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, **Stone GW**, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ; SYNERGY Library. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. *Am Heart J* 2004;148:269-76.
215. Sadeghi HM, Grines CL, Chandra HR, Mehran R, Fahy M, Cox DA, Garcia E, Tchong JE, Griffin JJ, Stuckey TD, Lansky AJ, O'Neill WW, **Stone GW**. Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the CADILLAC trial). *Am J Cardiol*. 2004;94:637-40.

216. Guagliumi G, **Stone GW**, Cox DA, et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation*. 2004;110:1598-604.
217. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Lansky AJ, **Stone GW**. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. *J Am Coll Cardiol*. 2004;44:547-53.
218. Nikolsky E, Mehran R, Halkin A, Aymong ED, Mintz GS, Lasic Z, Negoita M, Fahy M, Krieger S, Moussa I, Moses JW, **Stone GW**, Leon MB, Pocock SJ, Dangas G. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. *J Am Coll Cardiol*. 2004;44(6):1200-9.
219. McLaughlin MG, **Stone GW**, Aymong E, et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *J Am Coll Cardiol*. 2004;44:1215-23.
220. Halkin A, **Stone GW**. Polymer-based Paclitaxel-eluting stents in percutaneous coronary intervention. *J Interv Cardiol*. 2004;17(5):271-82.
221. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Jacoboff D, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, **Stone GW**, Leon MB, Moses JW. Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound. *Am J Cardiol*. 2004;94(8):1067-70.
222. Kandzari DE, Tcheng JE, Grines CL, Cox DA, Stuckey T, Griffin JJ, Turco M, Garcia E, Carroll JD, Fahy M, Lansky AJ, Mehran R, **Stone GW**. Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol*. 2004;94(8):1029-33.
223. Nikolsky E, Mehran R, Aymong ED, Mintz GS, Lansky AJ, Lasic Z, Negoita M, Fahy M, Pocock SJ, Na Y, Krieger S, Moses JW, **Stone GW**, Leon MB, Dangas G. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. *Am J Cardiol*. 2004;94(8):1023-7.
224. Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, **Stone GW**. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). *Am J Cardiol*. 2004;94(8):983-8.

225. Heggum PS, Harjai KJ, **Stone GW**, et al. Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol*. 2004;44(7):1400-7.
226. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, **Stone GW**, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol*. 2004;44:1393-9.
227. Heggum PS, Harjai KJ, **Stone GW**, et al. Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol*. 2004;44:1400-7.
228. Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, **Stone GW**. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). *Am J Cardiol*. 2004;94:983-8.
229. Stone GW. Advantages of direct thrombin inhibition in high- and low-risk patients *J Invasive Cardiol* 2004;16(suppl G):12-17.
230. Nikolsky E, Mehran R, Aymong ED, Mintz GS, Lansky AJ, Lasic Z, Negoita M, Fahy M, Pocock SJ, Na Y, Krieger S, Moses JW, **Stone GW**, Leon MB, Dangas G. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. *Am J Cardiol*. 2004;94:1023-7.
231. Kandzari DE, Tcheng JE, Grines CL, Cox DA, Stuckey T, Griffin JJ, Turco M, Garcia E, Carroll JD, Fahy M, Lansky AJ, Mehran R, **Stone GW**. Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol*. 2004;94:1029-33.
232. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Jacoboff D, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, **Stone GW**, Leon MB, Moses JW. Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound. *Am J Cardiol*. 2004;94:1067-70.
233. Halkin A, **Stone GW**. Polymer-based Paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. *J Interv Cardiol*. 2004;17:271-82.
234. **Stone GW**, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial: study design and rationale. *Am Heart J*. 2004;148:764-75.
235. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps E, Collins M, Colombo A, **Stone GW**, Leon MB, Moses JW. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. *Circulation* 2004;110:3430-4
236. Yang YM, Mehran R, Dangas G, Reyes A, Oin J, **Stone GW**, Leon MB, Moses JW. Successful use of the Frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. *Catheter Cardiovasc Interv* 2004;63:462-468.

237. Stuckey TD, **Stone GW**, Cox DA, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). *Am J Cardiol.* 2005;95:1-7.
238. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, **Stone GW**, Moses JW, Leon MB, Mehran R. Contrast-Induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. *Am J Cardiol.* 2005;95:13-9.
239. Costa RA, Lansky AJ, Mintz GS, Mehran R, Tsuchiya Y, Negoita M, Gilutz Y, Nikolsky E, Fahy M, Pop R, Cristea E, Carlier S, Dangas G, **Stone GW**, Leon MB, Muller R, Techen G, Grube E. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). *Am J Cardiol.* 2005;95:113-6.
240. Abbas AE, Brodie B, **Stone GW**, et al. Frequency of returning to work one and six months following percutaneous coronary intervention for acute myocardial infarction. *Am J Cardiol.* 2004;94:1403-5.
241. Lasic Z, Mehran R, Dangas G, Mintz G, Nikolsky E, Tsounias E, Udani PC, Adamian M, Adamian J, Moussa I, Collins M, **Stone GW**, Moses J. Comparison of safety and efficacy between first and second generation of angio-seal closure devices in interventional patients. *J Invasive Cardiol.* 2004 Jul;16(7):356-8.
242. Lansky AJ, Mehran R, Dangas G, Cristea E, Shirai K, Costa R, Costantini C, Tsuchiya Y, Carlier S, Mintz G, Cottin Y, **Stone GW**, Moses J, Leon MB. Comparison of differences in outcome after percutaneous coronary intervention in men versus women <40 years of age. *Am J Cardiol.* 2004;93:916-9.
243. Fujii K, Carlier SG, Mintz GS, Kobayashi Y, Jacoboff D, Nierenberg H, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW**, Leon MB, Moses JW. Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque. *Am J Cardiol.* 2005;95:355-9.
244. Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y, Pocock S, Negoita M, Moussa I, **Stone GW**, Moses JW, Leon MB, Dangas G. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. *Kidney Int.* 2005;67:706-13.
245. Lansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, New G, Grines CL, Pietras CG, Kern MJ, Ferrell M, Leon MB, Mehran R, White C, Mieres JH, Moses JW, **Stone GW**, Jacobs AK. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. *Circulation.* 2005 Feb 22;111(7):940-53.
246. Takebayashi H, Kobayashi Y, Mintz GS, Carlier SG, Fujii K, Yasuda T, Moussa I, Mehran R, Dangas GD, Collins MB, Kreps E, Lansky AJ, **Stone GW**, Leon MB, Moses JW. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. *Am J Cardiol.* 2005 Feb 15;95(4):498-502.



247. Prasad A, **Stone GW**, Stuckey TD, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. *J Am Coll Cardiol*. 2005 Feb 15;45(4):508-14.
248. Swaminathan A, **Stone GW**, Rogers C, et al. Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention. *Am J Cardiol*. 2005 Mar 1;95(5):651-4.
249. Gersh BJ, **Stone GW**, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? *JAMA*. 2005 Feb 23;293(8):979-86.
250. Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tchong JE, Mehran R, Lansky AJ, Kandzari DE, Grines CL, **Stone GW**. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. *Eur Heart J*. 2005;26(7):667-74.
251. **Stone GW**, Webb J, Cox DA, Brodie BR, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. *JAMA*. 2005 Mar 2;293(9):1063-72.
252. Nikolsky E, Kosinski E, Mishkel GJ, Kimmelstiel C, McGarry TF Jr, Mehran R, Leon MB, Russell ME, Ellis SG, **Stone GW**. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). *Am J Cardiol*. 2005 Mar 15;95(6):709-15.
253. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, **Stone GW**, Wijns W. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. *Eur Heart J*. 2005 Apr;26(8):804-47.
254. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW**, Moses JW, Leon MB. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. *J Am Coll Cardiol*. 2005 Apr 5;45(7):995-8.
255. Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tchong JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, **Stone GW**. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation*. 2005 Apr 5;111(13):1611-8.
256. De Luca G, Suryapranata H, **Stone GW**, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. *JAMA*. 2005 Apr 13;293(14):1759-65.
257. Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russell ME, Ellis SG, **Stone GW**. Outcomes with the paclitaxel-eluting stent in patients

- with acute coronary syndromes: analysis from the TAXUS-IV trial. *J Am Coll Cardiol*. 2005 Apr 19;45(8):1165-71.
258. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, **Stone GW**. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. *J Am Coll Cardiol*. 2005 Apr 19;45(8):1172-9.
  259. Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, Mehran R, Leon MB, Russell ME, Ellis SG, **Stone GW**. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. *J Am Coll Cardiol*. 2005 Apr 19;45(8):1180-5.
  260. Dangas G, Ellis SG, Shlofmitz R, Katz S, Fish D, Martin S, Mehran R, Russell ME, **Stone GW**. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. *J Am Coll Cardiol*. 2005 Apr 19;45(8):1186-92.
  261. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, **Stone GW**. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. *J Am Coll Cardiol*. 2005 Apr 19;45(8):1193-200.
  262. Weissman NJ, Koglin J, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Kutcher M, Wong SC, Strickland W, Mooney M, Russell ME, Ellis SG, **Stone GW**. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. *J Am Coll Cardiol*. 2005 Apr 19;45(8):1201-5.
  263. Wong SC, Hong MK, Ellis SG, Buchbinder M, Reisman M, Delago A, Kellett M, Popma JJ, Russell ME, Mehran R, Moses JW, **Stone GW**. Influence of Stent Length to Lesion Length Ratio on Angiographic and Clinical Outcomes After Implantation of Bare Metal and Drug-Eluting Stents (the TAXUS-IV Study). *Am J Cardiol*. 2005 May 1;95(9):1043-8.
  264. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, Lansky AJ, Gersh BJ, O'Neill WW, Mehran R, **Stone GW**. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. *J Am Coll Cardiol*. 2005 May 3;45(9):1397-405.
  265. **Stone GW**. Protecting the Patient from Saphenous Vein Graft Intervention. *J Interv Cardiol*. 2005 Apr;18(2):77-79.
  266. **Stone GW**, Ellis SE, Russell ME. Paclitaxel-eluting stents. *N Engl J Med* 2004;350:2100.
  267. Yang YM, **Stone GW**, Moses JW, Leon MB, Mintz GS. Novel method for extraction of a massive refractory coronary thrombus after stent implantation. *Catheter Cardiovasc Interv*. 2005;65:276-279.
  268. Ross AM, Gibbons RJ, **Stone GW**, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). *J Am Coll Cardiol*. 2005;45:1775-80.

269. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, **Stone GW**, Wijns W. Guidelines for Percutaneous Coronary Interventions. *Rev Esp Cardiol*. 2005 Jun;58(6):679-728
270. de Ribamar Costa J Jr, Mintz GS, Carlier SG, Costa RA, Fujii K, Sano K, Kimura M, Lui J, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW**, Moses JW, Leon MB. Intravascular Ultrasonic Assessment of Stent Diameters Derived from Manufacturer's Compliance Charts. *Am J Cardiol*. 2005 Jul 1;96(1):74-8.
271. Halkin A, **Stone GW**, Dixon SR, et al. Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. *Am J Cardiol*. 2005 Aug 1;96(3):325-31.
272. Fujii K, Carlier SG, Mintz GS, Takebayashi H, Yasuda T, Costa RA, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW**, Moses JW, Leon MB. Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques. *Am J Cardiol*. 2005 Aug 1;96(3):352-7.
273. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, **Stone GW**, Wijns W; Task Force per le Procedure Coronariche Percutanee della Societa Europea di Cardiologia. Guidelines for percutaneous coronary interventions. *Ital Heart J Suppl*. 2005 Jul;6(7):427-74.
274. Weisz G, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, Mehran R, Aymong E, Lansky A, Grines CL, **Stone GW**. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. *Am Heart J*. 2005 Aug;150(2):358-64.
275. Nikolsky E, Sadeghi HM, Effron MB, Mehran R, Lansky AJ, Na Y, Cox DA, Garcia E, Tchong JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD, Grines CL, **Stone GW**. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. *Am J Cardiol*. 2005 Aug 15;96(4):474-81.
276. Guerrero M, Harjai K, **Stone GW**, et al. Comparison of the prognostic effect of left versus right versus no bundle branch block on presenting electrocardiogram in acute myocardial infarction patients treated with primary angioplasty in the primary angioplasty in myocardial infarction trials. *Am J Cardiol*. 2005 Aug 15;96(4):482-8.
277. Teirstein PS, Kao J, Watkins M, Tannenbaum MA, Laufer N, Chang M, Mehran R, Dangas G, Russell ME, Ellis SG, **Stone GW**. Impact of Platelet Glycoprotein IIb/IIIa Inhibition on the Paclitaxel-Eluting Stent in Patients With Stable or Unstable Angina Pectoris or Provocable Myocardial Ischemia (A TAXUS IV Substudy). *Am J Cardiol*. 2005 Aug 15;96(4):500-5.
278. Costa RA, Mintz GS, Carlier SG, Lansky AJ, Moussa I, Fujii K, Takebayashi H, Yasuda T, Costa JR Jr, Tsuchiya Y, Jensen LO, Cristea E, Mehran R, Dangas GD, Iyer S, Collins M, Kreps EM, Colombo A, **Stone GW**, Leon MB, Moses JW. Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis. *J Am Coll Cardiol*. 2005 Aug 16;46(4):599-605.

279. Brodie BR, Grines CL, **Stone GW**. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United states (letter). *Circulation*. 2005 Aug 16;112(7):e99; author reply e99-100.
280. Guerrero M, Harjai K, **Stone GW**, et al. Usefulness of the Presence of Peripheral Vascular Disease in Predicting Mortality in Acute Myocardial Infarction Patients Treated With Primary Angioplasty (from the Primary Angioplasty in Myocardial Infarction Database). *Am J Cardiol*. 2005 Sep 1;96(5):649-54.
281. Dangas G, Lasic Z, Mehran R, Cox D, Ghali MG, Henry TD, Teirstein PS, Stella JF, Browne KF Jr, Lewis SA, Knopf W, Leon MB, Moses JW, **Stone GW**. Effectiveness of the Concomitant Use of Bivalirudin and Drug-Eluting Stents (from the Prospective, Multicenter BivAlirudin and Drug-Eluting STents [ADEST] Study). *Am J Cardiol*. 2005 Sep 1;96(5):659-63.
282. Mukherjee D, Topol EJ, Bertrand ME, Kristensen SD, Herrmann HC, Neumann FJ, Yakubov SJ, Bassand JP, McClure RR, **Stone GW**, Ardissino D, Moliterno DJ. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. *Eur Heart J*. 2005; 26(23):2524-8.
283. **Stone GW**, Colombo A, Teirstein PS, et al. Percutaneous recanalization of chronically occluded coronary arteries: Procedural techniques, devices, and results. *Catheter Cardiovasc Interv*. 2005 Sep 9;66(2):217-236.
284. **Stone GW**, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME; TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. *JAMA*. 2005 Sep 14;294(10):1215-23.
285. Kipshidze NN, Tsapenko MV, Leon MB, **Stone GW**, Moses JW. Update on drug-eluting coronary stents. *Expert Rev Cardiovasc Ther*. 2005 Sep;3(5):953-68.
286. Mehta RH, Harjai KJ, Cox DA, **Stone GW**, Brodie BR, Boura J, Grines L, O'Neill W, Grines CL; Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Comparison of coronary stenting versus conventional balloon angioplasty on five-year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. *Am J Cardiol*. 2005 Oct 1;96(7):901-6.
287. **Stone GW**, Kandzari DE, Mehran R, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. *Circulation*. 2005 Oct 11;112(15):2364-72.
288. **Stone GW**, Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. *Circulation*. 2005 Oct 18;112(16):2530-7.
289. Moussa I, Ellis SG, Jones M, Kereiakes DJ, McMartin D, Rutherford B, Mehran R, Collins M, Leon MB, Popma JJ, Russell ME, **Stone GW**. Impact of Coronary Culprit Lesion

- Calcium in Patients Undergoing Paclitaxel-Eluting Stent Implantation (a TAXUS-IV Sub Study). *Am J Cardiol.* 2005 Nov 1;96(9):1242-7.
290. Voeltz MD, Feit F, **Stone GW**, Manoukian SV. Anemia and Outcomes in ACS. *Acute Coronary Syndromes* 2005;7:47-55.
  291. Fujii K, Carlier SG, Mintz GS, Wijns W, Colombo A, Bose D, Erbel R, de Ribamar Costa J Jr, Kimura M, Sano K, Costa RA, Lui J, **Stone GW**, Moses JW, Leon MB. Association of plaque characterization by intravascular ultrasound virtual histology and arterial remodeling. *Am J Cardiol.* 2005 Dec 1;96(11):1476-83.
  292. Halkin A, Mehran R, Casey CW, Gordon P, Matthews R, Wilson BH, Leon MB, Russell ME, Ellis SG, **Stone GW**. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. *Am Heart J.* 2005;150:1163-70.
  293. Halkin A, **Stone GW**, Grines CL, Cox DA, Stuckey TD, Garcia E, Guagliumi G, Mehran R, Rutherford BD, Griffin JJ, Na Y, Tchong JE, Turco M. Outcomes of Patients Consented But Not Randomized in a Trial of Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (The CADILLAC Registry). *Am J Cardiol.* 2005;96:1649-55.
  294. Nikolsky E, **Stone GW**, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Negoita M, Lansky AJ, Mehran R. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. *Am Heart J.* 2006;151:168-75.
  295. Ellis SG, Popma JJ, **Stone GW**, Russell ME. Restenosis, statistics, and reasonable inferences. *J Am Coll Cardiol.* 2006;47:470-1.
  296. Weissman NJ, **Stone GW**. Intravascular Ultrasound Analysis of Polymer-Based Paclitaxel-Eluting Stents: Reply. *J Am Coll Cardiol.* 2006;47:470.
  297. Jonas M, **Stone GW**, Mehran R, et al. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. *Eur Heart J.* 2006;27:920-928.
  298. De Luca G, Suryapranata H, **Stone GW**, et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. *J Am Coll Cardiol.* 2006;47:685-6.
  299. **Stone GW**, Gersh BJ. Facilitated angioplasty: paradise lost. *Lancet.* 2006;367:543-6.
  300. **Stone GW**, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents versus vascular brachytherapy for in-stent restenosis within bare metal stents. The TAXUS V ISR randomized trial. *JAMA* 2006;295:1253-1263.
  301. Mehta RH, O'Neill WW, Harjai KJ, Cox DA, Brodie BR, Boura J, Grines L, **Stone GW**, Grines CL. Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. *Am J Cardiol.* 2006;97:817-22.

302. Halkin A, **Stone GW**, Grines CL, Cox DA, Rutherford BD, Esente P, Meils CM, Albertsson P, Farah A, Tcheng JE, Lansky AJ, Mehran R. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. *J Am Coll Cardiol*. 2006;47:951-61.
303. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, **Stone GW**, Wijns W; European Society of Cardiology. Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC. *Kardiol Pol*. 2005;63:265-320.
304. Dawkins KD, **Stone GW**, Colombo A et al. Integrated analysis of medically treated diabetic patients in the TAXUS program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments. *EuroIntervention* 2006;2:34-42.
305. Halkin A, Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, Haber RH, Cambier PA, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA, Mehran R, **Stone GW**. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. *Am Heart J*. 2006;151:915.e1-7.
306. Popp RL, Lorell BH, **Stone GW**, Laskey W, Smith JJ, Kaplan AV. An Outline for Public Registration of Clinical Trials Evaluating Medical Devices *J Am Coll Cardiol* 2006;47:1518-1521.
307. Moussa I, Costa RA, Leon MB, Lansky AJ, Lasic Z, Cristea E, Trubelja N, Carlier SG, Mehran R, Dangas GD, Weisz G, Kreps EM, Collins M, **Stone GW**, Moses JW. A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique". *Am J Cardiol*. 2006;97:1317-21.
308. **Stone GW** and Aronow HD. Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. *Mayo Clin Proc* 2006;81(5):641-652.
309. Fujii K, Ochiai M, Mintz GS, Kan Y, Awano K, Masutani M, Ashida K, Ohyanagi M, Ichikawa S, Ura S, Araki H, **Stone GW**, Moses JW, Leon MB, Carlier SG. Procedural implications of intravascular ultrasound morphologic features of chronic total coronary occlusions. *Am J Cardiol*. 2006 May 15;97(10):1455-62.
310. Sano K, Mintz GS, Carlier SG, Fujii K, Yasuda T, Kimura M, Costa JR Jr, Costa RA, Lui J, Weisz G, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW**, Moses JW, Leon MB. Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts. *Am J Cardiol*. 2006 May 15;97(10):1463-6.
311. **Stone GW**, Popma JJ, Ellis SE. Paclitaxel-eluting stents, brachytherapy, and in-stent restenosis—Reply. *JAMA* 2006;296:1838-9.
312. Shishehbor MH, Topol EJ, Mukherjee D, Hu T, Cohen DJ, **Stone GW**, McClure R, Roffi M, Moliterno DJ. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. *Am J Cardiol*. 2006 Jun 1;97(11):1585-90.

313. Moses JW, **Stone GW**, Nikolsky E, et al. Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. *J Am Coll Cardiol*. 2006 Jun 6;47(11):2164-71.
314. Brodie BR, **Stone GW**, Cox DA, et al. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. *Am Heart J*. 2006 Jun;151(6):1231-8.
315. Kandzari DE, Tcheng JE, Gersh BJ, Cox DA, Stuckey T, Turco M, Mehran R, Garcia E, Zimetbaum P, McGlaughlin MG, Lansky AJ, Costantini CO, Grines CL, **Stone GW**. Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. *Am Heart J*. 2006 Jun;151(6):1288-95.
316. Dawkins KD, **Stone GW**, Colombo A, et al. Integrated analysis of medically treated diabetic patients in the Taxus program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments. *EuroIntervention* 2006;2:69-76.
317. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, **Stone GW**. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. *Eur Heart J*. 2006;27:2400-5.
318. Pinto DS, **Stone GW**, Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. *J Am Coll Cardiol*. 2006;48:32-6.
319. Bakhai A, **Stone GW**, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. *J Am Coll Cardiol*. 2006 Jul 18;48(2):253-61.
320. Cox DA, **Stone GW**, Grines CL, et al. Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non-ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial). *Am J Cardiol*. 2006 Aug 1;98(3):331-7.
321. Lansky AJ, Yang YM, Khan Y, Costa RA, Pietras C, Tsuchiya Y, Cristea E, Collins M, Mehran R, Dangas GD, Moses JW, Leon MB, **Stone GW**. Treatment of coronary artery perforations complicating percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. *Am J Cardiol*. 2006 Aug 1;98(3):370-4.
322. Jensen LO, Mintz GS, Carlier SG, Fujii K, Moussa I, Dangas G, Mehran R, **Stone GW**, Leon MB, Moses JW. Intravascular ultrasound assessment of fibrous cap remnants after coronary plaque rupture. *Am Heart J*. 2006 Aug;152(2):327-32.
323. Harjai KJ, Mehta RH, **Stone GW**, et al. Does Proximal Location of Culprit Lesion Confer Worse Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction? *J Interv Cardiol*. 2006 Aug;19(4):285-94.
324. Fujii K, Mintz GS, Carlier SG, di Ribamar Costa J Jr, Kimura M, Sano K, Tanaka K, Costa RA, Lui J, **Stone GW**, Moses JW, Leon MB. Intravascular ultrasound profile analysis of ruptured coronary plaques. *Am J Cardiol*. 2006 Aug 15;98(4):429-35.

325. Kimura M, Mintz GS, Carlier S, Takebayashi H, Fujii K, Sano K, Yasuda T, Costa RA, Costa JR Jr, Quen J, Tanaka K, Lui J, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW**, Moses JW, Leon MB. Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound. *Am J Cardiol*. 2006 Aug 15;98(4):436-42.
326. Forman MB, **Stone GW**, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. *Cardiovasc Drug Rev*. 2006;24(2):116-47.
327. Grube E, Laborde JC, Gerckens U, Felderhoff T, Sauren B, Buellesfeld L, Mueller R, Menichelli M, Schmidt T, Zickmann B, Iversen S, **Stone GW**. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. *Circulation*. 2006;114:1616-24.
328. Lasala JM, **Stone GW**, Dawkins KD, Serruys PW, Colombo A, Grube E, Koglin J, Ellis S. An Overview of the TAXUS Express, Paclitaxel-Eluting Stent Clinical Trial Program. *J Interv Cardiol*. 2006;19:422-31.
329. **Stone GW**, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. *N Engl J Med*. 2006;355:2203-16.
330. Sano K, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Kimura M, Costa JR Jr, Tanaka K, Costa RA, Lui J, Weisz G, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps EM, Collins M, **Stone GW**, Moses JW, Leon MB. Volumetric intravascular ultrasound assessment of neointimal hyperplasia and nonuniform stent strut distribution in sirolimus-eluting stent restenosis. *Am J Cardiol*. 2006;98:1559-62.
331. Brodie BR, Grines CL, **Stone GW**. Effect of door-to-balloon time on patient mortality. *J Am Coll Cardiol*. 2006 Dec 19;48(12):2600.
332. Carlier SG, Mintz GS, **Stone GW**. Imaging of atherosclerotic plaque using radiofrequency ultrasound signal processing. *J Nucl Cardiol*. 2006 Nov;13(6):831-40.
333. Kirtane AJ, **Stone GW**, Jacobs AK, Yeung AC. Best of the TCT Scientific Sessions 2006. *Rev Cardiovasc Med*. 2006 Fall;7(4):228-37.
334. Hodgson JM, **Stone GW**, Michael Lincoff A, Klein L, Walpole H, Bottner R, Weiner BH, Leon MB, Feldman T, Babb J, Dehmer GJ. Late stent thrombosis: Considerations and practical advice for the use of drug-eluting stents: A report from the society for cardiovascular angiography and interventions drug-eluting stent task force. *Catheter Cardiovasc Interv*. 2007 Feb 15;69(3):327-33.
335. **Stone GW**. Expert discussion of the latest trial results: summary remarks. *Rev Cardiovasc Med*. 2006;7 Suppl 3:S53-9.
336. Harjai KJ, **Stone GW**, Grines CL, et al. Usefulness of Routine Unfractionated Heparin Infusion Following Primary Percutaneous Coronary Intervention for Acute Myocardial



- Infarction in Patients Not Receiving Glycoprotein IIb/IIIa Inhibitors. *Am J Cardiol.* 2007 Jan 15;99(2):202-7.
337. de Ribamar Costa J Jr, Mintz GS, Carlier SG, Fujii K, Sano K, Kimura M, Tanaka K, Costa RA, Lui J, Na Y, Castellanos C, Biro S, Moussa I, **Stone GW**, Moses JW, Leon MB. Intravascular ultrasound assessment of drug-eluting stent expansion. *Am Heart J.* 2007 Feb;153(2):297-303.
338. **Stone GW**, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD. Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial. *JAMA.* 2007;297:591-602.
339. **Stone GW**, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. *N Engl J Med.* 2007;356:998-1008.
340. Young JJ, Cox DA, Stuckey T, Babb J, Turco M, Lansky AJ, Mehran R, **Stone GW**. Prospective, multicenter study of thrombectomy in patients with acute myocardial infarction: the X-Tract AMI registry. *J Interv Cardiol.* 2007;20:44-50.
341. De Luca G, Suryapranata H, **Stone GW**, Antoniucci D, Neumann FJ, Chiariello M. Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. *Am Heart J.* 2007;153:343-53.
342. Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Dawkins KD, **Stone GW**. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. *J Am Coll Cardiol.* 2007 Mar 13;49(10):1043-51.
343. **Stone GW**. Non-ST-elevation acute coronary syndromes. *Lancet.* 2007 Mar 10;369(9564):801-3.
344. **Stone GW**, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. *Lancet.* 2007 Mar 17;369(9565):907-19.
345. Tanaka K, Carlier SG, Mintz GS, Sano K, Liu X, Fujii K, de Ribamar Costa J Jr, Lui J, Moses JW, **Stone GW**, Leon MB. The accuracy of length measurements using different intravascular ultrasound motorized transducer pullback systems. *Int J Cardiovasc Imaging.* 2007 Dec;23(6):733-8.
346. Nikolsky E, **Stone GW**. Utility of Drug-eluting Stents in Complex Lesions and High-risk Patients. *Curr Treat Options Cardiovasc Med.* 2007 Feb;9(1):11-28.

347. Mehta L, Devlin W, McCullough PA, O'Neill WW, Skelding KA, **Stone GW**, Boura JA, Grines CL. Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. *Am J Cardiol*. 2007 Apr 1;99(7):906-10.
348. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, Ohman EM, **Stone GW**. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUTY Trial. *J Am Coll Cardiol*. 2007 Mar 27;49(12):1362-8.
349. Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, Mehran R, Lansky AJ, Na Y, **Stone GW**. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC Trial). *Am J Cardiol*. 2007 Apr 15;99(8):1055-61.
350. Prasad A, **Stone GW**, Stuckey TD, Costantini CO, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, Lansky AJ, Gersh BJ. Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty. *Am J Cardiol*. 2007 Apr 15;99(8):1067-71.
351. Nikolsky E, Pucelikova T, Mehran R, Balter S, Kaufman L, Fahy M, Lansky AJ, Leon MB, Moses JW, **Stone GW**, Dangas G. An evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention. *J Invasive Cardiol*. 2007;19:208-13.
352. Kirtane AJ, **Stone GW**. The Anchor-Tornus technique: A novel approach to "uncrossable" chronic total occlusions. *Catheter Cardiovasc Interv*. 2007 Oct 1;70(4):554-7.
353. **Stone GW**, Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. *Circulation*. 2007;115:2842-2847.
354. Weissman NJ, Ellis SG, Grube E, Dawkins KD, Greenberg JD, Mann T, Cannon LA, Cambier PA, Fernandez S, Mintz GS, Mandinov L, Koglin J, **Stone GW**. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. *Eur Heart J*. 2007 Jul;28(13):1574-82.
355. De Luca G, Suryapranata H, **Stone GW**, Antoniucci D, Biondi-Zoccai G, Kastrati A, Chiariello M, Marino P. Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. *Int J Cardiol*. 2007;119:306-9.
356. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, **Stone GW**. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *Eur Heart J*. 2001;28(14):1709-16.
357. Brodie BR, Webb J, Cox DA, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford B, Antoniucci D, Stuckey T, Krucoff M, Gibbons R, Lansky A, Na Y, Mehran R, **Stone GW**. Impact of time to treatment on myocardial reperfusion and infarct size with

- primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). *Am J Cardiol.* 2007;99(12):1680-6.
358. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, Lincoff AM, **Stone GW**. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. *Eur Heart J.* 2007 Aug;28(16):1936-45.
  359. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, **Stone GW**. Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from the EMERALD Trial). *Am J Cardiol.* 2007;100(2):206-210.
  360. Sorajja P, Gersh BJ, Mehran R, Lansky AJ, Krucoff MW, Webb J, Cox DA, Brodie BR, **Stone GW**. Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction. *Am Heart J.* 2007 Aug;154(2):379-84.
  361. **Stone GW**, Moses JW, Leon MB. Left main drug-eluting stents: natural progression or a bridge too far? *J Am Coll Cardiol.* 2007;50:498-500.
  362. de Ribamar Costa J Jr, Mintz GS, Carlier SG, Mehran R, Teirstein P, Sano K, Liu X, Lui J, Na Y, Castellanos C, Biro S, Dani L, Rinker J, Moussa I, Dangas G, Lansky AJ, Kreps EM, Collins M, **Stone GW**, Moses JW, Leon MB. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. *Am J Cardiol.* 2007 Sep 1;100(5):812-7.
  363. Cheruvu PK, Finn AV, Gardner C, Caplan J, Goldstein J, **Stone GW**, Virmani R, Muller JE. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. *J Am Coll Cardiol.* 2007;50:940-9.
  364. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, **Stone GW**, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttrop MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *Lancet.* 2007 Sep 15;370(9591):937-48.
  365. **Stone GW**. Timing of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. *JAMA* 2007;298:37-8.
  366. Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR Jr, Krucoff MW, O'Neill WW, Waksman R, Williams DO, Popma JJ, Buchbinder M, Mehran R, Meredith IT, Moses JW, **Stone GW**. The truth and consequences of the COURAGE trial. *J Am Coll Cardiol.* 2007;50:1598-603.
  367. **Stone GW**, Dixon SR, Grines CL, Cox DA, Webb JG, Brodie BR, Griffin JJ, Martin JL, Fahy M, Mehran R, Miller TD, Gibbons RJ, O'Neill WW. Predictors of infarct size after

- primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. *Am J Cardiol.* 2007;100:1370-5.
368. Sano K, Mintz GS, Carlier SG, de Ribamar Costa J Jr, Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps EM, Collins MB, **Stone GW**, Leon MB, Moses JW. Assessing intermediate left main coronary lesions using intravascular ultrasound. *Am Heart J.* 2007 Nov;154(5):983-8.
  369. Sano K, Mintz GS, Carlier SG, Solinas E, Costa Jde R Jr, Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps E, Collins M, **Stone GW**, Moses JW, Leon MB. Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. *J Invasive Cardiol.* 2007 Nov;19(11):464-8.
  370. **Stone GW**, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ; ACUITY Investigators. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. *JAMA.* 2007;298:2497-506.
  371. Aoki J, Kirtane AJ, Dangas GD, Lansky AJ, Morales A, Kimura M, Kim YH, Moussa I, Weisz G, Kreps EM, Collins M, Franklin-Bond T, **Stone GW**, Moses JW, Leon MB, Mehran R. Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings. *Am J Cardiol.* 2008 Jan 1;101(1):58-62.
  372. Pucelikova T, Mehran R, Kirtane AJ, Kim YH, Fahy M, Weisz G, Lansky AJ, Moussa I, Gray WA, Collins MB, Kodali SK, **Stone GW**, Moses JW, Leon MB, Dangas G. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. *Am J Cardiol.* 2008 Jan 1;101(1):63-8.
  373. Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, **Stone GW**. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. *J Am Coll Cardiol.* 2008 Jan 1;51(1):23-32.
  374. De Luca G, Suryapranata H, **Stone GW**, Marino P. Stenting versus plain old angioplasty in patients with ST segment elevation myocardial infarction: Understanding of the randomized trials. *Int J Cardiol.* 2008 Jan 14; [Epub ahead of print].
  375. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, Mehran R, **Stone GW**. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. *J Am Coll Cardiol.* 2008 Feb 19;51(7):708-15.
  376. Young JJ, Phillips HR, Marso SP, Granada JF, McPherson JA, Waksman R, Steinhubl SR, Schwartz RS, **Stone GW**. Vulnerable plaque intervention: State of the art. *Catheter Cardiovasc Interv.* 2008 Feb 15;71(3):367-74.
  377. Missel E, Mintz GS, Carlier SG, Sano K, Qian J, Kaple RK, Castellanos C, Dangas G, Mehran R, Moses JW, **Stone GW**, Leon MB. Necrotic core and its ratio to dense calcium

- are predictors of high-risk non-ST-elevation acute coronary syndrome. *Am J Cardiol.* 2008 Mar 1;101(5):573-8.
378. Kim YH, Dangas GD, Solinas E, Aoki J, Parise H, Kimura M, Franklin-Bond T, Dasgupta NK, Kirtane AJ, Moussa I, Lansky AJ, Collins M, **Stone GW**, Leon MB, Moses JW, Mehran R. Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis. *Am J Cardiol.* 2008 Mar 15;101(6):801-6.
  379. De Luca G, **Stone GW**, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, Valgimigli M, Di Lorenzo E, Dirksen MT, Spaulding C, Pittl U, Violini R, Percoco G, Marino P. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. *Int J Cardiol.* 2008 Apr 2; [Epub ahead of print]
  380. Weisz G, **Stone GW**. Safety and efficacy of drug-eluting stents: on-label and off-label perspectives. *Rev Cardiovasc Med.* 2008;9:46-61.
  381. Otsuka M, Bruining N, Van Pelt NC, Mollet NR, Ligthart JM, Vourvouri E, Hamers R, De Jaegere P, Wijns W, Van Domburg RT, **Stone GW**, Veldhof S, Verheye S, Dudek D, Serruys PW, Krestin GP, De Feyter PJ. Quantification of Coronary Plaque by 64-slice Computed Tomography: A Comparison with Quantitative Intracoronary Ultrasound. *Invest Radiol.* 2008;43:314-321.
  382. **Stone GW**, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *JAMA.* 2008 Apr 23;299(16):1903-13.
  383. Kimura M, Mintz GS, Weissman NJ, Dawkins KD, Grube E, Ellis SG, Cannon LA, Masud Z, Mandinov L, Baim D, **Stone GW**. Meta-analysis of the Effects of Paclitaxel-Eluting Stents Versus Bare Metal Stents on Volumetric Intravascular Ultrasound in Patients With Versus Without Diabetes Mellitus. *Am J Cardiol.* 2008 May 1;101(9):1263-8.
  384. Feit F, Manoukian SV, Ebrahimi R, Pollack CV, Ohman EM, Attubato MJ, Mehran R, **Stone GW**. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *J Am Coll Cardiol.* 2008 Apr 29;51(17):1645-52.
  385. White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV Jr, Feit F, Lincoff AM, Bertrand M, Pocock S, Ware J, Ohman EM, Mehran R, **Stone GW**. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. *J Am Coll Cardiol.* 2008 May 6;51(18):1734-41.
  386. Pocock SJ, Fahy MP, Mehran R, **Stone GW**. Surrogate endpoints in stent trials. Reply. *J Am Coll Cardiol.* 2008;51:1992.
  387. **Stone GW**, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R;

HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med*. 2008;358:2218-30.

388. Ellis SG, O'Shaughnessy CD, Martin SL, Kent K, McGarry T, Turco MA, Kereiakes DJ, Popma JJ, Friedman M, Koglin J, **Stone GW**. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis—the TAXUS V ISR trial. *Eur Heart J* 2008;29:1625–1634.
389. Dangas G, **Stone GW**, Weinberg MD, Webb J, Cox DA, Brodie BR, Krucoff MW, Gibbons RJ, Lansky AJ, Mehran R. Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). *Am Heart J*. 2008 Jun;155(6):1090-6.
- 390.

## Abstracts

1. Bulkley BH, Platia EV, **Stone GW**, Hochman JS. Ventricular aneurysms and endocardial pathology: relationship to malignant arrhythmias. *Circulation* 64(Suppl-IV):IV-306, 1981.
2. Platia EV, Berdoff R, **Stone G**, Ord S, Reid PR. Comparison of acebutolol and propranolol therapy for ventricular arrhythmias. *Clinical Research* 29:276A, 1981.
3. **Stone GW**, Griffin B, Brown D, Siegal R, Maurer G, Cook S, Shah PK, Berman DS. Systolic and diastolic dysfunction in acute pulmonary edema: A prospective consecutive series. *J Nucl Med* 28(Suppl):1987.
4. **Stone GW**, Griffin B, Brown D, Siegal R, Maurer G, Cook S, Berman DS, Shah PK. Is diastolic dysfunction the cause of acute pulmonary edema with normal global systolic dysfunction? *Circulation* 76(Suppl IV):IV-514, 1987.
5. Yang L, Barry CN, Rozanski A, **Stone G**, Nichols K, Friedman J, Areeda J, Suyenaga K, Syun M, Berman D. Validation of the ambulatory ventricular function monitor (VEST) for measuring left ventricular ejection fraction (LVEF). *J Nucl Med* 29:741, 1988.
6. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Acute outcome and long term follow-up of patients with acute myocardial infarction and single vessel disease treated with angioplasty without thrombolytic therapy. *J Am Coll Cardiol* 13:94A, 1989.
7. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Factors relating to improvement in regional wall motion and ejection fraction in patients with acute myocardial infarction and single vessel disease treated with coronary angioplasty without prior thrombolytic therapy. *Cath and Cardiovasc Diagn* 17:65-66, 1989.
8. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Elective angioplasty of totally occluded coronary arteries: an analysis of 971 cases. *Circulation* 80:II-480, 1989.
9. **Stone GW**, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Ligon RW, Hartzler GO. Outcome following multilesion angioplasty targeted to the "culprit coronary artery" in pts with unstable angina. *J Am Coll Cardiol* 15:169A, 1990.
10. Grines CL, Browne K, Rothbaum D, Overlie P, Marco J, O'Keefe J, **Stone GW**, Chelliah N, Strzelecki M, O'Neill WW. The Primary Angioplasty in Myocardial Infarction (PAMI) Trial: Preliminary Report. *Circulation*;84(Suppl II):II-538, 1991.
11. Grines CL, Browne KF, Vandormael M, **Stone GW**, O'Keefe J, Overlie P, Puchrowicz-Ochocki S, Strzelecki M, O'Neill WW. Primary Angioplasty in Myocardial Infarction (PAMI) Trial. *Circulation*;86(Suppl I):I-641, 1992.
12. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Primary Angioplasty Reduces In-Hospital Mortality and Morbidity in Acute Anterior Myocardial Infarction - Results of the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. *J Am Coll Cardiol* 21:331A, 1993.

13. **Stone GW**, St. Goar F, Klette MA, Linnemeier TJ. Initial Clinical Experience with a Novel Low-Profile Integrated Coronary Ultrasound-Angioplasty Catheter: Implications for Routine Use. *J Am Coll Cardiol* 21:134A, 1993.
14. **Gregg W. Stone**, Cindy L. Grines, Ronald Vlietstra, Michel Vandormael, Donald Rothbaum, James O'Keefe, Paul Overlie, Brian Donohue, Noah Chelliah, Mellisa May, Sylvia Puchrowicz-Ochocki, William W. O'Neill. Primary Angioplasty is the Preferred Therapy for Women and the Elderly with Acute Myocardial Infarction - Results of the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. *J Am Coll Cardiol* 21:330A, 1993.
15. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, Timmis GC, O'Neill WW. Acute Outcome After Primary Angioplasty in Myocardial Infarction - The Primary Angioplasty In Myocardial Infarction (PAMI) Trial. *J Am Coll Cardiol* 21:331A, 1993.
16. Wilson WS and **Stone GW**. Is Prolonged Angina Free Survival Possible in Pts with Multivessel Disease Treated by PTCA?- Effect of Multiple, Repeated Procedures. *Circulation*, 88;I-217,1993.
17. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, Timmis GC. Primary Angioplasty Reduces Recurrent Ischemic Events Compared to tPA in Myocardial Infarction: Implications for Early Discharge. *Circulation*, 88;I-105,1993.
18. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. Adverse Catheterization Laboratory Events after Primary PTCA vs. PTCA Following Thrombolytic Therapy - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. *J Am Coll Cardiol* 1A-484A;244A, 1994.
19. Bernard ST, Grines CL, Browne K, Marco J, Rothbaum D, **Stone GW**, O'Keefe J, Overlie P, Donohue B, Chelliah N, Puchrowicz-Ochocki S, Timmis GC, O'Neill WW. Does antecedent angina predict whether reperfusion by thrombolysis or primary angioplasty will be most beneficial? *J Am Coll Cardiol* 1A-484A;244A, 1994.
20. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, Corbell N, Puchrowicz S, O'Neill WW. Predictors of In-Hospital and 6-Month Outcome after Myocardial Infarction in the Reperfusion Era - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. *J Am Coll Cardiol* 1A-484A;226A, 1994.
21. Topaz O, McIvor M, **Stone G**, Foschi A, Sutton J, de Marchena E, and the Holmium Laser Multicenter Investigators. Solid State Laser Coronary Angioplasty: Multicenter Registry Report. *Circulation* 1994;90:I-332.
22. Grines CL, Griffin JJ, Brodie BR, **Stone GW**, Donohue BC, Balestrini C, Wharton TP, Spain MG, Shimshak T, Jones D, Mason D, O'Neill WW. The Second Primary Angioplasty for Myocardial Infarction Study (PAMI-II): Preliminary Report. *Circulation* 1994;90:I-433.



23. **Stone GW**, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, Strzelecki M, Puchrowicz-Ochocki S, Timmis G. Outcome of Different Reperfusion Strategies in Thrombolytic "Eligible" Versus "Ineligible" Patients with Acute Myocardial Infarction. *J Am Coll Cardiol* 1995;25:401A.
24. **Gregg W. Stone**, Cindy L. Grines, Kevin F. Browne, Jean Marco, Donald Rothbaum, James O'Keefe, Paul Overlie, Brian Donohue, Noah Chelliah, Sylvia Puchrowicz-Ochocki, William W. O'Neill. Is Primary Angioplasty Less Effective in Patients Presenting in the Early Morning Hours? - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. *J Am Coll Cardiol* 1995;25:295A.
25. **Gregg W. Stone**, Cindy L. Grines, Kevin F. Browne, Jean Marco, Donald Rothbaum, James O'Keefe, Geoffrey O. Hartzler, Paul Overlie, Brian Donohue, Noah Chelliah, Sylvia Puchrowicz, William W. O'Neill. Does Primary Angioplasty Improve the Prognosis of Patients with Diabetes and Acute Myocardial Infarction? *J Am Coll Cardiol* 1995;25:401A.
26. Patricia Caverio, James O'Keefe, **Gregg W. Stone**, Ben McCallister, Cheryl Dreiling, Robert Ligon, Ray Kacich. Lovastatin and Probucol for the Prevention of Restenosis After Coronary Angioplasty. *J Am Coll Cardiol* 1995;25:226A.
27. Raffi Krikorian, Sylvia Puchrowicz, James O'Keefe, Cindy Grines, Kevin F. Browne, Donald Rothbaum, Ronald Vlietstra, **Gregg W. Stone**, William W. O'Neill. Differential Effects of Long-term Beta-blocker Therapy Following Thrombolysis Versus Primary Angioplasty. *J Am Coll Cardiol* 1995;25:402A.
28. Bruce Brodie, Cindy L. Grines, Michael Spain, John Griffin, Carlos Balestrini, **Gregg W. Stone**, Costantino Costantini, Paolo Esente, Michael Ayres, Masakiyo Nobuyoshi, Bryan Donohue, Noah Chelliah, Donald Rothbaum, Thomas Wharton, Denise Jones, Denise Mason, Debra Sachs, William W. O'Neill. A Prospective, Randomized Trial Evaluating Early Discharge (Day 3) Without Non-Invasive Risk Stratification in Low Risk Patients with Acute Myocardial Infarction: PAMI-2. *J Am Coll Cardiol* 1995;25:5A.
29. **Stone GW**. Who is suitable for early discharge after acute myocardial infarction? *ACCEL* 27:1, January 1995.
30. John Griffin, Cindy L. Grines, Dominic Marsalese, Michael Spain, Bruce Brodie, Bryan Donohue, Thomas Wharton, **Gregg W. Stone**, Carlos Balestrini, Costantino Costantini, Thomas Shimshak, Juan Luis Delcan, Denise Jones, Denise Mason, Debra Sachs, William W. O'Neill. A Prospective, Randomized Trial Evaluating the Prophylactic Use of Balloon Pumping in High Risk Myocardial Infarction Patients: PAMI-2. *J Am Coll Cardiol* 1995;25:86A.
31. John Hodgson, **Gregg W. Stone**, Fred St. Goar, Thomas Linnemeier, Helen Sheehan for the CLOUT Investigators. Can Intracoronary Ultrasound Improve PTCA Results?: Preliminary Core Lab Ultrasound Analysis from the CLOUT Pilot Study. *J Am Coll Cardiol* 1995;25:143A.
32. **Gregg W. Stone**, Fred G. St. Goar, Tom Linnemeier, Helen Sheehan and John Hodgson for the CLOUT Investigators. Can the Results of Standard Balloon Angioplasty be Improved with Intracoronary Ultrasound Guidance? - The CLOUT Pilot Study. *J Inv Cardiol* 1995;7:23A.

33. **Gregg W. Stone**, Michael McIvor, On Topaz, Joseph Sutton, Eduardo J. DeMarchena. Holmium Laser Multicenter Registry Results: Effect of lesion morphology on procedural success and complications. *J Inv Cardiol* 1995;7:5A.
34. JMcB Hodgson, **GW Stone**, HM Sheehan, FG. St. Goar, T Linnemeier for the CLOUT Investigators. Intravascular ultrasound guided "oversized" balloon angioplasty: initial results from the CLOUT pilot trial. *Cath and CV Diag* 1995;35:81.
35. **Gregg W. Stone**, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, Carlos Balestrini, Thomas Wharton, Denise Jones, Debra Sachs, Cindy L. Grines. The Routine Use of Intra Aortic Balloon Pumping After Primary PTCA Improves Clinical Outcomes in Very High Risk Patients with Acute Myocardial Infarction - Results of the PAMI-2 Trial. *Circulation* 1995;92 (suppl I):I-139.
36. **Gregg W. Stone**, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, Carlos Balestrini, Thomas Wharton, Denise Jones, Debra Sachs, Gerald Timmis. Is Prophylactic IABP Use Beneficial or Harmful in a High Risk Elderly Population with Acute Myocardial Infarction? - PAMI-2. *Circulation* 1995;92 (suppl I):I-139.
37. Cindy Grines, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, A. Sampolesi, Costantino Costantini, **Gregg Stone**, Michael Spain, Denise Jones, Debra Sachs, Denise Mason, William O'Neill. Acute Cath Provides the Best Method of Risk Stratifying MI Patients. *Circulation* 1995;92 (suppl I):I-531.
38. Victoria Hollingsworth, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, A. Sampolesi, **Gregg Stone**, M Nobuyoshi, Michael Ayres, Thomas Shimshak, Denise Jones, Denise Mason, Debra Sachs, Cindy Grines. Should Primary PTCA be Performed Around the Clock? *Circulation* 1995;92 (suppl I):I-663.
39. Thomas P. Wharton, Dominic Marsalese, Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, Carlos Balestrini, **Gregg W. Stone**, Paolo Esente, Jeffrey Moses, Nancy McNamara, Denise Jones, Debra Sachs, Cindy L. Grines. How Often do Infarct-Related Arteries Show Early Perfusion Without Prior Thrombolytic Therapy, and Should These Vessels be Dilated Acutely? *Circulation* 1995;92 (suppl I):I-530.
40. Cindy Grines, Bruce Brodie, John Griffin, Bryan Donohue, A. Sampolesi, Costantino Costantini, Debra Sachs, Thomas Wharton, Paolo Esente, Michael Spain, **Gregg Stone**. Which Primary PTCA Patients may Benefit from New Technologies? *Circulation* 1995;92 (suppl I):I-146.
41. Tom Linnemeier, **Gregg W. Stone**, John McB. Hodgson, Coverdale J, Sheehan H, Landin R, Hodes Z, Ball M, Rothbaum D, Lips D, Elsner G, Riddell R, Dodin E, Yamada G, Lewis S. OSTI: Optimal Stent Implantation Protocol. *The Journal of Endovascular Surgery* 1996;3:I-25.
42. **Gregg W. Stone**, Tom Linnemeier, Fred G. St. Goar, Harald Mudra, Helen Sheehan and John McB. Hodgson. Improved Outcome of Balloon Angioplasty with Intracoronary Ultrasound Guidance - Core Lab Angiographic and Ultrasound Results from the CLOUT Study. *J Am Coll Cardiol* 1996;27(Suppl A):155A.

43. **Gregg W. Stone**, Fred G. St. Goar, Tom Linnemeier, Helen Sheehan and John McB. Hodgson for the CLOUT Investigators. Variability in Balloon Sizing During Routine PTCA - Quantitative Coronary and Ultrasound Analysis. J Am Coll Cardiol 1996;27(Suppl A):361A.
44. **Gregg W. Stone**, Tom Linnemeier, Fred St. Goar, Ron Landin, Michael Ball, Don Rothbaum, Zachary Hodes, Janice Coverdale, Helen Sheehan, John McB. Hodgson. What is the Optimal Pressure for Stent Implantation (How High is High)? J Am Coll Cardiol 1996;27(Suppl A):154A.
45. O'Neill W, Griffin J, **Stone GW**, Brodie B, Jones D, Sachs D, Esente P, Spain M, Ayres M, Grines CL. Operator and institutional volume do not affect the procedural outcome of primary angioplasty therapy. J Am Coll Cardiol 1996;27(Suppl A):13A.
46. Grines CL, Brodie B, Griffin J, Donohue B, Costantini C, Balestrini C, **Stone GW**, Wharton T, Mitina L, Graham M, Jones D, Sachs D, O'Neill WW. Prophylactic intraaortic balloon pumping for acute myocardial infarction does not improve left ventricular function. J Am Coll Cardiol 1996;27(Suppl A):167A.
47. Theodore Schreiber, Dominic Marsalese, Bryan Donohue, A. Sampolesi, Costantino Costantini, **Gregg Stone**, Denise Jones, Debra Sachs, Denise Mason, Thomas Wharton, Donald Rothbaum, Bruce Brodie, William W. O'Neill, Cindy Grines. Identification of Ultra Low-Risk Patients Following Primary Angioplasty for Acute Myocardial Infarction. J Am Coll Cardiol 1996;27(Suppl A):83A.
48. John Griffin, William W. O'Neill, Bruce Brodie, Sherry Theodosiou, Denise Jones, Debra Sachs, C. Costantini, C. Balestrini, **Gregg Stone**, Cindy Grines. Primary PTCA results in similar in-hospital outcomes in females and males presenting with acute MI. J Am Coll Cardiol 1996;27(Suppl A):154A.
49. Peter P. Scalise III, William W. O'Neill, Bryan Donohue, Denise Jones, Bruce Brodie, John Griffin, C. Costantini, C. Balestrini, **Gregg Stone**, Cindy Grines. Significance of antecedent angina (AA) in Primary PTCA: the PAMI-II Experience. J Inv Cardiol 1996;8:88.
50. Bryan Donohue, William W. O'Neill, Erik Jackson, Bruce Brodie, John Griffin, C. Balestrini, **Gregg Stone**, Thomas Wharton, Denise Jones, Cindy Grines. Cost analysis of different management strategies for myocardial infarction. J Am Coll Cardiol 1996;27(Suppl A):221A.
51. Timothy J. Byrne, William W. O'Neill, Bryan Donohue, Bruce Brodie, **Gregg Stone**, Adrien Van Strien, Floyd Casaday, Peter Scalise III. John Cava, Susan Petruolo, Denise Jones, Cindy Grines. Primary Angioplasty in Acute Myocardial Infarction: Does Urgent Transport Incur Added Risk? J Inv Cardiol 1996;8:67.
52. Bruce Brodie, Terry Bowers, William W. O'Neill, John Griffin, Bryan Donohue, C. Costantini, C. Balestrini, **Gregg Stone**, Denise Jones, Cindy Grines. Why do smokers have a better prognosis with acute myocardial infarction? Insights from the PAMI-2 trial. J Am Coll Cardiol 1996;27(Suppl A):193A.
53. **Gregg W. Stone**, Marie C. Morice, Bruce Brodie, John Griffin, Costantino Costantini, Fred St. Goar, Paul Overlie, Denise Jones, William W. O'Neill, Cindy L. Grines. Primary

Stenting in Acute Myocardial Infarction: Interim Report from the PAMI Stent Pilot Trial. *Eur Heart J* 1996;17(Suppl):297

54. **Gregg W. Stone**, Tom Linnemeier, Fred St. Goar, Janice Coverdale, Helen Sheehan and John McB. Hodgson. Defining the Relationship Between Implantation Pressure and Stent Expansion: Core Lab Results from the Optimal Stent Implantation (OSTI) Trial. *Eur Heart J* 1996;17(Suppl):518
55. **Gregg W. Stone**, Bruce Brodie, John Griffin, Bryan Donohue, Costantino Costantini, Denise Jones, Marianne Graham, Cindy L. Grines. Should the Risk of Delaying Reperfusion Prohibit Inter-Hospital Transfer to Perform Primary PTCA in Acute Myocardial Infarction? *Circulation* 1996;94:I-331.
56. **Gregg W. Stone**, Bruce Brodie, John Griffin, Marie-Claude Morice, Fred St. Goar, Costantino Costantini, Paul Overlie, Denise Jones, William W O'Neill, Cindy L. Grines. A Prospective, Multicenter Trial of Primary Stenting in Acute Myocardial Infarction - The PAMI Stent Pilot Study. *Circulation* 1996;94:I-570.
57. **Gregg W. Stone**, Cindy L. Grines, Donald Rothbaum, Tom Catlin, William W. O'Neill. Primary Angioplasty Reduces Hospital Costs While Improving Outcomes in AMI - Comprehensive Cost Efficacy Analysis from the PAMI Study. *Circulation* 1996;94:I-330.
58. **Gregg W. Stone**, Eduardo de Marchena, David Dageforde, Alberto Foschi, Brent Muhlestein, Michael McIvor, David Rizik, Ronald Vanderlaan. A Prospective, Randomized, Multicenter Comparison of Laser Angioplasty Versus Balloon Angioplasty - The LAVA Trial. *Circulation* 1996;94:I-435.
59. **Gregg W. Stone**, Tom J. Linnemeier, Fred G. St. Goar, Helen Sheehan and John Hodgson. Correlation of Angiographic and Ultrasound Measures in Patients Undergoing Coronary Stenting Vs. Balloon Angioplasty. *Circulation* 1996;94:I-261.
60. **Gregg W. Stone**, Tom Linnemeier, Axel Frey, Harald Mudra, Fred St. Goar, Helen Sheehan and John McB. Incidence and Implications of Coronary Dissection after PTCA Using Oversized Balloons with Intravascular Ultrasound Guidance - The CLOUT Trial. *Circulation* 1996;94:I-261.
61. **Gregg W. Stone**, Bruce Brodie, John Griffin, Costantino Costantini, Carlos Balestrini, Denise Jones, Marianne Graham, Cindy L. Grines. Primary Angioplasty in Patients with Prior Bypass Surgery. *Circulation* 1996;94:I-243.
62. **Gregg W. Stone**, William W. O'Neill, Denise Jones, Cindy L. Grines. The Central Unifying Concept of TIMI-3 Flow after Primary PTCA and Thrombolytic Therapy in Acute Myocardial Infarction. *Circulation* 1996;94:I-515.
63. **Gregg W. Stone**, Tom J. Linnemeier, Fred G. St. Goar, John Hodgson, Janice Coverdale, Paul Yock and Peter Fitzgerald. Defining the Relationship Between Stent Implantation Pressure and Optimal Expansion - Core Lab Analysis from the OSTI Trial. *Circulation* 1996;94:I-259.
64. Nobuyuki Komiyama, **Gregg W. Stone**, Edwin L. Alderman, Frederick St. Goar, Tom. J. Linnemeier, Paul G. Yock, Peter J. Fitzgerald. Relative stent expansion is dependent upon

- target segment calcification: An intravascular ultrasound assessment. *Circulation* 1996;94:I-262.
65. Linnemeier T, **Stone G**, Hodgson J, et al. OSTI: Optimal Stent Implantation Trial I. *The Journal of Endovascular Surgery* 1997;4:I-21.
  66. **Stone GW**. The PAMI Trials. *The Journal of Endovascular Surgery* 1997;4:I-37.
  67. **Gregg W. Stone**, Bruce Brodie, John Griffin, Fred St. Goar, Marie-Claude Morice, Costantino Costantini, Paul A. Overlie, Denise Jones, William W O'Neill, Cindy L. Grines. Safety and Feasibility of Primary Stenting in Acute Myocardial Infarction - In-hospital and 30 Day Results of the PAMI Stent Pilot Trial. *J Am Coll Cardiol* 1997;29:389A.
  68. **Gregg W. Stone**, Fred St. Goar, Peter Fitzgerald, Ed Alderman, Paul Yock, John McB. Hodgson, Tom Linnemeier. The Optimal Stent Implantation Trial - Final Core Lab Angiographic and Ultrasound Analysis. *J Am Coll Cardiol* 1997;29:369A.
  69. **Gregg W. Stone**, Fred St. Goar, Tom Linnemeier, John McB. Hodgson, Paul Yock, Ed Alderman, Peter Fitzgerald. Clinical, Angiographic and Ultrasound Predictors of Stent Expansion After High Pressure Implantation. *J Am Coll Cardiol* 1997;29:275A.
  70. Grines, CL, Morice MC, Mattos L, **Stone GW**, O'Neill WW, Firth B, Fernandez EG, Kiemenev F, Jones D, Serruys P. A prospective, multicenter trial using the JJIS heparin-coated stent for reperfusion of acute myocardial infarction. *J Am Coll Cardiol* 1997;29:389A.
  71. Frey AW, Muller C, Mudra H, Klauss V, Roskamm H, Linnemeier T, Hodgson JM, **Stone GW**. Verbesserung der Ergebnisse nach angiographisch erfolgreicher PTCA durch mit intrakoronarem Ultraschall (ICUS) bestimenten Dilatations-ballons: Die multizentrische CLOUT Pilot Studie. Presented at the 63rd Annual Scientific Sessions of the German Heart Association, Mannheim, Germany, April 4th, 1997.
  72. Abizaid AS, **Stone GW**, Rothbaum DA, Brodie BR, Griffin JJ, Shimshak T, Costantini C, St. Goar FG, Overlie PA, McDonnell J, Jones D. Quantitative angiographic outcomes for stenting in acute myocardial infarction: core lab analysis from the PAMI Stent Pilot Trial. *Circulation* 1997;96:I-237.
  73. Oshima A, Handen CE, Alderman E, Linnemeier TJ, **Stone GW**, Yock PY, Fitzgerald PJ. Inflow and outflow disease in stent reference segment: IVUS analysis of the second Optimal Stent Implantation (OSTI-2) trial. *Am J Cardiol* 1997;78:57S.
  74. **Stone GW**, Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, Overlie PA, McDonnell J, Jones D, and Grines CL. Improved short-term outcomes of primary stenting compared to primary angioplasty in acute myocardial infarction - the PAMI stent pilot trial. *Circulation* 1997;96:I-594.
  75. **Stone GW**, Brodie BR, Griffin JJ, Morice MC, Costantini C, St. Goar FG, Overlie PA, McDonnell J, Jones D, and Grines CL. Is stenting the treatment of choice for thrombus containing lesions? core lab analysis from the PAMI Stent Pilot Trial. *Circulation* 1997;96:I-397.

76. Tilli FV, O'Neill WW, Marsalese DL, Brodie BR, Griffin JJ, Donohue B, **Stone GW**, Jones DE, Graham M, Grines LL, Grines CL. Pre-hospital delay accounts for increased time to treatment in women undergoing direct angioplasty for acute myocardial infarction. *Circulation* 1997;96:I-398.
77. **Stone GW**, Kiesz RS, Oshima A, Alderman E, Bailey S, Sanborn T, Roberts DK, Yock P, St. Goar FG, and Linnemeier TJ. Improved Procedural Results of Coronary Stenting with Focal Balloon "Overexpansion" - The OSTI-2A Trial. *Circulation* 1997;96:I-402.
78. Grines C, Cox E, Fernandez EG, Katz S, Giambartolomei, **Stone GW**, Mattos L, Madonna O, Eijgelshoven M, Jones D, O'Neill WW, Morice MC. Stent PAMI: A multicenter randomized trial of heparin coated stenting for AMI vs. primary PTCA for AMI. Late Breaking Trials II, The 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.
79. **Stone GW**, Brodie B, Griffin J, et al. In-hospital and late outcomes following primary stenting in acute myocardial infarction - comparison with primary PTCA. *J Am Coll Cardiol* 1998;31:270A.
80. **Stone GW**, Brodie B, Griffin J, et al. Adverse outcomes prior to hospital discharge after primary stenting for acute myocardial infarction are often predictable, and related to correctable technical factors. *J Am Coll Cardiol* 1998;31:271A.
81. **Stone GW**, Linnemeier T, St. Goar F, et al. Incremental value of IVUS after coronary stenting when a "perfect" angiographic result is obtained. *J Am Coll Cardiol* 1998;31:103A.
82. Griffin J, Brodie B, Morice MC, Costantini C, Popma JJ, Overlie PA, St. Goar F, Kenerson JG, Merritt A., Theodosiou S, McDonnell JA, O'Neill WW, Grines CL, **Stone GW**. Incidence and predictors of 6 month angiographic restenosis and reocclusion after primary infarct stenting - core lab analysis from the PAMI Stent Pilot Study. *J Am Coll Cardiol* 1998;31:210A.
83. **Stone GW**, Kiesz S, Bailey S, et al. Improved procedural results of coronary stenting with focal balloon "overexpansion" - final core lab analysis from the prospective, multicenter OSTI-2A trial. *J Am Coll Cardiol* 1998;31:16A.
84. **Stone GW**, O'Keefe J, Brodie B, O'Neill WW, Grines CL. Lack of relationship between the time to reperfusion and short-term mortality after primary infarct angioplasty. *J Am Coll Cardiol* 1998;31:271A.
85. Tilli F, Grines C, **Stone GW**, et al. Is operator interpretation or core lab analysis more accurate in predicting in-hospital adverse events after primary PTCA? *J Am Coll Cardiol* 1998;31:417A.
86. **Stone GW**, Morice MC, Costantini C, et al. Clinical and angiographic restenosis after primary stenting in acute myocardial infarction: Final results of the PAMI Stent Pilot Trial. *Eur Heart J* 1998;19:59.
87. Morice MC, Grines C, Cox D, Garcia Fernandez E, Katz S, Giambartolomei A, **Stone GW**, Mattos L, Griffin J, Brodie B, Kiemeneij F, Madonna O, Eijgelshoven M, Jones D, O'Neill WW. One month preliminary results of the PAMI trial. *Eur Heart J* 1998;19:239.

88. **Stone GW.** Beyond primary PTCA: stenting and abciximab in acute myocardial infarction. *J Endovasc Surg* 1998;5:1-32.
89. **Stone GW.** Improved short-term outcomes of primary stenting compared to primary angioplasty in acute myocardial infarction: the PAMI Stent Pilot Trial. *ACCEL* 30:2, February 1998.
90. **Stone GW, Bailey S, Roberts DK, et al.** Long-term results following "maximal stenting" using ultrasound guided balloon overexpansion - the Second Optimal Stent Implantation Study. *Circulation*: 1998;98:1-160.
91. **Stone GW, Brodie BR, Griffin J, et al.** Angiographic luminal "gain" occurs within the first 6 months after stenting thrombotic lesions in patients with acute myocardial infarction - a unique phenomenon. *Circulation*: 1998;98:1-295.
92. **Stone GW, Shawl FA, Taussig A, Power JA, Kosinski E, St. Goar FG.** Percutaneous myocardial laser revascularization in patients with class III-IV angina and lesions at high risk for restenosis - results of a phase I study as a preamble to a large, randomized trial. *Circulation*: 1998;98:1-557.
93. **Stone GW, Garcia E, Griffin J, et al.** Does stent implantation in acute myocardial infarction degrade TIMI flow and result in higher early mortality than PTCA? - The PAMI Stent Randomized Trial. *Circulation*: 1998;98:1-150.
94. **Stone GW, Brodie BR, Griffin J, et al.** Stenting of thrombotic lesions in acute myocardial infarction results in less late loss and greater freedom from restenosis than non-thrombotic lesions - core lab analysis from the PAMI Stent Pilot Trial. *Circulation*: 1998;98:1-152.
95. **Stone GW, Garcia E, Giambartolomei A, et al.** The powerful interaction between age and gender in determining short-term mortality after mechanical reperfusion therapy in acute myocardial infarction. Insights from the PAMI Stent Randomized Trial. *Circulation*: 1998;98:1-152.
96. **Stone GW, Garcia E, Brodie BR, et al.** By sealing dissection planes, primary stenting reduces ischemia driven target vessel revascularization at 30 days compared to primary PTCA - Analysis from the PAMI Stent Randomized Trial. *Circulation*: 1998;98:1-287.
97. Grines C, Cox D, Fernandez EG, **Stone G**, Mattos L, Katz S, Giambartolomei A, Brodie B, Donohue B, Griffin J, Madonna O, Eijgelshoven M, Graham M, O'Neill W, Morice MC. Stent PAMI: Final results of a multicenter randomized trial of heparin coated stenting vs. primary PTCA for AMI. *Circulation*: 1998;98:1-22.
98. Johnston JD, Wharton T, Turco M, Slota P, O'Neill WW, **Stone GW**, Brodie B, Grines LL, Graham M, Barsamian M, Grines CL. Primary PTCA is performed effectively and with less delay at community hospitals without surgical backup, compared to tertiary care centers. *Circulation*: 1998;98:1-770.
99. **Stone GW.** Is abciximab necessary with coronary stenting? *ACCEL* 30:4, April 1998.

100. Mattos L, Grines CL, Sousa JE, **Stone GW**, et al. Final procedural diameter stenosis and its influence on the 6 month outcome after primary PTCA: results from the Stent PAMI Trial. *J Am Coll Cardiol* 1999;33:92A.
101. Mattos L, Sousa JE, **Stone GW**, et al. Primary stenting versus PTCA in diabetic patients with acute myocardial infarction: six month results of the Stent PAMI Trial. *J Am Coll Cardiol* 1999;33:33A.
102. Grines CL, **Stone GW**, Cox DA, et al. Stent PAMI 6 month angiographic follow-up: incidence and predictors of reocclusion following primary PTCA and stenting. *J Am Coll Cardiol* 1999;33:397A.
103. Ahmed JM, Hong MK, Mehran R, Kent KM, Pichard AD, Satler LF, Greenberg A, Deforty D, Slack S, Wu H, **Stone GW**, Leon MB. Rescue ReoPro (Abciximab) does not improve peri-procedural outcomes in patients undergoing high risk angioplasty of degenerated saphenous vein grafts. *J Am Coll Cardiol* 1999;33:11A.
104. Gruberg L, Mehran R, Hong MK, Dangas G, Kornowski R, Laird JR, Peterson M, Satler LF, Pichard AD, Kent KM, **Stone GW**, Leon MB. Percutaneous revascularization of the internal mammary artery graft: in-hospital and long-term outcome. *J Am Coll Cardiol* 1999;33:51A.
105. Gruberg L, Mehran R, Hong MK, Lansky AJ, Pichard AD, Peterson M, Walters CT, Murphy M, Laird JR, Satler LF, Kent KM, **Stone GW**, Leon MB. Stents do not improve acute and long-term clinical outcomes in patients with chronic renal failure and coronary disease. *J Am Coll Cardiol* 1999;33:28A.
106. Hong MK, Mintz GS, Satler LF, Pappas CK, Pichard AD, Kent KM, Peterson M, Murphy M, **Stone GW**, Leon MB. Full lesion stent coverage reduces subsequent target lesion revascularization: an intravascular ultrasound study. *J Am Coll Cardiol* 1999;33:61A.
107. Lansky AJ, Mehran R, Popma JJ, Hanzel G, Kent KM, **Stone GW**, et al. Insulin treatment of diabetic women predicts a worse outcome after intracoronary stenting. Clinical results of 564 consecutive patients. *J Am Coll Cardiol* 1999;33:97A.
108. Lansky AJ, **Stone GW**, Mehran R, et al. Impact of baseline TIMI flow on outcomes after primary stenting versus primary PTCA in acute myocardial infarction. Results from PAMI Stent. *J Am Coll Cardiol* 1999;33:368A.
109. Mehran R, Dangas G, Mintz GS, Hong MK, Lansky AJ, Peterson M, Abizaid AS, Ahmed JM, Kornowski R, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Excimer laser vs. rotational atherectomy for the treatment of diffuse in-stent restenosis: acute and long-term results. *J Am Coll Cardiol* 1999;33:62A.
110. Mehran R, Kornowski R, Dangas G, Lansky AJ, Hong MK, Pichard AD, Laird JR, Satler LF, Kent KM, **Stone GW**, Leon MB. Multivessel stenting reduces in-hospital complication compared with repeat aortocoronary bypass surgery. *J Am Coll Cardiol* 1999;33:51A.
111. Mehran R, Pfister A, Corso P, Dullum M, Dangas G, Lansky AJ, Hong MK, Greenberg A, Deible R, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Minimally invasive direct



- coronary artery bypass (MIDCAB): have we reached the plateau of the learning curve? J Am Coll Cardiol 1999;33:551A.
112. Mehran R, Mintz GS, Dangas G, Hong MK, Peterson M, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, **Stone GW**, Leon MB. One year follow-up after intravascular ultrasound guided coronary stenting of 2075 lesions. J Am Coll Cardiol 1999;33:74A.
  113. Mehran R, Lansky AJ, Hong MK, Dangas G, Kornowski R, Peterson M, Waksman R, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Percutaneous revascularization of patients with prior coronary bypass surgery: saphenous vein graft or native coronary stenting? J Am Coll Cardiol 1999;33:51A.
  114. Mehran R, Lansky AJ, Dangas G, Hanzel G, Ahmed JM, Byrne M, Peterson M, **Stone GW**, Kent KM, Pichard AD, Satler LF, Leon MB. The impact of diabetes on the outcomes after treatment if in stent restenosis. J Am Coll Cardiol 1999;33:98A.
  115. Mehran R, Dangas G, Mintz GS, Hong MK, Lansky AJ, Peterson M, Hanzel G, Laroche A, Slack S, Laird JR, Pichard AD, Kent KM, Satler LF, **Stone GW**, Leon MB. PTCA alone versus stent alone therapy for focal in-stent restenosis: acute and long-term results. J Am Coll Cardiol 1999;33:26A.
  116. Mehran R, Dangas G, Mintz GS, Waksman R, Hong MK, Abizaid A, Abizaid AS, Kornowski R, Lansky AJ, Laird JR, Kent KM, Pichard AD, Satler LF, **Stone GW**, Leon MB. In-stent restenosis: "the great equalizer" – disappointing clinical outcomes with ALL interventional strategies. J Am Coll Cardiol 1999;33:63A.
  117. Peterson M, Carter A, Mehran R, Kornowski R, Golden B, Negotia MA, Pichard AD, Satler LF, Kent KM, Mintz GS, Lansky AJ, **Stone GW**, Leon MB. Can debulking prior to stenting be justified as standard treatment for right coronary artery ostial lesions? J Am Coll Cardiol 1999;33:27A.
  118. Brodie BR, **Stone GW**, Morice MC, et al. Importance of time to reperfusion on outcomes after primary PTCA for acute myocardial infarction: results from Stent PAMI. J Am Coll Cardiol 1999;33:353A.
  119. Cox DA, **Stone GW**, Grines CL, et al. Do proximal LAD lesions in acute myocardial infarction benefit from stenting? The PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:353A.
  120. Cox DA, **Stone GW**, Grines CL, et al. Predictors of minimal lumen diameter after stenting in acute myocardial infarction: Insights from the PAMI Stent Trial. J Am Coll Cardiol 1999;33:368A.
  121. Cox DA, **Stone GW**, Niess GS, et al. Does "stent-like" primary PTCA in acute myocardial infarction confer long-term freedom from restenosis similar to primary stenting? Analysis from the PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:382A.
  122. Flachskampf FA, Ziada KM, Pieper M, Crowe T, Nissen SE, Tuczu M, Brodie BR, Griffin J, Feit F, Costantini C, Mintz GS, Grines CL, **Stone GW**. Do interventionalists undersize devices during acute infarct intervention? Comparison of angiographic and intravascular measures from the PAMI Stent Randomized Trial. J Am Coll Cardiol 1999;33:54A.

123. **Stone GW**, Morice MC, Lansky AJ, et al. Routine stent implantation reduces restenosis after primary angioplasty in acute myocardial infarction – results from the PAMI Stent Randomized Trial. *J Am Coll Cardiol* 1999;33:361A.
124. **Stone GW**, Morice MC, Cox D, et al. Predictors of six month event-free survival after mechanical reperfusion in acute myocardial infarction - the PAMI Stent Randomized Trial. *J Am Coll Cardiol* 1999;33:379A.
125. **Stone GW**, Marcovitz P, Lansky AJ, et al. Differential effects of stenting and angioplasty in women versus men undergoing a primary mechanical reperfusion strategy in acute myocardial infarction - the PAMI Stent Randomized Trial. *J Am Coll Cardiol* 1999;33:357A.
126. **Stone GW**, Mehran R, Lansky AJ, et al. Long-term influence of CPK-MB elevation on mortality after percutaneous intervention – analysis of 7359 patients. *J Am Coll Cardiol* 1999;33:80A.
127. **Stone GW**, Mehran R, Lansky AJ, et al. What is the clinical significance of an elevated CPK-MB band fraction after percutaneous intervention if the total CPK is normal? *J Am Coll Cardiol* 1999;33:80A.
128. **Stone GW**, Morice MC, Cox D, et al. Outcomes of bail-out stenting after failed primary angioplasty in acute myocardial infarction – analysis from the PAMI Stent Randomized Trial. *J Am Coll Cardiol* 1999;33:361A.
129. **Stone GW**, Frey A, Linnemeier T, et al. 2.5 year follow-up of the CLOUT study – long-term implications for an aggressive IVUS guided balloon angioplasty strategy. *J Am Coll Cardiol* 1999;33:81A.
130. O'Neill WW, **Stone GW**, Morice MC, et al. Ventricular function after mechanical reperfusion therapy: observations from the Stent-PAMI Trial. *J Am Coll Cardiol* 1999;33:398A.
131. Bailey SR, Kiesz RS, Linnemeier TJ, Cooper-Reade GM, St. Goar FG, **Stone GW**. Stent implantation in small vessels using ultrasound guided implantation: comparison of late outcome of LAD and non-LAD lesions. *J Am Coll Cardiol* 1999;33:68A.
132. Hasnie AMA, Grines CL, Boura JA, Grines LL, O'Neill WW, Garcia E, Brodie B, **Stone GW**. Mechanisms of failed primary PTCA for acute MI. Submitted to the 22<sup>nd</sup> annual scientific sessions of the Society for Cardiac Angiography and Interventions, May 1999.
133. DeGeare VS, O'Neill WW, Grines L, **Stone GW**, Brodie BR, Cox DA, Garcia E, Wharton T, Boura JA, Grines CL. Angiographic and clinical predictors of increased in-hospital mortality in elderly patients with acute myocardial infarction. Submitted to the 22<sup>nd</sup> annual scientific sessions of the Society for Cardiac Angiography and Interventions, May 1999.
134. Morice MC, Grines CL, Eijgelshoven M, van Es GA, **Stone GW**, Mattos L, Garcia E, Madonna O, Cox D, Kiemeny F, Van der Giessen W. Twelve-month follow-up of the Stent PAMI trial. Submitted to the 1999 Annual Scientific Sessions of the European Society of Cardiology.

135. Morice MC, Rutsch W, Mattos L, **Stone GW**, Eijgelshoven M, Cox D, Garcia E, Kiemeney F, Pieper M, Grines CL. Characteristics and in-hospital outcome of patients included in the registry of the Stent PAMI trial. Submitted to the 1999 Annual Scientific Sessions of the European Society of Cardiology.
136. Robert J. Freedman Jr, Michael F. Miller, E. Magnus Ohman, Debra L. Joseph, Robert R. Cuffey Jr., Marc Cohen, Geoffrey M. Graeber, James J. Ferguson, **Gregg W. Stone**. Proactive vs. Reactive Use of IABP Support in High Risk Cases. Am J Cardiol 1999; 84(supp1 6A): 125P.
137. C. Costantini, S. Tarbine, E. Sousa, A. Sampaolesi, S. Silva, C. Gosttchall, A. Rodriguez, R. De Barros, M. Martinez Rios, G. Bonzon, E. Ribeiro, **G. Stone**, on behalf of SOLACI Investigators. Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) Pilot Study--Preliminary Results. Am J Cardiol 1999; 84(supp1 6A): 101P.
138. Luis Gruberg, George D. Dangas, Roxana Mehran, Lucy B. Van Voorhees, Chester Clark, **Gregg W. Stone**, Mun K. Hong, Gary S. Mintz, Ran Kornowski, Alexandra J. Lansky, Kenneth M. Kent, Ron Waksman, Augusto D. Pichard, Lowell F. Satler, Martin B. Leon. Outcome of Critically Ill Patients With Acute Renal Failure Requiring Hemodialysis After Percutaneous Coronary Interventions Am J Cardiol 1999; 84(supp1 6A): 71P.
139. Luis Gruberg, George Dangas, Roxana Mehran, **Gregg W. Stone**, Mun K. Hong, Gary S. Mintz, Ron Waksman, Ran Kornowski, Alexandra J. Lansky, Javed Ahmed, Kenneth M. Kent, Augusto D. Pichard, Lowell F. Satler, Martin B. Leon. Stenting of the Internal Mammary Artery Graft: Angiographic Characteristics, In-hospital and Long-term Outcomes. Am J Cardiol 1999; 84(supp1 6A): 48P.
140. Shmuel Fuchs, Ran Kornowski, Roxana Mehran, Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Mun K. Hong, Steve T. Slack, **Gregg W. Stone**, Martin B. Leon. Cardiac Troponin I Levels and Clinical Outcomes in Patients With Acute Coronary Syndromes: The Potential Role of Early Percutaneous Coronary Interventions. Am J Cardiol 1999; 84(supp1 6A): 100P.
141. AMA Hasnie, CL Grines, JA Boura, LL Grines, WW O'Neill, E. Garcia, B. Brodie, **G. Stone**. Mechanisms of Failed Primary PTCA for Acute MI. Am J Cardiol 1999; 84(supp1 6A): 33P.
142. Shmuel Fuchs, Ran Kornowski, Roxana Mehran, Alexandra J. Lansky, Lowell F. Satler, Augusto D. Pichard, **Gregg W. Stone**, Martin B. Leon. Prognostic Value of Cardiac Troponin I Levels Following Percutaneous Coronary Interventions. Am J Cardiol 1999; 84(supp1 6A): 33P.
143. J. Gary Gustafson, Cindy L. Grines, David A. Cox, Elogio Garcia, **Gregg W. Stone**, Mariann Graham, Judith A. Boura, Lorelei L. Grines, William W. O'Neill, Marie Claude-Morice. Spontaneous Patency in the Early Hours of AMI: Incidence, Predictors and Prognostic Implications. Am J Cardiol 1999; 84(supp1 6A): 103P.
144. Luis Gruberg, George Dangas, Roxana Mehran, **Gregg W. Stone**, Mun K. Hong, Gary S. Mintz, Ron Waksman, Ran Kornowski, Alexandra J. Lansky, Kenneth M. Kent, Augusto D. Pichard, Lowell F. Satler, Martin B. Leon. Should Balloon Angioplasty be the Standard of Care for Internal Mammary Artery Percutaneous Revascularization? Am J Cardiol 1999; 84(supp1 6A): 47P.

145. Shmuel Fuchs, Ran Kornowski, Javed M. Ahmed, Alexandra Lansky, Roxana Mehran, Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Chester E. Clark, **Gregg W. Stone**, Martin B. Leon Percutaneous Coronary Interventions in Atherosclerotic Coronary Artery Aneurysms: Short and Long-term Clinical Outcomes. *Am J Cardiol* 1999; 84(supp1 6A): 80P.
146. Waksman R, White LR, Chan RC, Mehran R, Bhargava B, Lansky AJ, Pichard AD, **Stone GW**, Leon MB. Intracoronary beta radiation therapy for patients with in-stent restenosis: Beat WRIST 6 month clinical and angiographic results. *Circulation* 1999;100(18):I-75.
147. Waksman R, Mehran R, Bhargava B, Chan RC, Lansky AJ, Gierlach LM, **Stone GW**, Leon MB. Recurrent restenosis after "failed" intra-coronary radiation therapy: angiographic patterns and predictors. *Circulation* 1999;100(18):I-222.
148. Dangas G, Mehran R, Peterson M, Duncan C, Paliou MN, Purush A, Hong MK, **Stone GW**. Combination antiplatelet therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after native coronary stent implantation. *Circulation* 1999;100(18):I-379.
149. Waksman R, Bhargava B, Chan RC, Mehran R, Gierlach LM, Gruberg L, **Stone GW**, Leon MB. Late total occlusions following intracoronary radiation therapy for patients with in-stent restenosis. *Circulation* 1999;100(18):I-222.
150. **Stone GW**, Castner CM, Cuffey RR, et al. Contemporary patterns of utilization and outcomes of intraaortic balloon counterpulsation in acute myocardial infarction: the Benchmark Registry. *Circulation* 1999;100(18):I-809.
151. **Stone GW**, Dangas G, Peterson M, et al. Prognostic value of peri-procedural CK-MB elevation after percutaneous intervention in patients with and without Q-wave infarction. *Circulation* 1999;100(18):I-85.
152. Cohen DR, **Stone GW**, Cox D, et al. Cost-effectiveness analysis of primary stenting in the PAMI Stent randomized trial. *Circulation* 1999;100(18):I-87.
153. Waksman R, Mehran R, Chan RC, Murphy M, **Stone GW**, Duncan C, et al. One year follow-up after intracoronary gamma radiation therapy for in-stent restenosis: results from a randomized clinical trial. *Circulation* 1999;100(18):I-154.
154. **Stone GW**. The CADILLAC Trial. Late Breaking Trials. The 72<sup>nd</sup> Annual Scientific Sessions of the American Heart Association, November 8<sup>th</sup>, 1999.
155. Mattos LA, Grines CL, Sousa JE, Morice MC, Garcia E, **Stone GW**, Boura JA, Cox DA, O'Neill WW, Eigelshoven M, Brodie BR, Graham M. The safety of routine ticlopidine administration after primary coronary interventions in acute myocardial infarction: a serial hematologic analysis from the STENT PAMI trial. *Circulation* 1999;100(18):I-86.
156. Mattos LA, Grines CL, Sousa JE, **Stone GW**, Morice MC, Garcia E, Cox DA, O'Neill WW, Firth B, Boura JA, Graham M, Eigelshoven M. Influence of maximal inflation pressure in acute myocardial infarction: 30 day and 6 month outcomes from the STENT PAMI trial. *Circulation* 1999;100(18):I-856.

157. Fuchs S, Kornowski R, Satler LF, Pichard AD, Kent KM, **Stone GW**, Leon MB. Cardiac troponin I levels and clinical outcomes in patients with acute coronary syndromes: The role of early percutaneous revascularization. *Int J Cardiovasc Intervent* 1999;2(2):48.
158. Fuchs S, Kornowski R, Mehran R, Lansky AJ, Satler LF, Pichard AD, **Stone GW**, Leon MB. Prognostic value of cardiac troponin I levels following catheter based coronary interventions. *Int J Cardiovasc Intervent* 1999;2(2):7.
159. Ahmed JA, Mehran R, Dangas G, Hong MK, Negoita M, Lansky AJ, Faraj H, Hashmi N, Okubagzi P, Modi N, Astatkie M, Kent KM, Weissman NJ, Curry B, Kupper F, Satler LF, Pichard AD, **Stone GW**, Leon MB. Predictors of late clinical outcomes in patients with unstable angina undergoing percutaneous coronary intervention. *J Am Coll Cardiol* 2000;35(2):18A.
160. Lansky AJ, **Stone GW**, Grube E, et al. A multicenter registry of the JoSTENT PTFE Stent Graft for the treatment of arterial perforations complicating percutaneous coronary interventions. *J Am Coll Cardiol* 2000;35(2):26A.
161. **Stone GW**, Cox D, Lowe RI, Matthews R, Leon MB. First United States experience with a novel atherectomy and thrombectomy device in thrombotic lesions in native coronary arteries and saphenous vein grafts. *J Am Coll Cardiol* 2000;35(2):40A.
162. **Stone GW**, Bailey S, Roberts DK, Linnemeier TJ, St. Goar FG, Sanborn T, Fitzgerald PJ, Alderman EL, Kiesz S. A Prospective, Multicenter Trial of the Safety, Feasibility, and Efficacy of Ultrasound Guided "Maximal" Stenting to the Media-Adventitial Border - Final Late Clinical and Angiographic Results from the OSTI-2 Study. *J Am Coll Cardiol* 2000;35(2):46A.
163. Gruberg L, Mehran R, Dangas G, **Stone GW**, Hong MK, Mintz GS, Waksman R, Kornowski R, Lansky AJ, Kent KM, Satler LF, Pichard AD, Leon MB. Acute renal failure requiring hemodialysis after percutaneous coronary intervention: In-hospital and one-year outcomes. *J Am Coll Cardiol* 2000;35(2):53A.
164. Gruberg L, Mehran R, Dangas G, Hong MK, Mintz GS, Waksman R, Kornowski R, Lansky AJ, Kent KM, Satler LF, Pichard AD, **Stone GW**, Leon MB. Revascularization of the internal mammary artery graft: in-hospital and one year outcomes. *J Am Coll Cardiol* 2000;35(2):54A.
165. Grines LL, Cox DA, Garcia E, Johnston JJ, Turco MA, Wharton TP, Griffin JJ, McGarvey J, Shadlinger D, Graham M, Boura JA, O'Neill WW, **Stone GW**, Grines CL. Divergent effects of "directional" versus "mandated" stenting on acute myocardial infarction survival in women. *J Am Coll Cardiol* 2000;35(2):56A.
166. Mattos L, Grines CL, Sousa E, **Stone GW**, et al. One year follow-up after primary coronary intervention for acute myocardial infarction in diabetic patients: Stent PAMI Trial results. *J Am Coll Cardiol* 2000;35(2):72A.
167. Mehran R, Dangas G, Gruberg L, Lansky AJ, Okubagzi P, Astatkie M, Purush A, Desai K, Kupper F, Faraj H, Kent KM, **Stone GW**, Leon MB. The detrimental effect of chronic renal insufficiency and diabetes mellitus on late prognosis after percutaneous coronary interventions. *J Am Coll Cardiol* 2000;35(2):73A.

168. Fuchs S, Kornowski R, Mehran R, Satler LF, Hong MK, Slack S, **Stone GW**, Leon MB. The deleterious prognostic impact of cardiac troponin I re-elevation following percutaneous coronary interventions in patients with acute coronary syndromes. *J Am Coll Cardiol* 2000;35(2):75A.
169. Kornowski R, Fuchs S, Mehran R, Satler LF, Pichard AD, Kent KM, Slack S, Hong MK, **Stone GW**, Leon MB. Prognostic value of recurrent episodes of CK-MB elevation following repeated catheter-based coronary interventions. *J Am Coll Cardiol* 2000;35(2):75A.
170. Mehran R, Pfister A, Dangas G, Dullum MKC, Peterson MA, Hashmi N, Stamou SC, Deible R, Purush A, **Stone GW**, Leon MB, Corso PJ. Acute and long-term outcomes of minimally invasive direct coronary artery bypass (MIDCAB) surgery. A comparison to single vessel stenting of the left anterior descending artery. *J Am Coll Cardiol* 2000;35(2):354A.
171. Cox DA, **Stone GW**, Brodie BR, et al. Stent PAMI: Are excellent outcomes achieved only be experienced sites? *J Am Coll Cardiol* 2000;35(2):363A.
172. **Stone GW**, Cox DA, Garcia E, et al. Relative prognostic importance of preserved antegrade coronary blood flow before compared to after angioplasty in patients undergoing primary PTCA. *J Am Coll Cardiol* 2000;35(2):363A.
173. Grines CL, Cox DA, **Stone GW**, et al. Stent PAMI: 12 month results and predictors of mortality. *J Am Coll Cardiol* 2000;35(2):402A.
174. **Stone GW**, Lansky AJ, Mehran R, et al. Beyond TIMI-3 flow: The importance of restored myocardial perfusion for survival in high risk patients undergoing primary or rescue PTCA. *J Am Coll Cardiol* 2000;35(2):403A.
175. Cox DA, **Stone GW**, Brodie BR, et al. Do proximal RCA lesions in acute MI benefit from stenting?: The Stent PAMI randomized trial. *J Am Coll Cardiol* 2000;35(2):403A.
176. Mehran R, Dangas G, Gruberg L, Lansky AJ, Okubagzi P, Astatkie M, Purush A, Desai K, Kupper F, Faraj H, Kent K, **Stone GW**, et al. Chronic renal insufficiency and diabetes mellitus have an additive adverse effect on late clinical outcome after percutaneous coronary revascularization. *J Inv Cardiol* 2000;12(5):253.
177. J Ahmed, GD Dangas, R Mehran, MK Hong, GS Mintz, AD Pichard, LF Satler, KM Kent, **GW Stone**, M.B. Leon. Clinical, procedural, angiographic and intravascular ultrasound predictors of late cardiac events in patients with unstable angina undegoing percutaneous interventions. *Eur Heart J* 2000;21:168.
178. J Ahmed, GD Dangas, R Mehran, MK Hong, GS Mintz, AD Pichard, LF Satler, KM Kent, **GW Stone**, M.B. Leon. Predictive factors of target lesion revascularisation and late cardiac events after stent implantation in saphenous vein grafts. *Eur Heart J* 2000;21:637.
179. Mehran R, Dangas G, Gruberg L, A. Lansky AJ, Okubagzi P, Astakie M, Purush A, Desai K, Kupper F, Faraj H, Kent KM, **Stone GW**, Leon MB. Chronic renal insufficiency and diabetes mellitus have an additive adverse effect of late clinical outcomes after percutaneous coronary revascularization. *J Inv Cardiol* 2000;12:253.

180. Gruberg L, Dangas G, Mehran R, Waksman R, Mintz GS, Satler L, Laird J, Astakie M, Santiago M, Brahimi AK, **Stone GW**, Leon MB. The impact of further renal impact function deterioration after percutaneous coronary intervention in patients with chronic renal insufficiency. *J Inv Cardiol* 2000;12:253.
181. Gruberg L, Dangas G, Mehran R, Lansky AJ, Satler L, Astakie M, Santiago M, Bui A, Brahimi AK, **Stone GW**, Leon MB. Short and long term outcomes after stenting of coronary arteries in patients with chronic renal failure. *J Inv Cardiol* 2000;12:253.
182. Gruberg L, Dangas G, Mehran R, Lansky AJ, Astakie M, Santiago M, Bui A, Brahimi AK, Satler L, **Stone GW**, Leon MB. Short and long term clinical outcomes after percutaneous revascularization of the internal mammary artery graft. *J Inv Cardiol* 2000;12:256.
183. Mehran R, Dangas G, Pfister A, **Stone GW**, Leon MB, Corso PJ. Minimally invasive direct coronary artery bypass (MIDCAB) surgery versus single-vessel stenting of the left anterior descending artery. *J Inv Cardiol* 2000;12:265.
184. Dangas G, Mehran R, Lansky AJ, Faraj H, Negoita M, Astakie M, Santiago M, Pichard AD, **Stone GW**, Leon MB. Arteriotomy closure devices versus manual compression after percutaneous coronary intervention: Is there a difference in vascular complications? *J Inv Cardiol* 2000;12:267.
185. Mattos LA, Grines CL, Cox D, Sousa JE, Costantini C, Stone G, Morice MC, O'Neill W, Garcia E, Boura J. A comparative analysis of primary stenting and optimal balloon coronary angioplasty in acute myocardial infarction. Six month results from the STENT PAMI trial. *Arq Bras Cardiol* 2000;75:499-514.
186. Dangas G, Laird JR, Mehran R, Pappas CK, Astakie M, Bui A, Santiago M, Lansky AJ, **Stone GW**, Leon MB. Impact of baseline renal insufficiency in the one-year clinical outcome following renal artery stenting in patients with uncontrolled hypertension. *J Inv Cardiol* 2000;12:268.
187. Ahmed JM, Dangas G, Lansky AJ, Mehran R, Hong MK, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Impact of gender on immediate and late clinical outcomes after stent implantation in saphenous vein grafts. *J Inv Cardiol* 2000;12:270.
188. Ahmed JM, Dangas G, Mehran R, Hong MK, Astakie M, Mintz GS, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. "Rescue" abciximab therapy does not improve periprocedural complications in patients undergoing percutaneous intervention of degenerated saphenous vein grafts. *J Inv Cardiol* 2000;12:270.
189. Ahmed JM, Hong MK, Mehran R, Dangas G, Pappas C, Kent KM, Pichard AD, Satler LF, Mintz GS, Greenberg A, Slack S, **Stone GW**, Leon MB. Effect of diabetes after stent implantation in saphenous vein grafts: immediate and late clinical outcomes. *J Inv Cardiol* 2000;12:270.
190. Ahmed JM, Dangas G, Mehran R, Hong MK, Mintz GS, Pappas C, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Clinical, angiographic and intravascular ultrasound predictors of target lesion revascularization and late cardiac events following stent implantation in saphenous vein grafts. *J Inv Cardiol* 2000;12:271.

191. Serruys P, Grines C, **Stone G**, Garcia E, Kiemeny F, Morice M, Sousa J, Hamm C, Costantini C, Probst P, Rutsch W, Penn I, Fernandez-Aviles F, Vandormael M, Bartorelli A, Bilodeau L, Eijgelshoven M. Stent implantation in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting. *Int J Cardiovasc Intervent* 1998;1:19-27.
192. Ahmed JM, Hong MK, Mehran R, Larrain G, Kent K, Pichard AD, Satler LF, Mintz GS, **Stone GW**, Leon MB. Debulking plus stenting versus stenting alone for aorto-ostial saphenous vein graft lesions: procedural results and late clinical outcomes. *J Inv Cardiol* 2000;12:271.
193. Ahmed JM, Dangas G, Mehran R, Hong MK, Mintz GS, Pichard AD, Satler LF, Kent KM, **Stone GW**, Leon MB. Predictors of target lesion revascularization and late cardiac events in patients with unstable angina undergoing percutaneous coronary intervention. *J Inv Cardiol* 2000;12:271.
194. M. Adamian, Y. Kobayashi, G. Dangas, A. Lansky, G. New, I. Moussa, **G. Stone**, M. Leon, J. Moses. Elective Versus "Rescue" Abciximab Administration in Percutaneous Coronary Interventions. *Am J Cardiol* 2000; 86(supp1 8A): 78i.
195. M. Adamian, A. Lansky, R. Mehran, A.S. Abizaid, A. Abizaid, G. Dangas, **G. Stone**, J. Moses, M. Leon. "Rescue" Administration of Platelet GP IIb/IIIa Inhibitors During Percutaneous Coronary Interventions: Are There Any Gender Differences in Outcome? *Am J Cardiol* 2000; 86(supp1 8A): 90i.
196. M. Adamian, G. Dangas, R. Mehran, A. Abizaid, A.S. Abizaid, L. Gruberg, A. Lansky, **G. Stone**, J. Moses, M. Leon. One-Year Clinical Outcome in Diabetic Patients with Single-Vessel Versus Multivessel Native Coronary Stenting. *Am J Cardiol* 2000; 86(supp1 8A): 90i.
197. M. Adamian, R. Mehran, Y. Kobayashi, G. Dangas, M. Collins, **G. Stone**, M. Leon, A. Colombo, J. Moses. Recurrence After Treatment of In-Stent Restenosis In Large Vessels: Impact of Diabetes Mellitus. *Am J Cardiol* 2000; 86(supp1 8A): 125i.
198. M. Adamian, A. Abizaid, A.S. Abizaid, R. Mehran, G. Dangas, A. Lansky, **G. Stone**, J. Moses, M. Leon. Acute and Long-Term Outcome of Stenting Multiple Saphenous Vein Graft Lesions in Diabetics Versus Non-Diabetics. *Am J Cardiol* 2000; 86(supp1 8A): 90i.
199. Y. Kobayashi, I. Moussa, R. Mehran, A. Abizaid, M. Adamian, G. Mintz, G. Dangas, **G. Stone**, M. Leon, J. Moses. Are All "Small" Vessels Really Small? Implications for Stent Implantation. *Am J Cardiol* 2000; 86(supp1 8A): 23.
200. J. Ahmed, A. Pichard, M. Hong, A. Abizaid, A. S. Abizaid, G. Dangas, **G. Stone**, A. Lansky, R. Mehran, M. Leon. Direct Stenting in Saphenous Vein Grafts: Immediate and Late Clinical Outcome. *Am J Cardiol* 2000; 86(supp1 8A): 3i.
201. G. Dangas, D. J. D'Agate, R. Mehran, D. Feldman, A. J. Lansky, K. M. Kent, A. D. Pichard, L. F. Satler, H. Wu, **G.W. Stone**, M. B. Leon. Racial Differences in Clinical Outcome After Percutaneous Coronary Interventional Procedures. *Am J Cardiol* 2000; 86(supp1 8A): 49i.



202. Y. Kobayashi, R. Mehran, G. Dangas, I. Moussa, A. Abizaid, M. Adamian, **G. Stone**, M. Leon, J. Moses. Stent Implantation Compared to Balloon Angioplasty in Small Vessels. *Am J Cardiol* 2000; 86(suppl 1 8A): 91.
203. **Stone GW**, Rubinstein P, Schmidt D, et al. A Prospective, Randomized, Multicenter Trial of Percutaneous Transmyocardial Laser Revascularization in Patients with Non-Recanalizable Chronic Total Occlusions. *Circulation* 2000;18(suppl2):II-689.
204. Kobayashi Y, Dangas GD, Adamian MG, Faraj H, Glasser LA, **Stone GW**. Effect of Plaque Morphology Behind the Stent on Lumen Enlargement after Angioplasty for Treatment of In-Stent Restenosis: An Intravascular Ultrasound Study. *Circulation* 2000;18(suppl2):II-691.
205. **Stone GW**, Grines CL, Cox DA, et al. A Prospective, Randomized Trial Comparing Primary Balloon Angioplasty with or without Abciximab to Primary Stenting with or without Abciximab in Acute Myocardial Infarction - Primary Endpoint Analysis from the Cadillac Trial. *Circulation* 2000;18(suppl2):II-664.
206. Cohen M, Ferguson JJ, Freedman RJ, Miller MF, **Stone GW**. Comparison of Outcomes after 8 vs 9.5 French Size Intra-Aortic Balloon Counterpulsation Catheters Based on 7212 Patients in the Prospective Benchmark Registry. *Circulation* 2000;18(suppl2):II-854.
207. Dangas G, Feldman D, D'Agate DJ, Santiago M, Faraj H, Ahmed JM, Wu H, Slack ST, **Stone GW**. Impact of Race on Clinical Outcome after Percutaneous Coronary Interventions: Results in 6945 Patients. *Circulation* 2000;18(suppl2):II-479.
208. A Abizaid, G Dangas, AS Abizaid, R Mehran, M Negoita, C Ciora, R Narasimaiah, AD Pichard, AJ Lansky, **GW Stone**, GS Mintz, MB Leon. Intravascular Ultrasound Versus Angiography-Guided Stent Implantation: Acute and Long-Term Outcome in 2,883 Patients. *J Am Coll Cardiol* 2001;37:648A.
209. Y Kobayashi, G Dangas, R Mehran, I Moussa, G New, O Balan, GS Roubin, S Iyer, N Al-Mubarak, N Cohen, **GW Stone**, MB Leon. Stenting Elderly Patients in the New Millennium: Results in the Year 2000. *J Am Coll Cardiol* 2001;37:648A.
210. G Dangas, R Mehran, AJ Lansky, D Feldman, DJ D'Agate, LF Satler, KM Kent, AD Pichard, L Gruberg, JM Ahmed, **GW Stone**, MB Leon. Gender and Racial Differences in Clinical Outcomes After Percutaneous Coronary Interventions. *J Am Coll Cardiol* 2001;37:648A.
211. AS Abizaid, R Mehran, G Dangas, S Fuchs, A Abizaid, AJ Lansky, R Kornowski, R Waksman, AD Pichard, LF Satler, **GW Stone**, MB Leon. Positive Troponin-I Predicts Early and Late Mortality After Percutaneous Coronary Intervention. *J Am Coll Cardiol* 2001;37:648A.
212. A Abizaid, G Dangas, AS Abizaid, R Mehran, M Negoita, C Ciora, R Narasimaiah, AD Pichard, AJ Lansky, **GW Stone**, GS Mintz, MB Leon. Intravascular Ultrasound Versus Angiography-Guided Stent Implantation: Acute and Long-Term Outcome in 2,883 Patients. *J Am Coll Cardiol* 2001;37:648A.

213. AS Abizaid, R Mehran, G Dangas, S Fuchs, A Abizaid, AJ Lansky, R Kornowski, R Waksman, AD Pichard, LF Satler, **GW Stone**, MB Leon. Positive Troponin-I Predicts Early and Late Mortality After Percutaneous Coronary Intervention. *J Am Coll Cardiol* 2001;37:648A.
214. A Abizaid, AD Pichard, R Mehran, GS Mintz, L Gruberg, J Ahmed, **GW Stone**, AS Abizaid, LF Satler, KM Kent, G Dangas, MB Leon. Intravascular Ultrasound-Guided Provisional Stenting in Small Coronary Stenosis. *J Am Coll Cardiol* 2001;37:648A.
215. AJ Lansky, R Mehran, K Desai, C Constantini-Ortiz, B Proctor, T Conway, M Fahy G Dangas, **GW Stone**, R Waksman, JW Moses, MB Leon. Impact of Gamma and Beta Radiation vs. Placebo on the Changing Pattern of In-Stent Restenosis: A Matched Angiographic Analysis. *J Am Coll Cardiol* 2001;37:648A.
216. Y Kobayashi, R Mehran, G Dangas, I Moussa, AS Abizaid, A Abizaid, M Adamian, G New, AJ Lansky, GS Roubin, S Iyer, **GW Stone**, JW Moses, MB Leon. Effect of Coronary Plaque Calcification on the Final Lumen Dimensions After Stenting Without Rotational Atherectomy: An Intravascular Ultrasound Study *J Am Coll Cardiol* 2001;37:648A.
217. Y Kobayashi, I Moussa, R Mehran, G Dangas, AJ Lansky, G New, M Adamian, AS Abizaid, A Abizaid, S Iyer, G Roubin, **GW Stone**, MB Leon, JW Moses. Stenting Without Rotational Atherectomy in Lesions With at Least Moderate Calcification by IVUS but Insignificant Calcification Angiographically *J Am Coll Cardiol* 2001;37:648A.
218. A Abizaid, G Dangas, R Mehran, Y Kobayashi, AS Abizaid GS Mintz, MG Adamian, R Narasimaiah, C Ciora, AD Pichard, **GW Stone**, MB Leon. One-Year Results After Multivessel Stenting in Diabetic vs. Non-Diabetic Patients *J Am Coll Cardiol* 2001;37:648A.
219. A Abizaid, GS Mintz, AS Abizaid, R Mehran, G Dangas, AD Pichard, LF Satler, I Hijazi, R Narasimaiah, KM Kent, AJ Lansky, **GW Stone**, MB Leon. Intravascular Ultrasound Predictors of Late Recurrence After Stent Implantation in Small Coronary Arteries. *J Am Coll Cardiol* 2001;37:648A.
220. JE Tcheng, ME Effron, CL Grines, E Garcia, D Cox, T Stuckey, J Carroll, G Guagliumi, B Rutherford, P Essente, AJ Lansky, J Griffin, **GW Stone**. Abciximab Use During Percutaneous Intervention in Patients With Acute Myocardial Infarction Improves Early and Late Clinical Outcomes: Final Results of the CADILLAC Trial. *J Am Coll Cardiol* 2001;37:648A.
221. T Stuckey, CL Grines, D Cox, JE Tcheng, E Garcia, J Carroll, G Guagliumi, B Rutherford, P Essente, AJ Lansky, J Griffin, **GW Stone**. Does Stenting and Glycoprotein IIb/IIIa Receptor Blockade Improve the Prognosis of Diabetics Undergoing Primary Angioplasty in Acute Myocardial Infarction? The CADILLAC Trial. *J Am Coll Cardiol* 2001;37:648A.
222. CL Grines, E Garcia, JE Tcheng, T Stuckey, J Carroll, G Guagliumi, B Rutherford, P Essente, AJ Lansky, J Griffin, **GW Stone**. Effect of Stent Implantation and Glycoprotein IIb/IIIa Receptor Blockade on TIMI Flow and Mortality After Primary PTCA in Acute Myocardial Infarction: Final Results of the CADILLAC Trial. *J Am Coll Cardiol* 2001;37:648A.

223. **Stone GW**, Grines CL, Cox D, et al. A Prospective, Multicenter, International Randomized Trial Comparing Four Reperfusion Strategies in Acute Myocardial Infarction: Principal Report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. *J Am Coll Cardiol* 2001;37:648A.
224. MG Adamian, R Mehran, Y Kobayashi, G Dangas, I Moussa, M Collins, AJ Lansky, G New, **GW Stone**, MB Leon, A Colombo, JW Moses. Recurrence After Treatment of In-Stent Restenosis: Does Diabetes Impact Outcomes in Large Vessels? *J Am Coll Cardiol* 2001;37:648A.
225. C Costantini, S Tarbine, E Sousa, A Sampaolesi, S Silva, C Gosttchall, A Rodriguez, M Martinez Rios, G Bonzon, E Ribeiro, F Tortoledo, **GW Stone**. Impact of Operators Skill on Direct PTCA Outcomes in Acute Myocardial Infarction. A View of the SOLACI Registry. *J Am Coll Cardiol* 2001;37:648A.
226. Finta , Frumin H, Boura J, **Stone GW**, Brodie BR, Cox DA, Garcia E, Grines LL, Skelding KA, Grines CL. Are Risk Factors for Sudden Death in Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention Different? Analysis of the PAMI Database. *J Am Coll Cardiol* 2001;37:648A.
227. Ahmed JA, Dangas GD, Mehran R, Pichard AD, Satler LF, Kent KM, Hong MK, **Stone GW**, Martin B. Leon MB. Clinical, Angiographic, and Intravascular Ultrasound Predictors of Target Lesion Revascularization and Late Cardiac Events After Stent Implantation in Saphenous Vein Grafts. *J Am Coll Cardiol* 2001;37:648A.
228. Dixon SR, Grines CL, Cox DA, **Stone GW**, Garcia E, Mattos LA, Brodie BR, Alessandro Giambartolomei A, Grines LL,. Boura JA, O'Neill WW, Morice MC. Creatinine Clearance but Not Serum Creatinine on Admission Predicts Early and Late Death After Primary Angioplasty. *J Am Coll Cardiol* 2001;37:648A.
229. AS Abizaid, R Mehran, G Dangas, S Fuchs, A Abizaid, AJ Lansky, R Kornowski, R Waksman, AD Pichard, LF Satler, **GW Stone**, MB Leon. Positive Troponin-I Predicts Early and Late Mortality After Percutaneous Coronary Intervention. *J Am Coll Cardiol* 2001;37:648A.
230. A Abizaid, G Dangas, AS Abizaid, R Mehran, M Negoita, C Ciora, R Narasimaiah, AD Pichard, AJ Lansky, **GW Stone**, GS Mintz, MB Leon. Intravascular Ultrasound Versus Angiography-Guided Stent Implantation: Acute and Long-Term Outcome in 2,883 Patients. *J Am Coll Cardiol* 2001;37:648A.
231. AS Abizaid, R Mehran, G Dangas, S Fuchs, A Abizaid, AJ Lansky, R Kornowski, R Waksman, AD Pichard, LF Satler, **GW Stone**, MB Leon. Positive Troponin-I Predicts Early and Late Mortality After Percutaneous Coronary Intervention. *J Am Coll Cardiol* 2001;37:648A.
232. AS Abizaid, R Mehran, A Abizaid, G Dangas, , L Gruberg, AD Pichard, Waksman R, LF Satler, KM Kent, AJ Lansky, **GW Stone**, MB Leon. Intravascular Ultrasound-Guided Provisional Stenting in Small Coronary Stenosis. *J Am Coll Cardiol* 2001;37:648A. Staged Versus Non Staged Approach for Multivessel Percutaneous Coronary Interventions. *J Am Coll Cardiol* 2001;37:648A.

233. DJ Moliterno, HC Herrmann, ER Powers, CL Grines, SJ Yakubov, DJ Cohen, HG Parker, MJ Frey, **GW Stone**, Topol EJ, for the TARGET Investigators. The Effects of Tirofiban Versus Abciximab Among Diabetic Patients Undergoing Stent Placement: The TARGET Trial. *J Am Coll Cardiol* 2001;37:648A.
234. DA Cox, T Stuckey, R Low, L Cannon, R Iwaka, A Lansky, **GW Stone**. Adjunctive Thrombectomy Combined With Stenting for AMI: The Endicor X-SIZER AMI Registry. *J Am Coll Cardiol* 2001;37:648A.
235. DJ Cohen, C Grines, D Cox, T Stuckey, J Carroll, J Griffin, RS Cosgrove, L Githiora, RH Berezin, J Tcheng, **GW Stone**. Cost-Effectiveness of Abciximab and Stenting in Acute Myocardial Infarction: Results from the CADILLAC Trial. *J Am Coll Cardiol* 2001;37:648A.
236. Adamian MG, Lansky AJ, Feldman DN, Grayver E, Dangas G, Mehran R, Abizaid AS, New G, Abizaid A, Kobayashi Y, Moussa I, Collins M, **Stone GW**, Moses JW, Leon MB. Gender differences in outcome after platelet GP IIb/IIIa inhibitor administration during percutaneous coronary intervention. *J Inv Cardiol* 2001;13:475.
237. Adamian MG, Mehran R, Dangas G, Feldman DN, Grayver E, Kobayashi Y, New G, Moussa I, Satler L, Pichard AG, Kent KM, Lansky AJ, **Stone GW**, Leon MB. Elective versus “rescue” abciximab administration in percutaneous coronary interventions. *J Inv Cardiol* 2001;13:475.
238. Feldman DN, Dangas G, Mehran R, Aymong E, Grayver E, Kobayashi Y, Gruberg L, Kent KM, Pichard AG, Satler L, Lansky AJ, **Stone GW**, Leon MB. Impact of chronic renal failure on one-year clinical outcome in non-diabetic patients after PCI. *J Inv Cardiol* 2001;13:477.
239. Adamian MG, Dangas G, Mehran R, Feldman DN, Grayver E, Abizaid AS, Abizaid A, Pichard AG, Satler L, Kent KM, Lansky AJ, **Stone GW**, Leon MB. One-year clinical outcome in diabetic patients with single vs. multivessel native coronary stenting. *J Inv Cardiol* 2001;13:477.
240. Kobayashi Y, Mehran R, Dangas G, Feldman DN, Grayver E, Moussa I, Adamian MG, New G, Roubin GS, Iyer S, Al-Mubarak N, **Stone GW**, Leon MB, Moses JW. Stent implantation compared to balloon angioplasty in small vessels. *J Inv Cardiol* 2001;13:477.
241. Kobayashi Y, Dangas G, Feldman DN, Grayver E, Mehran R, Abizaid A, New G, Coehn N, Collins M, Adamian MG, Moussa I, **Stone GW**, Leon MB, Moses JW. Are all “small” vessels really small? Implications for optimal stent implantation. *J Inv Cardiol* 2001;13:481.
242. Feldman DN, Dangas G, Mehran R, Aymong E, Grayver E, Kobayashi Y, Gruberg L, Kent KM, Pichard AG, Satler L, Lansky AJ, **Stone GW**, Leon MB. Vascular complications in non-diabetic patients with chronic renal failure and dialysis after PCI. *J Inv Cardiol* 2001;13:483.
243. M. Adamian, M. Farkouh, R. Mehran, G. Dangas, I. Moussa, D. Feldman, D. Ashby, A. Reyes, I. Iakovou, Y. Adamyan, M. Mohamed, A.J. Lansky, **G.W. Stone**, J.W. Moses, M.B. Leon. Effect of Diabetes Mellitus on Immediate and 1-Year Outcome After Stenting in Acute Myocardial Infarction. *Am J Cardiol* 2001; 88(suppl 5A):214.

244. D.N. Feldman,, G. Dangas, R. Mehran, E. Aymong, E. Grayver<sup>1</sup>, Y. Kobayashi<sup>1</sup>, L. Gruberg, K.M. Kent, A.D. Pichard, L.F. Satler, A.J. Lansky, **G.W. Stone**, M.B. Leon. Impact of Dialysis and Chronic Renal Failure in Nondiabetic Patients on 1-Year Clinical Outcome after Percutaneous Coronary Intervention. *Am J Cardiol* 2001; 88(supp1 5A):122.
245. C.O. Costantini, K. Shirai, K. Desai, A. Lansky, N. Dave, R. Mehran, G. Dangas, M. Negoitia, Y. Iakovu, D. Ashby, M. El-Omar, M. Hirose, **G. Stone**, R. Waksman, M. Leon. Debulking Versus No Debulking Before Vascular Brachytherapy. *Am J Cardiol* 2001; 88(supp1 5A):176.
246. D. A. Cox, C. L. Grines, E. Garcia, T. Stuckey, J. E. Tcheng, G. Guagliumi, A. Johnson, J. Griffin, A. J. Lansky, **G. W. Stone**. Does "Optimal" Percutaneous Transluminal Coronary Angioplasty (PTCA) Provide Equivalent Outcomes in Acute Myocardial Infarction (AMI) Compared with Stenting? Insights from the CADILLAC Trial. *Am J Cardiol* 2001; 88(supp1 5A):80.
247. E. Garcia, D.A. Cox, C.L. Grines, T. Stuckey, J.E. Tcheng, B.D. Rutherford, J. McLean, J. Carroll, A.J. Lansky, **G.W. Stone**. Does Primary Stenting Benefit Proximal LAD Infarction? The CADILLAC Trial. *Am J Cardiol* 2001; 88(supp1 5A):196.
248. D.T. Ashby, M. El-Omar, Y. Iakovou, E. Aymong, M. Negoita, I. Hjazi, R. Mehran, G. Dangas, J. Moses, **G.W. Stone**, M.B. Leon. Effect of Body Mass Index on In-Hospital Outcomes After Percutaneous Coronary Interventions. *Am J Cardiol* 2001; 88(supp1 5A):126.
249. R.A. Corpus, J.A. Boura, **G.W. Stone**, B.R. Brodie, D.A. Cox, E. Garcia, L.L. Grines, W.W. O'Neill, C.L. Grines. Outcome After Acute Myocardial Infarction in Young Patients: Analysis of the Percutaneous Intervention for Acute Myocardial Infarction (PAMI) Database. *Am J Cardiol* 2001; 88(supp1 5A):221.
250. G. Guagliumi, D.A. Cox, C.L. Grines, E. Garcia, T. Stuckey, J.E. Tcheng, J. Pasquini, J. Carroll, A.J. Lansky, **G.W. Stone**. Outcomes in Elderly Patients Undergoing Primary Coronary Intervention for AMI: Insights from the CADILLAC Trial. *Am J Cardiol* 2001; 88(supp1 5A):197.
251. D. Cox, T. Stuckey, J. Babb, R. Low, L. Cannon, R. Iwaka, B. Brodie, A. Lansky, **G. Stone**. The EndiCOR X-SIZER Acute Myocardial Infarction (AMI) Registry: Adjunctive Thrombectomy Combined with Stenting for AMI. *Am J Cardiol* 2001; 88(supp1 5A):76.
252. Srinivas Addala, Cindy L Grines, Judith A Boura, Gregory Pellizzon, Simon R Dixon, **Gregg W. Stone**, Joel K Kahn. The PAMI Clinical Risk Score : Predicting Mortality in 3452 patients with ST Elevation MI without Cardiogenic Shock treated with Primary Angioplasty. *Circulation* 2001;104:II-630.
253. Eve Aymong, Roxana Mehran, Alexandra J Lansky, **Gregg W. Stone**, Martin Bert Leon, Paul Teirstein. Effect of Radiation in Prevention of Target Vessel Revascularization: Results from the SCRIPPS II Trial. *Circulation* 2001;104:II-578.
254. Costantino Costantini-Ortiz, Alexandra J Lansky, Paul Teirstein, Kartik Desai, Roxana Mehran, Kazuyuki Shirai, George Dangas, **Gregg W. Stone**, Martin Fahy, Eve Aymong,

- Magdy Badereldin, Martin Leon. Patterns of Restenosis after P-32 Vascular Brachytherapy in the INHIBIT trial. *Circulation* 2001;104:II-576.
255. David Cox, Thomas Stuckey, Joseph Babb, Reggie Low, Yemi Johnson, Louis Cannon, Mark Turco, Alexandra Lansky, **Gregg W. Stone**. The EndiCOR X-SIZER AMI Registry: Improvement in Myocardial Blush Scores with Adjunctive Thrombectomy Combined with Stenting for AMI. *Circulation* 2001;104:II-504.
256. James J Ferguson III, Marc Cohen, Robert Freedman, Magnus Ohman, **Gregg W. Stone**, Jan Christenson, Ramachandra Reddy, Philip Urban, Michael Miller. Evolving Indications, Complications and Outcomes of IABC: Results of the Benchmark<sup>®</sup> Registry. *Circulation* 2001;104:II-439.
257. Alexandra J Lansky, David Cox, Thomas Stuckey, Manuela Negoita, Kartik Desai, Costantino Costantini, Nishe Dave, Brian Proctor, Octavia Balan, Ecaterina Cristea, **Gregg W. Stone**. Improved Myocardial Blush Score after Acute Myocardial Infarction Intervention with the X-SIZER Device. Results from the X-TRACT AMI Trial. *Circulation* 2001;104:II-466.
258. Alexandra J Lansky, Roxana Mehran, Kartik Desai, Magdi El-Omar, Costantino Costantini, Kazuyuki Shirai, Moses Tasawali, Nishe Dave, Faranza Arif, Chinenye Obicheta, Martin Fahy, **Gregg W. Stone**. Time Course of Restenosis Following Iridium-192 IntraVascular Brachytherapy for In-Stent Restenosis. *Circulation* 2001;104:II-546.
259. Kazuyuki Shirai, Alexandra J Lansky, Kartik Desai, Tereza Conway, Brian Proctor, Ecaterina Cristea, Martin Fahy, Maria Corral, Nishe Dave, Cristina Brestowski, **Gregg W. Stone**, Paul Teirstein. Feasibility and Efficacy of Tandem Positioning on Angiographic Outcomes in the INHIBIT Trial. *Circulation* 2001;104:II-546.
260. Kazuyuki Shirai, Roxana Mehran, Alexandra J Lansky, George Dangas, Martin Fahy, **Gregg W. Stone**, Manuela Negoita, Kartik Desai, Ecaterina Cristea, Valavanur Subramanian. Minimally Invasive Coronary Artery Bypass Grafting Versus Stenting for Patients with Proximal LAD Disease: Long Results in a Matched Population of 775 Patients. *Circulation* 2001;104:II-423.
261. **Gregg W. Stone**, Steve Ramee, Steve Bailey, Steve Almany, John George, Jeffrey Moses, Christopher White, Marian Hawkey, Richard Kuntz, Campbell Rogers. Safety and Efficacy of Distal Protection During Saphenous Vein Graft Intervention with the EPI FilterWire EX<sup>™</sup> - First Report from the U.S. Phase I Feasibility Study. *Circulation* 2001;104:II-623.
262. Farzana Arif, Yoshio Kobayashi, Makoto Hirose, Octavia Balan, Arlene Reyes, Ioannis Iakovou, Milena Adamian, Roxana Mehran, George Dangas, Alexandra J. Lansky, Issam Moussa, **Gregg W. Stone**, Martin B. Leon, Jeffrey W. Moses, Gary S. Mintz. Different Mechanism of Lumen Enlargement in Lesions With Stent Underexpansion After Balloon Angioplasty for In-Stent Restenosis Compared to Those With Optimal Stent Expansion: an Intravascular Ultrasound Study. *J Am Coll Cardiol* 2002;39:36A.
263. Makoto Hirose, Yoshio Kobayashi, Farzana Arif, Octavia Balan, Arlene Reyes, Ioannis Iakovou, C. Constantini, Issam Moussa, George Dangas, Roxana Mehran, Alexandra J. Lansky, **Gregg W. Stone**, Martin B. Leon, Jeffrey W. Moses. Different Mechanism of

Lumen Enlargement during Balloon Angioplasty Between Focal and Diffuse In-Stent Restenosis. J Am Coll Cardiol 2002;39:37A.

264. Andrea S. Abizaid, Roxana Mehran, Gary S. Mintz, Alexandra J. Lansky, **Gregg W. Stone**, Alexandre Abizaid, George Dangas, Thos Limpijankit, Yanis Iakovou, Jeffrey W. Moses, Martin B. Leon. Direct Stenting Improves Target Lesion Revascularization in Saphenous Vein Graft Lesions: An Intravascular Ultrasound-Guided Study. J Am Coll Cardiol 2002;39:35A.
265. Dale T. Ashby, George Dangas, Roxana Mehran, Alexandra J. Lansky, Milena Adamian, Michael Collins, Edward Kreps, Gishel New, Issam Moussa, **Gregg W. Stone**, Gary S. Roubin, Sriram Iyer, Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstein. Do Multiple Prior Interventions for In-Stent Restenosis Impact the Success of Gamma Brachytherapy? J Am Coll Cardiol 2002;39:58A.
266. Milena Adamian, Roxana Mehran, George Dangas, Gishel S. New, A.S. Abizaid, Alexandra J. Lansky, Giora Weisz, M.A. Grise, Michael Collins, Edward M. Kreps, Issam Moussa, **Gregg W. Stone**, Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstein. Does Vessel Size Have an Impact on Recurrence Rates Following Gamma Vascular Brachytherapy: Acute and 9 Month Results From SCRIPPS III Registry. J Am Coll Cardiol 2002;39:64A.
267. Costantino O. Costantini, Alexandra J. Lansky, Roxana Mehran, Martin Fahy, Kazuyuki Shirai, Nishi Dave, **Gregg W. Stone**, George Dangas, Martin B. Leon. Efficacy of Gamma Vascular Brachytherapy for Ostial vs. Non-Ostial In Stent Restenotic Lesions. J Am Coll Cardiol 2002;39:66A.
268. Milena Adamian, Issam Moussa, Roxana Mehran, George Dangas, Alexandra J. Lansky, Gary S. Mintz, M. Moussavian, Alexandre Abizaid, Mohamed Mohamed, R.Kuntz, **Gregg W. Stone**, Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstein. Gamma Vascular Brachytherapy Neutralizes the Negative Impact of Diabetes Mellitus on Clinical Outcomes After PCI for In-Stent Restenosis: Pooled Data From GAMMA I, II and SCRIPPS III Trials. J Am Coll Cardiol 2002;39:64A.
269. Dale T. Ashby, Roxana Mehran, Alexandra J. Lansky, Ioannis Iakovou, Giora Weisz, Costantino Costantini, Kazuyuki Shirai, Izat HJazi, Michael Farkouh, George Dangas, **Gregg W. Stone**, Gishel New, Jeffrey W. Moses, Martin B. Leon. Gender Differences in Clinical Outcomes After PCI in Small Coronary Arteries. J Am Coll Cardiol 2002;39:2A.
270. Costantino Costantini-Ortiz, Alexandra J. Lansky, Kartik Desai, Roxana Mehran, Kazuyuki Shirai, Ecaterina Cristea, Hora Marginean, George Dangas, **Gregg W. Stone**, Martin B. Leon. Geographic Miss is Not Associated with Restenosis or the Edge Phenomenon in the INHIBIT Trial. J Am Coll Cardiol 2002;39:13A.
271. Milena Adamian, **Gregg W. Stone**, Roxana Mehran, George Dangas, A.S. Abizaid, Alexandre Abizaid, Mohamed Mohamed, Yuliya Adamian, Arlene Reyes, Izat HJazi, Iannis Iakovou, Makoto Hirose, Alexandra J. Lansky, Jeffrey W. Moses, Martin B. Leon. Have the Outcomes of Rescue Angioplasty After Failed Thrombolytic Therapy in Acute Myocardial Infarction Improved in the Stent Era? J Am Coll Cardiol 2002;39:309A.

272. Iakovou, R. Merhan, G. Mintz, G. Dangas, Y. Kobayashi, A. Abizaid, D. Ashby, T. Limpijankit, R. Narasimaiah, I. Hjaz, N. Kipshidze, A. L. Lansky, **G. W. Stone**, J. W. Moses, M. B. Leon. Increased CKMB Release is a Trade-off for Optimal Stent Implantation. An Intravascular Ultrasound Study. *J Am Coll Cardiol* 2002;39:28A.
273. **G.W. Stone**, D.J. Moliterno, M. Bertrand, F.J. Neumann, H.C. Herrmann, E.R. Powers, C.L. Grines, D.J. Cohen, E.A. Cohen, M. Cohen, P.M. DiBattiste for the TARGET Investigators. Impact of Clinical Syndrome Acuity on the Differential Response to Two Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial. *J Am Coll Cardiol* 2002;39:22A.
274. Iakovou, G. Dangas, A. J. Lansky, M. Negoita, I. Hjaz, D. Ashby, C. Costantini, M. Guiry, R. Brandwein, M. Losquadro, J. Forman, J. W. Moses, **G. W. Stone**, M. B. Leon, R. Mehran. Impact of Gender on the Incidence and Outcome of Contrast Induced Nephropathy After Percutaneous Coronary Intervention. *J Am Coll Cardiol* 2002;39:2A.
275. Kazuyuki Shirai, Alexandra J. Lansky, Roxana Mehran, Kartik Desai, Costantino Costantini-Ortiz, Brian Proctor, Teraza Conway, Martin Fahy, Maria Corral, Christina Brestowski, George Dangas, **Gregg W. Stone**, Paul Teirstein, Jeffrey Moses, Martin B. Leon. Impact of Lesion Length on Vascular Brachytherapy Failure: A Comparison of Beta (b) Versus Gamma (g) Irradiation in 990 Patients. *J Am Coll Cardiol* 2002;39:13A.
276. Dale T. Ashby, George Dangas, Michael Farkouh, Ioannis Iakovou, Giora Weisz, Izat Hjaz, Milena Adamian, Eve Aymong, Mohamed Mohamed, Roxana Mehran, **Gregg W. Stone**, Alexandra J. Lansky, Michael Collins, Jeffrey W. Moses, Martin B. Leon. Impact of Smoking Habit on Clinical Outcomes After Percutaneous Coronary Intervention. *J Am Coll Cardiol* 2002;39:63A.
277. Costantino Costantini-Ortiz, Alexandra J. Lansky, Roxana Mehran, Kartik Desai, George Dangas, **Gregg W. Stone**, Ron Waksman, Jeffrey Moses, Martin B. Leon. Impact of Vessel Size After Coronary Vascular Brachytherapy: A Report of 990 Patients. *J Am Coll Cardiol* 2002;39:14A.
278. I. Iakovou, G. Dangas, A. Abizaid, G. Mintz, R. Mehran, Y. Kobayashi, D. Ashby, M. Hirose, S. Iyer, **G. W. Stone**, M. Collins, G. Roubin, M. Astatkie, J. W. Moses, M. B. Leon. In SVGs Bigger is not Significantly Better. An Intravascular Ultrasound Study. *J Am Coll Cardiol* 2002;39:74A.
279. Andrea S. Abizaid, Roxana Mehran, Alexandra J. Lansky, George Dangas, Alexandre Abizaid, Mohamed Mohamed, Izat Hjaz, **Gregg W. Stone**, Martin B. Leon. IVUS Guidance Decreases Target Lesion Revascularization in Long-Diffuse Coronary Lesions. *J Am Coll Cardiol* 2002;39:55A.
280. Thosaphol Limpijankit, George Dangas, Roxana Mehran, Alexandra J. Lansky, **Gregg W. Stone**, Nicholas Kipshidze, Michael Astatkie, Marian Hawkey, Dale Ashby, Mohamed Mohamed, Issam Moussa, Michael B. Collins, Jeffrey W. Moses, Martin B. Leon. Predictors and Prognostic Values of CK-MB Cardiac Enzymes Elevation After Coronary Intervention With Radiation Treatment in In-Stent Restenosis. *J Am Coll Cardiol* 2002;39:23A.



281. Iakovou, G. Dangas, A. J. Lansky, M. Negoita, I. Hjaz, D. Ashby, J. Forman, M. Guiry, R. Brandwein, M. Losquadro, T. Limpijankit, **G. W. Stone**, J. W. Moses, M. B. Leon, R. Mehran. Predictors of Contrast Induced Nephropathy After Percutaneous Coronary Intervention in Patients With and Without Chronic Renal Failure. *J Am Coll Cardiol* 2002;39:56A.
282. Thosaphol Limpijankit, Alexandre Abizaid, Roxana Mehran, George Dangas, Alexandra J. Lansky, Nicholas Kipshidze, **Gregg W. Stone**, Michael B. Collins, Jeffrey W. Moses, Martin B. Leon. Predictors of Radiation Failure After Treatment of In-Stent Restenosis With Gamma Vascular Brachytherapy: Pooled Analysis From GAMMA I, II and SCRIPPS III Studies. *J Am Coll Cardiol* 2002;39:46A.
283. Alexandra J. Lansky, Cindy Grines, Kartik Desai, Ecaterina Cristea, Maria Corral, David Cox, Susan Gedney, John J. Griffin, Thomas Stuckey, Eulogia Garcia, Barry D. Rutherford, **Gregg W. Stone**. Primary Stenting Optimizes the Outcome of Women With Acute Myocardial Infarction: Results From the CADILLAC Trial. *J Am Coll Cardiol* 2002;39:39A.
284. Dale T. Ashby, George Dangas, Roxana Mehran, Thos Limpijankit, Giora Weisz, **Gregg W. Stone**, Costantino Costantini, Alexandra J. Lansky, Martin B. Leon, Gishel New, Sriram Iyer, Edward Kreps, Gary S. Roubin, Michael Collins, Jeffrey W. Moses. Relationship of the Degree of Procedural Anticoagulation to Outcomes After Stent Implantation. *J Am Coll Cardiol* 2002;39:27A.
285. Makoto Hirose, Yoshio Kobayashi, Roxana Mehran, Issam Moussa, George Dangas, Ramona Pop, Milena Adamian, Michael Collins, Mark A. Grise, Alexandra J. Lansky, Gary S. Mintz, **Gregg W. Stone**, Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstein. Retreatment Immediately After Gamma Radiation for In-Stent Restenosis Results in Need for Target Vessel Revascularization Beyond Target Lesion. *J Am Coll Cardiol* 2002;39:65A.
286. Yoshio Kobayashi, Issam Moussa, Makoto Hirose, Farzana Arif, Octavia Balan, Arlene Reyes, Mohamed Mohamed, Milena Adamian, Roxana Mehran, George Dangas, Alexandra J. Lansky, **Gregg W. Stone**, Martin B. Leon, Jeffrey W. Moses, Gary S. Mintz. Small Proximal Vessels Are Not Always Small: An Intravascular Ultrasound Study. *J Am Coll Cardiol* 2002;39:5A.
287. Milena Adamian, Roxana Mehran, George Dangas, Michael Farkou, Alexandre Abizaid, Arlene Reyes, Izat Hjaz, Manuela Negoita, Yuliya Adamyan, Cristian Cioara, Ramona Pop, Alexandra J. Lansky, **Gregg W. Stone**, Jeffrey W. Moses, Martin B. Leon. Stenting in Acute MI in Patients With Chronic Renal Failure: Predictors of In-Hospital and Long-Term Outcome. *J Am Coll Cardiol* 2002;39:309A.
288. Costantino O. Costantini, Alexandra J. Lansky, Roxana Mehran, Gary S. Mintz, Kartik Desai, Kazuyuki Shirai, Horia Marginean, **Gregg W. Stone**, George Dangas, Martin B. Leon. Vascular Brachytherapy for Ostial In-Stent Restenotic Lesions. *J Am Coll Cardiol* 2002;39:46A.
289. Iakovou, G. Dangas, A. J. Lansky, G. Mintz, D. Ashby, M. Losquadro, M. Guiry, N. Kipshidze, R. Brandwein, T. Limpijankit, J. Forman, I. Hjaz, **G. W. Stone**, M. B. Leon, R. Mehran. Incidence, predictors and economic impact of contrast induced nephropathy.

- Results in 8,628 patients treated with percutaneous coronary interventions. J Am Coll Cardiol 2002;39:2A.
290. Iakovou, G. Dangas, A. J. Lansky, M. Negoita, I. Hjaz, D. Ashby, C. Costantini, M. Guiry, R. Brandwein, M. Losquadro, J. Forman, J. W. Moses, **G. W. Stone**, M. B. Leon, R. Mehran. Impact of Gender on the Incidence and Outcome of Contrast Induced Nephropathy After Percutaneous Coronary Intervention. J Am Coll Cardiol 2002;39:2A.
  291. Milena Adamian, Issam Moussa, Roxana Mehran, George Dangas, Michael Farkouh, Yuliya Adamyan, M Mohammed, Manuela Negoita, Arlene Reyes, M Losquadro, M. Collins, EM Kreps, Jeffrey W. Moses, **Gregg W. Stone**, Martin B. Leon. The role of mucomyst administration prior to percutaneous interventions on renal function in patients with chronic renal failure. J Am Coll Cardiol 2002;39:1A.
  292. Kazuyuki Shirai, Alexandra Lansky, Roxana Mehran, Kartik Desai, Costantino Costantini-Ortiz, B. proctor, T. Conway, Martin Fahy, N. Dave, I. Hijazi, George Dangas, **Gregg W. Stone**, PS Teirstein, JW Moses, Martin Leon. Should Small Proximal Arteries be Stented? J Am Coll Cardiol 2002;39:21A.
  293. Harjai KJ, Grines CL, **Stone GE**, et al. Frequency, determinants and clinical implications of angiographically-visible thrombus following primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2002;39:49A.
  294. Baumgart D, Limpijanki T, Serruys P, Colombo A, Silber S, eekhout E, Urban P, Bonan R, Zeihar A, Gershlick AH, Dangas G, Lansky AJ, Mehran R, **Stone GW**, Leon MB. Efficacy of long radiation treatment in native in-stent restenosis: a subanalysis from the RENO registry. J Am Coll Cardiol 2002;39:57A.
  295. Garcia E, Cox D, Grines CL, Morena R, Tchong J, Stuckey T, Rutherford B, McClean J, Lansky A, **Stone GW**. Does stenting benefit patients with left anterior descending infarction? Results from the CADILLAC trial. J Am Coll Cardiol 2002;39:74A.
  296. Moliterno DJ, Lange RA, Hamm C, Meier B, Dibattiste PM, Lakkis N, Gang J, Chew DP, Cohen DM, **Stone GW**, Demopoulos L, Topol EJ. Prolongation of activated clotting time (ACT) with tirofiban vs. abciximab and its association to clinical outcome: results from TARGET. J Am Coll Cardiol 2002;39:74A.
  297. Mehran R, Lotan C, Kranjec I, Holmer E, Haase K, Camenzind E, Zelizko M, maillard L, Gomes SR, Vandormael MG, Lansky AJ, Dangas G, **Stone GW**, Ashby DT, Leon MB. The HEP@NET study: an internet-based registry examining the efficacy of heparin-coating in patients undergoing coronary stent implantation. J Am Coll Cardiol 2002;39:75A.
  298. Harjai KJ, Grines CL, Pham T, **Stone GE**, et al. Disparate clinical outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction: is diabetes mellitus an independent predictor of poor outcome? J Am Coll Cardiol 2002;39:289A.
  299. Guagliumi G, Cox DA, Grines CL, Garcia E, Stuckey T, Tchong J, Pasquini J, Carroll J, Lansky A, **Stone GW**. Does abciximab and stenting improve outcomes in elderly patients undergoing primary PCI for acute myocardial infarction: data from the CADILLAC trial. J Am Coll Cardiol 2002;39:289A.

300. Skelding KA, Harjai K, Mehta L, **Stone GW**, et al. Gender is an independent predictor of both in-hospital and one-year outcomes following primary intervention for acute myocardial infarction. *J Am Coll Cardiol* 2002;39:290A.
301. Cox DA, Stuckey T, Babb J, Low R, Cannon L, Iwoaka R, Turco M, Brodie B, Lansky A, **Stone GW**. Early and late results of thrombectomy prior to stenting in acute myocardial infarction: principal report of the Endicor X-SIZER AMI registry. *J Am Coll Cardiol* 2002;39:308A.
302. Ledford CM, Grines CL, **Stone GW**, et al. Long-term outcomes in patients with acute myocardial infarction undergoing primary percutaneous intervention: a pooled analysis of the primary angioplasty in myocardial infarction trials. *J Am Coll Cardiol* 2002;39:309A.
303. Nguyen TT, O'Neill WW, Dixon SR, Boura JA, Grines L, Cox DA, **Stone GW**, Brodie BR, Grines CL. Poor one year prognosis in acute myocardial infarction patients with saphenous vein grafts as the infarct related vessel treated by primary balloon angioplasty. *J Am Coll Cardiol* 2002;39:309A.
304. Corpus RA, Boura JA, **Stone GW**, et al. Outcome after acute myocardial infarction in young patients: analysis of the PAMI database. *J Am Coll Cardiol* 2002;39:314A.
305. Stuckey T, Grines CL, Brodie BR, Cox DA, Griffin JJ, Carrol J, Guagliumi G, Garcia E, Rutherford B, Turco M, Tcheng J, **Stone GW**. Effect of stent implantation and glycoprotein IIb/IIIa receptor blockade on target vessel revascularization in diabetics after primary PCI in acute myocardial infarction: the CADILLAC trial. *J Am Coll Cardiol* 2002;39:337A.
306. Cox DA, Grines CL, Garcia E, Stuckey T, Tcheng J, Guagliumi G, Johnson A, Lansky A, Griffin JJ, **Stone GW**. Does optimal or stent-like PTCA provide equivalent outcomes compared to primary stenting in acute myocardial infarction: early and late results from the CADILLAC trial. *J Am Coll Cardiol* 2002;39:337A.
307. Harjai KJ, **Stone GW**, Boura J, et al. The salutary effect of prior beta blocker therapy on clinical outcomes following primary angioplasty for acute myocardial infarction: a pooled analysis from the Primary Angioplasty in Myocardial Infarction (PAMI) 1, 2 and Stent PAMI trials. *J Am Coll Cardiol* 2002;39:337A.
308. Ross A, Gibbons R, Kloner RA, Marder VJ, **Stone GW**, Alexander RW. Acute Myocardial Infarction Study of Adenosine (AMISTAD II). *J Am Coll Cardiol* 2002;39:338A.
309. G Weisz, G Dangas, A Colombo, I Moussa, M Collins, M Adamian, Y Adamyan, D Ashby, V LaRoche, A Lansky, R Mehran, P Teirstein, **GW Stone**, JW Moses, MB. Leon. T-Stenting Technique with Sirolimus-Eluting Stents for Bifurcation Lesions. *Am J Cardiol* 2002 90(suppl 6A): 5H.
310. D Cox, T Stuckey, J Babb, MTurco, R Iwoaka, LCannon, R Low, A Lansky, **G Stone**. The X-SIZER Acute Myocardial Infarction (AMI) Registry: Improvement in Myocardial Blush Scores and ST-Segment Resolution with the Use of Thrombectomy Before Stenting in AMI. *Am J Cardiol* 2002;90(suppl 6A):18H.

311. C Rogers, **G Stone**. The FilterWire EX Distal Protection Device for Use During Saphenous Vein Graft Interventions: Preliminary FIRE Trial Results. *Am J Cardiol* 2002;90(suppl 6A):26H.
312. H Arjomand, B Roukoz, S Surabhi, A Espinoza, M Cohen, Z Turi, **G Stone**, D Baim, S Goldberg. In-hospital Outcome of Saphenous Vein Graft Intervention with Membrane-Covered Stents with and without Distal Protection. *Am J Cardiol* 2002;90(suppl 6A):27H.
313. KJ Harjai, CL Grines, **GW Stone**, D Cox, B Brodie, JA Boura, L Grines, WW O'Neill. Technical Success of Primary Angioplasty Overrides Clinical Risk Status in Determining Outcome of Acute Myocardial Infarction: Guidelines for Discharge Planning. *Am J Cardiol* 2002;90(suppl 6A):48H.
314. G Weisz, DA Cox, E Garcia, JE Tcheng, JJ Griffin, G Guagliumi, TD Stuckey, JD Carroll, R Mehran, CL Grines, **GW Stone**. The Smoker's Paradox Revisited: Insights from the CADILLAC Trial. *Am J Cardiol* 2002;90(suppl 6A):52H.
315. MA Turco, DA Cox, T Stuckey, J Babb, B Brodie, DE Shaddinger, **GW Stone**. Impact of Glycoprotein IIb/IIIa Inhibitors in Conjunction with the X-SIZER Thrombectomy Catheter System During Acute Myocardial Infarction (AMI) Intervention: Results from the X-SIZER AMI Registry. *Am J Cardiol* 2002;90(suppl 6A):52H.
316. DA Cox, M Turco, T Stuckey, J Babb, B Brodie, J McLean, A Lansky, **GW Stone**. Stent Placement Combined with Thrombectomy Improves Outcomes in Thrombotic Lesions: Results from the X-SIZER Acute Myocardial Infarction Registry. *Am J Cardiol* 2002;90(suppl 6A):53H.
317. B Roukoz, H Arjomand, S Surabhi, D McCormick, Z Turi, **G Stone**, D Baim, S Goldberg. Initial US Experience with Covered Stents in the Treatment of Saphenous Vein Graft Lesions: 30-Day Follow-Up. *Am J Cardiol* 2002;90(suppl 6A):79H.
318. I Iakovou, G Dangas, R Mehran, G Mintz, A Abizaid, F Kuepper, Y Kobayashi, D Ashby, M Hirose, **GW Stone**, MB Leon. Neutral Impact of Preintervention Remodeling of Saphenous Vein Grafts on Subsequent Target Lesion Revascularization. *Am J Cardiol* 2002;90(suppl 6A):132H.
319. M Adamian, R Mehran, I Moussa, G Dangas, GS Mintz, AJ Lansky, Y Adamyan, S Ibrahim, M Fahy, C Cioara, M Losquadro, A Reyes, **GW Stone**, JW Moses, MB Leon. Mucomyst Administration in Percutaneous Coronary Interventions in Patients with Impaired Renal Function: A Matched Comparison. *Am J Cardiol* 2002;90(suppl 6A):144H.
320. G Weisz, R Mehran, S Polena, D Ashby, I Moussa, **G Stone**, GS Roubin, JW Moses, MB Leon, G Dangas. In Patients Receiving Oral Antiplatelet Agents, Platelet Glycoprotein IIIa Heterozygous Polymorphism Does Not Increase Risk of Percutaneous Coronary Intervention. *Am J Cardiol* 2002;90(suppl 6A):161H.
321. M Adamian, M Farkouh, R Mehran, I Moussa, G Weisz, I Hjaz, R Pop, T Limpanjikit, Y Adamyan, M Collins, M Losquadro, G Dangas, **GW Stone**, JW Moses, MB Leon. A Matched Comparison of Safety and Feasibility of Bivalirudin in Patients with Diabetes Mellitus During Percutaneous Coronary Interventions. *Am J Cardiol* 2002;90(suppl 6A):161H.

322. M Adamian, R Mehran, GS Mintz, G Dangas, I Moussa, DT Ashby, S Ibrahim, Y Adamyan, M Negoita, A Reyes, R Narasimaiah, EM Kreps, **GW Stone**, JW Moses, MB Leon. Safety and Feasibility of Direct Thrombin Inhibitor Bivalirudin During Percutaneous Coronary Interventions in Patients with Chronic Renal Failure. Results of the Pilot Study. *Am J Cardiol* 2002;90(suppl 6A):162H.
323. TA Sanborn, JD Ogilby, J Ritter, **GW Stone**, B Klugherz, R Fields, C White, J McGarvey, DL Morris, R Wilensky. Reduced Vascular Complications After Percutaneous Coronary Interventions with a Nonmechanical Suture Device: Results from the Randomized Rapid Ambulation After Closure (RACE) Study. *Am J Cardiol* 2002;90(suppl 6A):172H.
324. F Kuepper, AJ Lansky, G Dangas, I Iakovou, DT Ashby, CO Costantini, M Farkouh, **GW Stone**, MB Leon, R Mehran. Patients with Diabetes After Percutaneous Interventions in Saphenous Vein Grafts: Sex-Based Differences in Clinical Outcomes at 1-Year Follow-up. *Am J Cardiol* 2002;90(suppl 6A):178H.
325. S Addala, CL Grines, SR Dixon, **GW Stone**, JA Boura, AB Ochoa, G Pellizzon, JK Kahn. PAMI Risk Score: Predicting Mortality in ST Elevation Myocardial Infarction Treated with Primary Angioplasty. *Am J Cardiol* 2002;90(suppl 6A):182H.
326. D Cox, C Grines, T Stuckey, E Garcia, J Griffin, J Tcheng, J Pasquini, G Guagliumi, B Brodie, M Turco, A Lansky, **G Stone**. Do Acute Myocardial Intervention Patients Without ST-Segment Elevation Have Better Outcomes After Primary Percutaneous Coronary Intervention? An Analysis from the CADILLAC Trial. *Am J Cardiol* 2002;90(suppl 6A):184H.
327. BA Bartholomew, KJ Harjai, JA Boura, LL Grines, **GW Stone**, D Cox, B Brodie, W O'Neill, CL Grines. Declining Length of Stay in Primary Angioplasty in Myocardial Infarction (PAMI) Studies Despite Increased Disease Severity. *Am J Cardiol* 2002;90(suppl 6A):185H.
328. D Cox, C Grines, A Lansky, T Stuckey, E Garcia, J Williams, J Tcheng, G Guagliumi, J Griffin, **G Stone**. Impact of Small Vessel Size on Long-Term Outcomes After Primary Angioplasty and Stenting in Acute Myocardial Infarction: Results from the CADILLAC Trial. *Am J Cardiol* 2002;90(suppl 6A):185H.
329. BA Bartholomew, KJ Harjai, JA Boura, LL Grines, **GW Stone**, D Cox, B Brodie, M Yerkey, W O'Neill, CL Grines. Factors Affecting Length of Stay in Acute Myocardial Infarction Patients Undergoing Primary Angioplasty. *Am J Cardiol* 2002;90(suppl 6A):185H.
330. B.A Bartholomew, KJ Harjai, JA Boura, M Yerkey, LL Grines, **GW Stone**, D Cox, B Brodie, WW O'Neill, CL Grines. Variation in Hospital Length of Stay in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty: Do We Need Multiple Diagnostic Related Groups? *Am J Cardiol* 2002;90(suppl 6A):186H.
331. MW Yerkey, KJ Harjai, **GW Stone**, DA Cox, TD Stuckey, JA Boura, BA Bartholomew, SJ Kernis, CL Grines. Late Hemodynamic Compromise After Successful Primary Angioplasty for Acute Myocardial Infarction. *Am J Cardiol* 2002;90(suppl 6A):189H.
332. **GW Stone**, R Mehran, M Midei, R Waksman, G Schaer, AJ Lansky, M Buchbinder. Beta Radiation for De Novo and In-stent Restenotic Lesions in Saphenous Vein Grafts: The SVG BRITE Trial. *Circulation* 2002;106(19):II-335.

333. AJ Lansky C Costantini, K Desai, M Adamian, D Cox, JE Tcheng, J Griffin, T Stuckey, E Garcia, J Carroll, **GW Stone**. Exposing the Gender Gap in Outcomes After Primary Intervention for Acute Myocardial Infarction: Results From the CADILLAC Trial. *Circulation* 2002;106(19):II-491.
334. G Weisz, GD Dangas, A Colombo, I Moussa, M Collins, M Adamian, Y Adamian, D Ashby, V Laroche, P Teirstein, **GW Stone**, JW Moses. Sirolimus-Eluting stents for Bifurcation Lesions: Comparison to Standard “Bare” Stents Using the T-Stenting Technique. *Circulation* 2002;106(19):II-519.
335. SG Ellis, JB Hermiller, DA Cox, MA Turco, JD Greenberg, JT Mann, ME Russell, **GW Stone**. The U.S. pivotal randomized trial of a polymer-based slow-rate release paclitaxel eluting stent: 30-day results of TAXUS-IV SR. *Circulation* 2002;106(19):II-393.
336. A Bakhai, **GW Stone**, SA Murphy, L Githiora, RH Berezin, CL Grines, DA Cox, JE Tcheng, DJ Cohen. Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial. *Circulation* 2002;106(19):II-518.
337. Kandzari DE, Tcheng JE, Grines CL, Cohen DJ, Bakhai A, Cox DA, Stuckey TD, Effron M, Griffin JJ, Turco M, Carroll JD, Fahy M, Mehran R, **Stone GW**. Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial. *J Am Coll Cardiol*. 2003;41(6 Suppl B):538-9.
338. Aymong ED, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Carroll JD, Rutherford BD, Lansky AJ, Mehran R, **Stone GW**. Predictors and sequelae of subacute thrombosis after percutaneous intervention in acute myocardial infarction: The CADILLAC trial. *J Am Coll Cardiol*. 2003;41(6 Suppl B):393.
339. McLaughlin MG, Gardner G, Aymong ED, Mehran R, Lansky AJ, Grines CL, Tcheng JE, Cox DA, Stuckey TD, Garcia E, Guagliumi G, Turco M, Zimetbaum P, **Stone GW**. ST-segment elevation resolution as a predictor of mortality in patients with thrombolysis in myocardial infarction III flow in the infarct artery after primary angioplasty: The CADILLAC trial. *J Am Coll Cardiol*. 2003;41(6 Suppl B):392.
340. Costantini CO, Lansky AJ, Shirai K, Cristea E, Brestowski C, Slack S, Fahy M, Grines CL, Carroll JD, Thomas S, Guagliumi G, Rutherford B, Turco M, Mathias D, Leon MB, **Stone GW**. Clinical implications of myocardial perfusion status assessed by myocardial blush after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial. *J Am Coll Cardiol*. 2003;41(6 Suppl B):391-2.
341. Mehrdad Sadeghi H, Grines CL, Mehran R, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Carroll JD, Rutherford BD, **Stone GW**. Marked mortality risk of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol*. 2003;41(6 Suppl B):384.
342. Mehrdad Sadeghi H, Grines CL, **Stone GW**, et al. Circadian fluctuations in thrombogenicity in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol*. 2003;41(6 Suppl B):384.

343. Turco MA, Fahy M, Mehran RA, Lansky A, Grines CL, Tcheng JE, Garcia E, Guagliumi G, Cox DA, Stuckey TD, Shaddinger DE, **Stone GW**. Predictors of treatment delay in patients with acute myocardial infarction undergoing primary angioplasty: An analysis from the CADILLAC trial. *J Am Coll Cardiol*. 2003;41(6 Suppl B):376.
344. Pellizzon GG, Harjai K, Addala S, Ochoa A, **Stone GW**, Cox DA, Grines L, Boura JA, Brodie BR, O'Neill WW, Grines CL. Multiple lesion coronary intervention is associated with higher mortality in primary angioplasty for acute myocardial infarction: The stent PAMI trial. *J Am Coll Cardiol*. 2003;41(6 Suppl B):369.
345. Turco MA, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Carroll JD, Grines CL, Rutherford BD, Slack S, Fahy M, Mehran R, Lansky AJ, **Stone GW**. Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: The CADILLAC Registry. *J Am Coll Cardiol*. 2003;41(6 Suppl B):368.
346. Brodie BR, Cox DA, Stuckey TD, Turco M, Garcia E, Griffin JJ, Fahy M, Tcheng JE, Grines CL, Mehran R, **Stone GW**. How important is time to treatment with primary percutaneous coronary intervention for acute myocardial infarction? Results from the CADILLAC trial. *J Am Coll Cardiol*. 2003;41(6 Suppl B):368.
347. Kandzari DE, E Tcheng J, Grines CL, Effron M, Fox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Lansky AJ, Mehran R, **Stone GW**. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: The CADILLAC trial. *J Am Coll Cardiol*. 2003;41(6 Suppl B):357.
348. Brodie BR, Gersh B, Stuckey TD, Zimetbaum P, McLaughlin MG, Aymong ED, Mehran R, O'Neill B, Tcheng JE, Turco M, Cox DA, Grines CL, **Stone GW**. Relationship between time to treatment, electrocardiographic ST-segment resolution, and outcomes with primary percutaneous coronary intervention for acute myocardial infarction: Results from the CADILLAC trial. *J Am Coll Cardiol*. 2003;41(6 Suppl B):342-3.
349. Vagaonescu TD, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BR, Fahy M, Mehran R, **Stone GW**. Impact of an elevated white blood cell count and treatment with abciximab on survival in patients with acute myocardial infarction undergoing percutaneous coronary intervention: The CADILLAC trial. *Cathet Cardiovasc Interv* 2003;59:127.
350. P.S. Chowdhury, K.J. Harjai, J.A. Boura, **G. Stone**, D. Cox, B. Brodie, J.A. Goldstein, W.W. O'Neill, C.L. Grines. Incidence, Predictors, and Prognostic Implications of Coronary Artery Dissection in the Setting of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. *Am J Cardiol* 2003;92:4L
351. S. Kesanakurthy, G.D. Dangas, Z. Lasic, T. Vagaonescu, A. Halkin, Z. Qin, **G. Stone**, J.W. Moses, M.B. Leon, R. Mehran. Clinical Outcomes With the Use of Bivalirudin Versus Unfractionated Heparin in Octogenarians Undergoing Percutaneous Coronary Interventions. *Am J Cardiol* 2003;92:11L.
352. E. Nikolsky, A. Halkin, S. Krieger, R. Mehran, E. Aymong, G.S. Mintz, M. Negoita, Y. Gilutz, I. Hjaz , R. Narasimaiah, **G.W. Stone**, J.W. Moses, M.B. Leon, G.D. Dangas. Arteriotomy



Closure Devices in Patients Undergoing Percutaneous Coronary Procedures: A Meta-Analysis. *Am J Cardiol* 2003;92:17L.

353. R. Mehran, S. Marx, S. Kesanakurthy, Y. Adamian, Z. Qin, I. Moussa, M. Collins, G. New, S. Polena, J. Cosico, M. Negoita, A.J. Lansky, J.W. Moses, **G.W. Stone**, M.B. Leon, A.R. Marks, G. Dangas. Oral Rapamycin for Prevention of In-Stent Restenosis: Long-Term Clinical, Angiographic, and Intracoronary Ultrasound Results. *Am J Cardiol* 2003;92:26L.
354. D. Cox, J. Popma, C. Rogers, J. Hermiller, R. Feldman, P. Hall, R. Haber, A. Masud, P. Cambier, M. Turco, G. Tully, **G. Stone**. Baseline Clinical and Procedural Predictors of Adverse Events During Stenting in Saphenous Vein Grafts Using Distal Protection With the FilterWire EX or With the GuardWire: The FIRE Trial. *Am J Cardiol* 2003;92:32L.
355. A.Z. Masud, J. Hermiller, R. Feldman, P. Hall, R. Haber, P.A. Cambier, R. Caputo, M.A. Turco, R. Kovach, B. Brodie, H. Herrmann, R.E. Kuntz1, J. Popma1, S.R. Ramee, D. Cox, J.G. Conley, C. Rogers, **G.W. Stone**. The FIRE Trial: 30-Day and 6-Month Results of a Multicenter Randomized Trial Comparing Distal Protection with the FilterWire EX and GuardWire During Saphenous Vein Graft Intervention. *Am J Cardiol* 2003;92:33L.
356. D. Cox, A. Masud, F. Myers, R. Kovach, P. Cambier, B.R. Brodie, G. Mishkel, J. Hermiller, G. Tully, **G. Stone**. Stenting in Saphenous Vein Grafts with Distal Protection Using the Second Generation FilterWire EZ: The BLAZE Registry. *Am J Cardiol* 2003;92:33L.
357. A.Z. Masud, C. Rogers, J. Hermiller, R. Feldman, P. Hall, R. Haber, R. Kovach, P. Cambier, R. Caputo, D.A. Cox, R. Pop, M. Fahy, R. Mehran, **G.W. Stone**. Results of Intervention in Ostial and Nonostial Saphenous Vein Graft Lesions Using Different Distal Protection Devices. The FIRE Trial. *Am J Cardiol* 2003;92:33L.
358. J.B. Hermiller, A. Masud, D. Cox, R. Feldman, P. Hall, R. Haber, P. Cambier, R. Caputo, M. Turco, R. Kovach, B.R. Brodie, H.C. Herrmann, J. Popma, R. Mehran, E. Aymong, C. Rogers, **G.W. Stone**. Impact of Transient Flow Reduction on the Efficacy of Embolic Protection Filters: Results From the FIRE Trial. *Am J Cardiol* 2003;92:34L.
359. H.M. Sadeghi, C.L. Grines, R. Mehran, A.J. Lansky, M. Fahy, D.A. Cox, J.E. Tchong, S.R. Dixon, J.J. Griffin, T.D. Stuckey, B.R. Brodie, M. Turco, J.D. Carroll, **G.W. Stone**. Incidence and Implications of In-Hospital Acquired Thrombocytopenia in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. *Am J Cardiol* 2003;92:40L.
360. C.O. Costantini, H. Marginea, E. Cristea, Y. Tsushiya, R.A. Costa, T. Stuckey, M. Turco, G. Guagliumi, D.A. Cox, J.E. Tchong, C.L. Grines, J.J. Griffin, A.J. Lansky, **G.W. Stone**. Are There Any Angiographic Predictors of Abciximab Benefit After Primary Angioplasty for Acute Myocardial Infarction? Analysis From the CADILLAC Trial. *Am J Cardiol* 2003;92:41L.
361. T.D. Stuckey, C.L. Grines, D.A. Cox, B.R. Brodie, M. Turco, P. Zimetbaum, J.E. Tchong, E. Garcia, J.J. Griffin, G. Guagliumi, R.A. Mehran, E. Aymong, **G.W. Stone**. Does Stenting and Glycoprotein IIb/IIIa Receptor Blockade Improve ST Segment Recovery and Outcome in Patients Undergoing Primary Angioplasty in Acute Myocardial Infarction? The CADILLAC Trial. *Am J Cardiol* 2003;92:41L.



362. K.J. Harjai, C.L. Grines, **G.W. Stone**, A.J. Lansky, E. Aymong, M. Fahy, D.A. Cox, E. Garcia, J.E. Tchong, J.J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, B.D. Rutherford, J.D. Carroll, B.R. Brodie. Does the Use of Heparin After Primary Angioplasty for Acute Myocardial Infarction in Patients Not Receiving Glycoprotein IIb/IIIa Antagonists Alleviate Recurrent Cardiac Ischemia? Insights From the CADILLAC Study. *Am J Cardiol* 2003;92:42L.
363. C.O. Costantini, A.J. Lansky, R.A. Costa, R. Mehran, E. Aymong, D.A. Cox, J.E. Tchong, T. Stuckey, J.D. Carroll, E. Garcia, G. Guagliumi, M. Fahy, J.J. Griffin, C.L. Grines, **G.W. Stone**. Impact of Myocardial Blush Analysis Methodologies in Predicting Short and Long-Term Mortality After Primary Angioplasty. The CADILLAC Trial. *Am J Cardiol* 2003;92:43L.
364. M.A. Turco, P. Zimetbaum, M. McLaughlin, E. Aymong, R. Mehran, D. Cox, C. Grines, J. Tchong, E. Garcia, J. Griffin, G. Guagliumi, T. Stuckey, **G.W. Stone**. Is ST Segment Resolution Predictive of Mortality after Primary PCI in Both Anterior and Non-Anterior Infarction? Analysis from the CADILLAC Trial. *Am J Cardiol* 2003;92:43L.
365. C.O. Costantini, K. Shirai, R.A. Costa, M. Turco, D.A. Cox, T. Stuckey, J.J. Griffin, J.D. Carroll, M. Tarawalli, Y. Tsuchiya, A.J. Lansky, **G.W. Stone**. Prognostic Implications of Site Location After Primary Angioplasty: Analysis of U.S. Versus Non-U.S. Sites in the CADILLAC Trial. *Am J Cardiol* 2003;92:69L.
366. R.A. Costa<sup>1</sup>, Y. Tsuchiya<sup>1</sup>, D.A. Cox, J. Babb, D. Nukta, L. Bilodeau, L. Cannon, T.D. Stuckey, J. Hermiller, E. Aymong, S. Slack, R. Mehran, A.J. Lansky, **G.W. Stone**. Late Outcomes of Patients Treated With Thrombectomy Prior to Stenting in Saphenous Vein Grafts and Thrombus Containing Native Coronary Arteries: Results From the X-TRACT Trial. *Am J Cardiol* 2003;92:73L.
367. T.D. Stuckey, D.A. Cox, M.A. Turco, B.R. Brodie, J. Babb, A. Lansky, R. Kuntz, M. Krucoff, **G.W. Stone**. Impact of Pre-stent Thrombectomy on Periprocedural Myonecrosis in Thrombus Containing Lesions in Saphenous Vein Grafts and Native Coronary Arteries: Results of the X-Tract Trial. *Am J Cardiol* 2003;92:73L.
368. Y. Tsuchiya, R.A. Costa, M. Fahy, S. Slack, E. Aymong, R. Mehran, A.J. Lansky, **G.W. Stone**, D.A. Cox, J. Babb, D. Nukta, L. Bilodeau, L. Cannon, T. Stuckey. Impact of Gender on Outcomes of Thrombectomy in Patients Undergoing Stenting of Diseased Saphenous Vein Grafts or Thrombotic Native Coronary Arteries--Results From the X-TRACT Trial. *Am J Cardiol* 2003;92:74L.
369. Y. Tsuchiya<sup>1</sup>, R.A. Costa<sup>1</sup>, M. Fahy, S. Slack<sup>1</sup>, E. Aymong, R. Mehran, A.J. Lansky, **G.W. Stone**, D.A. Cox, J. Babb, D. Nukta, L. Bilodeau, L. Cannon, T. Stuckey. Utility of Thrombectomy in Women Undergoing Stenting of Diseased Saphenous Vein Grafts and Thrombus Containing Native Coronary Arteries--Results From the X-TRACT Trial. *Am J Cardiol* 2003;92:74L.
370. E. Nikolsky, R. Mehran, E. Aymong, G.S. Mintz, G. Dangas, A.J. Lansky, M. Negoita, M. Fahy, R. Pop, G.S. Roubin, J.W. Moses, **G.W. Stone**, M.B. Leon. The Impact of Symptomatic Peripheral Arterial Disease on 1-Year Mortality in Patients Undergoing Percutaneous Coronary Interventions. *Am J Cardiol* 2003;92:77L.

371. Aymong E, Limpijankit T, Fahy M, Mehran R, Leon M, Moses J, **Stone GW**, et al. Interaction of diabetes and acute coronary syndromes in predicting death, myocardial infarction and non-target lesion revascularization at 1-year follow-up after percutaneous coronary intervention. *Am J Cardiol* 2003;92:80L.
372. Moussa, M. Jaff, S. Iyer, R. Mehran, H. Klein, G. Dangas, **G.W. Stone**, A. Lansky, M.B. Leon, J.W. Moses. Detection of Peripheral Arterial Disease in Patients Presenting for Coronary Angiography or Intervention for Coronary Artery Disease: The Peripheral Arterial Disease in Interventional Patients. *Am J Cardiol* 2003;92:83L.
373. Moussa, M.B. Leon, R. Mehran, G. Dangas, G. Weiss, A. Lansky, **G.W. Stone**, J.W. Moses. The Impact of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors on Outcome of Diabetic Patients Undergoing Sirolimus-Eluting Versus Bare Metal Stent Implantation: Results From the SIRIUS Trial. *Am J Cardiol* 2003;92:91L.
374. Halkin, E. Aymong, E. Nikolsky, A. Lansky, R. Mehran, D.A. Cox, C.L. Grines, J.J. Griffin, **G.W. Stone**. Prediction of Survival by Index Left Ventricular Ejection Fraction Measured During Primary Percutaneous Intervention in Patients with Acute Myocardial Infarction. *Am J Cardiol* 2003;92:112L.
375. Halkin, E. Aymong, A. Lansky, R. Mehran, D.A. Cox, C.L. Grines, E. Garcia, G. Guagliumi, **G.W. Stone**. Determinants of Convalescent Left Ventricular Function After Acute Myocardial Infarction Treated by Primary Percutaneous Intervention. *Am J Cardiol* 2003;92:113L.
376. R.A. Costa<sup>1</sup>, Y. Tsuchiya<sup>1</sup>, M. Tarawali<sup>1</sup>, H. Marginean<sup>1</sup>, R. Sanchez<sup>1</sup>, E. Cristea<sup>1</sup>, R. Mehran, T. Stuckey, G. Guagliumi, D.A. Cox, J.E. Tchong, J.D. Carroll, J.J. Griffin, C.L. Grines, A.J. Lansky, **G.W. Stone**. Impact of Age on the Outcomes of Women With Acute Myocardial Infarction Undergoing Primary Coronary Stenting. *Am J Cardiol* 2003;92:115L.
377. S.J. Kernis, K.J. Harjai, **G.W. Stone**, L.L. Grine<sup>1</sup>, J.A. Boura, W.W. O'Neill. Does Beta-Blocker Therapy Improve Clinical Outcomes of Acute Myocardial Infarction After Successful Primary Angioplasty? *Am J Cardiol* 2003;92:117L.
378. R. Mehran, E. Aymong, J. Moses, A. Lansky, **G. Stone**, M. Leon, I. Moussa, G. Dangas. Early Clinical Benefit with Bivalirudin Compared to Unfractionated Heparin During Percutaneous Coronary Intervention. *Am J Cardiol* 2003;92:134L.
379. R. Mehran, E. Aymong, **G. Stone**, J. Moses, M. Leon, G. Dangas. Very High Activated Clotting Time Values With Bivalirudin Therapy During Percutaneous Coronary Intervention Do Not Confer High Bleeding Risk. *Am J Cardiol* 2003;92:134L.
380. Iakovou, G. Dangas, G.S. Mintz, R. Merhan, A.J. Lansky, E.D. Aymong, E. Nikolsky, T. Vagaonescu, D.T. Ashby, **G.W. Stone**, M.B. Leon, J.W. Moses. Glycoprotein IIb/IIIa inhibitors use during percutaneous coronary interventions in very elderly patients increases the risk of hemorrhagic stroke. *Am J Cardiol* 2003;92:134L.
381. E. Nikolsky, R. Mehran, E. Aymong, G.S. Mintz, G. Dangas, A.J. Lansky, M. Negoita, R. Pop, J.W. Moses, **G.W. Stone**, M.B. Leon. The Impact of Anemia on Outcome After Percutaneous Coronary Intervention. *Am J Cardiol* 2003;92:138L.

382. E. Aymong, M. Fahy, A. Lansky, R. Mehran, C.L. Grines, D.A. Cox, C.E. Garcia, J.E. Tchong, J.J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, **G.W. Stone**. Can Stents and Glycoprotein IIb/IIIa Inhibitors Improve the Prognosis of Young Patients with Acute Myocardial Infarction? A Report from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Study. *Am J Cardiol* 2003;92:142L.
383. E. Nikolsky, E. Aymong, A.J. Lansky, **G.W. Stone**, M. Turco, D.A. Cox, J.E. Tchong, T. Stuckey, J.D. Carroll, J.J. Griffin, C.L. Grines. Anemia Worsens Prognosis After Primary Angioplasty in Acute Myocardial Infarction: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (Cadillac Study). *Am J Cardiol* 2003;92:143L.
384. S. Kesanakurthy, R. Mehran, A. Tchelebi, **G. Stone**, Z. Lasic, Z. Qin, T. Vagaonescu, N. Coplan, S. Balter, J.W. Moses, G.D. Dangas. Superior Clinical Outcomes with Bivalirudin During Intracoronary Brachytherapy. *Am J Cardiol* 2003;92:172L.
385. Halkin, E. Nikolsky, E. Aymong, R. Mehran, J.E. Tchong2, D.A. Cox, T. Stuckey, A.J. Lansky, **G.W. Stone**. The Survival Benefit of Periprocedural beta-Blockers in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty Is Determined by Use of These Drugs Before Admission. *Am J Cardiol* 2003;92:228L.
386. T.D. Vagaonescu, C.L. Grines, D.A. Cox, E. Garcia, J.E. Tchong, J.J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, J.D. Carroll, B.D. Rutherford, M. Fahy, C. Costantini, R. Mehran, **G.W. Stone**. Does Treatment with Abciximab Influence Survival in Patients with Acute Myocardial Infarction and Elevated Baseline White Blood Cell Count Undergoing Primary Angioplasty? The CADILLAC Trial. *Am J Cardiol* 2003;92:228L.
387. Masud A, Hermiller J, Brodie B, Cambier P, Haber R, Hall P, Hermann H, Popma J, **Stone G**, Ramee S, Caputo R, Cox D, Kuntz R, Feldman R. Thirty day and six month results of a multicenter randomized trial comparing distal protection with a filter-based catheter to balloon occlusion and aspiration during percutaneous intervention of saphenous vein grafts: The FIRE Trial. *Circulation* 2003;108:IV-640.
388. Prasad A, **Stone G**, Aymong A, et al. Impact of ST-segment resolution following primary angioplasty on outcomes after myocardial infarction in the elderly: An analysis from the CADILLAC trial. *Circulation* 2003;108:IV-537.
389. **Stone GW**, Ellis S, Cox DA, et al. The Pivotal U.S. Study of the Slow-Rate Release Polymer-Based Paclitaxel-Eluting TAXUS Stent in Patients with De Novo Coronary Lesions: 1-Year Clinical Results of the TAXUS-IV Trial. *Circulation* 2003;108:IV-533.
390. Stuckey TD, Cox DA, Brodie BR, Griffin JJ and **Stone GW**. Does stenting and glycoprotein IIb/IIIa receptor blockade improve ST segment recovery and outcomes in patients undergoing primary angioplasty in acute myocardial infarction: The CADILLAC trial. *Circulation* 2003;108:IV-577.
391. Ellis S, **Stone GW**, Popma JJ, et al. The TAXUS-IV trial: Final angiographic results. *Circulation* 2003;108:IV-533.

392. Halkin A, Aymong E, Nikolsky E, Tcheng JE, Rutherford BD, Costantini C, Grines CL and **Stone GW**. Marked survival benefit of peri-procedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty not previously treated with beta-blockers. *Circulation* 2003;108:IV-467.
393. Aymong E, Nikolsky E, Cox DA, Griffin JJ, Stuckey TD, Costantini C, Lansky AJ, and **Stone GW**. Additive prognostic value of myocardial perfusion score and ST segment resolution after primary angioplasty in AMI. Core laboratory analysis from the CADILLAC trial. *Circulation* 2003;108:IV-457.
394. Costantini C, Lansky AJ, Grines CL, Shirai K, Costa RA, Fahy M, Marginean H, Griffin JJ, and **Stone GW**. Impact of myocardial blush methodologies in predicting short- and long-term mortality after primary angioplasty - the CADILLAC trial. *Circulation* 2003;108:IV-415.
395. **Stone GW**, David A. Cox DA, Bruce R. Brodie BR, et al. Primary Angioplasty in Acute Myocardial Infarction with Distal Protection of the Microcirculation: Results from the Roll-in Phase of the EMERALD Trial. *Circulation* 2003;108:IV-414.
396. Hermiller JB, Ellis SG, Cannon L, Mooney M, Lui H, Midei M, Koglin J, Russell ME, Popma JJ, **Stone GW**. TAXUS IV Diabetic subset Analysis: Improvements in Nine-Month Outcomes in Diabetics on Oral Medication as Well as Insulin. *JACC* 2004 43:V:11A
397. **Stone GW**, Ellis, SG, O'Shaughnessy, CO, et al. Reduction in Late Loss and Restenosis in Patients with Small Vessels Treated With the Slow Rate-Release, Polymer-Based Paclitaxel-Eluting Stent: Results From TAXUS-IV. *JACC* 2004;43:V-87A
398. Mintz GS, Nikolsky E, Wijns W, Kobayashi Y, Erbel R, Mehran, R, Pop R, Colombo A, Serruys P, Carlier SG, Abizaid A, Vince DG, Moses JW, **Stone GW**, Leon, MB. Virtual Histology of Intravascular Ultrasound Images: feasibility and Clinical Correlations in Humans. *JACC* 2004;43:V-33A
399. Dae MW, Gao DW, Stillson CA, **Stone GW**, Ursell P. Hypothermia, but not N-Acetylcysteine or Fenoldopam, Prevents Experimental Contrast –Induced Nephropathy. *JACC* 2004;43:V-48A
400. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cambier P, Caputo R, Turco M, Kovach R, Brodie B, Herrmann HC, Cod DA, Mehran R, **Stone GW**. Predilation Before Distal Protection Device Placement Is Associated with Increased Procedure-Related Myocardial Infarction: Analysis from the FIRE Trial. *JACC* 2004;43:V 52A
401. Fujii K, Kobayashi Y, Mintz GS, Jacoboff D, Takebayashi, Yasuda T, Moussa I, Mehran R, Dangas G, Lansky AJ, Kreps E, Collins M, **Stone GW**, Leon MB, Moses JW. Creatinine-Kinase-MB Elevation After Coronary Artery Stenting In Lesions With Ruptured Plaque. *JACC* 2004;43:V-54A
402. Nikolsky E, Halkin A, Mehran R, Krieger SR, Ayomg EA, Lasic Z, Negoita M, Sulaiman R, Costa RA, Moses JW, **Stone GW**, Leon MB, Dangas GD. Vascular Complications Associated With Arteriotomy Closure Devices in Patients Undergoing Percutaneous Coronary Procedures: A Meta-Analysis. *JACC* 2004;43:V-62A

403. Takebayashi H, Kobayashi Y, Mintz GS, Fujii K, Yasuda T, Mehran R, Jacoboff D, Dangas GD, Lansky AJ, Moussa I, Collins MB, Kreps E, **Stone GW**, Leon MB, Moses JW. Intravascular Ultrasound and Drug-Eluting Stents. *JACC* 2004;43:V-65A
404. Weissman, NJ, Ellis S, Turco M, Greenberg J, Mann JT, Kutcher M, Wong, SC, O'Shaughnessy C, Russell M, **Stone GW**. TAXUS IV: Results From the Intravascular Ultrasound Substudy. *JACC* 2004;43:V-66A.
405. Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Yasuda T, Jacoboff D, Moussa I, Mehran R, Dangas G, Lansky AJ, Kreps E, Collins M, Stone GW, Leon MB, Moses JW. Contribution of Stent Underexpansion to Target Lesion Revascularization After Sirolimus-Eluting Stenting for In-Stent Restenosis. *JACC* 2004;43:V-66A
406. Jonas M, **Stone GW**, Hermiller J et al. Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment During Saphenous Vein Graft Stenting: Differential Effects After Randomization to Occlusion or Filter-Based Embolic Protection. *JACC* 2004;43:V-71A
407. Swaminathan A, Herrmann, HC, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Cox DA, Pop R, Fahy M, Mehran R, **Stone GW**. Impact of Vessel Size on Outcomes of Different Distal Protection Devices During Saphenous Vein Graft Intervention: A FIRE Trial Substudy. *JACC* 2004;42:V-72A.
408. Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Negoita M, Cristea E, Marginean H, Corral M, Tarawali M, Babb J, Cox DA, **Stone GW**. The Impact of Myocardial Blush Grade on Clinical Outcomes of patients Treated With Saphenous Vein Grafts and Thrombotic Native Coronary Arteries: Analysis from the X-TRACT Trial. *JACC* 2004;42:V-72A
409. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Cox DA, Mehran R, **Stone GW**. Relationship Between Embolic Material Retrieval and Adverse Events With Different Distal Protection Devices During Saphenous Vein Graft Stenting. *JACC* 2004;42:V-72A
410. **Stone GW**, Ellis SG, O'Shaughnessy C et al. Reduction in Late Loss and Restenosis in Patients With Small Vessels Treated With the Slow Rate-Release, Polymer-Based Paclitaxel-Eluting Stent: Results From TAXUS-IV. *JACC* 2004;42:V-87A.
411. Lasic Z, Mehran R, Nikolsky E, Negoita M, Costa R, Cox DA, Babb J, Nukta D, Bilodeau L, Cannon L, Stuckey TD, Hermiller J, Lansky AJ, Leon MB, **Stone GW**. Implications and Prevention of Large Periprocedural Myocardial Infarction After Percutaneous Intervention of Diseased Saphenous Vein Grafts and Thrombotic Native Coronary Lesions. *JACC* 2004;42:V-88A
412. Nikolsky E, Mehran R, Lansky AJ, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Rutherford B, **Stone GW**. Impact of Body Mass Index on Outcomes After Primary Angioplasty in Acute Myocardial Infarction: The Obesity Paradox. *JACC* 2004;42:V-244A.
413. Costa RA, Lansky AJ, Costantini CO, Tsuchiya Y, Caluser C, Sahid B, Fahy M, Nikolsky E, Aymong E, Negoita M, Mehran R, Cox DA, Grines CL, **Stone GW**. Predictors of Survival after Primary Percutaneous Coronary Intervention: The Impact of Myocardial Perfusion Grade in Female Patients. *JACC* 2004;42:V-266A.

414. Pellizzon GG, Marso SP, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Lansky AJ, Mehran R, Rutherford BD, **Stone GW**. Predictors of Reinfarction after ST Elevation Myocardial Infarction and Glycoprotein Receptor Blockade: Analysis From the CADILLAC Trial. JACC 2004;42:V-266A.
415. Nikolsky E, Halkin A, Aymong EA, Mehran R, Lansky A, Grines CL, Turco M, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey T, Cohen DA, Rutherford BD, **Stone GW**. Anemia Worsens Prognosis After Primary Angioplasty in Acute Myocardial Infarction: Analysis from the CADILLAC Trial. JACC 2004;42:V-267A.
416. **Stone GW**, Webb J, Cox DA et al.. Primary Angioplasty in Acute Myocardial Infarction With Distal Protection of the Microcirculation: Principal Results From the Prospective, Randomized EMERALD Trial. JACC 2004;42:V-285A.
417. Brodie BR, Costantini C, Aymong E, Stuckey TD, Cox DA, Zimetbaum P, McLaughlin M, Garcia E, Turco MA, Mehran R, Grines CL, Lansky AJ, **Stone GW**. Relationship Between Time to Reperfusion, ST-Segment Resolution, Myocardial Blush Scores and Mortality With Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Results from the CADILLAC Trial. JACC 2004;42:V-303A.
418. Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tchong JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong EA, Lansky AJ, **Stone GW**. Impact of Intravenous Beta-Blockade During Primary Percutaneous Intervention on Convalescent Left Ventricular Function. JACC 2004;42:V-303A.
419. Turco MA, **Stone GW**, Hall PX et al. The First Use of Medical Simulation for the Training of a New Device Roll-Out. JACC 2004;42:V-423A
420. Ellis S, Popma JJ, Weissman N, Turco M, Caputo R, Bergin P, Greenberg J, Raizner A, Koglin J, Russell ME, **Stone GW**. Impact of Late Loss on Clinical, Angiographic and Intravascular Ultrasound Outcomes in the TAXUS IV Trial. JACC 2004;42:V-12A.
421. Nikolsky E, Mehran R, Lasic Z, Weisz G, Negoita M, Na Y, Krieger CI, Dunne-Tramis A.M., Sikand R, Gilutz Y, Kesanakurthy S, Mogg M, Raj N, **Stone GW**, Moses JW, Leon MB, Dangas, GD. Anemia is a Novel Risk Factor for Contrast-Induced Nephropathy after Percutaneous Coronary Intervention. Am J Cardiol. 2004;94(suppl 6A): 23E
422. Mehran R, Kesanakurthy S, Dangas GD, Lasic Z, Iyer S, Yadegar D, Moussa I, Nikolsky E, Kreps E, Collins M, Weisz G, Sulaiman R, Scott T, Moses JW, **Stone GW**, Leon MB. The Risk of Stent Thrombosis after Drug-Eluting Stenting in an Unselected Population. Am J Cardiol. 2004;94(suppl 6A):26E
423. Turco MD, Virmani R, **Stone GW**, Webb J, Cox DA, Brodie BR, Rutherford B, Krucoff M, Gibbons R, Jones D, Weber DK, Mehran R. Is Debris Retrieval from the Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty of Prognostic Importance? Results from the Roll-In Phase of the EMERALD Trial. Am J Cardiol. 2004;94(suppl 6A):35E
424. Clark MA, Bakhai A, Lavelle T, Berezin R, Shi C, Justason B, **Stone GW**, Ellis S, Cohen D. Cost-Effectiveness of the TAXUS™ Paclitaxel-Eluting Coronary Stent System vs. Bare

- Stent Implantation in the Diabetic Population: The TAXUS IV Trial. *Am J Cardiol.* 2004;(suppl 6A):72E.
425. Nikolsky E, Kosinski E, Mishkel GJ, Kimmelstiel C, McGarry, Jr. TF, Mehran, R, Leon MB, Russell ME, Ellis SG, Negoita M, Pop R, Fahy M, **Stone GW**. Impact of Obesity on Revascularization and Restenosis Rates after Bare-Metal and Drug-Eluting Stent Implantation: Analysis from the TAXUS IV Trial. *Am J Cardiol.* 2004;94(suppl 6A):73E
  426. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cox DA, Cambier P, Caputo R, Turco M, Mehran R, Popma J, **Stone GW**. Thrombus Score in Saphenous Vein Grafts Predicts Adverse Events After Stenting with Distal Embolic Protection.. *Am J Cardiol.* 2004;94(suppl. 6A): 104E
  427. Moussa I, Leon MB, Lansky A, Lasic Z, Trubelja N, Yang YM, Katherine V, Ibraheem M, Mehran R, Cristea E, Coral M, Weisz G, Nikolsky E, Coplan N, Iyer S, Kreps E, Collins M, **Stone GW**, Dangas G, Moses JW. Treatment of Coronary Bifurcation Lesions with Sirolimus-Eluting Stents using the "Crush Technique." *Am J Cardiol.* 2004;94(suppl 6A):109E.
  428. Fujii K, Carlier SG, Mintz GS, Wijns W, Colombo A, Costa, Jr. JDR, Takebayashi H, Yasuda T, Costa RA, **Stone GW**, Moses JW, Leon MB. A Comparison of Morphologic Features Between Patients With and Without Diabetes: A Virtual Histology Study. *Am J Cardiol.* 2004;94(suppl 6A):115E.
  429. Yasuda T, Carlier S, Mintz GS, Fujii K, Takebayashi H, Costa, Jr. JDR, Costa R, Sano K, Kimura M, **Stone GW**, Leon MB, Moses JW. Intravascular Ultrasound Assessment of Ulcerated Ruptured Plaques in Saphenous Vein Grafts. *Am J Cardiol.* 2004;94(suppl 6A):116E.
  430. Weisz G, Moussa I, Kesanakurthy S, Halkin A, Yadegar D, Mehran R, Dangas G, Collins M, Kreps E, **Stone GW**, Moses JW. Early Experience with Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery. *Am J Cardiol.* 2004;94(suppl 6A):132E.
  431. Halkin A, Mehran R, Casey CW, Gordon P, Matthews R, Wilson BH, Leon MB, Russell ME, Ellis SG, **Stone GW**. Impact of Renal Insufficiency on Restenosis & Adverse Clinical Events after Paclitaxel Eluting and Bare metal Stent Implantation: Results from the TAXUS IV Trial. *Am J Cardiol.* 2004;94(suppl 6A).
  432. Costa RA, Lansky AJ, Tsuchiya Y, Mehran R, Cristea E, Pop R, Sahid B, Chen Y, Brodie BR, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Krucoff M, Gibbons R, **Stone GW**. Impact of Staged Nontarget Vessel Revascularization on Clinical Outcomes After Primary Stenting for Acute Myocardial Infarction: Results from the EMERALD Trial. *Am J Cardiol.* 2004;(suppl 6A):172E.
  433. Costa RA, Mintz GS, Carlier S, Moussa I, Fujii K, Takebayashi H, Takenori Y, Costa Jr, JDR, Tsuchiya Y, Lasic Z, Halkin A, Lansky AJ, Dangas G, Mehran R, Collins M, Kreps E, **Stone GW**, Colombo A, Leon MB, Moses JW. Coronary Bifurcation Lesions Treated with the Crush Technique: An Intravascular Analysis. *Am J Cardiol.* 2004;(suppl 6A):182E.
  434. Nikolsky E, Grines CL, Cox, DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Halkin A, Weisz G, Na Y, Slack S, Lansky AJ,

- Stone GW.** Implications of Stroke after Primary Angioplasty in Acute Myocardial Infarction. *Am J Cardiol.* 2004;94(suppl 6A):200E.
435. Costa RA, Lansky AJ, Tsuchiya Y, Cristea E, Tarawalli M, Sanchez R, Chen Y, Mooney M, Midei MG, Lui H, Strickland W, **Stone GW.** Impact of Female Sex on Outcomes After Paclitaxel-Eluting Stent Implantation in Patients with de Novo Coronary Lesions: Results of the TAXUS IV Trial. *Am J Cardiol.* 2004;94(suppl 6A):204E
436. Lasic Z, Mehran R, Moussa I, Nikolsky E, Addo T, Kipshidze N, Collins M, Kreps E, Qin J, Plent S, Tsounias E, Sikand R, Trubelja N, Mohammad A, Katsishevsky L, Moses JW, Leon MB, **Stone GW,** Dangas G. Sirolimus-Eluting Stents Plus Bivalirudin and Outcome of Percutaneous Coronary Intervention in Saphenous Vein Grafts: Results of the ADEST Study. *Am J Cardiol.* 2004;94(suppl 6A):209E.
437. Lasic Z, Mehran R, Nikolsky E, Gilutz Y, Addo T, Mogg M, Negoita M, Dunne-Tramis AM, Sikand R, Plent S, Collins M, Kreps E, Moussa I, Trubelja N, Tsounias E, Kipshidze N, Moses JW, Leon MB, **Stone GW,** Dangas G. Bivalirudin- and Sirolimus-Eluting Stents in Multilesion Percutaneous Coronary Intervention: Results of the ADEST Study. *Am J Cardiol.* 2004;94(suppl 6A):210E.
438. Mehran R, Kesanakurthy S, Dangas G, Iyer S, Spatareanu C, Elliott N, Bajraktari F, Lander J, Nikitina A, Moussa I, Kreps E, Collins M, Moses JW, **Stone GW,** Leon MB. Drug-Eluting Stents and Patterns of In-Stent Restenosis. *Am J Cardiol* 2004;94(suppl 6A):211E.
439. Caputo R, Cox DA, Popma JJ, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Ellis SG, **Stone GW.** Paclitaxel-Eluting Stents Reduce Need for Subsequent Coronary Artery Bypass Graft Surgery by Changing the Incidence and Pattern of Restenosis. *Am J Cardiol.* 2004;94(suppl 6A):211E
440. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, **Stone GW.** What is the Threshold for "Acceptable" Late Loss in the Drug-Eluting Stent Era? Insights from the TAXUS IV Angiographic Substudy. *Am J Cardiol.* 2004;94(suppl 6A):212E.
441. Kutcher MA, Applegate RJ, Hermiller J, Cox DA, O'Shaughnessy C, Feldman R, Moak AS, Smalling R, Mehran R, Russell ME, Ellis SG, **Stone GW.** Optimal Stent Implantation Pressure in the Drug-Eluting Stent Era: Observations from the TAXUS IV Study. *Am J Cardiol.* 2004;94(suppl 6A):213E.
442. Lasic Z, Mehran R, Negoita M, Gilutz Y, Mogg M, Roopan S, Plent S, Nikolsky E, Addo T, Krieger C, Pop R, Na Y, Arif M, Katsishevsky L, Tsounias E, Moussa I, Kreps E, Moses JW, Leon MB, **Stone GW,** Dangas G. Outcome of Percutaneous Coronary Intervention in Diabetic Patients Treated with Bivalirudin- and Sirolimus-Eluting Stents: Results of the ADEST Study. *Am J Cardiol.* 2004;94(suppl 6A):218E.
443. Sheldon WS, O'Shaughnessy CD, Popma JJ, Ellis SE, **Stone GW,** Williams DO, Davidson CJ, Brown CL, Russell, ME. Clinical and Angiographic Reduction in Restenosis in Longer Drug-Eluting Stents Compared with Bare-Metal Stents from the TAXUS IV Trial. *Am J Cardiol.* 2004;94(suppl 6A):220E.



444. Kandzari DE, Cox DA, Stuckey T, Turco M, Mehran R, Gersh BJ, Garcia E, Zimmetbaum P, McLaughlin M, Lansky AJ, Costantini CO, Grines CL, Tcheng JE, **Stone GW**. Reperfusion Success and Prognosis in patients with Anterior Compared with Nonanterior Infarction: Insights from the CADILLAC Trial. *Am J Cardiol*. 2004;94(suppl 6A): 230E.
445. Sorajja P, Gersh BJ, Cox DA, Turco MA, Tcheng JE, Carroll JD, Brodie B, Garcia E, Guagliumi G, Grines CL, **Stone GW**. Adverse Impact of Multivessel Disease on ST-Segment Recovery and Clinical Outcome in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. *Am J Cardiol*. 2004;94(suppl 6A):233E.
446. Halkin A, Turco M, Cox, DA, Stuckey TD, Garcia E, Guagliumi G, Mehran R, Rutherford BD, Griffin JJ, Tcheng JE, Grines CL, **Stone GW**. Outcomes of Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Excluded from Randomization: The CADILLAC Trial. *Am J Cardiol*. 2004;(suppl 6A):234E.
447. Costa RA, Lansky AJ, Tsuchiya Y, Mehran R, Cristea E, Tarawalli M, Corral M, Pop R, Cox DA, Kalynych A, Turco M, Schultheiss HP, Krucoff M, Gibbons R, Brodie BR, Webb J, Qureshi M, Dulas D, Rutherford B, **Stone GW**. Correlation Between Myocardial Blush Grades with ST-Segment Resolution, Infarct Size, and Clinical Outcomes After primary Coronary Intervention: Results from the EMERALD Trial. *Am J Cardiol*. 2004;94(suppl 6A):235E
448. Sorajja P, Lansky AJ, Grines CL, Costantini C, McLaughlin MG, Tcheng JE, Gersh BJ, **Stone GW**. Prediction of Survival After Primary Percutaneous Coronary Intervention by Integration of ST-Segment Recovery and Myocardial Blush. *Am J Cardiol*. 2004;94(suppl 6A):237E
449. Costa RA, Lansky AJ, Tsuchiya Y, Mehran R, Cristea E, Pop R, Sanchez R, Caluser C, Brodie BR, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Krucoff M, Gibbons R, **Stone GW**. Impact of Female Sex on Reperfusion Success and Clinical Outcomes in Patients with Acute Myocardial Infarction Undergoing Primary Coronary Stenting: Results from the EMERALD Trial. *Am J Cardiol* 2004;94(suppl6A):237E.
450. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps E, Colilns M, Colombo A, **Stone GW**, Leon MB, Moses JW. Nonuniform Strut Distribution Correlates with More Neointimal Hyperplasia after Sirolimus-Eluting Stent Implantation. *Circulation*, Nov. 2004; 110: 3430-3434.
451. **Stone GW**, Goldberg S, Mehran R, O'Shaughnessy C, Midei M, Siegel R, George B, Satler L, Raizner A, Negoita M, Fahy M, Arjomand-Fard H, Lansky AJ. A prospective, Randomized U.S. Trial of the PTFE Covered JOSTENT for the treatment of Diseased Saphenous Vein Grafts: The BARRICADE Trial. *JACC*, February 2005;45:27A
452. Dangas G, Mehran R, Lasic Z, Cox D, Ghali MGH, Henry TD, Teirstein PS, Stella JF, Browne, Jr. KF, Lewis SA, Knopf W, Kreps E, Leon MB, Collins M, Moses JS, **Stone GW**. Clinical Evaluatin of the Concomitant Use of Bivalirudin and Drug-eluting Stents: Results of the Prospective, Multicenter ADEST Study. *JACC*, February 2005;45:32A

453. **Stone GW**, Lincoff AM, Weisz G, Ebrahimi R, Keren G, Carr J, Feit F, Mehran R, Moses JW, Leon MB, Schwartz A. Predictors and Clinical Impact of the Procedural ACT Level in Patients Receiving Bivalirudin during PCI; A REPLACE II Sub Study. JACC, February 2005;45:32A
454. Fujii K, Carlier SG, Mintz GS, Yang Y, Moussa I, Costa RA, Costa, Jr. JR, Kimura M, Sano K, Dangas G, Mehran R, Lansky AJ, **Stone GW**, Moses JW, Leon MB. Intravascular Ultrasound Assessment of Stent Thrombosis After Successful Implantation of Sirolimus-eluting Stents. JACC, February 2005;45:34A.
455. Addo T, Lincoff AM, Mehran R, Dangas G, Kleiman NS, Jackman DS, Feit F, **Stone GW**. Impact of Vascular Closure Devices on Hemorrhagic Complications After Angioplasty with Bivalirudin Compared to Heparin Plus IIb/IIIa Inhibitors: Analysis from REPLACE-2. JACC, February 2005;45:36A.
456. Prasad A, **Stone GW**, Stuckey T, Constantini C, Zimelbaum P, McLaughlin M, Mehran R, Garcia E, Tchong J, Cox D, Grines C, Lansky A, Gersh B. Impact of Diabetes Mellitus on Myocardial Perfusion Following Primary Angioplasty in Patients with Acute Myocardial Infarction. JACC, February 2005;45:39A
457. Ellis S, **Stone GW**, Cox DA, Hermiller J, O'Shaughnessy CD, Mann JT, Turco M, Caputo R, Bergin PJ, Greenberg J, Raizner A, Popma JJ, Russell ME. Durability of the Polymer-Based, Paclitaxel-eluting TAXUS Stent in Key Patient Subsets: Two-Year Results from the TAXUS-IV Trial. JACC, February 2005;45:49A
458. Nikolsky E, Grines CL, Cox DA, Stuckey T, Garcia E, Guagliumi G, Tchong JE, Mehran R, Negoita M, Sikand R, Lansky AJ, **Stone GW**. Stroke After Primary Angioplasty in Acute Myocardial Infarction: Analysis From the CADILLAC Trial. JACC, February 2005;45:52A.
459. Costa RA, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Yasuda T, Costa, Jr. J, Kimura M, Sani K, Tsuchiya Y, Lansky AJ, Mehran R, Dangas GD, Collins M, Kreps EM, Moussa I, Colombo A, **Stone GW**, Moses JW, Leon MB. Coronary Bifurcation Lesions Treated with the Crush Technique – An Intravascular Ultrasound (IVUS) Analysis. JACC, February 2005;45:56A.
460. Fujii K, Carlier SG, Mintz GS, Wijns W, Colombo A, Costa RA, Costa, Jr. JR, Takebayashi H, Yasuda T, Kimura M, Sano K, Moussa I, Dangas G, Mehran R, **Stone GW**, Moses JW, Leon MB. Association of Arterial Remodeling and Plaque Characterization by Intravascular Ultrasound Virtual Histology™ Analysis. JACC, February 2005;45:59A.
461. Carlier S, Costa, Jr. JR, Mintz G, Fujii K, Sano K, Kimura M, Costa R, Kreps E, Moses JW, **Stone GW**, Martin MB. Tissue Characterization of Human Coronary Plaques by Spectral Analysis of Backscattered Intravascular Ultrasound Signal: Initial Experience in 400 Arteries. JACC, February 2005;45:60A
462. Nikolsky E, Lincoff MA, Mehran R, Sarembock IJ, Cohen DJ, Spriggs D, **Stone GW**. Contemporary Outcomes of Coronary Artery Perforation During Percutaneous Coronary Intervention: Insights from the REPLACE-2 Trial. JACC, February 2005;45:61A
463. Sheldon WS, O'Shaughnessy CD, Cox DA, Hermiller J, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Weissman N, Russell ME, Ellis SG, **Stone GW**.

Angiographic and Clinical Reduction in Restenosis with Polymer-based Paclitaxel-eluting Stents as a Function of Lesion Length: Analysis from the TAXUS IV Study. JACC, February 2005;45:64A

464. Nikolsky E, Kosinski E, Mishkel J, McGarry TF, Kimmelstiel C, Na Y, Negoita M, Mehran R, **Stone GW**. Impact of Body Mass Index on Restenosis after Bare-Metal and Drug-eluting Stent Implantation: Analysis from the TAXUS-IV Study. JACC, February 2005;45:65A.
465. Moussa I, Ellis SG, Moses JW, Jones M, Kereiakes DJ, McMartin D, Rutherford B, Mehran R, Collins M, Leon MB, Popma JJ, Russell ME, **Stone GW**. The Impact of Culprit Lesion Calcification in Patients Undergoing Paclitaxel-Eluting Stent Implantation: A TAXUS-IV Sub Study. JACC, February 2005;45:65A
466. Costa RA, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Yasuda T, Costa, Jr. J, Kimura M, Sano K, Tsuchiya Y, Lansky AJ, Mehran R, Dangas GD, Collins M, Kreps EM, Moussa I, Colombo A, Stone GW, Moses JW, Leon MB. Impact of Final Stent Dimensions on Restenosis After Crush Drug-Eluting Stent Implantation for Bifurcation Lesions. JACC, February 2005;45:66A
467. Rodriguez AE, Rodriguez-Alemparte M, Fernandez-Pereira C, Pocovi A, Tronge J, Kaluza G, Raizner A, **Stone GW**. Efficacy and Tolerability of Oral Rapamycin to Prevent Restenosis After Coronary Stent Implantation: The Prospective, Randomized ORAR II Study. JACC, February 2005;45:70A.
468. Escolar E, Mintz GS, Koglin J, Lam P, Popma JJ, Russell M, Ellis S, **Stone GW**, Grube E, Dawkins K, Weissman NJ. Neointima Thickness: A Direct Intravascular Ultrasound Measure of Late Lumen Loss from the TAXUS IV and VI IVUS Substudy. JACC, February 2005;45:71A.
469. Costa, Jr. JR, Carlier S, Mintz GS, Costa R, Fujii K, Sano K, Takebayashi H, Yasuda T, Kimura M, Moses JW, **Stone GW**, Leon MB. A Critical Appraisal of Stent Diameters Derived from Manufacturer's Compliance Charts: An Intravascular Ultrasound Study. JACC, February 2005;45:72A.
470. Mehran R, Dangas GD, Kesanakurthy S, Siegal RM, Abizaid A, Abizaid A, Moussa I, Mintz GS, Lansky AJ, Collins MB, Kreps E, Nikolsky E, Schwartz A, **Stone GW**, Moses JW, Leon MB. The Changing Incidence and Patterns of In-Stent Restenosis: Impact of Drug-eluting Stents. JACC, February 2005;45:75A.
471. Dangas GD, Mehran R, Webb J, Cox DA, Brodie BR, Qureshi M, Dulas D, Kalynych A, Turco M, Schultheiss HP, Rutherford B, Krucoff M, Gibbons R, Lansky AJ, Spatareanu C, Popp R, Jones D, Schwartz A, Stone GW. JACC, February 2005;45:80A.
472. Weisz G, Lincoff M, Moussa I, Ebrahimi R, Keren G, Carr J, Feit F, Mehran R, Moses JW, Leon MB, **Stone GW**. Relationship Between Activated Clotting Times and Procedural Outcomes in Patients Undergoing Coronary Intervention with Unfractionated Heparin and Glycoprotein IIb/IIIa Inhibitors. JACC, February 2005;45:82A
473. **Stone GW**, Brodie BR, Caputo R, Feldman R, Rogers C, Cox DA, Roberts DK, Masud AZ, Hermiller J, Cambier P, Kovach R, Negoita M, Schwartz A, Pop R, Fahy M, Sikand R, Mehran R. Thirty Day and Six Month Outcomes after Saphenous Vein Graft Stenting with

distal protection in patients Excluded from Randomized Trials; The FilterWire EX High Risk Registry. JACC, February 2005;45:83A.

474. **Stone GW**, Ellis SG, O'Shaughnessy CD, Satler L, Martin S, McGarry T, Turco M, Kereiakes DJ, Jacobs WC, Russell ME. A Prospective, Multicenter Randomized Trial of the Paclitaxel-Eluting Stent Versus Vascular Brachytherapy in Patients with Coronary In-Stent Restenosis: the TAXUS-V ISR Trial. JACC, February 2005;45:83A.
475. Tuschia Y, Lansky AJ, Costa RA, Pietras C, Mehran R, Cristea E, Sanchez R, Sahid B, Negoita M, Gilutz Y, Fay M, Dangas G, Carlier S, Moussa I, **Stone GW**, Moses JW, Leon MB, Muller R, Rink M, Storger H, Hauptmann KE, Grube E. The Effect of Everolimus-eluting Stents in Different Vessel Sizes – Results from the FUTURE 1 & 2 Trials. JACC, February 2005;45:85A.
476. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cox D, Cambier P, Cauto R, Turco M, Mehran R, Popma J, Stone GW. Severity of Thrombus Score Predicts Adverse Events after Stenting in Saphenous Vein Grafts with Distal Embolic Protection: the FIRE Trial. JACC, February 2005;45:85A.
477. Mintz GS, Koglin J, Lam P, Popma JJ, Russell ME, Grube E, Dawkins K, Ellis S. **Stone GW**, Weissman N. Paclitaxel Increases the Length of Stent that is Free of Intimal Hyperplasia: An Intravascular Ultrasound Analysis from TAXUS-IV and TAXUS VI. JACC, February 2005;45:88A.
478. **Stone GW**, Webb J, Cox DA, Brodie BR, Qureshi M, Dulas D, Kalynych A, Turco M, Schultheiss H, Rutherford B, Kruckoff MW, Gibbons R, Lansky AJ, Schwartz A, Pop R, Jones D, Mehran R. Effectiveness of Distal Embolic Protection During Primary Angioplasty: Final 6-Month Results from the Prospective, Randomized, EMERALD Trial. JACC, February 2005;45:200A.
479. **Stone GW**, O'Neill WW, Dixon S, Cox DA, Webb JG, Brodie B, Griffith JJ, Martin J, Gibbons R, Fahy M, Mehran R, Grines C. Predictors of Infarct Size by Technetium-99m Sestamibi Imaging after Angioplasty in Acute Myocardial Infarction: Meta-Analysis from Four contemporary Randomized Trials. JACC, February 2005;45:208A.
480. Krucoff M, Johanson P, Baeza R, Brodie BR, Webb J, Cox DA, Qureshi M, Dulas D, Kalynych A, Turco M, Schultheiss HP, Rutherford B, Lansky AJ, Negoita M, Na Y, Mehran R, **Stone GW**. Continuous 12-Lead ST-Segment Recovery Predicts Ejection Fraction, Clinical Outcome and Death after PCI for Acute ST-Elevation MI: Results from the EMERALD study. JACC, February 2005;45:208A.
481. Mehta RJ, O'Neill W, Harjai KJ, Boura J, Fox D, Brodie B, **Stone GW**, Grines CL. Primary Percutaneous Coronary Interventions: Predictors of One-Year Mortality Among Patients Surviving 30 Days. JACC, February 2005;45:211A.
482. O'Neill W, Grines CL, Dixon SR, Griffin JJ, Martin JL, Cox DA, Webb JG, Brodie BR, Mehran R, Gibbons RJ, Held J, **Stone GW**. Does a 90-Minute Door-to-Balloon time Matter? Observations from Four Current Reperfusion Trials. JACC, February 2005;45:225A.

483. O'Neill W, Dixon SR, **Stone GW**, Griffin JJ, Cox DA, Webb JG, Mehran R, Brodie BR, Martin JL, Gibbons RJ, Held J, Grines CL. Excellent Clinical Outcomes in High Risk Non-shock Acute Myocardial Infarction Patients Treated in the Contemporary Mechanical Reperfusion Era: A Pooled Analysis of 4 Clinical Trials. JACC, February 2005;45:232A.
484. Bartholomew BA, Grines CL, **Stone GW**, Nikolsky E, Boura JA, Cox DA, Brodie BR, O'Neill WW. Blood Loss after Primary Percutaneous Intervention is Associated with Death and Major Adverse Cardiac Events in Acute Myocardial Infarction. JACC, February 2005;45:233A.
485. De Luca G, Suryapranata, **Stone GW**, Antoniucci D, Tcheng JE, Neumann F-J, Van der Werf F, Antman EM, Topol EJ. Adjunctive Abciximab to Reperfusion Therapy in Patients with Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Trials. JACC, February 2005;45:251A
486. Nikolsky E, Singh M, Grines CL, Tcheng JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, Lansky AJ, Gersh BJ, O'Neill WW, Mehran R, **Stone GW**. Prediction of Mortality Following Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: The CADILLAC Risk Score. JACC, February 2005;45:347A.
487. Cox D, Lui H, Caputo R, Bonnier H, Kovach R, Masud AZ, Brodie B, Stuckey T, Herrmann H, Hermiller J, Lansky AJ, Tully G, **Stone GW**. Lower MACE Can be Achieved in SVG PCI: Stenting in Saphenous Vein Grafts with Distal Protection Using a Second Generation Filter-Based Catheter--The Combined BLAZE I and BLAZE II Registries. AM J CARDIOL 2005;96:9.
488. Moussa I, Mehran R, Lansky AJ, Krucoff M, Gibbons R, Qureshi M, Kalynych A, Turco M, Schultheiss HP, **Stone GW**. Does Vessel Size Have an Impact on The Efficacy of Distal Protection in Patients Undergoing Primary Angioplasty? An EMERALD Trial Analysis. AM J CARDIOL 2005;96:56.
489. Lansky AJ, Costa RA, Mehran R, Mori K, Cristea E, Na Y, Sanchez R, Cassidy L, Brodie B, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Gibbons R, Krucoff M, **Stone GW**. Association of Myocardial Blush Grade (MBG) and ST-Segment Resolution (STR) Predicts Late Major Ischemic Events after Mechanical Reperfusion in Acute Myocardial Infarction (AMI) - Results from the EMERALD Trial. AM J CARDIOL 2005;96:58.
490. Nikolsky E, Mehran R, Grines CL, Turco M, Cox DA, Tcheng JE, Brodie BR, Guagliumi G, Griffin JJ, Lansky AJ, Negoita M, Mercado DJ, Addo T, **Stone GW**. Impact of Baseline Platelet Count on Outcomes of Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Analysis from the CADILLAC trial. AM J CARDIOL 2005;96:61.
491. Lee E, Dangas G, Mehran R, Nikolsky E, Lansky AK, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff M, Gibbons R, Jones D, **Stone GW**. Microvascular Function and Myocardial Perfusion after Acute MI Angioplasty in Anterior Versus Non-Anterior Infarcts: Results from the EMERALD Trial. AM J CARDIOL 2005;96:111.

492. Nikolsky E, Mehran R, Grines CL, Turco M, Cox DA, Stuckey T, Guagliumi G, Griffin JJ, Lansky AJ, Na Y, Turcanu G, Sulaiman R, Kodali S, Spatareanu C, **Stone GW**. Blood Transfusion in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Analysis from the CADILLAC trial. *AM J CARDIOL* 2005;96:123.
493. Dangas G, Mehran R, Moses JW, Collins MB, Nikolsky E, Lansky AJ, Weisz G, Puruhit A, Leon MB, Brodie BB, Krucoff M, Grines C, Dixon SR, **Stone GW**. Epicardial Vessel Patency, Myocardial Perfusion and Infarct Size after Percutaneous Revascularization in Acute Anterior Versus Non-Anterior Infarcts: Pooled Analysis from 4 Randomized Trials. *AM J CARDIOL* 2005;96:128.
494. Brodie BR, Webb J, Cox DA, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford B, Antoniucci D, Stuckey T, Krucoff M, Gibbons R, Lansky AJ, Na Y, Mehran R, **Stone GW**. Impact of Time to Treatment with Primary PCI on Infarct Size and Myocardial Reperfusion: Results from the EMERALD Trial. *AM J CARDIOL* 2005;96:141.
495. Addo TA, Kodali S, Weinberger J, Mehran R, Fahy M, Pop R, Dixon S, O'Neill W, Grines C, Gibbons R, Leon MB, **Stone GW**. Multi-Vessel Disease Does not affect Infarct Size but affects Clinical Outcomes following Primary Angioplasty for Acute Myocardial Infarction. *AM J CARDIOL* 2005;96:142.
496. Sorajja P, **Stone GW**, Miller TD, Dangas G, Dixon S, Gersh BJ, O'Neill W, Mehran R, Gibbons R. Rescue Percutaneous Coronary Angioplasty is an Independent Predictor of Infarct Size in Patients with Acute Myocardial Infarction. *AM J CARDIOL* 2005;96:144.
497. Costa RA, Carlier SG, Mintz GS, Fujii K, Costa J, Kimura M, Sano K, Tanaka K, Cristea E, Na Y, Lansky AJ, Dangas GD, Mehran R, Collins M, Kreps EM, **Stone GW**, Moses JW, Leon MB. Incidence and Implications of Incomplete "Crush" Stent Apposition after Sirolimus-Eluting Treatment of Coronary Bifurcation Lesions - An Intravascular Ultrasound (IVUS) Analysis. *AM J CARDIOL* 96:179
498. Mori K, Lansky AJ, Costa RA, Mintz GS, Nikolsky E, Mehran R, Dangas G, Fahy M, Bittl JA, Harrington R, Kleiman NS, Feit F, Lincoff AM, **Stone GW**. Do Women Undergoing Elective Percutaneous Intervention (PCI) Have Similar Late Outcomes Compared to Men at All Age Groups? A REPLACE-2 Sub-study. *AM J CARDIOL* 2005;96:277.
499. Nikolsky E, **Stone GW**, Mehran R, Mori K, Weinberger J, Dangas G, Bittl JA, Harrington RA, Kleiman NS, Feit F, Na Y, Addo T, Negoita M, Cohen Y, Lincoff AM. Impact of Age and Choice of Procedural Anti-thrombotic Regimen on Ischemic and Hemorrhagic Outcomes following Percutaneous Coronary Intervention: Analysis from the REPLACE-2 Trial. *AM J CARDIOL* 2005;96:312.
500. Weissman N, Ellis SG, Mintz GS, Cannon LA, McGarry T, Greenberg J, Mann T, Kutcher MA, Koglin J, Russell ME, **Stone GW**. Intravascular Ultrasound Results from the TAXUS V Study: The TAXUS Stent Reduces Neointimal Proliferation in Long Lesions and Overlapping Stents. *AM J CARDIOL* 2005;96:317.
501. Carlier S, Weissman NJ, Mintz G, Koglin J, Turco M, Greenberg J, Mann JT, Kutcher M, Caputo R, Mehran R, Russell ME, Ellis SG, **Stone GW**. Paclitaxel-Eluting Stents Reduce Neointimal Hyperplasia in Both Diabetic and Non-Diabetic Coronary Arteries: A Volumetric Intravascular Ultrasound TAXUS-IV Study. *AM J CARDIOL* 2005;96:345.

502. Nikolsky E, Lincoff MA, Mehran R, Bittl JA, Harrington RA, Gurm H, Micsa L, Kesanakurthy V, Na Y, Addo T, Kodali S, Mercado DJ, Turcanu G, **Stone GW**. Lower Body Mass Index is a Risk Factor for Hemorrhagic Complications Following Percutaneous Coronary Interventions: Analysis from the REPLACE-2 Trial. *AM J CARDIOL* 2005;96:387.
503. Weisz G, Gray W, Hathaway L, Knipper P, Bertling C, Gong M, Na Y, **Stone GW**, Leon MB. Interventional Vascular Simulation is Mostly Beneficial for Training of Fellows and Teaching the Use of New Devices and Procedures. *AM J CARDIOL* 2005;96:399.
504. Fujii K, Ochiai M, Mintz GS, Carlier SG, Kan Y, Awano K, Masutani M, Ashida K, Kawasaki D, Ichikawa S, Ura S, Araki H, Lui J, Sano K, Kimura M, De Ribamar Costa J, **Stone GW**, Leon MB. Incidence and Location of Coronary Calcification in Chronic Total Occlusions: An Intravascular Ultrasound Study. *AM J CARDIOL* 2005;96:415.
505. Kimura M, Carlier SG, Mintz SG, Lui J, De Ribamar Costa J, Sano K, Takebayashi H, Yasuda T, Fujii K, Mehran R, Dangas G, Moses JW, Leon MB. Serial Intravascular Ultrasound Analysis of Vascular Remodeling at Sites of Incomplete Stent Apposition after Sirolimus-Eluting Stent Implantation. *AM J CARDIOL* 2005;96:436.
506. Costa R, Carlier SG, Mintz GS, Fujii K, Kimura M, Sano K, Qian J, Tanaka K, Lui J, Weinberger J, Dangas G, Collins M, Kreps EM, 2005;Moses JW, Martin MB. "Black Holes" in Sirolimus-Eluting Stent Failures: A Marker of an Aggressive Variant of Restenosis. *AM J CARDIOL* 2005;96:441.
507. Moses JM, Nikolsky E, Mintz GS, Dangas G, Grube E, Lansky AJ, Weisz G, Addo T, Na Y, **Stone GW**, Leon MB, Mehran R. Drug-Eluting Stents May Challenge the Treatment Paradigm of Patients with Intermediate Coronary Lesions. *AM J CARDIOL* 2005;96:470.
508. Esteban E, Mintz GS, Koglin J, Lam P, Popma J, Russell M, Ellis SG, **Stone GW**, Grube E, Dawkins K, Weissman NJ. Predictors of Target Lesion Revascularization after Drug-Eluting Stent Implantation: Angiographic and Intravascular Ultrasound of the TAXUS IV and VI Studies. *AM J CARDIOL* 2005;96:479.
509. Esteban E, Mintz GS, Koglin J, Lam P, Popma JJ, Russell ME, Ellis SG, **Stone GW**, Grube E, Dawkins K, Weissman NJ. Intimal Hyperplasia Thickness is Independent of Stent Size in Paclitaxel Polymer Coated (TAXUS) Stents. *AM J CARDIOL* 2005;96:480.
510. De Ribamar Costa J, Mintz GS, Carlier SG, Fujii K, Kimura M, Sano K, Costa R, Qian J, Tanaka K, Lui J, Na Y, Dangas G, Collins M, Krepps EM, Moussa I, Weisz G, **Stone GW**, Moses JW, Leon MB. Limitations of the Stent-Package Compliance Chart in Predicting Final Drug-Eluting Stent Dimensions: An Intravascular Ultrasound Study. *AM J CARDIOL* 2005;96:495.
511. De Ribamar Costa J, Leon MB, Mintz GS, Mehran R, Teirstein P, Waksman R, Mauri L, Turco M, Lee D, Fujii K, Costa R, Sano K, Kimura M, Qian J, Tanaka K, Lui J, Na Y, Dangas G, Weinberger J, Moussa I, Krepps EM, **Stone GW**, Moses JW, Carlier SG
512. Results from the Intravascular Ultrasound Sub-Study from the Angio-Sculpt® Scoring Balloon Catheter Multi-center Clinical Trial. *AM J CARDIOL* 2005;96:501.

513. Tanaka K, Carlier SG, Mintz GS, Fujii K, Kimura M, Sano K, De Ribamar Costa J, Lui J, **Stone GW**, Leon MB. The Accuracy of Stent Length Measurements Using Different Intravascular Ultrasound Motorized Transducer Pullback Systems. *AM J CARDIOL* 2005;96:509.
514. Fujii K, Carlier SG, Mintz SG, De Ribamar Costa J, Kimura M, Sano K, Tanaka K, Quin J, Lui J, Moussa I, Dangas G, Mehran R, Collins M, Kreps EM, **Stone GW**, Moses JW, Leon MB. A Pre-Rupture Intravascular Ultrasound Profile of Vulnerable Plaques. *AM J CARDIOL* 2005;96:513.
515. Jensen LO, Mintz GS, Carlier SG, Fujii K, Moussa I, Dangas G, Mehran R, **Stone GW**, Leon MB, Moses JM. Intravascular Ultrasound Analysis of the Residual Fibrous Cap after Vulnerable Plaque Rupture. *AM J CARDIOL* 2005;96:515.
516. Shishenhbor M, Lincoff AM, Lansky AJ, Mahaffey KW, **Stone GW**, Yang H, Marian AJ, Ferguson JJ, Califf RM, Goodman SG, Kleiman NS, Topol E, Hazen SL. Lipid Peroxidation Productions Independently Predict Mortality in Patients Presenting with Non-ST-segment Elevation Acute Coronary Syndrome: A SYNERGY Library Analysis. *Circulation* 2005;112:1902.
517. Addo TA, Kodali S, Weinberger J, Mehran R, Grines C, Gibbons R, Dixon S, O'Neill B, **Stone GW**. Impact of Multi-Vessel Disease on Infarct Size and Clinical Outcomes following Primary Angioplasty for Acute Myocardial Infarction. *Circulation* 2005;112:2698..
518. Shishenhbor M, Lincoff AM, Yang H, Mahaffey KW, Becker RC Goodman SG, Lansky AJ, Marian AJ, **Stone GW**, Kleiman NS, Ferguson JJ, Califf RM, Topol E, Hazen SL. Plasminogen Activator Inhibitor-1 Activity Predicts Clinical Outcome in Patients Presenting with Non-ST Segment Elevation Acute Coronary Syndromes: A SYNERGY Library Analysis. *Circulation* 2005;112:759.
519. Miller TD, Gibbons RJ, Web J, Cox DA, Brodie BR, Kruckoff MW, Mehran R, Lansky AJ, **Stone GW**. Diabetic Patients with Acute Myocardial Infarction Treated with Primary Angioplasty have Decreased Coronary Perfusion, Larger Infarcts and Higher Mortality then Patients without Diabetes. *Circulation* 2005;112:1830.
520. Mann T, Ellis SG, Kellett M, Russell Raymond ME, Coy K, Stine R, Masud AR Zaki, Douglas J, Koglin J, **Stone GW**. Beneficial Effect of the 2.25mm Paclitaxel-Eluting TAXUS Stent in Patients with Small Coronary Arteries: Results from the TAXUS-V Trial. *Circulation* 2005;112:2617.
521. Cannon LA, Ellis SG, Chang M, Jacobs C, Brown C, Kieval J, Turco M, Iyer SS, Koglin J, **Stone GW**. Risks and Benefits of the Paclitaxel-Eluting TAXUS Stent in large Vessels: Results from the 4.0mm Stent Subgroup of the TAXUS-V Trial. *Circulation* 2005;112:2619.
522. De Ribamar Costa J, Mintz GS, Carlier SG, Fujii K, Sano K, Kimura M, Qian J, Tanaka K, Na Y, Lui J, Sangas G, Moussa I, **Stone GW**, Weinberger J, Moses JW, Leon MB. Limitations of Manufacturers' Compliance in Predicting Final Drug-Eluting Stent Dimensions: An Intravascular Ultrasound Study. *Circulation* 2005;112:2892.
523. Fujii K, Carlier SG, Mintz GS, De Ribamar Costa J, Kimura M, Sano K, Lui J, Qian J, Tanaka K, Moussa I, Dangas G, Mehran R, Kreps EM, Collins M, **Stone GW**, Moses JW,



- Leon MB. A Pre-Rupture Intravascular Ultrasound Profile of Vulnerable Plaque. *Circulation* 2005;112:2910.
524. Ellis SG, O'Shaughnessy CD, Powers E, Goli V, Vellinga T, Midwall J, Low R, Russell ME, **Stone GW**. Twelve Month Clinical Outcomes of Paclitaxel-Eluting Stents in Complex Lesions (TAXUS V). Focus on Late Clinical Benefits and Stent Thrombosis Risk. *Circulation* 2005;112:3062.
525. **Stone GW**, Ellis SG, Cox DA, O'Shaughnessy CD, Mann T, Turco M, Caputo R, Greenberg JD, Raizner AE, Popma JJ, Koglin J, Russell ME. Three-Year Safety and Efficacy of the Polymer-Based Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial. *Circulation* 2005;112:2063.
526. Moses JM, Nikolsky E, Mintz GS, Dangas G, Grube E, Na Y, Lansky AJ, **Stone GW**, Leon MB, Mehran R. Drug-Eluting Stents in the Treatment of Intermediate Lesions: Pooled Analysis from Four Randomized Trials. *Circulation* 2005;112:3068..
527. Nikolsky G, Mehran R, Grines CL, Turco M, Cox DA, Tchong JE, Brodie BR, Guagliumi G, Griffin JJ, Addo T, Kodali S, Lansky AJ, Na Y, Negoita M, **Stone GW**. Higher Baseline Platelet Count predicts Reinfarction and Death in patients Undergoing Primary Percutaneous Coronary intervention for Acute Myocardial Infarction: Analysis from the CADILLAC Trial. *Circulation* 2005;112:3255.
528. Lansky AJ, Costa RA, Mehran R, Mori K, Cristea E, Silva EC, Addo T, Na Y, Dox DA, Brodie BR, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schiltheiss HP, Turco M, Gibbons R, Kruckoff M, **Stone GW**. Implications of Myocardial Blush Grade (MBG) on Late Clinical Outcomes After Mechanical Reperfusion in Acute Myocardial Infarction (AMI) and its Interaction with Different Biomarkers of Reperfusion – Results from the EMERALD Trial. *Circulation* 2005;112:3566.
529. Kimura M, Carlier SG, Mintz GS, De Ribamar Costa J, Sano K, Yasuda T, Fujii K, Takebayashi H, Mehran R, Dangas G, **Stone GW**, Moses JM, Leon MB. The Vascular Remodeling at the Site of Post-Procedural Incomplete Stent Apposition after Sirolimus-Eluting Stent Implantation. *Circulation* 2005;112:3576..
530. Weissman NJ, Ellis SG, Mintz GS, Cannon LA, McGarry T, Greenberg J, Mann JT, Kutcher M, Koglin J, Russell ME, **Stone GW**. Insights on the Effect of Polymer-Based Paclitaxel-Eluting Stents in Long Lesions and Overlapping Stents: Final Results from the TAXUS-V IVUS Substudy. *Circulation* 2005;112:3581.
531. Kimura M, Carlier SG, Mintz GS, Fujii K, DeRibamar Costa J, Sano K, Takebayashi H, Yasuda T, Dangas G, Mehran R, **Stone GW**, Moses JW, Leon MB. Stent Edge Vascular Responses after Sirolimus Eluting Stent Implantation: SA Serial Intravascular Ultrasound Analysis. *Circulation* 2005;112:3582.
532. Kloner RA, Gibbons RJ, Ross AM, Alexander RW, Forman MB, **Stone GW**. Impact of Time to Presentation and Reperfusion Modality on the Efficacy of Adenosine During Reperfusion Therapy for Acute Myocardial Infarction: The AMISTAD-2 Trial. *JACC* 2006;47(Suppl A):175A

533. Kodali S, Mehran R, Agahtehrani A, Addo T, Na Y, Dangas G, Goyal N, Nikolsky E, Weisz G, Sherman W, Lansky AJ, Rabbani L, **Stone GW**, Moses JW, Leon MB. Predictors of Target Lesion Revascularization and Target Vessel Revascularization After Implantation of Sirolimus-Eluting Stent: Pooled Analysis from 6 Randomized Trials and Registries. JACC 2006;47(Suppl A):187A
534. **Stone GW**, Ellis SG, Popma JJ, Cox DA, Hermiller J, Cannon L, Mann JT, Mehran R, Koglin J, Russell ME. Do the Traditional Risk Factors of Vessel Size, Lesion Length and Diabetes Mellitus Predict Restenosis With TAXUS Stents? Insights From a TAXUS Meta-Analysis. JACC 2006;47 (suppl A):188A
535. Pocock S, **Stone GW**, Fahy M, Mehran R, Lansky AJ, Nikolsky E, Moses JW, Leon MB, Popma JJ. Relationship Between Late Loss, Diameter Stenosis and Target Lesion Revascularization After Stent Implantation: An Examination of Surrogate Endpoints From a Pooled Analysis of Eight Large Randomized DES Trials. JACC 2006;47 (suppl A):188A
536. Mehran RM, Collins M, Krebs E, Lansky AJ, Dangas G, Moussa I, Weisz G, Nikolsky E, Negoita M, Kodali S, Liuzzo J, Sulaiman R, Moses JM, **Stone GW**, Leon MB. Overlapping Sirolimus-Eluting Stents: Analysis from the Matrix Registry. JACC 2006;47 (suppl A):203A
537. Nikolsky E, Mehran R, Grines CL, Turco M, Cox DA, Stuckey T, Guagliumi G, Griffin JJ, Lansky AJ, Negoita M, Mercado DJ, Moussa I, Na Y, **Stone GW**. Blood Transfusion in patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Analysis from the CADILLAC Trial. JACC 2006;47 (suppl A):215A
538. Lee EA, Dangas G, Mehran R, Nikolsky E, Lansky AJ, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoinucci D, Kruckoff MW, Gibbons RJ, Jones D, **Stone GW**. Microvascular Flow and Myocardial Perfusion After Acute MI Angioplasty in Anterior Versus Non-Anterior Infarcts: Results from the EMERALD Trial. JACC 2006;47 (suppl A):220A
539. Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Russell ME, **Stone GW**. Early and Late Stent Thrombosis After Paclitaxel-Eluting Stents: Analysis From the Integrated TAXUS Randomized Trail Program. JACC 2006;47 (suppl A):221A
540. Nikolsky E, Mehran R, Dangas G, Leon MB, Moses JW, Lansky AJ, Na Y, Lincoff AM, **Stone GW**. Risk Score for Prediction of Major Bleeding After Percutaneous Coronary Intervention. JACC 2006;47 (suppl A):231A
541. Cohen MG, Danna P, Fearon W, Price MJ, Weisz G, Moses JW, Yeung A, Cohen P, Mehran R, Madyoon H, Mathur V, Leon MB, Collins M, **Stone GW**, Rogers C. Safety and Performance of Targeted Renal Therapy for Prevention of Contrast-Induced Nephropathy: Data From the Be-Rite Registry. JACC 2006;47 (suppl B):29B
542. Weisz, G, Gray W, Hathaway L, Knipper P, Bertling C, Gong M, **Stone GW**, Leon MB. Interventional Vascular Simulation is Mostly Beneficial for Training of Fellows and Teaching the Use of New Devices and Procedures. JACC 2006;47 (suppl B):10B
543. Mintz G, Weissman NJ, Popma J, Dawkins K, Grube E, Ellis S, Katz-Sawyer D, Lam P, Koglin J, **Stone GW**. What is the Best Quantitative Surrogate of Target Lesion

- Revascularization? An Angiographic and Volumetric Intravascular Ultrasound Meta-analysis from the TAXUS IV, V and VI Trials. JACC 2006:47 (suppl B):11B
544. Costa RA, Lansky AJ, Cristea E, Fahy M, Leon MB, Moses JW, **Stone GW**. Methodology and Validation of Myocardial Blush Grade (MBG) Assessment in patients with Acute Myocardial Infarction (AMI) Undergoing Mechanical Reperfusion. JACC 2006:47 (suppl B):19B
545. Mintz G, Weissman N, Dawkins K, Grube E, Ellis S, Fernandez S, Greenberg J, Kutcher M, Zhou F, Koglin J, **Stone GW**. Frequency, Predictors and Clinical Outcomes of Late-Acquired Incomplete Stent Apposition in Patients Treated with TAXUS Stents: A Volumetric Intravascular Ultrasound Meta-Analysis From the TAXUS IV, V and VI Trials. JACC 2006:47 (suppl B):26B
546. Mintz G, Weissman N, Dawkins K, Grube E, Ellis S, Fong H, Cannon L, Masud ARZ, Mandinov L, Koglin J, **Stone GW**. TAXUS Neutralizes the Impact of Diabetes Mellitus on In-Stent Restenosis: A Volumetric Intravascular Ultrasound Meta-Analysis From the TAXUS IV, V and VI Trials. JACC 2006:47 (suppl B):30B
547. Costa RA, Lansky AJ, Mori K, Mehran R, Sahid B, Cristea E, Silva EC, Brodie BR, Dulas D, Cox DA, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Kruckoff M, Gibbons R, **Stone GW**. Impact of Staged Non-Target Vessel Revascularization of Clinical Outcomes Following Primary Stenting for Acute Myocardial Infarction (AMI): Results from the EMERALD Trial. JACC 2006:47 suppl B):52B
548. Mori K, Lansky AJ, Costa RA, Mehran R, Cristea E, Sahid B, Filipovic Z, Brodie BR, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Kruckoff M, Gibbons R, **Stone GW**. Gender Differences in Outcomes After Primary Stenting for Acute Myocardial Infarction: A Substudy From the EMERALD Trial. JACC 2006:47 (suppl B):52B
549. Fujii K, Ochiai M, Mintz GS, Kan Y, Awano K, Mastuani M, Ashida K, Ohyanagi M, Ichikawa S, Ura S, Araki H, **Stone GW**, Moses JW, Leon MB, Carlier SG. Procedural Implications for the Intravascular Ultrasound Morphologic Features of Chronic Total Coronary Occlusions. JACC 2006:47 (suppl B):54B
550. Sano K, Carlier S, Mintz GS, Fujii K, Costa J, Kimura M, Tanaka K, Dangas G, Mehran R, Moussa I, Kreps E, Collins MB, **Stone GW**, Moses JE, Leon MB. The Magnitude of Neointimal Hyperplasia as a Mechanism of In-Stent Restenosis in Diabetes Mellitus After Sirolimus Eluting Stent Implantation: A Volumetric Intravascular Ultrasound Study. JACC 2006:47 (suppl B):10B
551. DeRibamar Costa J, Mintz GS, Carlier SG, Fujii K, Kimura K, Sano K, Tanaka K, Na Y, Lui J, Biro S, Castellanos C, Dangas G, Kreps E, Collins M, Moussa I, **Stone GW**, Moses JW, Leon MB. Assessing Drug-Eluting Stent Expansion: Lessons Learned from Intravascular Ultrasound. JACC 2006:47 (suppl B):11B
552. Manoukian SV, Voeltz MD, Feit F, Mehran R, Dangas GD, Nikolsky E, Lincoff AM, King III, SB, Ohman EM, **Stone GW**. Transfusion is Associated with Increased 30-Day Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUITY Trial. AJC 2006:98(suppl 8A):1M.

553. Feit F, Manoukian SV, Ebrahimi R, Pollack CV, Ohman EM, Attubato MJ, Mehran R, **Stone GW**. Is Bivalirudin Monotherapy Sufficient For Diabetic Patients With Acute Coronary Syndrome (ACS) Undergoing PCI? AJC 2006;98(suppl 8A):14M.
554. Alexander KP, Ohman EM, Bertrand ME, Feit F, Pollack CV, Hoekstra J, Gersh BJ, White HD, **Stone GW**. Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results from the Randomized ACUITY trial. AJC 2006;98(suppl 8A):18M.
555. Hermiller JB, Ellis SG, Cox DA, O'Shaughnessy CD, Mann T, Turco M, Caputo R, Bergin PJ, Greenberg JD, Raizner AE, Popma JJ, Koglin J, **Stone GW**. Four-Year Clinical Outcomes of the Polymer-based Paclitaxel-eluting TAXUS Stent: The TAXUS IV Trial. AJC 2006;98(suppl 8A):27M.
556. Mehran R, Moses JW, Nikolsky E, Dangas G, Manoukian S, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Gersh B, Pocock SJ, Ware JH, Feit F, Colombo A, **Stone GW**. Drug Eluting Stents in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions: The ACUITY Trial. AJC 2006;98(suppl 8A):27M.
557. Solinas E, Nikolsky E, Pucelikova T, Franklin-boind T, Fahy M, Syros G, Boland P, Bur A, Cho C, Moussa I, Dangas G, **Stone GW**, Moses J, Leon MB, Mehran R. Treatment of Drug-Eluting Stent Failure: Analysis of Consecutive Patients. AJC 2006;98(suppl 8A):30M.
558. Nikolsky E, Lincoff M, Harrington RA, Bittle JA, Feit F, Solinas E, Pucelikova T, Agahtehrani A, Costa J, Kesanakurthy V, Kimura M, Mehran R, Dangas G, **Stone GW**. Decrease in Hemoglobin in the Absence of Overt Bleeding after Percutaneous Coronary Intervention is a Predictor of One-year Mortality. AJC 2006;98(suppl 8A):31M.
559. Ebrahimi R, Manoukian SV, Feit F, Lincoff AM, Mehran R, Pollack CV, Cox DA, Dyke C, Gersh BJ, Steinhubl SR, Moses JW, Ohman EM, White HD, **Stone GW**. Implications of Preoperative Thienopyridine Use Prior to Coronary Artery Bypass Graft Surgery\_ Time for a Paradigm Shift? AJC 2006;98(suppl 8A):31M.
560. Cheruvu PK, Finn A, Virmani R, Goldstein J, **Stone GW**, Gardner C, Caplan J, Muller JE. Focality and Composition of Thin Cap Fibroatheroma, Suspected Precursors of Coronary Plaque Rupture. AJC 2006;98(suppl 8A):36M.
561. Jozic J, Steinhubl SR, Dangas GD, Hooper WC, **Stone GW**. Markers of Inflammation and Their Changes Over Time in Relationship to Clinical Outcomes and Therapeutic Interventions in the Acute Coronary Syndrome Patient: Results From the ACUITY Inflammation Sub-Study. AJC 2006;98(suppl 8A):36M.
562. Manoukian SV, Voeltz MD, Feit F, Mehran R, Nikolsky E, Dangas GD, Ebrahimi R, Lincoff AM, King III SB, **Stone GW**. Major Bleeding is Associated with Increased 30-Day Mortality and Ischemic Complications in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUITY Trial. AJC 2006;98(suppl 8A):45M.

563. Webb JG, Kuck K-H, Stone G, Vahanian A, Sarano M, Weismann N, Buller C, James S, Harnek J. Percutaneous Mitral Annuloplasty With The MONARC System: Preliminary Results From The EVOLUTION Trial. *AJC* 2006;98(suppl 8A):49M.
564. Tanaka K, Carlier SG, Mintz GS, Castellanos C, McPherson J, Farhat N, Marso S, de Bruyne B, Serruys P, **Stone GW**. High Risk Fibroatheroma Lesions Are Remote from the Minimal Lumen Area Site: A Virtual Histology IVUS Analysis from the PROSPECT Study. *AJC* 2006;98(suppl 8A):94M.
565. Sano K, Mintz GS, Carlier SG, Costa JdR, Liu X, Kimura M, Tanaka K, Dangas GD, Mehran R, **Stone GW**, Leon MB, Moses JW. Assessing Intermediate Left Main Coronary Lesions: Lessons Learned from Intravascular Ultrasound. *AJC* 2006;98(suppl 8A):99M.
566. Leon M, Klauss V, **Stone G**, Suzuki T, Ferreira RC, Konig A, Wijns W. The Right Coronary Artery Has a Different Plaque Component Profile When Compared to the Other Two Epicardial Arteries:VH-IVUS Report from the Global VH-IVUS Registry. *AJC* 2006;98(suppl 8A):103M.
567. Ellis SG, Cannon LA, Mann T, Greenberg JD, DeMaio S, Goli V, Knapp W, McGarry T, Kutcher MA, Koglin J, **Stone GW**. Safety and Efficacy of the Polymer-based, Paclitaxel-Eluting TAXUS Stent in Complex Lesions: Two-Year Clinical Results from the TAXUS V de novo Trial. *AJC* 2006;98(suppl 8A):142M-143M.
568. Ellis SG, Kent K, Raizner AE, Zaki-Masud AR, Kereiakes DJ, O'Shaugnessy CD, Turco MA, Martin SL, Brown CL, Greenberg J, McGarry T, Koglin J, **Stone GW**. 1-Year Results from the TAXUS-V ISR Trial: A Randomized Trial of Paclitaxel-Eluting Coronary Stents versus Vascular Brachytherapy for Treatment of Restenosis in Bare Metal Stents. *AJC* 2006;98(suppl 8A):143M.
569. Mori K, Lansky AJ, Costa RA, Bertrand M, Feit F, Pietras C, Cristea E, Pocock S, Ohman M, **Stone GW**. Angiographic Findings in the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. *AJC* 2006;98(suppl 8A):144M-145M.
570. Solina E, Nikolsky E, Pucelikova T, Franklin-Bond T, Fahy M, Syros G, Goyal N, Sano K, Costa J, Collins M, Dangas G, **Stone GW**, Moses J, Leon MB, Mehran R. Patterns of In-Stent Restenosis in Patients Treated with Drug-Eluting Stents and Predictors of Repeat Failure. *AJC* 2006;98(suppl 8A):178M.
571. Kimura M, Mintz GS, Carlier SG, Na Y, Dani L, Castellanos C, Biro S, Lui J, Mori K, Tanaka K, Sano K, Fujii K, Liu X, Costa JdR, Nikolsky E, Mehran R, Lansky AJ, Dangas G, Kreps E, Collins M, **Stone GW**, Moses JW, Leon MB. Different Mechanisms of Neointimal Hyperplasia Formation at the Edges vs the Body of Sirolimus Eluting Stents. An Intravascular Ultrasound Analysis. *AJC* 2006;98(suppl 8A):181M.
572. Hamon M, Rasmussen LH, Manoukian S, Cequier A, Lincoff M, Rupprecht H-J, Bersh B, Bertrand M, **Stone GW**. Impact of the arterial access site on bleeding complications in patients with acute coronary syndromes undergoing early invasive management: The ACUITY Trial. *AJC* 2006;98(suppl 8A):187M.
573. Pinto DS, **Stone GW**, McLaurin BT, Cox DA, Shi C, Schneider EA, Machon DA, Berezin RH, Mehran R, Moses JW, Ohman EM, White HD, Bertrand ME, Lincoff AM, Cohen DJ.

- Cost-Effectiveness of Bivalirudin Monotherapy for Patients Undergoing an Early Invasive Management for Acute Coronary Syndromes without ST-Elevation: Results from the Randomized ACUTY Trial. *AJC* 2006;98(suppl 8A):195M.
574. Cox D, Pollack CV, Hoekstra J, White HD, Ebrahimi R, Rasmussen LH, Rupprecht HJ, **Stone GW**. Safety and Efficacy of Bivalirudin in ACS Patients Undergoing PCI: Impact of Duration of Upstream Infusion in the ACUTY Trial. *AJC* 2006;98(suppl 8A):195M-196M.
575. Costa RA, **Stone GW**, Mahaffey K, Califf R, White H, Ferguson J, Gulba D, Col J, Lansky AJ. Impact of Enoxaparin on Coronary Flow and Myocardial Blush Grade After Early Invasive Treatment During Acute Coronary Syndrome (ACS) - Results From the SYNERGY Library. *AJC* 2006;98(suppl 8A):196M-197M.
576. Solinas E, Nikolsky E, Pucelikova T, Na Y, Orta M, Cole H, Desgupta N, Irozuru M, Magennis E, Morales A, Dangas G, **Stone GW**, Moses GW, Leon MB, Mehran R. Gender Comparison in Patients Undergoing PCI using Sirolimus-Eluting Stents. *AJC* 2006;98(suppl 8A):249M-250M.
577. Mori K, Lansky AJ, Costa RA, Cequier A, Pollack CV, Hoekstra J, Bertrand M, Gersh B, **Stone GW**. Gender Differences in Outcomes Following Percutaneous Coronary Intervention of Patients with Non-ST elevation Acute Coronary Syndrome: A Substudy of the Acute Catheterization and Urgent Intervention Triage strategY (ACUTY) trial. *AJC* 2006;98(suppl 8A):250M.
578. Cheruvu PK, Finn AV, Gardner C, Caplan J, Goldstein JA, **Stone GW**, Virmani R, Muller JE. Density and Distribution of Thin-Cap Fibroatheroma and Ruptured Plaque in Human Coronary Arteries -- A Pathologic Study. *Circulation* 2006;114(suppl II):II-22.
579. Prasad A, **Stone G**, Stuckey T, Constantini C, Mehran R, Garcia E, Tcheng J, Cox D, Grines C, Lansky A, Gersh, B. Relationship Between Leukocyte Count, Myonecrosis, Myocardial Perfusion and Outcomes Following Primary Angioplasty. *Circulation* 2006;114(suppl II):II-347.
580. Escolar E, Mintz GS, Popma JJ, Lam P, Michalek A, Kim S-W, Dawkins KD, Madinov L, Koglin J, Grube E, Ellis SG, **Stone GW**, Weissman NJ. Angiographic versus Intravascular Ultrasound Parameters of Drug-Eluting Stent Efficacy: A Meta-Analysis from TAXUS IV, V and VI. *Circulation* 2006;114(suppl II):II-395.
581. Koizumi T, Fitzgerald PJ, Honda Y, Ellis SG, Kent K, Martin SL, Brown CL, Masud ARZ, Patterson JB, Greenberg J, Koglin J, **Stone GW**. A Randomized Comparison of Paclitaxel-Eluting Stents vs. Intra-coronary Brachytherapy in the Treatment of In-stent Restenosis: Intravascular Ultrasound Results from the TAXUS-V ISR Trial. *Circulation* 2006;114(suppl II):II-547.
582. **Stone GW**, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Mehran R, Moses JW. Comparison of Heparin Plus IIb/IIIa Inhibition Versus Bivalirudin With or Without IIb/IIIa Inhibition in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUTY Trial. *Circulation* 2006;114(suppl II):II-551.

583. Feit F, Manoukian SV, Ebrahimi R, Pollack CV Jr, Ohman EM, Attubato MJ, Mehran R, **Stone GW**. Bivalirudin Monotherapy Improves 30 Day Clinical Outcomes In Diabetics With Acute Coronary Syndrome (ACS). Report From The ACUTY Trial. *Circulation* 2006;114(suppl II):II-551.
584. White HD, Hoekstra J, Pollack CV Jr, Ohman EM, **Stone GW**. Safety and Efficacy of Crossover from Enoxaparin or Unfractionated Heparin to Bivalirudin: Results from ACUTY. *Circulation* 2006;114(suppl II):II-551.
585. Manoukian SV, Voeltz MD, Feit F, Ebrahimi R, Mehran R, Nikolsky E, Moses JW, Lincoff AM, King SB III, **Stone GW**. Major Bleeding is Associated with Increased Short-Term Mortality and Ischemic Complications in Non-ST Elevation Acute Coronary Syndromes: The ACUTY Trial. *Circulation* 2006;114(suppl II):II-551-II-552.
586. Costa R, **Stone GW**, Clare R, Mahaffey KW, Califf RM, White HD, Ferguson JJ III, Gulba DC, Col JJ, Lansky A. Impact of Enoxaparin on Thrombus Formation, Coronary Blood Flow, and Myocardial Perfusion After Early Invasive Treatment During Acute Coronary Syndrome: Results from the SYNERGY Library. *Circulation* 2006;114(suppl II):II-600.
587. **Stone GW**, Colombo A, Grube E, Ellis SG, Dawkins KD, Jovanovich D, Koglin J. Long-Term Outcomes Following Treatment of In-Stent Restenosis with Drug-Eluting Stents: Insights from the TAXUS Meta-Analysis. *Circulation* 2006;114(suppl II):II-689.
588. Ohman EM, Bertrand ME, Feit F, White HD, **Stone GW**, Pollack CV Jr, Hoekstra J, Gersh BJ. Outcomes in Elderly Patients Treated with Bivalirudin Monotherapy Versus Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results from the Randomized ACUTY Trial. *Circulation* 2006;114(suppl II):II-701.
589. Desmet W, Rasmussen LH, Lincoff AM, Cequier AR, Rupprecht H-J, Gersh BJ, Manoukian SV, Bertrand ME, **Stone GW**. Safety and Efficacy of Bivalirudin in Patients with non-ST Elevation Acute Coronary Syndromes Undergoing Medical Management: Results from the Randomized ACUTY Trial. *Circulation* 2006;114(suppl II):II-701.
590. Liu X, Mintz G, Carlier S, Sano K, Costa J Jr, Tanaka K, Moussa I, Dangas G, Mehran R, Lansky A, Collins M, **Stone G**, Moses J, Leon M. Intravascular Ultrasound Assessment of the Incidence and Predictors of Edge Dissections and Intramural Hematomas After Drug-Eluting Stent Implantation. *Circulation* 2006;114(suppl II):II-732.
591. Costa JR Jr, Leon MB, Mintz GS, Mehran R, Teirstein P, Sano K, Kimura M, Tanaka K, Liu X, Lui J, Na Y, Castellanos C, Biro S, Dani L, Rinker J, Dangas G, **Stone GW**, Moses JW, Carlier SG. Impact of Different Pre-dilatation Strategies on Stent Expansion: An Intravascular Ultrasound Study. *Circulation* 2006;114(suppl II):II-732.
592. **Stone GW**, Dixon SR, Foster M, Diaz C, Thambar S, Carrozza J, Griffin J, Nseir G, Rutherford BD, O'Neill W. Systemic Hypothermia to Prevent Contrast Nephropathy: the COOL RCN Pilot Trial. *Circulation* 2006;114(suppl II):II-811-II-812.
593. Pollack C, Hoekstra JW, White HD, Hollander JE, Diercks DB, Ebrahimi R, Rasmussen LH, Rupprecht H-J, **Stone GW**. Safety and Effectiveness of Bivalirudin in Non ST-Segment Elevation Acute Coronary Syndromes by Duration of Upstream Infusion in the

ACUITY Trial: Implications for Emergency Department and Upstream Management. *Circulation* 2006;114(suppl II):II-814.

594. Haugen SJ, Brodie BR, Cox DA, **Stone GW**, Lansky AJ, Carroll JD, Kruckoff MW, Mehran R, Lindenfeld J, Webb J. Left ventricular end diastolic pressure is a predictor of suboptimal myocardial reperfusion in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction. *JACC* 2007;49:9A.
595. Jozic J, Mehran R, Hooper WC, Steinhubl SR, Dangas G, **Stone GW**. Major bleeding in acute coronary syndrome patients is associated with a marked pro-inflammatory response: Results from the ACUITY inflammatory biomarker sub-study. *JACC* 2007;49:9A.
596. Miller CD, Diercks DB, Brogan GX, **Stone GW**, Gersh B, Pollack CV, Hoekstra JW, Peacock FW, Manoukian SV, Hollander JE, Blomkalns AL. Safety and efficacy of Bivalirudin in high-risk patients with acute coronary syndrome admitted through the emergency department: Implications for upstream management. *JACC* 2007;49:9A.
597. Ebrahimi R, Feit F, Dyke C, Moses J, Manoukian S, Lincoff AM, Gersh B, Mehran R, **Stone GW**. Outcome in Acute Coronary Syndrome Patients Managed Surgically Based on Clopidogrel Exposure and Delay to Surgery. *JACC* 2007;49:9A.
598. Ostuka M, Weustink A, Mollet N, Dudek D, Serruys P, Ligthart J, Hamers R, Vouvouri E, DeFeyter P, Van Pelt N, **Stone GW**, Wijns W, Verheye S, Bruining N. Three-dimensional quantification of coronary plaque burden by 64-slice computed tomography: A PROSPECT-MSCT study. *JACC* 2007;49:9A.
599. Ebrahimi R, Lincoff AM, Feit F, Mehran R, Moses J, Syke C, Gersh B, **Stone GW**, Manoukian S. Upstream therapy with Bivalirudin is as safe and effective as heparin for patients with acute coronary syndrome undergoing coronary artery bypass surgery: A report from the ACUITY trial. *JACC* 2007;49:9A.
600. **Stone GW**, Wennerblom B, Mintz GS, Lansky AJ, Mehran R, Marso S, Carlier S, DeBruyne B, Farhat N, Serruys P, McPherson J. A Prospective, natural history study of multimodality invasive imaging to characterize vulnerable plaque. First report of the baseline findings from the PROSPECT Trial. *JACC* 2007;49:9B.
601. **Stone GW**, Pollack C, Mehran R, Hoekstra J, Ware JH, Ohman EM, McLaurin BT, Cequir A, Feit F, Rasmussen LH, Colombo A, Desmet W, Lincoff AM, Ebrahimi R, Bertrand ME, Moses JW, Cox DA, Aylward P, Darius H, Pocock SJ, White HD, Hamon M, Rupprecht HJ, Lansky A. A prospective, randomized trial of Bivalirudin in acute coronary syndromes: One year results from the ACUITY Trial. *JACC* 2007;49:9B.
602. **Stone GW**, Koglin J, Ellis SG, Grube E, Colombo A, Baim D, Dawkins KD. Are paclitaxel-eluting stents safe and effective compared to bare metal stents? Long term results from the TAXUS Meta-analysis. *JACC* 2007;49:9B.
603. Mehran R, Ohman M, Bertrand M, Manoukian S, Dangas G, Kirtane A, Gersh B, Cequir A, **Stone GW**, Hamon M, Stella J, Pollack C, Cohen D, Feit F, Desmet W, Stuckey T, Pocock S, Hoekstra J. Chronic kidney disease is associated with increased mortality, bleeding and ischemic events in moderate and high-risk patients with acute coronary syndromes: An ACUITY substudy. *JACC* 2007;49:9B.



604. Nikolsky E, Pucelikova T, Mehran R, **Stone GW**, Bittle JA, De Los Santos F, Kimura M, Feit F, Solinas E, Dangas G, Lincoff AM, Harrington RA. Implications of hemoglobin decrease in the absence of overt bleeding after percutaneous coronary intervention. *JACC* 2007;49:9B.
605. Solinas E, Rabbani L, Lansky AJ, Kreps E, **Stone GW**, Weisz G, Moussa I, Sano K, Obunai K, Atmakuri S, Moses JW, Pucelikova T, Boland P, Franklin-Bond T, Nikolsky E, Leon MB, Mehran R, Dangas G, Kirtane A, Syros G. Long-term (one year) follow-up after treatment of drug-eluting stent Restenosis (DES-ISR) with repeat DES: to SWITCH or not to SWITCH? *JACC* 2007;49:9B.
606. Manoukian SV, Mehran R, Ebrahimi R, Fazel R, Dangas G, Feit F, Voeltz MD, Hoekstra J, King SB, Ohman EM, Lincoff AM, Pollack CV, Hamon M, **Stone GW**. Major bleeding is an independent Predictor of short-term mortality in moderate and high-risk acute coronary syndromes: An analysis from the ACUITY Trial. *JACC* 2007;49:9B.
607. Kirtane AJ, Pollack C, Feit F, Bertrand M, Desmet W, Cequir A, Ohman EM, **Stone GW**, Dangas G, Manoukian S, Mehran R, Stuckey T, Pocock S, Gersh B, Hamon M, Cohen D, Hoekstra J, Stella J. Outcomes of Bivalirudin in moderate-and high-risk patients with acute coronary syndromes and renal insufficiency: An ACUITY substudy. *JACC* 2007;49:9B.
608. Kimura M, **Stone GW**, Popma JJ, Mehran R, Baim DC, Ellis SG, Kirtane A, Koglin J. Predictors for Diffuse in-stent Restenosis after Taxus stent implantation: Analysis from the TAXUS IV and V Trials. Predictors for diffuse in-stent Restenosis after TAXUS stent implantation: Analysis from the TAXUS IV and V trials. *JACC* 2007;49:9B.
609. Pucelikova T, Mehran R, Kirtane AJ, Dangas G, Solinas E, Morales A, Williams M, Agahtehrani A, Gray W, Collins M, Weisz G, Kreps E, Lansky AJ, Leon MB, **Stone GW**, Kodali S, Boland P, Aoki P, Kimura M, Moussa I, Nikolsky E, Moses JW, Franklin-Bond T, Kim YH. Short and long term outcomes after stent assisted percutaneous treatment of Saphenous vein grafts with drug-eluting stents: Have we made any progress? *JACC* 2007;49:9B.
610. Weisz G, Parise H, Fahy M, Ramee S, Reisman M, Moussa I, Leon MB, **Stone GW**, Gray W. Evaluation of proficiency using a simulator: Results from the assessment of operator performance by the Symbionix carotid stenting study (ASSESS). *Am J Cardiol* 2007;(suppl 8a):13.
611. Missel E, Mintz GS, Qian J, Kaple RK, Shan S, Lui J, Castellanos C, Dangas G, Mehran R, Moses JW, **Stone GW**, Leon MB. Coronary Plaque Burden is Related to Serum HDL-C levels, But not to Other Lipid Parameters: Volumetric Intravascular Ultrasound Analysis. *Am J Cardiol* 2007;(suppl 8a):18.
612. Mehran R, Kirtane AJ, Dangas GD, Ohman EM, Pocock SJ, Gersh BJ, Bertrand ME, Hamon M, Manoukian SV, Hoekstra J, Pollack CV, Desmet W, Feit F, Stella J, Cequir AR, Stuckey T, Cohen DJ, Lansky AJ, **Stone GW**. Long-term Outcomes of Patients with Acute Coronary Syndromes and Chronic Renal Insufficiency Undergoing Percutaneous Coronary Intervention and being treated with Bivalirudin vs Heparin plus a Glycoprotein

- IIb/IIIa Inhibitor: Results from the Randomized ACUTY Trial. *Am J Cardiol* 2007;(suppl 8a):54.
613. Steinhubl S, Feit F, Colombo A, Ebrahimi R, Cox DA, McLaurin BT, Mehran R, Dangas GD, Manoukian SV, White HD, Lincoff AM, Moses JW, Bertrand ME, Ohman EM, Desmet W, **Stone GW**. Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUTY Trial: Does it Really Matter? *Am J Cardiol* 2007;(suppl 8a):55.
  614. Manoukian SV, Voeltz MD, Feit F, Dangas GD, Fazel R, Ebrahimi E, Hamon M, Lincoff AM, Moses JW, King S, White HD, Ohman EM, Mehran R, **Stone GW**. Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. *Am J Cardiol* 2007;(suppl 8a):56.
  615. Ellis S, Cannon LA, Mann T, Greenberg JD, Cambier P, O'Shaughnessy CD, DeMaio S, Hall P, Powers E, Friedman M, **Stone GW**. Three-Year Clinical Results From the TAXUS V de novo Trial: Long-Term Safety and Efficacy of the Paclitaxel-Eluting TAXUS Stent in Complex Lesions. *Am J Cardiol* 2007;(suppl 8a):64.
  616. **Stone GW**, Ellis SG, Cox DA, Hermiller JB, O'Shaughnessy CD, Mann T, Turco M, Caputo R, Bergin PJ, Greenberg JD, Raizner AE, Popma JJ, Baim DS. Safety and Durable Efficacy of the Polymer-based Paclitaxel-eluting TAXUS Stent: Final 5 year outcomes from the TAXUS IV Trial. *Am J Cardiol* 2007;(suppl 8a):65.
  617. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin B, Cox DA, Pocock SJ, Ware JH, Feit F, Manoukian SV, Lansky AJ, Mehran R, Moses JW, **Stone GW**. Safety and Efficacy of Bivalirudin with and without Glycoprotein IIb/IIIa Inhibitors in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: One Year Results from the Randomized ACUTY Trial. *Am J Cardiol* 2007;(suppl 8a):102.
  618. Manoukian SV, Voeltz MD, Feit F, Dangas GD, Fazel R, Ebrahimi E, Hamon M, Lincoff AM, Moses JW, King S, White HD, Ohman EM, Mehran R, **Stone GW**. Impact of Transfusion on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. *Am J Cardiol* 2007;(suppl 8a):116.
  619. Kuck KH, Webb J, Harnek J, Buller C, Pauschinger M, Tiefenbacher C, James S, Vahanian A, **Stone GW**. Percutaneous Treatment of Functional Mitral Regurgitation: Interim Evolution Study Results with the Monare System. *Am J Cardiol* 2007;(suppl 8a):124.
  620. White H, Chew DP, Hoekstra JW, Pollack CV, Feit F, Ohman EM, Mehran R, Miller C, **Stone GW**. Safety and Efficacy of Switching from either Unfractionated Heparin or Enoxaparin Plus a Glycoprotein IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with non-ST Elevation Acute Coronary Syndromes Managed with an Invasive Strategy: Results from the Randomized ACUTY Trial. *Am J Cardiol* 2007;(suppl 8a):137.
  621. Dawkins KD, **Stone GW**, Colombo A, Ellis SG, Grube E, Leadley K, Baim DS. Safety and Clinical Utility of the RAXUS Express Stent in Unstable and Stable Angina. A Pooled Analysis of TAXUS Randomized Clinical Trials. *Am J Cardiol* 2007;(suppl 8a):139.

622. Ebrahimi E, Feit F, Manoukian SV, Lincoff AM, Dyke C, Gersh BJ, Mehran R, Moses JW, **Stone GW**. Preoperative Thienopyridine with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Reduces Adverse Ischemic Events: One-Year Results from the ACUTY Trial. *Am J Cardiol* 2007;(suppl 8a):147.
623. Obuani K, Moses JW, Leon MB, **Stone GW**, Dangas GD, Moussa I, Collins MB, Kreps EM, Sherman W, Weisz G, Kodali SK, Kimura M, Gupta A, Amakuri S, Franklin-Bond T, Naraya R, Dasgupta N, Mehran R. Are Second Attempts Justified After a Failed Intervention in Coronary Chronic Total Occlusions? *Am J Cardiol* 2007;(suppl 8a):216.
624. Obuani K, Moses JW, **Stone GW**, Mehran R, Dangas GD, Collins MB, Kreps EM, Moussa I, Sherman W, Weisz G, Kirtane A, Kimura M, Amakuri S, Gupta A, Franklin-Bond T, Syros G, Tyagi S, Leon MB. Clinical Outcomes After Successful Percutaneous Revascularization of Chronic Total Occlusions in the Drug-Eluting Stent Era. *Am J Cardiol* 2007;(suppl 8a):216.
625. Lansky AJ, Mehran R, Mori K, Costa R, Cequir AR, Pollack CV, Hoekstra J, Bertrand ME, Gersh BJ, **Stone GW**. Gender Differences in Long-Term Outcomes Following Percutaneous Intervention of Patients with Non-ST Elevation Acute Coronary Syndrome: Results from the ACUTY Trial. *Am J Cardiol* 2007;(suppl 8a):391.
626. Manoukian SV, Fazel R, Sanborn TA, Ebrahimi R, Feit F, Hamon M, Voeltz MD, Dangas GD, Moses JW, King SB, White HD, Ohman EM, Mehran R, **Stone GW**. Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights from the ACUTY Trial. *Am J Cardiol* 2007;(suppl 8a):393.
627. Manoukian SV, Feit F, Voeltz MD, Dangas GD, Ebrahimi R, Hamon M, Chew DP, Desmet W, Steinhubl SR, Lincoff AM, King SB, Ohman OM, White HD, Mehran R, **Stone GW**. Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUTY Trial. *Am J Cardiol* 2007;(suppl 8a):394.
628. Aoki J, Mehran R, Kirtane A, Kim YH, Boland P, Dasgupta N, Franklin-Bond T, Grigos A, Herscher M, Higginbotham L, Isaiaka V, Singh R, Kreps E, Weisz G, Lansky AJ, Collins M, Moussa I, **Stone GW**, Leon MB, Moses JW, Dangas GD. Impact of Diabetic Status and Insulin Treatment on Two-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation in the MATRIX Registry. *Am J Cardiol* 2007;(suppl 8a):425.
629. Kirtane A, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, Mehran R, **Stone GW**. Paclitaxel-Eluting Coronary Stents in Patients with Diabetes Mellitus: Pooled Analysis from Five Randomized Trials. *Am J Cardiol* 2007;(suppl 8a):428.
630. Martin JL, Ellis SG, Colombo A, Grube E, Friedman M, Koglin J, **Stone GW**. Incidence and Predictors of Coronary Artery Bypass Surgery Following Bare-Metal and TAXUS Drug-Eluting Coronary Stent Implantation. *Am J Cardiol* 2007;(suppl 8a):504.
631. Ellis SG, Colombo A, Grube E, Friedman M, Koglin J, Baim DS, **Stone GW**. Long-term and Clinical Efficacy Outcomes of the Paclitaxel-Eluting Stent from a Patient-level Meta-Analysis of the TAXUS Clinical Trials. *Am J Cardiol* 2007;(suppl 8a):534.

632. Rabbani L, Stant J, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Mehran R, **Stone GW**. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. *Am J Cardiol* 2007;(suppl 8a):552.
633. Missel E, Mintz GS, Carlier SG, Qian J, Shan S, Castellanos C, Kaple R, Biro S, Dangas G, Mehran R, Moses JW, Stone GW, Leon MB. High-Risk Lipid Profile Related to the Ratio of Necrotic Core to Calcification in Human Coronary Arteries: Results from the Prospective Multi-center, Global VH-IVUS Registry. *Am J Cardiol* 2007;(suppl 8a):602.
634. Missel E, Mintz GS, Carlier SG, Sano K, Qian J, Shan S, Kaple RK, Castellanos C, Lui J, Dangas G, Mehran R, Moses JW, Stone GW, Leon MB. Necrotic Core and its Ratio to Dense Calcium are Predictors of High-Risk Non ST-Elevation Acute Coronary Syndromes: Results from the prospective, multi-center, Global VH-IVUS Registry. *Am J Cardiol* 2007;(suppl 8a):605.
635. Missel E, Mintz GS, Carlier SG, Qian J, Shan S, Castellanos C, Kaple RK, Dangas G, Mehran R, Moses JW, **Stone GW**, Leon MB. Necrotic Core and its Ratio to Dense Calcium are Predictors of High-Risk Non-ST-Elevation Acute Coronary Syndromes: Results from the Prospective, Multi-Center, Global VH-IVUS Registry. *Circulation* 2007;116:171.
636. Yamasaki M, Ako J, Tsujino I, Sakurai R, Waseda K, Hasegawa T, Shimohama T, Honda Y, Lansky AJ, Sudhir K, **Stone GW**, Fitzgerald PJ. Post-Procedural Incomplete Stent Apposition after Implantation of Everolimus-Eluting or Paclitaxel-Eluting Stents: Insights from the Randomized SPIRIT III Trial. *Circulation* 2007;116:1717.
637. Missel E, Mintz GS, Carlier SG, Qian J, Shan S, Castellanos C, Kaple RK, Dangas G, Mehran R, Moses JM, **Stone GW**, Leon MB. In Vivo Virtual Histology Intravascular Ultrasound Correlates of Risk Factors for Sudden Coronary Death in Men: Results from the Prospective, Global, Multi-center VH-IVUS Registry. *Circulation* 2007;116:1982.
638. Vasi S, **Stone GW**, Brown DL. Short and Long Term Effects of Abciximab in Patients Undergoing Primary Stenting for Acute Myocardial Infarction: Meta-Analysis of Randomized Trials. *Circulation* 2007;116:1998.
639. Ormiston HA, Turco MA, Mandinov L, Popma JJ, Hall JJ, NMishkel GJ, Mann T, McGarry TF, Cannon LA, **Stone GW**, O'Shaughnessey CD, Gilchrist IC, Koglin J, Baim DS. TAXUS ATLAS SMALL VESSEL: First Report of 9-Month Clinical and Angiographic Outcomes – Evaluation of the TAXUS Liberte 2.25mm Stent, a Drug-Eluting Stent Specifically Designed for Small Vessels. *Circulation* 2007;116:2154.
640. Manoukian SV, Feit F, Voeltz MD, Ebrahimi R, Hamon M, Chew DP, Dangas GD, Desmet W, Lincoff AM, Moses JW, Pollack CV, Hoekstra JW, King SB, White HD, Ohman EM, Mehran R, **Stone GW**. Impact of the AUCITY and TIMI Major Bleeding Definitions on One-Year Mortality in Patients with Acute Coronary Syndromes. *Circulation* 2007;116:2217.
641. Mehran R, Kirtane AJ, Dangas GD, Ohman EM, Pocock S, Bersh BJ, Bertrand ME, Hamon M, Manoukian SV, Hoekstra J, Pollack CV, Desmet W, Feit F, Stella J, Cequier AR, Cohen DJ, Lansky AJ, **Stone GW**. Long-Term Outcomes of Acute Coronary

Syndrome Patients with Chronic Renal Insufficiency treated with Bivalirudin vs Heparin plus a Glycoprotein IIb/IIIa Inhibitor: One Year Results from the Randomized ACUTY Trial. *Circulation* 2007;116:2222.v

642. **Stone GW**, Ellis SG, Colombo A, Kong DK, Koglin J, Friedman MI, Baim DS. Effect of Prolonged Thienopyridene Use on Long-term Clinical Outcomes After Drug-Eluting Stents: Landmark Analysis from the TAXUS Trials. *Circulation* 2007;116:2357.
643. Aoki J, **Stone GW**, Mehran R, Moses JW, Bertrand ME, Lincoff AM, Ohman OM, White HD, Parise H, Leon MB, Lansky AJ. Predictors of Early Stent Thrombosis in Patients with Acute Coronary Syndromes in the Drug-Eluting Stent Era: Analysis from the ACUTY Trial. *Circulation* 2007;116:2564.
644. Sakurai R, Courtney BK, Yamasaki M, Tsujuno I, Waseda K, Hasegawa T, Shimohama T, Ako J, Hongo Y, Morino Y, Miyazawa A, Hur SO, Koizumi T, Honda Y, Yock PG, Lansky AJ, Sudhir K, **Stone GW**, Fitzgerald PJ. Neointimal Hyperplasia Patterns Among 3 Drug-Eluting Stents: A Comparative Intravascular Ultrasound Analysis of Everolimus, Sirolimus and Paclitaxel Eluting Stents. *Circulation* 2007;116:2770.
645. Yamasaki M, Tsujino I, Sakurai R, Waseda K, Hasegawa T, Shimohama T, Ako J, Honda Y, Sood P, Lansky A, Sudhir K, **Stone GW**, Fitzgerald PJ. Comparison of Everolimus-Eluting Stents with Paclitaxel-Eluting Stents in DeNovo Native Coronary Artery Lesions: Intravascular Ultrasound Results from the SPIRIT III Trial. *Circulation* 2007;116:2771.
646. Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, Mc Laurin BT, Cox DA, Ware JH, Pocock S, **Stone GW**. Comparison of Catheterization Lab Initiated Abciximab and Double-Bolus Eptifibatide during Percutaneous Coronary Intervention in Acute Coronary Syndromes: An ACUTY Substudy. *Circulation* 2007;116:2830.
647. Ebrahimi R, Feit F, Manoukian SV, Lincoff AM, Dyke C, Gersh B, Mehran R, Moses JW, **Stone GW**. Implications of preoperative Thienopyridine Use in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Coronary Artery Bypass Surgery: One year results from the ACUTY Trial. *Circulation* 2007;116:3204.v
648. Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, **Stone GW**. Comparison of Upstream Tirofiban and Eptifibatide Use in Patients with Moderate and High Risk Acute Coronary Syndromes: An ACUTY Substudy. *Circulation* 2007;116:3219.
649. Feit F, Manoukian SV, Dangas GD, Lincoff Am, Ohman EM, Attubato MJ, Mehran R, **Stone GW**. Bivalirudin Monotherapy Provides Similar One-Year Survival Compared to Heparin GP IIb/IIIa Inhibitors in Diabetic Patients with Acute Coronary Syndromes. Results from the Randomized ACUTY Trial. *Circulation* 2007;116:3220.
650. Amakaturi SR, Mehran R, Obuani K, Gupta A, Syros G, Kreps EM, Collins MB, Gray WA, Moses JW, Leon MB, **Stone, GW**, Dangas GD. *Circulation* 2007;116:3347.

### **National and International Lectures, Seminars and Courses**

1. Systolic and diastolic dysfunction in acute pulmonary edema: A prospective consecutive series. Presented at the Society of Nuclear Medicine Western Regional Meeting in San Diego, California, October 12th, 1987.
2. Is diastolic dysfunction the cause of acute pulmonary edema with normal global systolic dysfunction? Presented at the 60th Annual Scientific Sessions of the American Heart Association Meeting in Anaheim, California, November, 1987.
3. Acute outcome and long term follow-up of patients with acute myocardial infarction and single vessel disease treated with angioplasty without thrombolytic therapy. Presented at the 38th Annual Scientific Sessions of the American College of Cardiology in Anaheim, California, March 1989.
4. Factors relating to improvement in regional wall motion and ejection fraction in patients with acute myocardial infarction and single vessel disease treated with coronary angioplasty without prior thrombolytic therapy. Presented at the 62nd Annual Scientific Sessions of the American Heart Association Meeting in New Orleans, Louisiana, November, 1989.
5. Percutaneous transluminal coronary angioplasty vs. coronary artery bypass grafting for coronary artery disease. El Camino Hospital, Mountain View, CA, November 28, 1989.
6. Research aspects of guide catheter development, Advanced Cardiovascular Systems, Sunnyvale, CA, January 20, 1990.
7. Advances in coronary angioplasty, 1990. Medical Grand Rounds, El Camino Hospital, Mountain View, CA, February 23, 1990.
8. Coronary angioplasty of chronic total occlusions, at the course "Percutaneous Transluminal Coronary Angioplasty for the Advanced Dilator", The Big Island, Hawaii, February 8, 1990.
9. Outcome following multilesion angioplasty targeted to the "culprit coronary artery" in pts with unstable angina. Presented at the 39th Annual Scientific Sessions of the American College of Cardiology in Atlanta, Georgia, March 1990.
10. Factors relating to improvement in regional wall motion and ejection fraction in patients with acute myocardial infarction and single vessel disease treated with coronary angioplasty without prior thrombolytic therapy. Presented at the 10th annual national meeting of the Society for Cardiac Angiography and Interventions in Williamsburg, Virginia, May 1990.
11. Non-ionic and low osmolar contrast agents, Presented at the Annual Scientific Conference of the National Society for Cardiovascular and Pulmonary Technology, Reno, Nevada, June 16-19, 1990.
12. Simple and complex coronary angioplasty, El Camino Hospital, Mountain View, CA, July 9, 1990.

13. Principles of Complex Coronary Angioplasty. Cardiac Catheterization Conference, Stanford University Hospital, July 16, 1990.
14. Direct angioplasty in acute myocardial infarction. El Camino Hospital, Mountain View, CA, July 23, 1990.
15. The role of coronary angioplasty in acute myocardial infarction. Presented at the course Advanced Angioplasty, San Francisco, CA, August 29, 1990.
16. New directions in coronary angioplasty. Presented at the Western Region Advisory Board Meeting, Advanced Cardiovascular Systems, Santa Clara, October 1, 1990.
17. The biological and mechanical aspects of intravascular thrombus formation. Carlsbad, CA, October 25-26, 1990.
18. Percutaneous transluminal coronary angioplasty: future research and engineering aspects. Santa Barbara, CA, October 29, 1990.
19. Principles of cardiac catheterization: the choice of radio-contrast agents. Dallas, TX, November 10, 1990.
20. Reperfusion therapy of acute myocardial infarction 1991. Grand Rounds, El Camino Hospital, Mountain View, CA, January 14, 1991.
21. New interventional approaches in the cardiac catheterization lab. Napa Valley, CA, February, 22, 1991.
22. Restenosis Update. Presented at the course Advances in Interventional Cardiology, St. Louis, MO, April 12, 1991.
23. Alternatives to open heart surgery. The Center on Aging, Mountain View, CA, July 10, 1991.
24. Complex angioplasty cases. The 1991 Cardiology Fellows Conference, ACS, Carlsbad, CA, October 12-15, 1991.
25. Direct infarct angioplasty: the optimal treatment of acute myocardial infarction? The Invasive Cardiology Group, Portland, OR, October 28, 1991.
26. Developmental aspects of ultrasonic angioplasty. ACS, Santa Clara, CA December 4, 1991.
27. Recognition and management of heart disease. The El Camino Hospital, Mountain View, CA, December 18, 1991.
28. Directional coronary atherectomy. El Camino Hospital, Cardiology Grand Rounds, Mountain View, CA, January 14, 1992.
29. Women and Heart Disease. KRFC, San Francisco, CA, February 23<sup>rd</sup>, 1992.
30. Advances in Interventional Cardiology. Palo Alto, CA, March 24<sup>th</sup>, 1992.

31. Directional Coronary Atherectomy. Department of Radiology Grand Rounds, El Camino Hospital, Mountain View, CA, April 4<sup>th</sup>, 1992.
32. Diagnosis and Treatment of Heart Disease. Los Altos, CA, April 21<sup>st</sup>, 1992.
33. Complex Coronary Angioplasty: 1992. Presented at the Course Coronary Intervention and its Aftermath. Greeley, CO. May 15, 1992.
34. Direct Infarct Angioplasty; the Optimal Treatment of Acute Myocardial Infarction. Presented at the course Coronary Intervention and its Aftermath. Greeley, CO. May 15, 1992.
35. The Management of Complications and Restenosis following Balloon Angioplasty. Presented at the 6th Annual ACS Clinical Advisory Board Meeting, Colorado Springs, CO, June 6-11, 1992.
36. Clinical Applications of Intracoronary Ultrasound Imaging. Endosonics Corp., Pleasanton, CA July 8, 1992.
37. Interventional Cardiology Product Development – Trends and Predictions. Advanced Cardiovascular Systems, Inc., Santa Clara, CA July 9, 1992.
38. New Devices in Interventional Cardiology. Medical Grand Rounds. El Camino Hospital, Mountain View, CA, July 15, 1992.
39. Direct Infarct Angioplasty: Results of the Primary Angioplasty In Myocardial Infarction Trial. Cardiology Grand Rounds. Santa Rosa Memorial Hospital, Santa Rosa, CA, July 31, 1992.
40. Results of the Primary Angioplasty In Myocardial Infarction Trial. Grand Rounds, El Camino Hospital, Mountain View, CA, September 29, 1992.
41. Future directions for directional coronary atherectomy. Devices for Vascular Intervention, Inc. Redwood City, CA, October 5th, 1992.
42. Equipment selection and medication in directional coronary atherectomy. DVI Physician Training Course. San Diego, CA October 7th, 1992.
43. Technique of Directional Coronary Atherectomy. DVI Physician Training Course. San Diego, CA October 7th, 1992.
44. Treatment of Myocardial Infarction, 1992. Internal medicine meeting, Palo Alto, CA, October 12th, 1992.
45. Direct Infarct Angioplasty: Results of the Primary Angioplasty In Myocardial Infarction Trial. Cardiology Grand Rounds. Stanford University Medical Center, October 21, 1992.
46. The Changing Face of Interventional Cardiology. at the course "High Impact Interventions", Los Altos, CA, November 12th, 1992.



47. Primary Angioplasty Reduces In-Hospital Mortality and Morbidity in Acute Anterior Myocardial Infarction - Results of the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented at the 42nd Annual Scientific Sessions of the American College of Cardiology in Anaheim, CA, March 1993.
48. Initial Clinical Experience with a Novel Low-Profile Integrated Coronary Ultrasound-Angioplasty Catheter: Implications for Routine Use. Presented at the 42nd Annual Scientific Sessions of the American College of Cardiology in Anaheim, CA, March 1993.
49. Primary Angioplasty is the Preferred Therapy for Women and the Elderly with Acute Myocardial Infarction - Results of the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented at the 42nd Annual Scientific Sessions of the American College of Cardiology in Anaheim, CA, March 1993.
50. Acute Outcome After Primary Angioplasty in Myocardial Infarction - The Primary Angioplasty In Myocardial Infarction (PAMI) Trial. Presented at the 42nd Annual Scientific Sessions of the American College of Cardiology in Anaheim, CA, March 1993.
51. Clinical Utility of Intracoronary Ultrasound Imaging During Angioplasty. Presented at the 1993 Scientific Sessions for the Utah Affiliate of the American Heart Association, during the course "Interventional Cardiology Symposium at Snowbird", Snowbird, Utah, April 9th, 1993.
52. New Devices for Percutaneous Coronary Intervention: 1993 Update. The California Chapter of the American Heart Association, El Camino Hospital, Mountain View, CA, April 14th, 1993.
53. Direct Infarct Angioplasty - The Preferred Alternative to Thrombolytic Therapy. Presented during the annual meeting of the American College of Cardiovascular Invasive Specialists. Las Vegas, NV, May 1st, 1993.
54. Coronary Angioplasty-Ultrasound Case Demonstrations. Centre Cardiologie du Nord, Paris, France, May 18, 1993.
55. Applications of Intracoronary Ultrasound During Angioplasty. Centre Cardiologie du Nord, Paris, France, May 19, 1993.
56. Use of Intracoronary Ultrasound During Coronary Stenting - Case Demonstrations. University Hospital, Milan, Italy, May 20, 1993.
57. New Devices for Percutaneous Coronary Intervention. Cupertino Medical Center, Cupertino, CA, May 28, 1993.
58. Intracoronary Ultrasound Imaging. Cardiac catheterization conference, St. Agnes Hospital, Fresno, CA, June 17, 1993.
59. New Applications for Intracoronary Ultrasound Imaging. Cardiology Grand Rounds, Bakersfield, CA, July 13, 1993.
60. The Role of Primary Angioplasty in Acute Myocardial Infarction. Interventional Cardiology Conference, Boise, Idaho, August 17, 1993.

61. Primary Angioplasty is the Optimal Therapy for Acute Myocardial Infarction. Annual Meeting of the National Society For Cardiovascular Technology, Los Angeles, CA, August 28, 1993.
62. Primary PTCA as the Treatment Strategy of Choice in Acute Myocardial Infarction. Kaiser San Francisco General Hospital Grand Rounds, September 8th, 1993.
63. Holmium Laser Angioplasty Demonstrations and Research Council Meeting, El Camino Hospital and Palo Alto, CA, September 10th, 1993.
64. Is the Wind Gone from GUSTO? - Results of the Primary Angioplasty in Myocardial Infarction Trial. Scripps Memorial Hospital, San Diego, CA, September 14th, 1993.
65. Treatment of Acute Myocardial Infarction with Primary PTCA. Annual Cardiology Conference, Cardiology Care Specialists, Lawton, Oklahoma, September 17th, 1993.
66. Holmium Laser Angioplasty Demonstrations and Research Council Meeting, El Camino Hospital and Sunnyvale, CA, September 20th, 1993.
67. Intracoronary Ultrasound-Angioplasty Demonstrations, Dallas, Texas, September 21st, 1993.
68. Management of the Patient with Acute Myocardial Infarction in 1993. Borgess Medical Center Annual Cardiology Symposium, Kalamazoo, Michigan, October 6th, 1993.
69. Is Prolonged Angina Free Survival Possible in Pts with Multivessel Disease Treated by PTCA?- Effect of Multiple, Repeated Procedures. Presented at the 66th Annual Scientific Sessions of the American Heart Association, Atlanta, Georgia, November 9th, 1993.
70. Primary Angioplasty Reduces Recurrent Ischemic Events Compared to tPA in Myocardial Infarction: Implications for Early Discharge. Presented at the 66th Annual Scientific Sessions of the American Heart Association, Atlanta, Georgia, November 10th, 1993.
71. Aggressive Balloon Sizing using Intracoronary Ultrasound Imaging During Percutaneous Intervention. at the course *Beyond Angiography*, Atlanta, Georgia, November 6th, 1993.
72. Rationale for Laser Angioplasty. at the Eclipse Laser Investigator's Meeting. Atlanta, Georgia, November 9th, 1993.
73. Ultrasound-Guided Coronary Intervention. Interventional Cardiology Symposium, Keynote address, Tokyo, Japan, December 18th, 1993.
74. Ultrasound Angioplasty Case Demonstrations, Mitsui Memorial Hospital, Tokyo, Japan, December 17th, 1993.
75. Lasers, Rotor-Rooters and Chicken Wire Baskets: Advances in Interventional Cardiology. Good Samaritan Hospital, San Jose, CA. January 11th, 1994.

76. FDA presentation: The role of primary angioplasty in acute myocardial infarction. Washington D.C., February 2nd, 1994.
77. Primary Angioplasty in Acute Myocardial Infarction. Medicine Grand Rounds, Peninsula Hospital, Burlingame, CA, February 22nd, 1994.
78. Controversial DCA case presentations. The 3rd annual Devices for Vascular Intervention Physician Advisory Board Meeting, Monterey, CA, March 2nd-6th, 1994.
79. The Laser Angioplasty Vs. Angioplasty (LAVA) Trial - Update. Atlanta, GA, March 13th, 1994.
80. Adverse Catheterization Laboratory Events after Primary PTCA vs. PTCA Following Thrombolytic Therapy - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented at the 43rd Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, March 15, 1994.
81. Predictors of In-Hospital and 6-Month Outcome after Myocardial Infarction in the Reperfusion Era - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented at the 43rd Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, March 15, 1994.
82. Primary Angioplasty in Myocardial Infarction. Fireside panel presentation, the 43rd Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, March 15, 1994.
83. Directional Coronary Atherectomy Physician Training Course, Devices for Vascular Intervention, Menlo Park, CA, March 25th, 1994.
84. Advances in Directional Coronary Atherectomy - a Physician's Perspective. Devices for Vascular Intervention, Redwood City, CA, March 28th, 1994.
85. Intracoronary ultrasound demonstrations. Vancouver General Hospital, Vancouver, Canada, April 5th, 1994.
86. Update on Primary Infarct Angioplasty. Presented at the American Heart Association course Update on Therapy for Cardiovascular Disease and Stroke, Portland Convention Center, Portland, OR, May 13th, 1994.
87. Laser Angioplasty Training. Latter Day Saints Hospital, Salt Lake City, Utah, July 12th, 1994.
88. PTCA in AMI: PAMI Trials. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IV." Aspen, CO, August 1st, 1994.
89. Holmium Laser Facilitated Coronary Angioplasty. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IV." Aspen, CO, August 2nd, 1994.
90. Directional Coronary Atherectomy Training Course. Sponsored by Devices for Vascular Intervention, Inc. Redwood City, CA, August 24th, 1994.

91. Advances in Intracoronary Ultrasound Imaging. Berlin, Germany, September 9th, 1994.
92. Clinical Utility of Intracoronary Ultrasound Imaging Using the Endosonics Cathscanner. Berlin, Germany, September 10th, 1994.
93. Potential Applications for Biologic Coatings, Berlin Germany, September 11th, 1994.
94. Lessons from the PAMI-1 Trial. Presented at the 7th Annual Interventional Cardiology Course, sponsored by William Beaumont Hospital, Detroit, Michigan, October 3rd, 1994.
95. Is Directional Coronary Atherectomy Obsolete in the Era of Stenting? Presented at the 8th Annual Advanced Cardiovascular Systems Advisory Board Meeting, Denver Colorado, October 6th, 1994.
96. Principles and Practice of Intracoronary Stenting. El Camino Hospital, Mountain View, CA, October 12th, 1994.
97. Results of Holmium Photoacoustic Laser Atherectomy - Multicenter Results. Scottsdale Memorial Hospital, Scottsdale, Arizona, October 25th, 1994.
98. Reperfusion therapy in acute myocardial infarction - primary angioplasty or thrombolysis? Mercy General Hospital, Sacramento, CA, November 1st, 1994.
99. Directional Coronary Atherectomy vs. Intracoronary Stenting. Presented to the Devices for Vascular Intervention national sales force and research division. San Francisco, CA, November 2nd, 1994.
100. Improving Results of Holmium Photoacoustic Laser Atherectomy. Presented at the Eclipse Laser Investigator's meeting at the 67th Annual Scientific Sessions of the American Heart Association, Dallas, Texas, November 13th, 1994.
101. Clinical Application of Intracoronary Ultrasound Imaging. Presented at the Course "Beyond Angiography II" at the 67th Annual Scientific Sessions of the American Heart Association, Dallas, Texas, November 12th, 1994.
102. Aggressive Angioplasty using Intracoronary Ultrasound Imaging: The CLOUT Hypothesis. Presented at the Course "Beyond Angiography II" at the 67th Annual Scientific Sessions of the American Heart Association, Dallas, Texas, November 12th, 1994.
103. What is the Optimal Means to Achieve and Sustain Perfusion in Acute Myocardial Infarction? Presented at the 67th Annual Scientific Sessions of the American Heart Association, Clinical Council of Cardiology, Dallas Texas, November 16th, 1994.
104. Who is Eligible for Early Discharge After Acute Myocardial Infarction? Presented at the 67th Annual Scientific Sessions of the American Heart Association, Clinical Council of Cardiology, Dallas Texas, November 13th, 1994.
105. What is the role of newer interventional devices in 1995? Thought Leaders in Interventional Cardiology. Stanford University Medical Center, January 20th, 1995.

106. Advances in the non-operative management of coronary artery disease. The Older Adults Resource Center. Mountain View, CA, February 8th, 1995.
107. Abstract Panel Chairman, Alternative Imaging Modalities, Transcatheter Cardiovascular Therapeutics-VII Meeting, Washington D.C., February 22nd, 1995.
108. Abstract Panel Chairman, Mechanisms of Restenosis, Transcatheter Cardiovascular Therapeutics-VII Meeting, Washington D.C., February 22nd, 1995.
109. Can the Results of Standard Balloon Angioplasty be Improved with Intracoronary Ultrasound Guidance? - The CLOUT Pilot Study. Presented at the 7th Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, February 23-25, 1995.
110. Holmium Laser Multicenter Registry Results: Effect of lesion morphology on procedural success and complications. - The CLOUT Pilot Study. Presented at the 7th Annual Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, February 23-25, 1995.
111. PTCA vs. Thrombolysis in High Risk Patients. Presented during the course Direct PTCA in the 90's during the 44th Annual Scientific Sessions of the American College of Cardiology, New Orleans, CA, March 20th, 1995.
112. Outcome of Different Reperfusion Strategies in Thrombolytic "Eligible" Versus "Ineligible" Patients with Acute Myocardial Infarction. Presented during the 44th Annual Scientific Sessions of the American College of Cardiology, New Orleans, CA, March 22nd, 1995.
113. Is Primary Angioplasty Less Effective in Patients Presenting in the Early Morning Hours? - A Report from the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. Presented during the 44th Annual Scientific Sessions of the American College of Cardiology, New Orleans, CA, March 22nd, 1995.
114. Does Primary Angioplasty Improve the Prognosis of Patients with Diabetes and Acute Myocardial Infarction? Presented during the 44th Annual Scientific Sessions of the American College of Cardiology, New Orleans, CA, March 22nd, 1995.
115. Course Director, The First National Interventional Fellow's Course, Stanford University Medical Center, April 8<sup>th</sup>-10th, 1995.
116. Primary infarct angioplasty. Presented at the National Interventional Fellow's Course at Stanford University Medical Center, April 8th, 1995.
117. Holmium laser angioplasty. Presented at the National Interventional Fellow's Course at Stanford University Medical Center, April 8th, 1995.
118. The CLOUT Trial. Presented at the National Interventional Fellow's Course at Stanford University Medical Center, April 8th, 1995.

119. Primary PTCA for Acute Myocardial Infarction - What Challenges Remain? Eli Lilly Research Laboratories. Indianapolis, IN, April 18th, 1995.
120. Advances in the Recognition and Treatment of Heart Disease. El Camino Hospital, Mountain View, CA, April 26th, 1995.
121. Advanced Innovations in Ultrasound Guidance of Percutaneous Cardiology Procedures. Presented at Cardiology Grand Rounds, St. John's Hospital, Detroit, MI, May 9th, 1995.
122. Advances in the Percutaneous Management of Coronary Artery Disease. Medical Grand Rounds. El Camino Hospital, Mountain View, CA, June 27th, 1995.
123. Interpretation and Application of Intracoronary Ultrasound Imaging. St. Bernadine Hospital Division of Cardiology, San Bernadino, CA, July 18th, 1995.
124. Proctoring of Intracoronary Ultrasound Imaging cases. St. Bernadine Hospital, San Bernadino, CA, July 18th, 1995.
125. Treatment of Heart Disease: Beyond the Balloon. Cupertino Medical Center, Cupertino, CA, July 24th, 1995.
126. Rotational Atherectomy: Technique, Results and Future Expectations. Presented at the 1st meeting of the Congress of the Latin American Society of Interventional Cardiology, Maksoud Plaza, Sao Paulo, Brazil, July 28th, 1995.
127. Acute Myocardial Infarction: Angioplasty vs. Thrombolysis. Presented at the 1st meeting of the Congress of the Latin American Society of Interventional Cardiology, Maksoud Plaza, Sao Paulo, Brazil, July 29th, 1995.
128. High Speed Rotational Atherectomy: Present Results and Future Applications. Presented at the course Cardiovascular Interventions: Technology at the Summit V. Aspen, Colorado, August 4th, 1995.
129. PTCA in Acute Myocardial Infarction: PAMI I, II and III - Update 1995. Presented at the course Cardiovascular Interventions: Technology at the Summit V. Aspen, Colorado, August 6th, 1995.
130. Advanced Rotational Atherectomy Concepts and Techniques. University of California at San Diego, August 16th, 1995.
131. Is it Ethical not to Perform Primary PTCA in Acute Myocardial Infarction? Presented at the Annual Meeting of the Advanced Cardiovascular Systems Physician Advisory Board Meeting. Tuscon, AZ, August 28th, 1995.
132. Is Intracoronary Ultrasound Imaging Required for Stent Implantation? Presented at the Annual Meeting of the Advanced Cardiovascular Systems Physician Advisory Board Meeting. Tuscon, AZ, August 28th, 1995.
133. The Second Primary Angioplasty in Myocardial Infarction Trial. Presented at the Annual Complex Coronary Interventions Conference, Biwako Lakeside, Shiga Prefecture, Japan, September 8th, 1995.

134. Advanced Concepts in Intracoronary Ultrasound Guided Percutaneous Intervention. Presented at the Annual Complex Coronary Interventions Conference, Biwako Lakeside, Shiga Prefecture, Japan, September 9th, 1995.
135. The Optimal Stent Implantation Studies - the Role of Intravascular Ultrasound Guidance. Presented at the Annual Meeting of the Endosonics Physician Advisory Board, Sacramento, CA, September 11th, 1995.
136. Primary PTCA Vs. Thrombolysis for Acute Myocardial Infarction. Presented at the American Heart Association's 63rd Annual Fall Symposium, Los Angeles, CA, September 13th, 1995.
137. Coronary Stenting in 1995. Presented at the course Strategies for Intervention in Complex Coronary Artery Disease: A Real World Approach. Kansas City, MO, September 14th, 1995.
138. Direct PTCA in the Setting of Acute Myocardial Infarction - PAMI Results and Beyond. Presented at the course Strategies for Intervention in Complex Coronary Artery Disease: A Real World Approach. Kansas City, MO, September 15th, 1995.
139. Heparin Coated Stenting in Acute Myocardial Infarction. Johnson & Johnson Interventional Systems, Warren, NJ, Sept. 19th, 1995.
140. Primary Angioplasty in Acute Myocardial Infarction - 1995. The John L. Locke Symposium, Swedish Medical Center, Seattle, Wash., October 6th, 1995.
141. Cost effective approach to the patient with coronary artery disease. Case presentations. The John L. Locke Symposium, Swedish Medical Center, Seattle, Wash., October 6th, 1995.
142. Procedural guidance of complex coronary angioplasty procedures with intravascular ultrasound. Presented during the course "Beyond Angiography III" at the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11th, 1995.
143. The Optimal Stent Implantation Trial. Presented during the course "Beyond Angiography III" at the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11th, 1995.
144. Aggressive stent implantation with intravascular ultrasound guidance. Presented during the course "Beyond Angiography III" at the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11th, 1995.
145. Primary stenting in acute myocardial infarction. Presented during the course "Thrombolysis and Interventional Therapy in Acute Myocardial Infarction", at the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 12th, 1995.
146. The PAMI Stent Trial - Interim Results. Presented during the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 12th, 1995.

147. Primary Stenting in AMI. Presented at the International Heparin Coated Stent Investigator's meeting in Anaheim, CA, November 12th, 1995.
148. The Routine Use of Intra Aortic Balloon Pumping After Primary PTCA Improves Clinical Outcomes in Very High Risk Patients with Acute Myocardial Infarction - Results of the PAMI-2 Trial. Presented during the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 13th, 1995.
149. Is Prophylactic IABP Use Beneficial or Harmful in a High Risk Elderly Population with Acute Myocardial Infarction? - PAMI-2. Presented during the 68th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 13th, 1995.
150. Primary PTCA in Acute Myocardial Infarction: Where We've Been and Where We're Going. Presented at the course "management of Cardiovascular Problems in 1995: Greater Simplicity and Efficacy from Technological Progress. Laguna Niquel, CA, December 9th, 1995.
151. Advanced Techniques in Coronary Stenting - Live Case Demonstrations. Rigshospitalet, National University, Copenhagen, Denmark, December 18th, 1995.
152. Reperfusion Therapies for Acute Myocardial Infarction. Rigshospitalet, National University, Copenhagen, Denmark, December 18th, 1995.
153. Primary PTCA Workshop for the Interventionalists of Denmark. Rigshospitalet, National University, Copenhagen, Denmark, December 18th, 1995.
154. Advantages of Coronary Stenting Using Intracoronary Ultrasound Imaging. Presented at the JJIS Congress on Coronary and Peripheral Disease Management, Tuscon, Arizona, January 16, 1996.
155. Advanced Intracoronary Ultrasound Case Demonstrations - Session Chairman and Moderator. At the Interactive Course on Intravascular Ultrasound, Montreal Heart Institute, Montreal, Canada, January 19th, 1996.
156. Update on Ultrasound-Stent Trials. At the course Intravascular Ultrasound for the Interventionalist, Stanford University, Stanford, CA, January 26th, 1996.
157. Workshops on Ultrasound Guided Stent Implantation. At the course Intravascular Ultrasound for the Interventionalist, Stanford University, Stanford, CA, January 26th-27th, 1996.
158. Interventional Treatment of Acute Myocardial Infarction - What's New in 1996? Cardiology Grand Rounds, University of California at San Diego Medical Center, January 31, 1996.
159. Optimal Techniques for Stent Implantation. Presented at the 11th Annual Demonstrations Course on Interventional Cardiology and Advanced Coronary Stenting, Snowmass, CO, February 19th, 1996.
160. Direct PTCA for Acute Myocardial Infarction: The PAMI I and II Trials. Presented at the



11th Annual Demonstrations Course on Interventional cardiology and Advanced Coronary Stenting, Snowmass, CO, February 21st, 1996.

161. Stenting in Acute Myocardial Infarction. Presented at the 11th Annual Demonstrations Course on Interventional Cardiology and Advanced Coronary Stenting, Snowmass, CO, February 21st, 1996.
162. Vascular Remodeling in Coronary Artery Disease and Restenosis. Presented at the course Intracoronary Ultrasound Imaging: An Introduction for Interventional Cardiology. San Antonio, TX, February 23rd, 1996.
163. Intravascular Ultrasound Applications During PTCA. Presented at the course Intracoronary Ultrasound Imaging: An Introduction for Interventional Cardiology. San Antonio, TX, February 23rd, 1996.
164. Stents in Acute Myocardial Infarction. Presented at the symposium Direct PTCA in Acute Myocardial Infarction, Washington, D.C., February 29th, 1996.
165. Algorithms for Multi-Device, Lesion-Specific Angioplasty. Presented at the Transcatheter Cardiovascular Therapeutics-VIII Meeting, Washington, D.C., March 1st, 1996.
166. Stents for Acute Myocardial Infarction: Early results from the PAMI Stent Pilot Study. Presented at the Transcatheter Cardiovascular Therapeutics-VIII Meeting, Washington, D.C., March 1st, 1996.
167. The PAMI-2 Trial: Perspectives on Prophylactic IABP Use and Early Discharge after Direct PTCA in Acute Myocardial Infarction. Presented at the Transcatheter Cardiovascular Therapeutics-VIII Meeting, Washington, D.C., March 2nd, 1996.
168. Insights from the Optimal Stent Implantation Trials. Presented at the Transcatheter Cardiovascular Therapeutics-VIII Meeting, Washington, D.C., March 2nd, 1996.
169. Ultrasound Guided Stent Implantation. Stanford, CA, March 5th, 1996.
170. Primary PTCA for Acute Myocardial Infarction - The PAMI Trials. Presented at the 14th Annual Cardiovascular Nursing Scientific Sessions of the American Heart Association, Millbrae, CA, March 22nd, 1996.
171. Advanced Cardiovascular Systems MultiLink Stent Research and Development Board Meeting, Orlando, Florida, March 24th, 1996.
172. Treatment of Acute Myocardial Infarction with Stents and Other New Technologies. Presented at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 24th, 1996.
173. Primary Stenting for Acute Myocardial Infarction. Presented at the PAMI Investigator's Meeting, Orlando, Florida, March 24th, 1996.
174. Improved Outcomes of Balloon Angioplasty with Intracoronary Ultrasound Guidance - Core Lab Angiographic and Ultrasound Results from the CLOUT Study. Presented at

- the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 26th, 1996.
175. What is the Optimal Pressure for Stent Implantation (How High is High)? Presented at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 26th, 1996.
  176. Variability in Balloon Sizing During Routine PTCA - Quantitative Coronary and Ultrasound Analysis. Presented at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 27th, 1996.
  177. Choice of Interventional Device Based on Lesion Morphology and Clinical Presentation. Luncheon panel session chairman. Presented at the 45th Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 27th, 1996.
  178. High Speed Rotational Atherectomy - What's New in 1996?. Presented at the XVIII Meeting of the Brazilian Society of Cardiology, Natal, Brazil, April 11th, 1996.
  179. Ultrasound Insights into Coronary Angioplasty and Stenting. Presented at the XVIII Meeting of the Brazilian Society of Cardiology, Natal, Brazil, April 12th, 1996.
  180. New Horizons for Treatment of Acute Myocardial Infarction - Primary Stenting. Presented at the XVIII Meeting of the Brazilian Society of Cardiology, Natal, Brazil, April 13th, 1996.
  181. Course Director, The 2nd Annual National Interventional Fellows' Course, Durham, North Carolina, April 18<sup>th</sup>-20, 1996.
  182. Beyond Primary PTCA. Presented at the 2nd Annual Duke-Stanford National Interventional Fellows' Course, Durham, North Carolina, April 19th, 1996.
  183. Ultrasound Guided Coronary Intervention. Presented at the 2nd Annual Duke-Stanford National Interventional Fellows' Course, Durham, North Carolina, April 21st, 1996.
  184. Update on primary PTCA - The PAMI II and III Trials. Presented at the course Cardiology Fiesta in San Antonio: Update on Cardiac Diagnostic and Therapeutic Techniques, San Antonio, Texas, April 25th, 1996.
  185. Primary Stenting in Acute Myocardial Infarction. Presented at the course "State of the Art Update on Interventional Cardiology - Where Are We Going?", Chicago, IL, June 2nd, 1996.
  186. Better balloon angioplasty with ICUS imaging. Presented at the course "Intracoronary Ultrasound Imaging: An Introduction for Interventional Cardiology". Winston-Salem, NC, June 7th, 1996.
  187. The Role of Intracoronary Ultrasound Imaging during Stent Implantation. Presented at the course "Intracoronary Ultrasound Imaging: An Introduction for Interventional Cardiology". Winston-Salem, NC, June 7th, 1996.

188. PTCA and Stenting in Acute Myocardial Infarction - The PAMI Trials: Update 1996. Presented at the course "Cardiovascular Interventions - Technologies at the Summit VI", Aspen, CO, August 1st, 1996.
189. Intravascular Ultrasound Imaging during Elective Coronary Stent Implantation. Presented at the course "Cardiovascular Interventions - Technologies at the Summit VI", Aspen, CO, August 2nd, 1996.
190. New Concepts in Intravascular Ultrasound Guided Stent Implantation. Presented at the XVIIIth Congress of the European Society of Cardiology Annual Scientific Sessions, August 27th, 1996, Birmingham, U.K.
191. Primary Stenting in Acute Myocardial Infarction: Interim Report from the PAMI Stent Pilot Trial. Presented at the XVIIIth Congress of the European Society of Cardiology Annual Scientific Sessions, August 27th, 1996, Birmingham, U.K.
192. Defining the Relationship Between Implantation Pressure and Stent Expansion: Core Lab Results from the Optimal Stent Implantation (OSTI) Trial. Presented at the XVIIIth Congress of the European Society of Cardiology Annual Scientific Sessions, August 29th, 1996, Birmingham, U.K.
193. Angioplasty and Stenting in Acute Myocardial Infarction. Thought Leaders in Interventional Cardiology: Round Table Sessions. Detroit, MI, September 5th-6th, 1996.
194. Utility of ReoPro in Interventional Cardiology - A Real World Analysis. Presented at the course New Directions in Interventional Cardiology, September 8th, 1996, San Francisco, CA.
195. Stenting in Acute Myocardial Infarction - The PAMI Stent Pilot Trial Results. Presented at the course New Directions in Interventional Cardiology, September 8th, 1996, San Francisco, CA.
196. Direct PTCA in the Treatment of Myocardial Infarction. Lessons from the PAMI Trials, and Beyond. Presented at the course Strategies for Intervention in Complex Coronary Artery Disease: A "Real" World Approach. September 11th, 1996, Kansas City, MO.
197. Primary Stenting in Acute Myocardial Infarction. Presented at the PAMI Investigators' Meeting, September 17th, Dallas, TX.
198. Stents for Acute Myocardial Infarction. Presented at the course Coronary Interventions: 1996. The Scripps Clinic and Research Foundation, October 4th, 1996, San Diego, CA.
199. Treatment of Acute Myocardial Infarction: Is Thrombolytic Therapy Passé? Presented at the course Coronary Interventions: 1996. The Scripps Clinic and Research Foundation, October 4th, 1996, San Diego, CA.
200. Basic Principles of Intravascular Ultrasound and IVUS Guided Stenting. The Cordis/JJIS Palmaz-Schatz Stent Certification Course. San Diego, CA, October 6th, 1996.

201. Advanced Concepts in Intravascular Ultrasound Guided Stent Implantation. Presented at the course Coronary Interventions: 1996. The Scripps Clinic and Research Foundation, October 6th, 1996, San Diego, CA.
202. Complex Coronary Stenting: Advanced Case Review. Presented at the course Coronary Interventions: 1996. The Scripps Clinic and Research Foundation, October 6th, 1996, San Diego, CA.
203. The Use of Glycoprotein IIb-IIIa Receptor Antagonists During Complex Coronary Intervention. Cardiology Grand Rounds. Queen of the Valley Hospital, Napa, CA, October 8th, 1996.
204. Primary Stenting in Acute Myocardial Infarction - the Next Breakthrough. Presented at the course "Advanced Cardiovascular Guidance" in Atlanta, Georgia, October 18th, 1996.
205. Primary PTCA in Acute Myocardial Infarction - Technique, Results of Studies, and How to Establish a Primary PTCA Program. Torrance Memorial Hospital, Torrance, CA, October 28th, 1996.
206. Improved Results of Balloon Angioplasty with Intravascular Ultrasound Guidance. Presented at the course Beyond Angiography IV. New Orleans, LA, October 9th, 1996.
207. Should the Risk of Delaying Reperfusion Prohibit Inter-Hospital Transfer to Perform Primary PTCA in Acute Myocardial Infarction? Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 12th, 1996.
208. A Prospective, Multicenter Trial of Primary Stenting in Acute Myocardial Infarction - The PAMI Stent Pilot Study. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 13th, 1996.
209. Primary Angioplasty Reduces Hospital Costs While Improving Outcomes in AMI - Comprehensive Cost Efficacy Analysis from the PAMI Study. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 12th, 1996.
210. A Prospective, Randomized, Multicenter Comparison of Laser Angioplasty Versus Balloon Angioplasty - The LAVA Trial. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 12th, 1996.
211. Correlation of Angiographic and Ultrasound Measures in Patients Undergoing Coronary Stenting Vs. Balloon Angioplasty. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 11th, 1996.
212. Incidence and Implications of Coronary Dissection after PTCA Using Oversized Balloons with Intravascular Ultrasound Guidance - The CLOUT Trial. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 11th, 1996.
213. Primary Angioplasty in Patients with Prior Bypass Surgery. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November

11th, 1996.

214. The Central Unifying Concept of TIMI-3 Flow after Primary PTCA and Thrombolytic Therapy in Acute Myocardial Infarction. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 12th, 1996.
215. Defining the Relationship Between Stent Implantation Pressure and Optimal Expansion - Core Lab Analysis from the OSTI Trial. Presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 11th, 1996.
216. Clinical Trials with Intravascular Ultrasound Imaging. Presented at the course "Intravascular Ultrasound Applications - An Interactive Telemedicine Training Program " in Cincinnati, OH, November 18th, 1996.
217. Primary Stenting in Acute Myocardial Infarction. Presented at the course "Emerging Applications for Stents: A Thought Leader's Forum. New York City, NY, December 4th, 1996.
218. Subacute Thrombosis is No Longer a Problem (Debate). Presented at the Third Thoraxcenter Course on Coronary Stenting, Congress Center Erasmus University, Rotterdam, The Netherlands, December 12th, 1996.
219. The OSTI I and II Trials. Presented at the Third Thoraxcenter Course on Coronary Stenting, Congress Center Erasmus University, Rotterdam, The Netherlands, December 13th, 1996.
220. The PAMI Stent Pilot Trial. Presented at the Third Thoraxcenter Course on Coronary Stenting, Congress Center Erasmus University, Rotterdam, The Netherlands, December 13th, 1996.
221. Role of Glycoprotein IIb/IIIa Receptor Antagonists during PTCA. Presented at Medical Grand Rounds, Washington Hospital, Fremont, CA, January 17th, 1997.
222. Intravascular Ultrasound Guidance of Coronary Stenting: Case Demonstrations. Presented at the course Applied Intravascular Ultrasound for the Interventionalist, San Francisco, CA, January 23rd, 1997.
223. Treatment of Acute Myocardial Infarction: GUSTO vs. PAMI. Presented at the course Advanced Coronary Stenting: Fourteenth Annual International Symposium, in Miami Beach, FL, January 24th, 1997.
224. Primary Stenting in Acute Myocardial Infarction. Presented at the course Advanced Coronary Stenting: Fourteenth Annual International Symposium, in Miami Beach, FL, January 25th, 1997.
225. IVUS Study of Balloon Pressure and Stent Deployment: The OSTI Study. Presented at the course Advanced Coronary Stenting: Fourteenth Annual International Symposium, in Miami Beach, FL, January 25th, 1997.

226. The PAMI Trials. Presented at the Xth International Congress of Endovascular Interventions, Phoenix, AZ, February 10th, 1997.
227. Clinical Utility of IVUS and Review of Clinical IVUS Trials. Presented at the course "Intravascular Ultrasound Applications - An Interactive Telemedicine Training Program " in Cincinnati, OH, February 13th, 1997.
228. Stents as Primary Treatment for Acute Myocardial Infarction. Presented at the course "Seventh Annual Symposium on Coronary Stenting", San Diego, CA, March 12th, 1997.
229. Optimal intracoronary stent placement guided by intravascular ultrasound. Presented at the course "IVUS 1997", San Diego, CA, March 15th, 1997.
230. Stenting in Acute Myocardial Infarction. Presented at the course "Myocardial reperfusion X: Concepts and Controversies. Anaheim, CA, March 15th, 1997.
231. TIMI-3 flow or time to reperfusion - what's really important in reperfusion therapy of AMI? Presented at the course "Primary PTCA in the 90's - State of the Art and Future Breakthroughs". Anaheim, CA, March 17th, 1997.
232. Stenting in Acute Myocardial Infarction. Presented at the course "Primary PTCA in the 90's - State of the Art and Future Breakthroughs". Anaheim, CA, March 17th, 1997.
233. Clinical, Angiographic and Ultrasound Predictors of Stent Expansion After High Pressure Implantation. Presented at the 46th Annual Scientific Sessions off the American College of Cardiology, Anaheim, CA, March 18th, 1997.
234. The Optimal Stent Implantation Trial - Final Core Lab Angiographic and Ultrasound Analysis. Presented at the 46th Annual Scientific Sessions off the American College of Cardiology, Anaheim, CA, March 19th, 1997.
235. Safety and Feasibility of Primary Stenting in Acute Myocardial Infarction - In-hospital and 30 Day Results of the PAMI Stent Pilot Trial. Presented at the 46th Annual Scientific Sessions off the American College of Cardiology, Anaheim, CA, March 19th, 1997.
236. Use and usefulness of ReoPro in acute ischemic syndromes. Presented to the Department of Cardiology, Alta Bates Medical Center, Berkeley, CA, March 26th, 1997.
237. Course Director, The Third National Interventional Cardiology Fellow's Course, San Jose, CA, April 10<sup>th</sup>-12th, 1997.
238. Subacute Stent Thrombosis - Prediction and Prevention. Presented at the Third National Interventional Cardiology Fellow's Course, San Jose, CA, April 11th, 1997.
239. Advances in Primary PTCA - Cost-effectiveness, Early Discharge, and Primary Stenting. Presented at the Third National Interventional Cardiology Fellow's Course, San Jose, CA, April 12th, 1997.

240. Reperfusion Therapy in Acute Myocardial Infarction. Presented at the course "Madrid Interventional Cardiology (MIC) '97", Madrid, Spain, April 16th, 1997.
241. Results of the PAMI-III Stent Pilot Trial. Presented at the course "Madrid Interventional Cardiology (MIC) '97", Madrid, Spain, April 17th, 1997.
242. Treatment of the Thrombus Containing Lesion. Presented at the course "Madrid Interventional Cardiology (MIC) '97", Madrid, Spain, April 18th, 1997.
243. Primary Coronary Intervention in Acute Myocardial Infarction - The Preferred Approach. Presented at the course "Cardiology Fiesta in San Antonio", San Antonio, TX, April 24th, 1997.
244. Coronary Stents 1997. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.
245. Heparin Coated Stents - Promise or Reality. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.
246. Impact of IVUS in Coronary Artery Stenting. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.
247. Primary Angioplasty in Acute Myocardial Infarction - Optimal Reperfusion in 1997? Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.
248. Primary Stenting in Acute Myocardial Infarction. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, April 30th, 1997.
249. IVUS Contribution in Coronary Artery Disease and in Stent Implantation. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, May 1st, 1997.
250. Direct PTCA, Stenting and IVUS in AMI. Presented at the course "International Symposium Cardiology '97", Instituto Modelo de Cardiologia, Cordoba, Argentina, May 1st, 1997.
251. Primary Angioplasty and Stenting in Acute Myocardial Infarction. Orange County Medical Association, Santa Ana, CA, May 13th, 1997.
252. Advances in Mechanical Reperfusion of Acute Myocardial Infarction - Primary Angioplasty and Primary Stenting. Keynote address at the 20th Annual Scientific Meeting for Coronary Thrombolysis, Tokyo, Japan, May 31st, 1997.
253. Clinical Utility of Intracoronary Ultrasound Imaging; Present Status and Future Forecast. Volpe, Welty and Brown. San Francisco, June 9th, 1997.

254. Angioplasty and New Devices in Acute Myocardial Infarction. Presented at the 4th Annual Mayo Clinic Interventional Cardiology Symposium. Rochester, Minnesota, June 12th, 1997.
255. Optimizing Coronary Intervention with Intracoronary Ultrasound. Presented at the 4th Annual Mayo Clinic Interventional Cardiology Symposium. Rochester, Minnesota, June 12th, 1997.
256. Current Status of the PAMI Trials. Presented at the Fifth Annual Inter-American Symposium on Contemporary Approaches to the Treatment of Cardiovascular Disease. Key Biscayne, FL, June 13th, 1997.
257. Stenting in Acute Myocardial Infarction. Presented at the Fifth Annual Inter-American Symposium on Contemporary Approaches to the Treatment of Cardiovascular Disease. Key Biscayne, FL, June 13th, 1997.
258. Use of IIb/IIIa Inhibitors in Acute Coronary Syndromes. Presented at the Fifth Annual Inter-American Symposium on Contemporary Approaches to the Treatment of Cardiovascular Disease. Key Biscayne, FL, June 13th, 1997.
259. U.S. Interventional Cardiology Opinion Leader's Meeting, Cordis/JJIS Corporations, West Palm Beach, FL, June 19th-20th, 1997.
260. Intracoronary Stenting in Acute Myocardial Infarction. Presented at the course "Intervention in Acute Coronary Syndromes", Allegheny General Hospital, Pittsburgh, PA, June 21st, 1997.
261. Guidant/ACS MultiLink Stent Training Course. Dallas, TX, June 30th, 1997.
262. Stenting and New Devices in Acute Myocardial Infarction. Americus Research Foundation keynote speaker, Charlotte, NC, July 1st, 1997.
263. Primary Angioplasty vs. Thrombolytic Therapy in Acute Myocardial Infarction. Cardiovascular Conference, Presbyterian Hospital, Charlotte, NC, July 2nd, 1997.
264. Stenting in Acute Myocardial Infarction - Update of the PAMI Stent Pilot Trial. Presented at the course "Cardiovascular Interventions: Technology at the Summit VII", Aspen, CO, July 24th, 1997.
265. Ultrasound Imaging in Coronary Stenting. Presented at the course "Cardiovascular Interventions: Technology at the Summit VII", Aspen, CO, July 24th, 1997.
266. The CADILLAC Trial - Update. U.S. Investigator's Meeting. San Francisco, CA, July 28th, 1997.
267. The CADILLAC Trial - Update. European Investigator's Meeting. Stockholm, Sweden, August 23rd, 1997.
268. The CADILLAC Trial - Update. U.S. Investigator's Meeting. Washington D.C., September 24th, 1997.



269. Stenting in Acute Myocardial Infarction. Presented at the course "Mechanical Reperfusion in Acute MI: New Approaches and Future Breakthroughs" at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 24th, 1997.
270. Acute MI Stenting: An Introduction to CADILLAC. Presented at the course "The Advanced MultiLink Intracoronary Stent: Harmonizing Design and Function" at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 25th, 1997.
271. Elective or Provisional Stenting for Acute Myocardial Infarction. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 28th, 1997.
272. Glycoprotein IIb/IIIa Receptors Antagonists. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 26th, 1997.
273. Acute Myocardial Infarction in Women - Balancing the Risks and Benefits of Treatment Alternatives. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 26th, 1997.
274. The CADILLAC Trial - Examining the Role of Glycoprotein IIb/IIIa Receptors Antagonists and New Devices in Acute Myocardial Infarction. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 26th, 1997.
275. IVUS Guidance of Coronary Stenting is a Must! (Debate). Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 28th, 1997.
276. Optimizing the Results of Coronary Stenting. Presented at the 9th Annual Transcatheter Cardiovascular Therapeutics Symposium, Washington D.C., September 28th, 1997.
- New concepts in in-stent restenosis. Guidant Radiation Therapy Advisory Board Meeting. Washington D.C., September 28th, 1997.
277. Clinical Utility of Intravascular Ultrasound - Review of Clinical Trials. Presented at the course "Intravascular Ultrasound Applications - An Interactive Telemedicine Training Program " in Cincinnati, OH, October 9th, 1997.
278. The Guidant/ACS Multi-Link Stent Training Course, Santa Clara, CA, October 10th, 1997.
279. Primary Stenting in Acute Myocardial Infarction. Presented at the symposium "Interventional Cardiology: Toward the 3rd Millennium", San Francisco, CA. October 15th, 1997.
280. Stents as Primary Therapy for Acute Myocardial Infarction: what's the data? Presented at the course "Coronary Interventions: 1997", San Diego, CA, October 16th, 1997.

281. New Concepts in Stent Delivery: Maximizing the MLD - Is it Balloon Pressure or Size? Presented at the course "Coronary Interventions: 1997", San Diego, CA, October 16th, 1997.
282. Practical Aspects of Direct Intervention in Acute Myocardial Infarction: Pharmaceutical Adjuncts, Tips, Tricks and Technical Pearls. Presented at the course "Coronary Interventions: 1997", San Diego, CA, October 16th, 1997.
283. Revascularization Time in Unstable Angina. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 19th, 1997.
284. Controversy: Acute Myocardial Infarction - Angioplasty or Thrombolytics? Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 19th, 1997.
285. Angioplasty in Unstable Angina. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 19th, 1997.
286. Angioplasty in Acute Myocardial Infarction. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 20th, 1997.
287. Post Infarction Strategies: The PAMI Trials. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 20th, 1997.
288. Stents in Acute Myocardial Infarction. Presented at the XXIV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 20th, 1997.
289. Primary PTCA or Primary Stenting in AMI? Presented at the course "Acute Coronary Syndromes: New Drugs and Devices", Pasadena, CA, November 1, 1997.
290. Cardiogenic Shock: Can it be Treated? Presented at the course "Acute Coronary Syndromes: New Drugs and Devices", Pasadena, CA, November 1, 1997.
291. Beyond Primary PTCA: Stenting and Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction. Chicago, IL, November 6th, 1997.
292. Primary Mechanical Reperfusion in Acute Myocardial Infarction. Grand Rounds, Northwestern University Medical Center, Chicago, IL, November 7th, 1997.
293. Revascularization Strategies in Acute Myocardial Infarction. Presented at the course "Acute Management Strategies in Unstable Ischemic Syndromes", November 8th, 1997.
294. Course Coordinator, "Establishing a High Quality Primary PTCA Program". Presented at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 10th, 1997.
295. Comparative Analysis of Primary PTCA vs. Thrombolytic Therapy. Presented as part of the course "Establishing a High Quality Primary PTCA Program" at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 10th, 1997.

296. Glycoprotein IIb/III Blockade in Acute Myocardial Infarction: Urgent Reflow and its Preservation. Presented at the course "Advancing Treatment and Prevention of Acute Coronary Syndromes: From Parenteral to Oral Glycoprotein Blockade", Orlando, FL, November 10th, 1997.
297. Maximizing outcomes of coronary stenting with focal balloon stent expansion: The OSTI Trials. Evening Seminar, Orlando, FL, November 11th, 1997.
298. Improved Procedural Results of Coronary Stenting with Focal Balloon "Overexpansion" - The OSTI-2A Trial. Presented at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 11th, 1997.
299. Is Stenting the Treatment of Choice for Thrombus Containing Lesions? Core Lab Analysis from the PAMI Stent Pilot Trial. Presented at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 11th, 1997.
300. Improved Short-term Outcomes of Primary Stenting Compared to Primary Angioplasty in Acute Myocardial Infarction - The PAMI Stent Pilot Trial. Presented at the 70th Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 12th, 1997.
301. The Role of Stenting and Adjunctive Pharmacotherapy in Acute Myocardial Infarction. DANAMI-2 meeting, Aarhus, Denmark, November 21st, 1997.
302. Primary Angioplasty is Superior to Thrombolytic Therapy in Acute Myocardial Infarction (debate - protagonist). Presented at the course "4th Annual Point/Counterpoint in Interventional Cardiology", December 5th, 1997, NYC, NY.
303. Stenting in AMI: The PAMI, GRAMI, PASTA, PRISM, FRESCO and CADILLAC trials. Presented at the Cardiovascular Summit and 4th Thoraxcenter Course on Cardiovascular Stenting, December 12th, 1997, Erasmus University, Rotterdam, The Netherlands.
304. Intravascular ultrasound applications during complex coronary stenting. The New Jersey Society of Interventional Cardiology, Newark, New Jersey, January 6th, 1998.
305. Beyond Primary PTCA: Stenting and Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction. Cardiology Grand Rounds, The New Jersey University Hospital/School of Medicine and Dentistry, Newark, New Jersey, January 7th, 1998.
306. Visiting Professor's Rounds. Case Presentations. The New Jersey University Hospital/School of Medicine and Dentistry, Newark, New Jersey, January 7th, 1998.
307. Primary Angioplasty vs. Thrombolytic Therapy for Acute Coronary Ischemia. Presented at the Tenth Anniversary International Symposium on Vascular Diagnosis and Intervention, Miami, FL, January 13th, 1998.
308. Reperfusion therapy in women. Presented at the course "Women's Health Issues after Coronary Interventions", Washington, DC, January 23rd, 1998.

309. Stenting in Acute Coronary Syndromes. Cordis/Johnson and Johnson U.S. Key Opinion Leader Board Meeting, Miami, FL, January 26th-28th, 1998.
310. Advances in the treatment of myocardial infarction. St. Bernadine's Medical Center, San Bernardino, CA, February 4th, 1998.
311. Beyond Primary PTCA: Stenting and Abciximab in Acute Myocardial Infarction. Presented at the 11th Annual International Congress of Endovascular Interventions, Phoenix, CA, February 11th, 1998.
312. IVUS guided complex coronary stenting: New concepts and advanced techniques. Presented at the First Annual International Tropical Retreat, Hawaii, February 24th, 1998.
313. Stenting in acute myocardial infarction. Presented at the First Annual International Tropical Retreat, Hawaii, February 27th, 1998.
314. Present status of coronary stenting and IIb/IIIa receptor blockade in acute myocardial infarction. Lilly Research Labs, Indianapolis, IN, March 3rd, 1998.
315. Clinical challenges in interventional cardiology. ACS Radiation Therapy Advisory Board Meeting, Washington D.C., March 8th, 1998.
316. Stenting in AMI - PAMI Stent and CADILLAC. Presented at the course "Myocardial Reperfusion XI: Concepts and Controversies". Atlanta, GA, March 28th, 1998.
317. Reperfusion Strategies in Acute Myocardial Infarction: Focus on Stenting. Presented at the course "A New Generation of Coronary Stenting: Technique, Pharmacology and Design". Atlanta, GA, March 29th, 1998.
318. Stenting in Acute Myocardial Infarction - Non-Heparin Coated. Presented at the course Primary PTCA the Next Generation: Stenting and IIb/IIIa Receptor Blockade in AMI. Atlanta, GA, March 31st, 1998.
319. In-hospital and late outcomes following primary stenting in acute myocardial infarction - comparison with primary PTCA. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.
320. Primary stenting in acute myocardial infarction is associated with a low rate of late adverse events - The PAMI Stent Pilot. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.
321. Adverse outcomes prior to hospital discharge after primary stenting for acute myocardial infarction are often predictable, and related to correctable technical factors. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.
322. Incidence and predictors of 6 month angiographic restenosis and reocclusion after primary infarct stenting - core lab analysis from the PAMI Stent Pilot Study. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta,

GA, March 31, 1998.

323. Incremental value of IVUS after coronary stenting when a "perfect" angiographic result is obtained. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 30, 1998.
324. Improved procedural results of coronary stenting with focal balloon "overexpansion" - final core lab analysis from the prospective, multicenter OSTI-2A trial. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 29, 1998.
325. Lack of relationship between the time to reperfusion and short-term mortality after primary infarct angioplasty. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 31, 1998.
326. Primary Angioplasty: Where, When and How. Fireside Panel Presentation at the 47th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 29, 1998.
327. U.S. Eclipse Percutaneous Transluminal Myocardial Revascularization Meeting. Atlanta, GA, April 1st, 1998.
328. Tips and Tricks in Ultrasound Guided Stenting. Presented at the course "IVUS, Flow and Pressure Applications in Interventional Cardiology: Case Review with the Experts". San Jose, CA, April 23rd, 1998.
329. Primary PTCA is Superior to Thrombolytic Therapy in Acute Myocardial Infarction - Case Closed. Presented at the Fourth National Interventional Cardiology Fellows Course, San Jose, CA, April 26th, 1998.
330. IIb/IIIa Receptor Blockade and Primary Stenting in Acute Myocardial Infarction . Presented at the Fourth National Interventional Cardiology Fellows Course, San Jose, CA, April 26th, 1998.
331. The PAMI Stent Randomized Trial - In-Hospital and 30 Day Results. Presented at the Eighth Annual Symposium on Coronary Stenting, San Diego, CA, May 7th, 1998.
332. Percutaneous Transluminal Myocardial Revascularization (PTMR): The Eclipse System and Studies. Presented at the Eighth Annual Symposium on Coronary Stenting, San Diego, CA, May 7th, 1998.
333. Real World Stenting - Comparative Studies and Complex Case Review. Presented at the course Complex Coronary and Vascular Interventions, San Francisco, CA, May 9th, 1998.
334. New approaches to heart disease. Guidant multi-disciplinary advisory board meeting. Indianapolis, IN, May 20th, 1998.
335. Interpreting the stent vs. stent randomized comparative trials. University of Texas Medical Center, Houston, TX, May 28th, 1998.

336. Percutaneous transluminal myocardial revascularization – The Eclipse system and studies. Presented at the course “Angiogenesis and Direct Myocardial Revascularization”, Chantilly, Virginia, June 3<sup>rd</sup>, 1998.
337. Mechanical Approach to the AMI Patient. Presented at the Seventh Annual Symposium on Advanced Cardiovascular Interventions. Hilton Head, SC, June 12<sup>th</sup>, 1998.
338. Advances in Intravascular Ultrasound Guidance of Coronary Intervention. Walnut Creek, CA, June 23<sup>rd</sup>, 1998.
339. The EPISTENT Study – Application to the treatment of acute ischemic syndromes. Presented at the course “Madrid Interventional Cardiology (MIC) '98”, Madrid, Spain, July 8<sup>th</sup>, 1998.
340. The evolution of interventional treatment of the patient with acute myocardial infarction. Presented at the course “Madrid Interventional Cardiology (MIC) '98”, Madrid, Spain, July 9<sup>th</sup>, 1998.
341. Percutaneous transluminal myocardial revascularization by laser – evidence and technique. Presented at the course “Madrid Interventional Cardiology (MIC) '98”, Madrid, Spain, July 9<sup>th</sup>, 1998.
342. Stenting in Acute Myocardial Infarction – Is it Justified?. Presented at the course “Cardiovascular Interventions: Technology at the Summit, VIII”, Aspen, CO, July 24<sup>th</sup>, 1998.
343. Advanced Concepts and Techniques in Intravascular Ultrasound Guided Stenting. Presented at the course “Cardiovascular Interventions: Technology at the Summit, VIII”, Aspen, CO, July 24<sup>th</sup>, 1998.
344. Advanced Stent Workshop. Presented at the course “Cardiovascular Interventions: Technology at the Summit, VIII”, Aspen, CO, July 25<sup>th</sup>, 1998.
345. Primary PTCA vs. Thrombolytic Therapy in AMI: An Evidence Based Summary. National Acute Myocardial Infarction Advisory Board Meeting. Aspen, CO, July 25<sup>th</sup>, 1998.
346. Trials in intravascular ultrasound imaging. Endosonics Clinical Advisory Board Meeting, Chicago, IL, August 22<sup>nd</sup>, 1998.
347. Optimizing Outcomes after Coronary Stenting: Physics or Meta-Physics? Presented at the course “Coronary Interventions: 1998”, San Diego, CA, September 5<sup>th</sup>, 1997.
348. PAMI, FRESCO, Zwolle, Stentim, GRAMI, PASTA, PRISAM and CADILLAC – Stenting in Acute Myocardial Infarction. Presented at the course “Coronary Interventions: 1998”, San Diego, CA, September 6<sup>th</sup>, 1997.
349. TMR and PTMR – Clinical Update. Presented at the course “Coronary Interventions: 1998”, San Diego, CA, September 7<sup>th</sup>, 1997.

350. Course Director, "Vascular Visions", Cardiovascular Training and Education Center, Washington Hospital Center, September 15<sup>th</sup>-16<sup>th</sup>, 1998.
351. Interventional Trials in Acute Myocardial Infarction. Presented at the course "International Summit on Acute Coronary Care", Portobuffole, Italy, September 18<sup>th</sup>, 1998.
352. Course Co-Director, Transcatheter Cardiovascular Therapeutics X, Washington DC, October 6<sup>th</sup>-11<sup>th</sup>, 1998.
353. PTCA in Acute Ischemic Syndromes. Presented during the Interventional Cardiology Self-Assessment and Review Course at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 6<sup>th</sup>, 1998.
354. Case Demonstrations – Unstable Ischemic Syndromes and Acute Myocardial Infarction. Presented during the "Interventional Cardiology Self-Assessment and Review Course" at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 6<sup>th</sup>, 1998.
355. Case Demonstrations – Pharmacologic Adjuncts During PTCA, Featuring the IIb/IIIa Inhibitors. Presented during the "Interventional Cardiology Self-Assessment Course" at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7<sup>th</sup>, 1998.
356. Abstract Session Moderator, Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7<sup>th</sup>, 1998.
357. Surgical and Catheter-based Laser Myocardial Revascularization – A Valuable Therapeutic Intervention. Point-Counterpoint Discussion. Presented during Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7<sup>th</sup>, 1998.
358. Course Director, Comprehensive Management of the AMI Patient: From Reperfusion Therapy to Rhythm Stabilization. Washington DC, October 7<sup>th</sup>, 1998.
359. Integrating Pharmacotherapy with Mechanical Reperfusion in AMI. Presented during the course "Comprehensive Management of the AMI Patient: From Reperfusion Therapy to Rhythm Stabilization" at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7<sup>th</sup>, 1998.
360. Impact of New Pharmacologic Agents in the Treatment of Acute Thrombotic Syndromes. Presented during the course "The Role of the Platelet in Acute Coronary Syndromes: A new Perspective for the 21<sup>st</sup> Century" at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 7<sup>th</sup>, 1998.
361. Clinical Trials for the Next Generation of Devices. FDA Town Hall Meeting, Event Moderator. Transcatheter Cardiovascular Therapeutics X, Washington DC, October 8<sup>th</sup>, 1998.
362. The Cardiovascular Dynamics Self Expanding Arterial Liner (SEAL) Stent. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 8<sup>th</sup>, 1998.
363. Current standards and future trends in the management of acute myocardial infarction: Harmonizing interventional and pharmacological approaches. Presented at

Transcatheter Cardiovascular Therapeutics X, Washington DC, October 8<sup>th</sup>, 1998.

364. Perspectives on Stents in Acute Myocardial Infarction: U.S. Trials (PAMI-Stent and CADILLAC). Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 9<sup>th</sup>, 1998.
365. Can the case be made for routine IVUS guidance? – Maximizing stent lumen dimensions with pressure and volume (OSTI-1 and OSTI-2 results). Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 10<sup>th</sup>, 1998.
366. The Choice for women with acute myocardial infarction: Primary angioplasty is the way to go! (debate). Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 10<sup>th</sup>, 1998.
367. Summarizing the preliminary Clinical Trial data with the Eclipse Percutaneous Transmural Revascularization (PTMR) System. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 10<sup>th</sup>, 1998.
368. Does the heparin-coated stent provide enhanced clinical utility? Insights from Benestent II, TOSCA and PAMI-Stent. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 10<sup>th</sup>, 1998.
369. Choosing the right stent: Stents are more different than alike – design definitely counts! (Debate). Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11<sup>th</sup>, 1998.
370. Lesion specific stenting: Acute myocardial infarction lesions. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11<sup>th</sup>, 1998.
371. Is IVUS guided stenting necessary, helpful or worthless? Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11<sup>th</sup>, 1998.
372. The realities of provisional stenting: A strategy whose time has come and gone! (Debate). Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11<sup>th</sup>, 1998.
373. IVUS guidance during stenting: optimizing acute and late results. Presented at Transcatheter Cardiovascular Therapeutics X, Washington DC, October 11<sup>th</sup>, 1998.
374. Stenting in Acute Myocardial Infarction. Presented at the 4<sup>th</sup> Complex Coronary Intervention Conference, Himeji City, Japan, October 22<sup>nd</sup>, 1998.
375. Live case demonstrations. Presented at the 4<sup>th</sup> Complex Coronary Intervention Conference, Himeji City, Japan, October 23<sup>rd</sup>, 1998.
376. Stent vs. stent comparisons – making sense of the randomized trials. Presented at the 4<sup>th</sup> Complex Coronary Intervention Conference, Himeji City, Japan, October 23<sup>rd</sup>, 1998.
377. The Next Frontier in Treating the Patient with Acute Myocardial Infarction: Stents and IIb/IIIa inhibitors. “Cardiology Grand Rounds – Fall 1998”, Allegheny General Hospital,



October 29<sup>th</sup>, 1998.

378. Long-term results following “maximal stenting” using ultrasound guided balloon overexpansion - the Second Optimal Stent Implantation Study. Presented at the 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, TX, November 9<sup>th</sup>, 1998.
379. Angiographic luminal “gain” occurs within the first 6 months after stenting thrombotic lesions in patients with acute myocardial infarction - a unique phenomenon. Presented at the 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, TX, November 10<sup>th</sup>, 1998.
380. Percutaneous myocardial laser revascularization in patients with class III-IV angina and lesions at high risk for restenosis - results of a phase I study as a preamble to a large, randomized trial. Presented at the 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, TX, November 10<sup>th</sup>, 1998.
381. Does stent implantation in acute myocardial infarction degrade TIMI flow and result in higher early mortality than PTCA? - The PAMI Stent Randomized Trial. Presented at the 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, TX, November 9<sup>th</sup>, 1998.
382. Stenting of thrombotic lesions in acute myocardial infarction results in less late loss and greater freedom from restenosis than non-thrombotic lesions - core lab analysis from the PAMI Stent Pilot Trial. Presented at the 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, TX, November 9<sup>th</sup>, 1998.
383. The powerful interaction between age and gender in determining short-term mortality after mechanical reperfusion therapy in acute myocardial infarction. Insights from the PAMI Stent Randomized Trial. Presented at the 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, TX, November 9<sup>th</sup>, 1998.
384. By sealing dissection planes, primary stenting reduces ischemia driven target vessel revascularization at 30 days compared to primary PTCA - Analysis from the PAMI Stent Randomized Trial. Presented at the 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, TX, November 10<sup>th</sup>, 1998.
385. Novel IVUS Insights into Optimal Stenting techniques. Presented at the course Beyond Angiography V. Dallas, TX, November 7<sup>th</sup>, 1998.
386. Are IIB/IIIA Antagonists Required During Infarction Interventions? Not Yet Proven! Presented during the 14<sup>th</sup> International Workshop on Thrombolysis and Interventional Therapy. Dallas, TX, November 7<sup>th</sup>, 1998.
387. The role of IABP in AMI. Datascope Benchmark Registry Advisory Board Meeting. Dallas, TX, November 8<sup>th</sup>, 1998.
388. How To select the right devices for primary PTCA in acute myocardial infarction. Session Moderator. The 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, TX, November 9<sup>th</sup>, 1998.

389. Perspectives on IIB/IIIA Use in Acute Myocardial Infarction. Presented at the 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, TX, November 9<sup>th</sup>, 1998.
390. Primary angioplasty in acute myocardial infarction. Presented at the Cordis Interventional Course for Cardiology Fellows, Washington DC, December 3<sup>rd</sup>, 1998.
391. Adjunct therapy use in acute myocardial infarction. Presented at the Cordis Interventional Course for Cardiology Fellows, Washington DC, December 3<sup>rd</sup>, 1998.
392. Integrating Pharmacotherapy with Mechanical Reperfusion in Acute Myocardial Infarction. Presented at the annual meeting of the Washington State chapter of the ACC, Bellevue, WA, December 5<sup>th</sup>, 1998.
393. Subacute thrombosis – scope of the problem. Biocompatibles Ltd. Clinical Advisory Board meeting. Washington DC, December 6<sup>th</sup>, 1998.
394. New Vistas in Acute-Care Cardiovascular Therapeutics. Research Seminar. San Francisco, December 18<sup>th</sup>, 1998.
395. Expanded use of GP IIB/IIIA inhibitors during percutaneous interventions. Presented at the International Symposium on Endovascular Therapy (ISET), Miami Beach, January 22<sup>nd</sup>, 1999.
396. Value of intravascular ultrasound imaging during coronary stenting. Presented at the International Symposium on Endovascular Therapy (ISET), Miami Beach, January 22<sup>nd</sup>, 1999.
397. Understanding the U.S. multicenter stent trials. Are all stents equal? Presented at the International Symposium on Endovascular Therapy (ISET), Miami Beach, January 22<sup>nd</sup>, 1999.
398. Laser based myocardial revascularization and angiogenesis. Presented at the 22<sup>nd</sup> Annual Cardiovascular Symposium: New Horizons and Therapies. Fort Lauderdale, FL, February 4<sup>th</sup>, 1999.
399. Stenting in AMI – Review of Randomized Trials. Presented at the 22<sup>nd</sup> Annual Cardiovascular Symposium: New Horizons and Therapies. Fort Lauderdale, FL, February 4<sup>th</sup>, 1999.
400. Integrating Pharmacotherapy with Angioplasty in Acute Ischemic Syndromes. Presented at the 22<sup>nd</sup> Annual Cardiovascular Symposium: New Horizons and Therapies. Fort Lauderdale, FL, February 4<sup>th</sup>, 1999.
401. Stent design, form and function. Fort Lauderdale, FL, February 5<sup>th</sup>, 1999.
402. Advances in the Treatment of Acute Myocardial Infarction. Presented at “Case Reviews in Interventional Cardiology”, Washington DC, February 10<sup>th</sup>, 1999.
403. Live case moderator at the course Cardiovascular Radiation Therapy III. Washington DC, February 18<sup>th</sup> and 19<sup>th</sup>, 1999.

404. Review of Available Investigational Radiation Systems at the course Cardiovascular Radiation Therapy III. Washington DC, February 19<sup>th</sup> 1999.
405. Treatment of Acute Myocardial Infarction. Presented at the Board Review Course Cardiovascular Interventions '99, Tampa Bay, FL, Feb. 27<sup>th</sup>, 1999.
406. The Role of Stents in Acute Myocardial Infarction. Presented at the 48<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7<sup>th</sup>-10<sup>th</sup>, 1999.
407. Routine stent implantation reduces restenosis after primary angioplasty in acute myocardial infarction – results from the PAMI Stent Randomized Trial. Presented at the 48<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7<sup>th</sup>-10<sup>th</sup>, 1999.
408. Predictors of six month event-free survival after mechanical reperfusion in acute myocardial infarction - the PAMI Stent Randomized Trial. Presented at the 48<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7<sup>th</sup>-10<sup>th</sup>, 1999.
409. Differential effects of stenting and angioplasty in women versus men undergoing a primary mechanical reperfusion strategy in acute myocardial infarction - the PAMI Stent Randomized Trial. Presented at the 48<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7<sup>th</sup>-10<sup>th</sup>, 1999.
410. Long-term influence of CPK-MB elevation on mortality after percutaneous intervention – analysis of 7359 patients. Presented at the 48<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7<sup>th</sup>-10<sup>th</sup>, 1999.
411. What is the clinical significance of an elevated CPK-MB band fraction after percutaneous intervention if the total CPK is normal? Presented at the 48<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7<sup>th</sup>-10<sup>th</sup>, 1999.
412. Outcomes of bail-out stenting after failed primary angioplasty in acute myocardial infarction – analysis from the PAMI Stent Randomized Trial. Presented at the 48<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7<sup>th</sup>-10<sup>th</sup>, 1999.
413. 2.5 year follow-up of the CLOUT study – long-term implications for an aggressive IVUS guided balloon angioplasty strategy Presented at the 48<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 7<sup>th</sup>-10<sup>th</sup>, 1999.
414. Primary Stenting and Acute MI: PAMI Stent and CADILLAC. Presented at the symposium “Mission Possible: GP IIb/IIIa Inhibition for Acute Myocardial Infarction”, New Orleans, March 6<sup>th</sup>, 1998.
415. Chronic total occlusions – the final frontier. The Intraluminal Therapeutics Advisory Board meeting. New Orleans, March 7<sup>th</sup>, 1999.

416. Is thrombectomy necessary in AMI intervention? The annual Endicor Advisory Board meeting. New Orleans, March 6<sup>th</sup>, 1999.
417. Selection of Stents for Complex Lesions – Case Examples. Presented at the 5<sup>th</sup> Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 7<sup>th</sup>, 1999.
418. Conservative and Invasive Strategies in Acute Coronary Syndromes – Integrating IIb/IIIa Receptor Blockade. Presented at the 5<sup>th</sup> Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 8<sup>th</sup>, 1999.
419. Stenting and IIb/IIIa Inhibitors in Acute Myocardial Infarction – randomized Trials and Personal Perspectives. Presented at the 5<sup>th</sup> Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 9<sup>th</sup>, 1999.
420. Percutaneous Transmyocardial Revascularization by Laser. Presented at the 5<sup>th</sup> Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 10<sup>th</sup>, 1999.
421. The Interventional Approach to MI – New Therapeutic Strategies. Presented at the course "Cardiology Fiesta in San Antonio: Update on Cardiac Diagnostic and Therapeutic Techniques", San Antonio, TX, April 15<sup>th</sup>, 1999.
422. Gamma Radiation: Review of Systems and Studies. Presented at the course "The Third Annual Frontiers in Interventional Cardiology: Device and Pharmacology Synergy for the New Millenium", Houston, TX, April 15<sup>th</sup>, 1999.
423. Transmyocardial Laser Recanalization for Disabling Angina: Hope or Hype? Presented at the course "The Third Annual Frontiers in Interventional Cardiology: Device and Pharmacology Synergy for the New Millenium", Houston, TX, April 16<sup>th</sup>, 1999.
424. Direct PTCA – Not Lytics of IIb/IIIa antagonists is the simplest and best way to treat acute MI. Presented at the course "The Third Annual Frontiers in Interventional Cardiology: Device and Pharmacology Synergy for the new Millenium", Houston, TX, April 17<sup>th</sup>, 1999.
425. Debate: Primary PTCA in Acute MI is the Optimal reperfusion Strategy in Acute MI. Presented at the Inland Empire Heart Institute First Annual Cardiac Symposium, San Bernardino, CA, April 17<sup>th</sup>, 1999.
426. Understanding stent design: Analysis of the U.S. stent vs. stent comparative trials. Presented at the course "Advanced Coronary Stenting", Washington DC, April 26<sup>th</sup>, 1999.
427. Complex Coronary Stenting using Intravascular Ultrasound Guidance I. Presented at the course "Advanced Coronary Stenting", Washington DC, April 26<sup>th</sup>, 1999.
428. Complex Coronary Stenting with Intravascular Ultrasound Guidance II: Advanced case demonstrations. Presented at the course "Advanced Coronary Stenting", Washington DC, April 27<sup>th</sup>, 1999.

429. Approach to the thrombotic lesion and acute myocardial infarction. Presented at the course "Advanced Coronary Stenting", Washington DC, April 27<sup>th</sup>, 1999.
430. Antiplatelet and Antithrombotic Therapy: New Treatment Paradigms. Presented at the course "Interventional Cardiology for the Next Millenium", Washington DC, April 28<sup>th</sup>, 1999.
431. Pharmacologic and mechanical reperfusion in acute myocardial infarction. Presented at the course "Interventional Cardiology for the Next Millenium", Washington DC, April 28<sup>th</sup>, 1999.
432. Percutaneous laser myocardial revascularization – the non-guided approach. Presented at the course "Interventional Cardiology for the Next Millenium", Washington DC, April 29<sup>th</sup>, 1999.
433. Primary PTCA vs. Thrombolytic Therapy: Detailed Review of the Clinical Trials. Presented at the course "Primary PTCA: The Expert Approach", Washington DC, May 5<sup>th</sup>, 1999.
434. Primary Stenting in AMI: Observations, Insights, and Randomized Trials. Presented at the course "Primary PTCA: The Expert Approach", Washington DC, May 5<sup>th</sup>, 1999.
435. Use of IIb/IIIa Inhibitors During AMI Intervention. Presented at the course "Primary PTCA: The Expert Approach", Washington DC, May 5<sup>th</sup>, 1999.
436. The Importance of Patency and Time to Patency in Reperfusion Therapy in AMI. Presented at the course "Primary PTCA: The Expert Approach", Washington DC, May 6<sup>th</sup>, 1999.
437. Understanding the critical differences between contrast agents. Presented at the course "Primary PTCA: The Expert Approach", Washington DC, May 6<sup>th</sup>, 1999.
438. A balanced view of IIb/IIIa inhibitor use. Centocor/Lilly Advisory Board Meeting. Atlanta, GA, May 10<sup>th</sup>, 1999.
439. Prevention of restenosis with intravascular ultrasound imaging. Presented at the course "Treatment of In-Stent Restenosis", Washington DC, May 13<sup>th</sup>, 1999.
440. Management of diffuse disease with non-guided percutaneous transmyocardial laser revascularization. Presented at the course "Treatment of In-Stent Restenosis", Washington DC, May 14<sup>th</sup>, 1999.
441. Mechanical reperfusion therapy and the role of adjunctive pharmacologic agents in acute myocardial infarction. Presented at the Endovascular Therapy Course (ETC) 1999, Paris, France, May 20<sup>th</sup>, 1999.
442. Controversy: Will the new drugs equalize outcomes between pharmacologic and mechanical reperfusion therapy in AMI? – *No!* Presented at the Endovascular Therapy Course (ETC) 1999, Paris, France, May 21<sup>st</sup>, 1999.

443. Review of Intravascular Ultrasound Trials. Presented at the course "Intravascular Ultrasound Imaging and Physiology Applications", Washington DC, May 24<sup>th</sup>, 1999.
444. Application of Intravascular Ultrasound in Complex Stenting – Advanced Case Review. Presented at the course "Intravascular Ultrasound Imaging and Physiology Applications", Washington DC, May 24<sup>th</sup>, 1999.
445. Small vessel stents for acute and threatened closure – insights from the U.S. Trial registry data. Presented at the course "The Small Vessel Summit", Washington DC, May 26<sup>th</sup>, 1999.
446. Design and *In-Vitro* advantages of the heparin-coated stent. Presented at the course "The Small Vessel Summit", Washington DC, May 26<sup>th</sup>, 1999.
447. Heparin-coated stenting in AMI – the PAMI Trials. Presented at the course "The Small Vessel Summit", Washington DC, May 26<sup>th</sup>, 1999.
448. Controversies in the management of acute ischemic syndromes. Presented at Cardiology Grand Rounds, Monroe Medical Center, Delaware, June 1<sup>st</sup>, 1999.
449. Live case demonstration – Eclipse PTMR. Presented at the course "2nd Annual Angiogenesis and DMR Symposium", Washington DC, June 9<sup>th</sup>, 1999.
450. Can recently formed PTMR channels protect from acute or subacute ischemia? Results of a human pilot phase study. Presented at the course "2nd Annual Angiogenesis and DMR Symposium", Washington DC, June 10<sup>th</sup>, 1999.
451. CPK Elevations after Percutaneous Intervention – Innocent Bystander or Harbinger of Death? Presented at the course "Controversies in Interventional Cardiology" Washington DC, June 14<sup>th</sup>, 1999.
452. IIb/IIIa Antagonists should be used Routinely in all Percutaneous Interventions – Pro and Con. Presented at the course "Controversies in Interventional Cardiology" Washington DC, June 14<sup>th</sup>, 1999.
453. Laser Myocardial Revascularization for Refractory Ischemia – A Clinically Useful Tool, or all Hype and no Substance? Presented at the course "Controversies in Interventional Cardiology" Washington DC, June 15<sup>th</sup>, 1999.
454. Stenting in AMI: Final Results of Stent-PAMI and Update on CADILLAC. Presented at the course "Eighth Annual Advanced Cardiovascular Interventions Symposium", Hilton Head, South Carolina, June 17<sup>th</sup>, 1999.
455. Practical Procedural Approaches to PTMR. Presented at the course "Eighth Annual Advanced Cardiovascular Interventions Symposium", Hilton Head, South Carolina, June 18<sup>th</sup>, 1999.
456. Small vessel stents for acute and threatened closure – insights from the U.S. Trial registry data. Presented at the course "The Small Vessel Summit", Washington DC, June 16<sup>th</sup>, 1999.

457. Design and *In-Vitro* advantages of the heparin-coated stent. Presented at the course "The Small Vessel Summit", Washington DC, June 16<sup>th</sup>, 1999.
458. Clinical studies with the heparin-coated stent. Presented at the course "The Small Vessel Summit", Washington DC, June 16<sup>th</sup>, 1999.
459. Lessons from the PAMI Stent Trial. Presented at the 3<sup>rd</sup> Annual International Conference on Interventional Cardiology, Jerusalem, Israel, June 29<sup>th</sup>, 1999.
460. Interventional Cardiology Board Review Workshop. Presented at the course "Seventh Annual New Devices Seminar for the Cardiac and Peripheral Vascular Laboratories", Orlando, FL, July 3<sup>rd</sup>, 1999.
461. Radiation Vascular Therapy. Presented at the course "Seventh Annual New Devices Seminar for the Cardiac and Peripheral Vascular Laboratories", Orlando, FL, July 5<sup>th</sup>, 1999.
462. Anti-Platelet Therapy in Interventional Cardiology. Presented at the course "Seventh Annual New Devices Seminar for the Cardiac and Peripheral Vascular Laboratories", Orlando, FL, July 5<sup>th</sup>, 1999.
463. Anti-Platelet Therapy Workshop. Presented at the course "Seventh Annual New Devices Seminar for the Cardiac and Peripheral Vascular Laboratories", Orlando, FL, July 5<sup>th</sup>, 1999.
464. IIb/IIIa blockade in acute ischemic syndromes prior to (and during) cardiac catheterization – Evidence for routine use from PRISM, PRISM PLUS, PURSUIT, PARAGON and CAPTURE. Presented at the course "Acute Ischemic Syndromes: Pharmacologic and Mechanical Approaches", Washington DC, July 7<sup>th</sup>, 1999.
465. Invasive vs. Conservative Management of Acute Ischemic Syndromes – TIMI-3B, VANQUISH, FRISC-II. Presented at the course "Acute Ischemic Syndromes: Pharmacologic and Mechanical Approaches", Washington DC, July 8<sup>th</sup>, 1999.
466. PTCA and stenting in AMI: Harmonizing Pharmacologic and Mechanical Approaches. Presented at the course "Acute Ischemic Syndromes: Pharmacologic and Mechanical Approaches", Washington DC, July 8<sup>th</sup>, 1999.
467. CPK elevations after percutaneous intervention: Harmless bystander or harbinger of death? Presented at the course "Acute Ischemic Syndromes: Pharmacologic and Mechanical Approaches", Washington DC, July 8<sup>th</sup>, 1999.
468. New surgical and percutaneous strategies in patients with unapproachable refractory ischemic syndromes. Presented at Cardiology Grand Rounds, University of Colorado, July 12<sup>th</sup>, 1999.
469. Insights into stenting and pharmacotherapy in acute myocardial infarction. Presented at the Interventional Cardiology Research Conference, University of Colorado, July 12<sup>th</sup>, 1999.

470. Visiting Professorship, The University of Colorado, July 12<sup>th</sup>, 1999.
471. Direct Myocardial Revascularization for Patients with Non-Revascularizable Coronary Artery Disease. Presented at Cardiology Grand Rounds, The University of Colorado, July 12<sup>th</sup>, 1999.
472. New Insights into Stenting and IIb/IIIa Inhibitor Use in Acute Myocardial Infarction. Presented at the city-wide Denver Cardiovascular Research Conference, Denver, CO, July 12<sup>th</sup>, 1999.
473. Approach to the Patient with Acute Myocardial Infarction. Presented at the course "Interventional Cardiology for the Next Millenium", Washington DC, July 22<sup>nd</sup>, 1999.
474. IIb/IIIa Inhibitors Before, During and After Percutaneous Intervention. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IX", Aspen, CO, July 29<sup>th</sup>, 1999.
475. Stenting in AMI – Insights from the PAMI Stent Trial. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IX", Aspen, CO, July 29<sup>th</sup>, 1999.
476. Clinical significance of peri-procedural myocardial infarction. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IX", Aspen, CO, July 29<sup>th</sup>, 1999.
477. IVUS Guided Maximal Stenting - The OSTI-2 Trial. Presented at the course "Cardiovascular Interventions: Technology at the Summit, IX", Aspen, CO, July 29<sup>th</sup>, 1999.
478. Stent Design Considerations II: Does Stent Design Matter? Results of the U.S. Stent vs. Stent Comparative Trials. Presented at the course "Advanced Coronary Stenting", Washington DC, August 2<sup>nd</sup>, 1999.
479. Complex Coronary Stenting with Intravascular Ultrasound Guidance II: Complex Case Review. Presented at the course "Advanced Coronary Stenting", Washington DC, August 2<sup>nd</sup>, 1999.
480. Approach to the thrombotic lesion and acute myocardial infarction. Presented at the course "Advanced Coronary Stenting", Washington DC, August 3<sup>rd</sup>, 1999.
481. Why thrombolytic therapy will never equal primary PTCA: The pathology and pathophysiology of acute myocardial infarction. Presented at the course "Primary PTCA – The Expert Approach", Washington DC, August 16<sup>th</sup>, 1999.
482. Primary PTCA vs. Thrombolytic Therapy: Detailed Review of the Clinical trials. Presented at the course "Primary PTCA – The Expert Approach", Washington DC, August 16<sup>th</sup>, 1999.
483. Primary Stenting in AMI: Observations, Insights, and Randomized Trials. Presented at the course "Primary PTCA – The Expert Approach", Washington DC, August 16<sup>th</sup>,



1999.

- 484. Use of IIb/IIIa inhibitors during AMI intervention. Presented at the course "Primary PTCA – The Expert Approach", Washington DC, August 16th, 1999.
- 485. The importance of patency and time to patency. Presented at the course "Primary PTCA – The Expert Approach", Washington DC, August 17th, 1999.
- 486. Challenges to the acceptance of IVUS guided imaging and physiologic lesion assessment. Endosonics Scientific Advisory Board Meeting, September 22<sup>nd</sup> 1999, Washington DC.
- 487. Routine vs. Provisional Stenting in Small Vessels: Pro and Con. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 26th, 1999, Washington DC.
- 488. Non-heparin-coated stenting and PTCA in AMI with and without IIb/IIIa inhibition. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 24th, 1999, Washington DC.
- 489. TCT Evolutionary Changes – Roadmap for the Future. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.
- 490. IVUS Guided maximal "overstenting" – Clinical and angiographic results of the OSTI-II trial. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 24th, 1999, Washington DC.
- 491. Tirofiban Use in Percutaneous Coronary Interventions: U.S. Pharmacodynamic Data. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.
- 492. The CADILLAC Trial. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.
- 493. Harmonizing Pharmacologic and Mechanical Reperfusion Strategies in AMI: CADILLAC I, CADILLAC II and PercuSurge AMI. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 22nd, 1999, Washington DC.
- 494. OSTI-1 and OSTI-2: "Stentus Maximus". Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.
- 495. Distal Protection During Angioplasty and Stenting in AMI. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.
- 496. New Therapeutic Approaches in Acute Myocardial Infarction: The Integration of Pharmacologic and Interventional Strategies. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.

497. Design and Rationale of the TARGET Trial. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.
498. The EndiCOR X-Sizer Thrombectomy/Atherectomy Device. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.
499. Interpreting CPK-MB and Troponin Elevations after Percutaneous Interventions – Can the Different Viewpoints be Reconciled? Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 23rd, 1999, Washington DC.
500. The Guidant FlexiCut – The Next Generation Directional Atherocath. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.
501. The X-Site Suture Based Vascular Closure Device. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.
502. Consequences of CPK-MB Elevations after Percutaneous Intervention: Important or Overblown? Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 22nd, 1999, Washington DC.
503. Hybrid Approaches: Laser Myocardial Revascularization as an Adjunct to Percutaneous Intervention. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.
504. The Embolic Protections (EPI) Distal Filter. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.
505. The Endosonics Integrated IVUS Brachytherapy System. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 26th, 1999, Washington DC.
506. Intraluminal Therapeutics – Spectroscopic Guidance for Chronic Total Occlusions. Presented at the 11<sup>th</sup> Annual Transcatheter Cardiovascular Therapeutics Meeting, September 25th, 1999, Washington DC.
507. Improved outcomes of stenting and angioplasty with intravascular ultrasound. Presented at the 5<sup>th</sup> Complex Coronary Intervention Course (CCIC), October 8<sup>th</sup>, 1999, Shiga, Japan.
508. New approaches to acute myocardial infarction and cardiogenic shock. Presented at the 5<sup>th</sup> Complex Coronary Intervention Course (CCIC), October 8<sup>th</sup>, 1999, Shiga, Japan.
509. Intravascular ultrasound insights into vascular brachytherapy mechanisms and complications. Presented at the 5<sup>th</sup> Complex Coronary Intervention Course (CCIC), October 9<sup>th</sup>, 1999, Shiga, Japan.
510. Advances in stent design improve clinical results. Presented at the 5<sup>th</sup> Complex Coronary Intervention Course (CCIC), October 9<sup>th</sup>, 1999, Shiga, Japan.

511. Treatment of acute coronary syndromes, including AMI. Presenting at the 11<sup>th</sup> annual Cardiovascular Consultant's Course for the Practicing Physician, Boston University, Boston, MA, October 14<sup>th</sup>, 1999.
512. Update on Percutaneous Transluminal Myocardial Revascularization. Presented at the course Coronary Interventions: 1999. The Scripps Clinic and Research Foundation, October 15<sup>th</sup>, 1999, San Diego, CA.
513. Advances in the interventional treatment of acute myocardial infarction – harmonizing mechanical and pharmacological approaches. Presented at the course Coronary Interventions: 1999. The Scripps Clinic and Research Foundation, October 16<sup>th</sup>, 1999, San Diego, CA.
514. New drugs and devices for acute coronary syndromes. Presented at the course Coronary Interventions: 1999. The Scripps Clinic and Research Foundation, October 16<sup>th</sup>, 1999, San Diego, CA.
515. Stenting in Acute Myocardial Infarction. Presented at the course “Advanced Coronary Stenting”, Washington DC, October 19<sup>th</sup>, 1999.
516. Adjunct pharmacologic interventions during coronary stenting. Presented at the course “Advanced Coronary Stenting”, Washington DC, October 19<sup>th</sup>, 1999.
517. Primary PTCA vs. Thrombolytic Therapy – Is the debate over? Presented at the course “Controversies in Interventional Cardiology”, Washington DC, October 25<sup>th</sup>, 1999.
518. Laser myocardial revascularization is a clinically useful tool: Pro and Con. Presented at the course “Controversies in Interventional Cardiology”, Washington DC, October 25<sup>th</sup>, 1999.
519. Primary PTCA: The Expert Approach. Presented at the course “Harmonizing Pharmacologic and Mechanical Approaches in Acute Ischemic Syndromes”, Washington DC, December 8<sup>th</sup>, 1999.
520. A balanced view of the appropriate use (and abuse) of glycoprotein IIb/IIIa inhibitor therapy in the cath lab. Presented at the course “Harmonizing Pharmacologic and Mechanical Approaches in Acute Ischemic Syndromes”, Washington DC, December 8<sup>th</sup>, 1999.
521. Acute Infarct Angioplasty. The Cordis Opinion Leader's Advisory Board Meeting. January 13<sup>th</sup> – 14<sup>th</sup>, 2000, Coral Gables, FL.
522. Reviewing the stent vs. stent U.S. clinical trials: Are there any real differences? Presented at ISET 2000, the 12<sup>th</sup> Annual International Symposium on Endovascular Therapy, January 23<sup>th</sup>, 2000, Miami Beach, FL.
523. Debate: Provisional stenting – stent selectively or stent them all? Pro! Presented at ISET 2000, the 12<sup>th</sup> Annual International Symposium on Endovascular Therapy, January 23<sup>th</sup>, 2000, Miami Beach, FL.

524. Controversy: Should IIb/IIIa antagonists be used in every coronary intervention? Presented at ISET 2000, the 12<sup>th</sup> Annual International Symposium on Endovascular Therapy, January 23<sup>th</sup>, 2000, Miami Beach, FL.
525. Stent design and performance – from bench to bedside. University of Washington, St. Louis presentation, February 4<sup>th</sup>, 2000, St. Louis, MO.
526. Stent therapy for acute myocardial infarction. Presented at the 9<sup>th</sup> Annual Cardiovascular Conference at Beaver Creek, CO, February 9<sup>th</sup>, 2000.
527. Patient selection for multivessel stenting vs. coronary bypass. Presented at the 9<sup>th</sup> Annual Cardiovascular Conference at Beaver Creek, CO, February 9<sup>th</sup>, 2000.
528. Update: Principles and practice of coronary brachytherapy. Presented at the 9<sup>th</sup> Annual Cardiovascular Conference at Beaver Creek, CO, February 9<sup>th</sup>, 2000.
529. Controversial case presentations. Presented at the 9<sup>th</sup> Annual Cardiovascular Conference at Beaver Creek, CO, February 9<sup>th</sup>, 2000.
530. Radiocontrast nephropathy – scope of the problem. Neurox Pharmaceuticals/Abbott Advisory Board on contrast nephropathy. Palm Springs, CA, February 12<sup>th</sup>, 2000.
531. Datascope Benchmark Steering Committee meeting. Philadelphia, PA, March 4<sup>th</sup>, 2000.
532. Treatment of the lesions complicated by thrombus. Presented at the VIII Curso de Cardiologia Intervencionista, March 9<sup>th</sup>, 2000, Mexico City, Mexico.
533. Complex case demonstrations/moderation. Presented at the VIII Curso de Cardiologia Intervencionista, March 9<sup>th</sup>, 2000, Mexico City, Mexico.
534. Differences in Stent Design: Theoretical Considerations and Clinical Implications. March 11<sup>th</sup>, 2000, San Diego, CA.
535. Will the addition of GP IIb/IIIa inhibitors and thrombolytic therapy to primary PCI improve outcomes? Presented at the Acute Coronary Syndromes Town Hall Meeting: Applying Clinical Trials to Practice. March 11<sup>th</sup>, 2000, Anaheim, CA.
536. Are stents + GP IIb/IIIa inhibitors the new standard of care in patients with acute coronary syndromes? Presented at the Acute Coronary Syndromes Town Hall Meeting: Applying Clinical Trials to Practice. March 11<sup>th</sup>, 2000, Anaheim, CA.
537. Applications for distal protection. EPI AdvisoryBoard Meeting. March 12<sup>th</sup>, 2000, Anaheim, CA.
538. Distal protection in AMI. PercuSurge Medical Advisory Board meeting. March 12<sup>th</sup>, 2000, Anaheim, CA.
539. Primary PTCA for acute myocardial infarction. Symposium presentation at the 49<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, March 13<sup>th</sup>, 2000, Anaheim, CA.

540. First United States experience with a novel atherectomy and thrombectomy device in thrombotic lesions in native coronary arteries and saphenous vein grafts. Presented at the 49<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, March 13<sup>th</sup>, 2000, Anaheim, CA.
541. A Prospective, Multicenter Trial of the Safety, Feasibility, and Efficacy of Ultrasound Guided "Maximal" Stenting to the Media-Adventitial Border - Final Late Clinical and Angiographic Results from the OSTI-2 Study. Presented at the 49<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, March 13<sup>th</sup>, 2000, Anaheim, CA.
542. Relative prognostic importance of preserved antegrade coronary blood flow before compared to after angioplasty in patients undergoing primary PTCA. Presented at the 49<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, March 15<sup>th</sup>, 2000, Anaheim, CA.
543. Restenosis after saphenous vein graft intervention. Radiance Medical Systems Scientific Advisory Board meeting. March 13<sup>th</sup>, 2000, Anaheim, CA.
544. Beyond TIMI-3 flow: The importance of restored myocardial perfusion for survival in high risk patients undergoing primary or rescue PTCA. Presented at the 49<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, March 15<sup>th</sup>, 2000, Anaheim, CA.
545. X-TRACT Update. EndiCOR Medical Scientific Advisory Board meeting. March 14<sup>th</sup>, 2000, Anaheim, CA.
546. Acute Myocardial Infarction Angioplasty: When, Where, Whom? Presented at the 49<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, March 15<sup>th</sup>, 2000, Anaheim, CA.
547. Recent and future advances in the treatment of ischemic heart disease. Presented at the Bracco Diagnostics Advisory Board Meeting, March 17<sup>th</sup>, 2000, New York City, NY.
548. Does stent design matter? Comparative analysis of the U.S. stent vs. stent trials. Presented at the 6<sup>th</sup> Annual North American Interventional Cardiology Fellows Course, San Jose, CA, March 29<sup>th</sup>, 2000.
549. Old and new paradigms in the treatment of acute myocardial infarction. Presented at the 6<sup>th</sup> Annual North American Interventional cardiology Fellows Course, San Jose, CA, March 30<sup>th</sup>, 2000.
550. Rational application of glycoprotein IIb/IIIa inhibitors – an evidence based approach. Presented at the 6<sup>th</sup> Annual North American Interventional cardiology Fellows Course, San Jose, CA, March 30<sup>th</sup>, 2000.
551. Intra-aortic balloon counterpulsation in acute myocardial infarction and cardiogenic shock. Presented at the 6<sup>th</sup> Annual North American Interventional cardiology Fellows Course, San Jose, CA, March 30<sup>th</sup>, 2000.

552. Harmonizing pharmacologic and mechanical reperfusion strategies in acute myocardial infarction. Presented at the 12<sup>th</sup> International Congress of Interventional Cardiology, Campos de Jordao, Brazil, April 7<sup>th</sup>, 2000.
553. Brachytherapy: Ready for routine use? Presented at the 12<sup>th</sup> International Congress of Interventional Cardiology, Campos de Jordao, Brazil, April 8<sup>th</sup>, 2000.
554. Intracoronary ultrasound use for borderline lesion assessment and stent guidance. Presented at the 12<sup>th</sup> International Congress of Interventional Cardiology, Campos de Jordao, Brazil, April 8<sup>th</sup>, 2000.
555. Recent advances in the diagnosis and treatment of acute myocardial infarction. Presented at the 10<sup>th</sup> Annual Andreas Gruentzig Emory Practical Interventional Cardiology Course, Atlanta, GA, April 15<sup>th</sup>, 2000.
556. Direct Intervention for AMI – What’s new? Presented at the course “Preceptorship in Coronary Artery Disease Management”, New York City, NY, April 17<sup>th</sup>, 2000.
557. History of mechanical reperfusion therapy in acute myocardial infarction. Presented at the 20<sup>th</sup> Anniversary of the Mid America Heart Institute, Cardiovascular Care for a New Age, April 19<sup>th</sup>, 2000.
558. Debate: PTCA vs. CABG in Diabetics with Multivessel Coronary Artery Disease – Angioplasty is the way to go! Presented at the 4<sup>th</sup> Annual Frontiers in Interventional cardiology Course, Houston, TX, April 29<sup>th</sup>, 2000.
559. Clinical Implications of the ESPRIT Trial. Presented at the Merck Interventional Cardiology Consultants Meeting, Los Angeles, CA, April 30<sup>th</sup>, 2000.
560. Stent Deployment Strategies. Presented at the 23<sup>rd</sup> Annual Scientific Sessions of the Society for Cardiac Angiography and Interventions, Charleston, SC, May 5<sup>th</sup>, 2000.
561. Pitfalls of Radiation Therapy I: late Stent Thrombosis. Presented at the Radiation Readiness Seminar, New York City, NY, May 12<sup>th</sup>, 2000.
562. Percutaneous Interventions in Thrombus Rich lesions. Presented at the Paris Course on Revascularization, Paris, France, May 25<sup>th</sup>, 2000.
563. Primary PTCA in AMI – The real World. Presented at the Paris Course on Revascularization, Paris, France, May 26<sup>th</sup>, 2000.
564. Debate: Aggressive vs. Conservative management of Acute ischemic Syndromes: The Aggressive Approach. Presented at the course “Athens 2000”, Athens, Greece, May 27<sup>th</sup>, 2000.
565. Adjunctive Pharmacologic Therapy during Stent Implantation. Presented at the course “Athens 2000”, Athens, Greece, May 27<sup>th</sup>, 2000.
566. Pharmacologic and Interventional Reperfusion Strategies in Acute myocardial Infarction. Presented at the course “Athens 2000”, Athens, Greece, May 27<sup>th</sup>, 2000.

567. Primary Mechanical reperfusion Therapy in AMI. Presented at the course "Athens 2000", Athens, Greece, May 28<sup>th</sup>, 2000.
568. Distal protection and stent grafts to reduce distal embolization and restenosis in saphenous vein grafts. Presented at the 6<sup>th</sup> Biennial Meeting of the International Andreas Gruentzig Society, Crete, Greece, May 30<sup>th</sup>, 2000.
569. New Directions for AMI therapy. Presented at St. Mary's Hospital, Novi, MI, June 3<sup>rd</sup>, 2000.
570. Current Concepts and Future Directions in AMI therapy. Cardiology Grand Rounds, St. Joseph's Hospital, Syracuse, NY, June 7<sup>th</sup>, 2000.
571. The Case for Tirofiban: Update on the Target Trial. Presented at the 9<sup>th</sup> Annual Advanced cardiovascular Interventions Symposium, Hilton Head, SC, June 14<sup>th</sup>, 2000.
572. PTMR techniques: Equipment, Guidance and Mapping. Presented at the 9<sup>th</sup> Annual Advanced cardiovascular Interventions Symposium, Hilton Head, SC, June 14<sup>th</sup>, 2000.
573. Microvascular preservation and distal protection. Presented at the 3<sup>rd</sup> Live Symposium of Complex Coronary Cases. Mt. Sinai Hospital, New York City, NY, June 16<sup>th</sup>, 2000.
574. IVUS in PTCA and Stenting. Presented at the 3<sup>rd</sup> Live Symposium of Complex Coronary Cases. Mt. Sinai Hospital, New York City, NY, June 17<sup>th</sup>, 2000.
575. The Role of GP IIb/IIIa Inhibitors in Acute Coronary Syndromes: Trial Update, and combination with LMWH. Puerto Rico, June 18<sup>th</sup>, 2000.
576. Vascular Brachytherapy: Restenosis Cured? Presented at the 13<sup>th</sup> Asian Congress of Cardiology Meeting, Singapore, June 23<sup>rd</sup>, 2000.
577. Debate: Primary Angioplasty or Thrombolytic Therapy for AMI? Presented at the 13<sup>th</sup> Asian Congress of Cardiology Meeting, Singapore, June 23<sup>rd</sup>, 2000.
578. Current Status and Future Directions in Stent Design. Presented at the 13<sup>th</sup> Asian Congress of Cardiology Meeting, Singapore, June 23<sup>rd</sup>, 2000.
579. Current and Future Strategies for Treatment of Acute Myocardial Infarction. Presented at the 13<sup>th</sup> Asian Congress of Cardiology Meeting, Singapore, June 24<sup>th</sup>, 2000.
580. An overview of the thrombotic syndromes: variations in management. Presented at 8<sup>th</sup> Annual New Devices Seminar for the Cardiac and Peripheral Laboratories, Orlando, FL, June 30<sup>th</sup>, 2000.
581. Strategies for medical or mechanical management of AMI. Presented at 8<sup>th</sup> Annual New Devices Seminar for the Cardiac and Peripheral Laboratories, Orlando, FL, June 30<sup>th</sup>, 2000.
582. Aggressive Treatment of Acute Coronary Syndromes. Denver CO, July 25<sup>th</sup>, 2000.

583. Stenting, IIb/IIIa Inhibitors and Distal protection in AMI. Presented at Cardiology Grand Rounds, The University of Colorado Health Sciences Center, Denver CO, July 26<sup>th</sup>, 2000.
584. Radiation Pitfalls: Late Stent Thrombosis. Presented at the Radiation Readiness Seminar, Lenox Hill Hospital, New York City, NY, July 27<sup>th</sup>, 2000.
585. Transport for Primary PTCA in AMI: The American Experience. Presented at the XXII<sup>th</sup> Congress of the European Society of Cardiology, Amsterdam, the Netherlands, August 28<sup>th</sup>, 2000.
586. Revascularization options in patients with multivessel coronary artery disease. Presented at the course "New Frontiers in Treatment of Coronary heart Disease", Atlanta, GA. September 6<sup>th</sup>, 2000.
587. Cutting through the hype: How to choose and selectively apply glycoprotein IIb/IIIa inhibitors. Presented at the course "Advanced Coronary Stenting", New York, City, NY, September 7<sup>th</sup>, 2000.
588. Approach to the thrombotic lesion and acute myocardial infarction. Presented at the course "Advanced Coronary Stenting", New York, City, NY, September 7<sup>th</sup>, 2000.
589. Improving outcomes through IVUS and Physiologic lesion Assessment. Presented at the course "Advanced Coronary Stenting", New York, City, NY, September 8<sup>th</sup>, 2000.
590. Keynote address: The application of brachytherapy to ischemic coronary artery disease. Presented at the 5<sup>th</sup> Annual Vanderbilt University course "Interventional Approaches for a New Age", Nashville, TN, September 15<sup>th</sup>, 2000.
591. Evolving Concepts in the Understanding of Glycoprotein IIb/IIIa Inhibitors. Presented at Cardiology Grand Rounds, St. Francis Hospital, Roslyn, NY, September 19<sup>th</sup>, 2000.
592. The CADILAC Trial – First Presentation of 6 Month Results. Closed Research Update. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 17<sup>th</sup>, 2000.
593. Overview of Acute Coronary Syndromes: Therapeutic Strategies. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 17<sup>th</sup>, 2000.
594. Primary PTCA in AMI: Current Concepts and Standards. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 17<sup>th</sup>, 2000.
595. Benefits of IIb/IIIa Inhibitors in AMI: Insights from CADILAC. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 18<sup>th</sup>, 2000.
596. The CADILLAC Trial – 30 Day Results. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 18<sup>th</sup>, 2000.



597. Proving Facilitated Primary PTCA – Introduction to the CADILLAC-II Trial. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 18<sup>th</sup>, 2000.
598. TCT 2001 Opening Address – Interventional Therapy Beyond the Millenium. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 19<sup>th</sup>, 2000.
599. Late Breaking Trial: CADILLAC 6 Month Results – Controlled Abciximab and Device Evaluation to Lower Late Angioplasty Complications. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 19<sup>th</sup>, 2000.
600. A Prospective, Randomized Placebo-Controlled Trial of Fenoldopam to Prevent Contrast Nephropathy in Patients Undergoing Percutaneous Intervention – The CONTRAST Trial. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 19<sup>th</sup>, 2000.
601. Beyond TIMI-3 Flow: Protected Stent Intervention in AMI. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 19<sup>th</sup>, 2000.
603. Harmonizing Pharmacologic and Mechanical Treatment Strategies in Acute Myocardial Infarction. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 20<sup>th</sup>, 2000.
604. Saphenous Vein Graft Intervention: The Need for Distal Protection. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 20<sup>th</sup>, 2000.
606. Chronic Total Occlusions: The Last Refuge of the Cardiac Surgeon. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 20<sup>th</sup>, 2000.
607. Debate: High vs. Low Pressure Stenting - Higher Means Bigger, and Bigger is Better. Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 21<sup>st</sup>, 2000.
610. Debate: PTCA vs. Stenting for Small Vessels - Stent Routinely! Presented at the 12<sup>th</sup> Annual Scientific Symposium Transcatheter Cardiovascular Therapeutics 2000, October 21<sup>st</sup>, 2000.
612. Primary Angioplasty vs. Stenting for Treatment of AMI. Cardiology Grand Rounds. Montefiore Medical Center and the Albert Einstein College of Medicine. Bronx, New York, October 31, 2000.
613. Stenting and Platelet Glycoprotein IIb/IIIa Receptor Blockade in AMI: The CADILLAC Trial. Presented at the 16<sup>th</sup> International Symposium on Thrombolysis and Interventional Therapy in AMI. New Orleans, LA, November 11, 2000.

614. Stents and GP IIb/IIIa Inhibitors in AMI: From CADILLAC I to CADILLAC II. Presented at the symposium Defining New Guidelines and Studies in ACS. November 11, 2000.
615. Interventional Cardiology “From Bench to Bedside and Beyond” Case Demonstrations. Presented at the 73<sup>rd</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 12, 2000.
616. Optimizing Primary PTCA in AMI. Presented at the 73<sup>rd</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 13, 2000.
617. Impact of Race on Clinical Outcome after Percutaneous Coronary Interventions: Results in 6945 patients. Presented at the 73<sup>rd</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 13, 2000.
618. A Prospective, Randomized, Multicenter Trial of Percutaneous Transmyocardial Laser Revascularization in Patients with Non-recanalizable Chronic Total Occlusions. Presented at the 73<sup>rd</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 14, 2000.
619. A Prospective Randomized Trial Comparing Primary Balloon Angioplasty With or Without Abciximab To Primary Stenting With or Without Abciximab In Acute Myocardial Infarction – Primary Endpoint Analysis from the CADILLAC Trial. Presented at the 73<sup>rd</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 14, 2000.
620. Stenting in Acute Coronary Syndromes. Session Moderator. The 73<sup>rd</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 15, 2000.
621. The TARGET Trial – Late Breaking Results. Interventional Research Update – Glycoprotein IIb/IIIa Inhibitors in PCI and ACS. New Orleans LA, November 15<sup>th</sup>, 2000.
622. GP IIb/IIIa appropriate use from the ED to the CCL. Grand Rounds, Beth Israel Medical Center, New York, New York. November 20<sup>th</sup>, 2000.
623. The TARGET Trial – Implications for Patient Care. Sentara Hospital Cardiology Grand Rounds. Norfolk, Virginia, November 29, 2000.
624. Management of In-stent Restenosis. Cardiology Grand Rounds. Norfolk, Virginia, November 29, 2000.
625. TARGET Design and Rationale. Presented at the Merck TARGET and TACTICS Consultants Meeting, Orlando Florida, December 2, 2000.
626. Debate: Management of Multivessel CAD in Diabetics - An Aggressive Interventional Approach. Presented during the course Point-Counterpoint, New York, New York, December 10, 2000.
627. Radiation Pitfalls: Late Stent Thrombosis. Presented during the Radiation Readiness Seminar, New York, NY, December 12, 2000.

628. Primary PTCA in AMI: New Concepts and Future Directions. Grand Rounds, Vassar Hospital, Poughkeepsie, NY, December 18, 2000.
629. Incorporating IIb/IIIa Inhibitors and Revascularization Strategies in an Integrated Patient Care Program. Merck Consultants Meeting, New York, NY, December 20, 2000.
630. Complex Case Presentations. North General Hospital Cardiac Cath Conference, NYC, NY, January 4, 2001.
631. Live case demonstrations. The 10<sup>th</sup> Singapore Live Interventions in Vascular Endotherapy Course, Singapore, January 16, 2001.
632. State of the Art in Coronary Interventions in Acute Coronary Syndromes. Presented at The 10<sup>th</sup> Singapore Live Interventions in Vascular Endotherapy Course, Singapore, January 16, 2001.
633. New Milestones with GP IIb/IIIa Inhibition in Acute Coronary Syndromes. Presented at The 10<sup>th</sup> Singapore Live Interventions in Vascular Endotherapy Course, Singapore, January 17, 2001.
634. Integrating Pharmacologic and Mechanical Approaches into a Rational Strategy for Patients with Acute Coronary Syndromes. Cardiology Grand Rounds, Deborah Heart and Lung Center, Browns Mills, NJ, January 25<sup>th</sup>, 2001.
635. Transport Strategies for Patients with Acute Myocardial Infarction. Warren, New Jersey, January 26<sup>th</sup>, 2001.
636. Special Lecture: Overview of the PAMI and CADILLAC Trials. Presented at The Tenth Annual Cardiovascular Conference at Beaver Creek, Colorado, February 14, 2001.
637. Distal Protection Devices for Coronary Intervention. Presented at The Tenth Annual Cardiovascular Conference at Beaver Creek, Colorado, February 15, 2001.
638. Acute Coronary Syndromes: GP IIb/IIIa Inhibitors and Low Molecular Weight Heparins. Presented at Cardiology Grand Rounds, Morristown Memorial Hospital, Morristown NJ, March 9, 2001.
639. A Unifying Approach to IIb/IIIa Inhibitor Use in ACS and PCI. Presented at the symposium "ACS and AMI – Pharmacologic and Interventional Synergies", Orlando, Florida, March 16, 2001.
640. IIb/IIIa Inhibitors in Primary PTCA and stenting – RAPPORT and CADILLAC. Presented at the symposium "ACS and AMI – Pharmacologic and Interventional Synergies", Orlando, Florida, March 16, 2001.
641. Primary Angioplasty in AMI: Stent vs No Stent. Presented in the symposium "Decision Making During Percutaneous Coronary Interventions" at the 50<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 18<sup>th</sup>, 2001.
642. New Coronary Devices: Thrombus Removal. Presented at the 50<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 18<sup>th</sup>, 2001.

643. A Prospective, Multicenter, International Randomized Trial Comparing Four Reperfusion Strategies in Acute Myocardial Infarction: Principal Report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC). Presented at the 50<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 19<sup>th</sup>, 2001.
644. Rationale Application of IIb/IIIa Inhibitors: When to Use and When Not to Use. Presented at the 50<sup>th</sup> Annual Scientific Sessions of the American College of Cardiology, Orlando, Florida, March 20<sup>th</sup>, 2001.
645. Harmonizing Pharmacologic and Mechanical Reperfusion Strategies in Acute Myocardial Infarction. Cardiology Grand Rounds, Lankenau Hospital, Wynnewood, PA, March 28, 2001.
646. Harmonizing Pharmacologic and Mechanical Reperfusion Strategies in Acute Myocardial Infarction. Cardiology Grand Rounds, Bryn Mawr Hospital, PA, March 28, 2001.
647. New Strategies in Acute Coronary Syndromes – TARGET and TACTICS. Dayton, Ohio, March 29<sup>th</sup>, 2001.
648. A Unifying Approach to IIb/IIIa Inhibitor Use in ACS and PCI. Cardiology Grand Rounds. University of Cincinnati Hospital, Cincinnati Ohio, March 30<sup>th</sup>, 2001.
649. Rational Application of IIb/IIIa Agents: An Evidence Based Approach. Presented at the 7<sup>th</sup> North American Interventional Cardiology Fellow's Course, San Jose, CA, April 6<sup>th</sup>, 2001.
650. New Strategies in AMI: Thrombectomy, Distal Protection, Facilitated Angioplasty and More. Presented at the 7<sup>th</sup> North American Interventional Cardiology Fellow's Course, San Jose, CA, April 7<sup>th</sup>, 2001.
651. Contemporary Management of Acute Myocardial Infarction. Presented at Cardiology Grand Rounds, Case Western Reserve University Hospital, Cleveland, Ohio, April 24, 2001.
652. Controversies in the Treatment of Patients with Acute Coronary Syndromes. Presented at the Cardiac Catheterization Conference, Case Western Reserve University Hospital, Cleveland, Ohio, April 24, 2001.
653. Acute Coronary Syndromes – Update. Trenton , New Jersey, May 3, 2001.
654. The NICE Trials – Enoxaparin with and without GP IIb/IIIa inhibitors. Pharmacia Advisory Board Meeting. Chicago, IL, May 8, 2001
655. The role of GP IIb/IIIa Inhibitors in Acute Coronary Syndromes. Westport, CT, May 10, 2001

656. Opening Plenary Keynote Address: Interventional Cardiology 2000 – The Year in Review. Presented at the 24<sup>th</sup> Annual Scientific Sessions of the Society of Cardiac Angiography and Interventions, Houston, Texas, May 17<sup>th</sup>, 2001.
657. Controversies in Direct Myocardial Revascularization and Angiogenesis: Implications of the DIRECT Trial. Presented at the 24<sup>th</sup> Annual Scientific Sessions of the Society of Cardiac Angiography and Interventions, Houston, Texas, May 17<sup>th</sup>, 2001.
658. Opening Plenary Address: Acute MI - From Clinical Trials to Clinical Practice. Presented at the Euro-PCR 2001 Course, Paris, France, May 22<sup>nd</sup>, 2001.
659. Evidence Based Medicine – Approach to the Patient with Unstable Angina. Presented at the Euro-PCR 2001 Course, Paris, France, May 23<sup>rd</sup>, 2001.
660. Thrombus Removal Devices: Past, Present and Future. Presented at the Euro-PCR 2001 Course, Paris, France, May 23<sup>rd</sup>, 2001.
661. Applying Evidence Based Medicine to the Management of Acute Coronary Syndromes – What we have learned from clinical studies with GP IIb/IIIa antagonists? Presented at the course “New Paradigms in the treatment of ACS”. Held during the Euro-PCR 2001 Course, Paris, France, May 23<sup>rd</sup>, 2001.
662. A Taste of TCT at Euro-PCR: Pharmacologic and Interventional Strategies in AMI. Presented at the Euro-PCR 2001 Course, Paris, France, May 24<sup>th</sup>, 2001.
664. Assessment of Reperfusion: Salvaging the Myocardium. Presented at the Euro-PCR 2001 Course, Paris, France, May 25<sup>th</sup>, 2001.
665. Management of Clot Burden - Adjunctive use of IIb/IIIa agents. Presented at the course AET/All That Jazz, New York, NY, June 6, 2001.
666. GP IIb/IIIa therapy in Acute Coronary Syndromes – when is it appropriate? New York City, NY, June 7, 2001
667. TARGET Trial 6 month data – What It Means. Presented at the Merck Regional Consultants Meeting. Chicago, IL, June 9, 2001.
668. Acute Coronary Syndromes. St. Luke’s Hospital, Grand Rounds, St. Louis, Missouri, June 13, 2001.
669. Optimal management of acute coronary syndromes - integrating GP IIb/IIIa trials. Cardiology grand rounds. Barnes Jewish Hospital/Washington University. St. Louis, Missouri, June 13, 2001.
670. Acute Coronary Syndromes – The Aggressive Approach (Debate). Presented at the course “A Live Symposium of Complex Cases”, Mt. Sinai Medical Center, New York, NY, June 15, 2001.
671. TARGET & TACTICS – What they mean for the practicing interventional cardiologist. Ft. Lauderdale , FL, June 26, 2001

672. Cardiology cath lab conference - Interactive case review session. Memorial Regional Hospital, Hollywood, FL, June 26, 2001
673. TARGET & TACTIS. Implications for Safe and Effective Drug Use. Cardiology Grand Rounds, Sarasota Memorial Hospital, Sarasota, FL, June 26, 2001
674. Acute MI: Stenting with Thrombolysis: GP IIb/IIIa's or distal protection. Presented at the New Devices Seminar – UPMC, Orlando, FL, June 30, 2001.
675. The new antithrombotics and GP IIb/IIIa's – what the interventionalist needs to know. Presented at the New Devices Seminar – UPMC, Orlando, FL, July 3, 2001.
676. The TAXUS Trials: Rationale, Experimental Design and Enrollment Status. Presented at TCT 2001, the 13<sup>th</sup> Annual Scientific Sessions, Washington DC, September 11<sup>th</sup>, 2001.
677. Primary Angioplasty in AMI – State-of-the-Art Comparison with Thrombolytic Therapy. Presented at TCT 2001, the 13<sup>th</sup> Annual Scientific Sessions, Washington DC, September 11<sup>th</sup>, 2001.
678. Algorithms for Management of Patients with Acute Coronary Syndromes, and in those Undergoing PCI: Implications of the TARGET Trial. Presented at TCT 2001, the 13<sup>th</sup> Annual Scientific Sessions, Washington DC, September 11<sup>th</sup>, 2001.
679. The TARGET Trial – 6 Month Results. Presented at TCT 2001, the 13<sup>th</sup> Annual Scientific Sessions, Washington DC, September 12<sup>th</sup>, 2001.
680. TAXUS I-IV: Local drug delivery with a taxol coated stent. Presented at TCT 2001, the 13<sup>th</sup> Annual Scientific Sessions, Washington DC, September 12<sup>th</sup>, 2001.
681. The TAXUS Trials: Methodology, Stent and Polymer Design, and Trial Overview. Webcast on TCTMD.com, September 24<sup>th</sup>, 2001.
682. Use of Low Molecular Weight Heparins in patients with acute coronary syndromes – transitioning to the cath lab. Aventis Regional Consultant's Meeting. Las Vegas, NV, October 21<sup>st</sup>, 2001.
683. Pharmacologic and interventional strategies for acute coronary syndromes. Presented at Coronary Interventions: 2001. The Scripps Clinic and Research Foundation, October 17th, 2001, San Diego, CA.
684. Intervention in acute myocardial infarction – what every interventionalist needs to know. Presented at Coronary Interventions: 2001. The Scripps Clinic and Research Foundation, October 17th, 2001, San Diego, CA.
685. Johnson and Johnson – Role in Interventional Cardiology. Panel presenter at the Phoenix Medcial Devices CEO Conference, Phoenix, AZ, October 26<sup>th</sup>, 2001.
686. Current treatment strategies in AMI. Keynote speaker. Presented at the 3<sup>rd</sup> Annual Update in Cardiovascular Diseases course, St. Joseph's Hospital, Phoenix, AZ, October 27<sup>th</sup>, 2001.

687. Distal Protection Strategies in AMI – Beyond Stents and Drugs. Presented at the 17<sup>th</sup> Annual Symposium on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, Anaheim, CA, Nov. 10<sup>th</sup>, 2001.
688. What constitutes optimal mechanical reperfusion therapy in AMI? Presented at the course “Interventional Cardiology – Bench to Bedside and Beyond” at the 74<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11<sup>th</sup>, 2001.
689. How To Manage Acute ST-Elevation MI. Presented at the course “Interventional Cardiology – Bench to Bedside and Beyond” at the 74<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 11<sup>th</sup>, 2001.
690. What is Vulnerable Plaque, and What Determines Treatment Success? Presented at the Vulnerable Plaque Symposium at the 74<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 12<sup>th</sup>, 2001.
691. Safety and Efficacy of Distal Protection During Saphenous Vein Graft Intervention with the EPI FilterWire EX™ - First Report from the U.S. Phase I Feasibility Study. Presented at the 74<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 13<sup>th</sup>, 2001.
692. How To Reconcile Exercise Test Results with IVUS and Doppler. Presented at the 74<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 14<sup>th</sup>, 2001.
693. Abciximab vs. Tirofiban in Patients Undergoing PCI – Interpreting TARGET. Presented at the Merck Regional Consultants Meeting. New York City, NY, November 17<sup>th</sup>, 2001.
694. Current concepts and future approaches in AMI intervention. Presented at the XI<sup>th</sup> Annual Meeting of the Interventional Cardiology Society of Mexico, Cozumel, Mexico, November 23<sup>rd</sup>, 2001.
695. An overview of drug eluting stents. Presented at the XI<sup>th</sup> Annual Meeting of the Interventional Cardiology Society of Mexico, Cozumel, Mexico, November 24<sup>th</sup>, 2001.
696. Harmonizing Pharmacological and Mechanical Strategies in AMI. Cardiology Grand Rounds, University of Virginia, Charlottesville, VA, January 15, 2002.
697. The Guidant Galileo Vascular Brachytherapy system. Regional training. New York, NY, January 30, 2002.
698. Interventional Problems: A lesion specific approach. Presented at the 2<sup>nd</sup> Joint Interventional Meeting (JIM), Rome, Italy, February 6<sup>th</sup>, 2002.
699. Combination pharmacologic reperfusion regimens, alone and prior to PTCA. Presented at the 2<sup>nd</sup> Joint Interventional Meeting (JIM), Rome, Italy, February 6<sup>th</sup>, 2002.
700. The TAXUS I-VII trials. Presented at the 2<sup>nd</sup> Joint Interventional Meeting (JIM), Rome, Italy, February 6<sup>th</sup>, 2002.

701. Protection from distal embolization during AMI intervention: the Emerald Trial. Presented at the 2<sup>nd</sup> Joint Interventional Meeting (JIM), Rome, Italy, February 7<sup>th</sup>, 2002.
702. Overview of TAXUS Trials and Results. Presented at the 2<sup>nd</sup> Joint Interventional Meeting (JIM), Rome, Italy, February 7<sup>th</sup>, 2002.
703. Overview of AMI Intervention and the CADILLAC Trial. Presented at the 2<sup>nd</sup> Joint Interventional Meeting (JIM), Rome, Italy, February 7<sup>th</sup>, 2002.
704. Update: Interventional Therapy for AMI. Eleventh Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, CO, February 13, 2002.
705. Taxol Drug-eluting stents. Eleventh Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, CO, February 13, 2002.
706. The Great cases at TCT. Eleventh Annual Cardiovascular Conference at Beaver Creek, Beaver Creek, CO, February 14<sup>th</sup>, 2002
707. Drug Eluting Stents in Perspective. Who needs bypass surgery today? In 2 years? Presented at the symposium "Enter the Drug-Eluting Stent Revolution – A Critical Appraisal", Atlanta, GA, March 16<sup>th</sup>, 2002.
708. Results and Trials with a Polymer-based Paclitaxel Delivery System – TAXUS I-VII. Presented at the symposium "Enter the Drug-Eluting Stent Revolution – A Critical Appraisal", Atlanta, GA, March 16<sup>th</sup>, 2002.
709. Adverse Outcomes from a Taxane-loaded Polymeric Sleeved Stent: Final Results from the SCORE Trial. Presented at the symposium "Enter the Drug-Eluting Stent Revolution – A Critical Appraisal", Atlanta, GA, March 16<sup>th</sup>, 2002.
710. In vitro Studies and Clinical Trials with the JoMed Tacrolimus Eluting Ceramic and PTFE Stents. Presented at the symposium "Enter the Drug-Eluting Stent Revolution – A Critical Appraisal", Atlanta, GA, March 16<sup>th</sup>, 2002.
711. Filer Devices; Taped Interventional Case Presentations. Presented at the 51<sup>st</sup> Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 17<sup>th</sup>, 2002.
712. Impact of Clinical Syndrome Acuity on the Differential Response to Two Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial. Presented at the 51<sup>st</sup> Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 17<sup>th</sup>, 2002.
713. Primary PCI for AMI: State of the Art. Plenary Session. Presented at the 51<sup>st</sup> Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 18<sup>th</sup>, 2002.
714. Primary Stenting Optimizes the Outcome of Women With Acute Myocardial Infarction: Results From the CADILLAC Trial. Presented at the 51<sup>st</sup> Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 18<sup>th</sup>, 2002.



715. Embolic Filter Devices. Plenary Session. Presented at the 51<sup>st</sup> Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 20<sup>th</sup>, 2002.
716. Drug-eluting Stents: A breakthrough Technology. Presented at the Prudential Securities 3<sup>rd</sup> Annual "Ask the Doctors" conference. New York City, NY, March 26<sup>th</sup>, 2002.
717. Distal Vascular Protection Devices: Concept, Technology Overview and Clinical Trials. Presented at Medical Grand Rounds, Henry Ford Hospital, Detroit, MI, April 4<sup>th</sup>, 2002.
718. Development and results of a polymer based taxol eluting stent. Presented at the 8<sup>th</sup> Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 17<sup>th</sup>, 2002.
719. Perspectives of long-term anti-platelet therapy after PCI. Presented at the 8<sup>th</sup> Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 17<sup>th</sup>, 2002.
720. PCI applications of GP IIb/IIIa inhibitors and thienopyridines. Presented at the 8<sup>th</sup> Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 18<sup>th</sup>, 2002.
721. Thrombectomy, distal protection and pharmacologic facilitation of primary angioplasty. Presented at the 8<sup>th</sup> Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 18<sup>th</sup>, 2002.
722. The evolution of restenosis solutions. Presented at the 8<sup>th</sup> Annual Interventional Cardiology Fellow's Course, San Jose, CA, April 19<sup>th</sup>, 2002.
723. Direct PCI for AMI: Adjunctive strategies and pharmacologic facilitation. Presented at the course "Hot Topics in Coronary Artery Disease Treatment", April 26<sup>th</sup>, 2002, New York City, NY.
724. Distal protection update: Tips and tricks. Presented at the course "Hot Topics in Coronary Artery Disease Treatment", April 26<sup>th</sup>, 2002, New York City, NY.
725. Vascular Brachytherapy Training Program, Moderator New York City, NY, May 13<sup>th</sup>, 2002.
726. SVG BRITE. Late Breaking Trial. Presented at EuroPCR 2002, Paris, France, May 22<sup>nd</sup>, 2002.
727. The FIRE Trial – Phase II Registry Results. Late Breaking Trial. Presented at EuroPCR 2002, Paris, France, May 22<sup>nd</sup>, 2002.
728. AMISTAD-II. Late Breaking Trial. Presented at EuroPCR 2002, Paris, France, May 22<sup>nd</sup>, 2002.
729. Should we facilitate primary PCI in AMI – NO! Presented at EuroPCR 2002, Paris, France, May 22<sup>nd</sup>, 2002.
730. ACS and Non ST Segment Elevation MI – Frequently asked questions. Presented at EuroPCR 2002, Paris, France, May 23<sup>rd</sup>, 2002.

731. SVG Treatment Options – distal protection, thrombectomy and covered stents. Presented at EuroPCR 2002, Paris, France, May 23<sup>rd</sup>, 2002.
732. Beyond the open artery – patient management in AMI. Presented at EuroPCR 2002, Paris, France, May 24<sup>th</sup>, 2002.
733. Reperfusion Therapy in AMI – The First Blush. Presented at the course “Frontiers in Cardiac Care”, Northwestern University, Evanston, IL, June 1<sup>st</sup>, 2002.
734. Medical and interventional considerations in the diabetic patient. Presented at the Academic Scientific Conference, Lenox Hill Hospital, New York City, NY, June 5<sup>th</sup>, 2002.
735. Impact of New Devices in AMI; Thrombectomy and Distal Protection. Cath Lab Digest Symposium, Las Vegas, NV, June 7, 2002.
736. The TAXUS Trials. Videoconference to Annual Interventional Cardiology Trial, Turkey, June 7
737. Drug Coated Stents and Taxol
738. Presented at the Academic Scientific Conference, Lenox Hill Hospital, New York City, NY, June 12<sup>th</sup>, 2002.
739. Case presentations: NY Metropolitan cath lab conference, New York City, NY.
740. Drug Eluting Stents in Clinical Practice. Presented at the TAXUS Key Opinion Leader Presentation Review Session. Chicago, IL, July 16, 2002
741. Direct PCI for AMI in 2002: Adjunctive therapies? Stents? Thrombectomy? Pharmacologic facilitation? Presented at the Center of Excellence Meeting, New York City, NY, July 19<sup>th</sup>, 2002.
742. Distal protection update: tips and tricks. Presented at the Center of Excellence Meeting, New York City, NY, July 19<sup>th</sup>, 2002.
743. Direct PCI for AMI in 2002: Adjunctive therapies? Stents? Thrombectomy? Pharmacologic facilitation? Presented at the Center of Excellence Meeting, New York City, NY, August 23<sup>rd</sup>, 2002.
744. Distal protection update: tips and tricks. Presented at the Center of Excellence Meeting, New York City, NY, August 23<sup>rd</sup>, 2002.
745. Guidant Vulnerable Plaque Working Group Meeting, Moderator, Chicago, IL. August 26<sup>th</sup>, 2002.
746. The need for distal protection during vascular intervention. Presented at the Medtronic Distal Protection Symposium, Newport, Rhode Island, August 29, 2002.
747. Distal protection in acute myocardial infarction. Presented at the Medtronic Distal Protection Symposium, Newport, Rhode Island, August 29, 2002.

748. The future is now. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 24<sup>th</sup>, 2002.
749. Clinical Outcomes with Polymer and Non Polymer Based Taxol Drug Eluting Stents. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 24<sup>th</sup>, 2002.
750. The X-TRACT Trial. Late Breaking Trial Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 24<sup>th</sup>, 2002.
751. FDA Town hall Meeting – Introduction and Goals. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 24<sup>th</sup>, 2002.
752. Chronic Total Occlusions – evolutionary therapeutic perspectives. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25<sup>th</sup>, 2002.
753. The CONTRAST Trial – interim report. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25<sup>th</sup>, 2002.
754. Lecturer: TAXUS 2002: State of the Stent. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25<sup>th</sup>, 2002.
755. Distal Protection During Acute Myocardial Infarction Angioplasty. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25<sup>th</sup>, 2002.
756. An overview of the Bivalirudin Clinical Development Program. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25<sup>th</sup>, 2002.
757. Chronic Total Occlusions – A Comprehensive Overview of Current and Future Treatment Strategies. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 25<sup>th</sup>, 2002.
758. VasoScience program for phototherapy of vulnerable plaque and restenosis. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27<sup>th</sup>, 2002.
759. Implications of pre-procedural Clopidogrel to GP IIb/IIIa use and outcomes in patients with ACS and non-ACS undergoing PCI – TARGET insights. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27<sup>th</sup>, 2002.
760. Session: Harmonizing Pharmacologic and Mechanical Approaches in ACS and AMI – PART 1: Upstream use of bivalirudin in patients undergoing an early invasive strategy – rationale and design of the ACUTY trial. Presented at the 14<sup>th</sup> Annual Scientific

Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27<sup>th</sup>, 2002.

- 761. Med Systems – trans-aortic valve forward flow support. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27<sup>th</sup>, 2002.
- 762. X-SIZER I – insights from X-TRACT in patients with acute coronary syndromes. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27<sup>th</sup>, 2002.
- 763. Validation of a vulnerable plaque detection modality – what would a clinical trial look like? Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27<sup>th</sup>, 2002.
- 764. Primary Mechanical Reperfusion in AMI. 5<sup>th</sup> Annual Interventional Cardiology Self Assessment & Review Course. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 27<sup>th</sup>, 2002.
- 765. Featured Lecture: The US Pivotal trials of polymer based Taxol slow-rate release delivery – 30 day results of TAXUS IV and TAXUS V update. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 28<sup>th</sup>, 2002.
- 766. The CADILLAC Trial: 2002 Update. Presented at the 14<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 28<sup>th</sup>, 2002.
- 767. The TAXUS Trials. Videoconference to South Africa Interventional Cardiology Society. October 8, 2002
- 768. Moderator, New York Metropolitan Cath Lab Conference, New York City, New York, October 10<sup>th</sup>, 2002.
- 769. Other Drugs and Clinical Trials with Drug-Eluting Stents (Taxol and Beyond). The Drug Eluting Stent Symposium, Short Hills, NJ, October 16, 2002.
- 770. Vascular brachytherapy training program, Moderator. New York City, NY, October 17<sup>th</sup>, 2002.
- 771. Distal protection devices and results. Academic Scientific Conference. Lenox Hill Hospital, October 30<sup>th</sup>, 2002.
- 772. Aggrastat vs Reopro, matching the adjunctive therapy to the patient. Scripps Clinic Coronary Interventions 2002, November 1<sup>st</sup>, 2002
- 773. Lecture: Technique Boutique: Evolving therapies for AMI. Scripps Clinic Coronary Interventions 2002, November 1<sup>st</sup>, 2002
- 774. Myocardial Salvage: New strategies in AMI and ACS drugs, thrombectomy, distal protection, facilitated PTCA and beyond. New Cardiovascular Horizons. New Orleans, LA, November 2<sup>nd</sup>, 2002.

775. IIb/IIIa Inhibitors, Thienopyridines and New Anti-Thrombotic Agents in Acute Coronary Syndromes. Presented to Cardiology Grand Rounds, University of Texas Health Science Center, San Antonio, TX, November 7<sup>th</sup>, 2002.
776. Current Management of ST Segment Elevation MI. The San Antonio Cardiology Society, San Antonio, TX, November 7<sup>th</sup>, 2002.
777. PCI in AMI: CADILLAC Trial Update. The 7<sup>th</sup> International Symposium on Interventional Cardiology and Live Demonstration Course, Beijing, China, November 10<sup>th</sup>, 2002.
778. Drug-Eluting Stents – The Real World. The 7<sup>th</sup> International Symposium on Interventional Cardiology and Live Demonstration Course, Beijing, China, November 10<sup>th</sup>, 2002.
779. Management of Complications of PCI. The 7<sup>th</sup> International Symposium on Interventional Cardiology and Live Demonstration Course, Beijing, China, November 10<sup>th</sup>, 2002.
780. Vulnerable Plaque Detection: Thermographic Systems. Session moderator. The 4<sup>th</sup> Vulnerable Plaque Symposium. Chicago, IL, November 16<sup>th</sup>, 2002.
781. Update on the CADILLAC Trial. The 18<sup>th</sup> Annual George Washington Symposium on Thrombolysis and Interventional Therapy in AMI. Chicago, IL, November 16<sup>th</sup>, 2002.
782. New Advances in the Prevention of Radiocontrast Nephropathy. Presented at the course “ Controversies in Endovascular Treatment of Peripheral Vascular Disease. Chicago, IL, November 16<sup>th</sup>, 2002.
783. Prospective, Randomized Evaluation of Thrombectomy Prior to Intervention in Diseased Saphenous Vein Grafts and Thrombus Containing Native Coronary Arteries. The X-TRACT Trial. Late Breaking Clinical Trial. Presented at the 75<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 17<sup>th</sup>, 2002.
784. Beta Radiation for De Novo and In-stent Restenotic Lesions in Saphenous Vein Grafts: The SVG BRITE Trial. Presented at the 75<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 17<sup>th</sup>, 2002.
785. Renal Insufficiency and Coronary Artery Disease. Session Moderator. The 75<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 18<sup>th</sup>, 2002.
786. Prospective, Randomized Comparison of Distal Protection During Coronary Intervention with a Filter-based Device and Balloon Occlusion and Aspiration System. The FIRE Trial. Presented at a symposium during the 75<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 18<sup>th</sup>, 2002.
787. The TAXUS Trials – Clinical Update. Presented at a symposium during the 75<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Chicago, IL, November 18<sup>th</sup>, 2002.

- 788. Clinical and experimental outcomes with paclitaxel-eluting stents. The Drug Eluting Stent Symposium, New York City, December 2<sup>nd</sup>, 2002.
- 789. Further Improving Outcomes of Primary PTCA. Presented at the 2<sup>nd</sup> annual International Interventional Cardiology Symposium and Live Demonstration Course, Cardiologica Clinica C. Costantini, Curitiba, Brazil, December 5<sup>th</sup>, 2002.
- 790. RAVEL vs. SIRIUS vs. TAXUS-II: Explaining the Differences. Presented at the 2<sup>nd</sup> annual International Interventional Cardiology Symposium and Live Demonstration Course, Cardiologica Clinica C. Costantini, Curitiba, Brazil, December 6<sup>th</sup>, 2002.

790. Catheter Based Management of ACS: Vision for the future. Presented at the course "Hot Topics in Coronary Artery Disease Treatment", New York City, NY, January 17<sup>th</sup>, 2003.
791. Drug-Eluting Stent Update: "These things really work". Presented at the course "Hot Topics in Coronary Artery Disease Treatment", New York City, NY, January 17<sup>th</sup>, 2003.
792. New interventional approaches in acute myocardial infarction. Presented at the 15<sup>th</sup> International Symposium on Endovascular Therapy, Miami, FL, January 19<sup>th</sup>, 2003.
793. Paclitaxel-eluting stents – an update. Presented at the 15<sup>th</sup> International Symposium on Endovascular Therapy, Miami, FL, January 19<sup>th</sup>, 2003.
794. Drug-Eluting Stents: A Breakthrough Technology. Presented at Grand Rounds, St. Luke's Roosevelt Hospital, New York City, NY, January 22<sup>nd</sup>, 2003.
795. TAXUS III, IV and V. Presented at the annual Cardiovascular Revascularization Therapies Course, Washington DC, January 27<sup>th</sup>, 2003.
796. Acute Coronary Syndromes: Should Everyone go to the Cath Lab? Presented at the annual Cardiovascular Revascularization Therapies Course, Washington DC, January 27<sup>th</sup>, 2003.
797. Keynote address: State-of-the-Art Management of Acute Myocardial Infarction. Presented at the annual Cardiovascular Revascularization Therapies Course, Washington DC, January 28<sup>th</sup>, 2003.
798. Chronic Total Occlusions: Evolutionary Therapeutic Perspectives. Presented at the annual Cardiovascular Revascularization Therapies Course, Washington DC, January 28<sup>th</sup>, 2003.
799. Vulnerable plaque detection and treatment: the next holy grail. Keynote address at the AG Edwards annual scientific symposium on Emerging Medical Technologies, New York City, NY, February 11<sup>th</sup>, 2003.
800. The TAXUS Trials. Presented at the Joint Interventional Meeting (JIM) 2003, Rome, Italy, February 13<sup>th</sup>, 2003.
801. Distal protection: Occlusion balloons vs. filters. Presented at the Joint Interventional Meeting (JIM) 2003, Rome, Italy, February 13<sup>th</sup>, 2003.
802. Hot Topics: REPLACE-2. TCTMD.com Webcast, February 19<sup>th</sup>, 2003.
803. Drug-Eluting Stents and Anti-Proliferative Therapies. Medical Grand Rounds. Scottsdale Shea Hospital, Scottsdale, AZ, February 20<sup>th</sup>, 2003.
804. Radiocontrast nephropathy update. Presented at the 6<sup>th</sup> Thought Leader's Summit, Puerto Rico, March 14<sup>th</sup>, 2003.

805. Distal protection update. Presented at the 6<sup>th</sup> Thought Leader's Summit, Puerto Rico, March 14<sup>th</sup>, 2003.
806. Drug-eluting Stent Overview: Comparison of Sirolimus and Paclitaxel. Abbott Laboratories, Abbott Park, IL, March 28, 2003.
807. Great Cypher cases. Presenting at the symposium "Enter the Drug-eluting Stent Revolution: A critical appraisal II", Chicago, IL, March 28<sup>th</sup>, 2003.
808. Status Update: TAXUS IV, V and VI. Presenting at the symposium "Enter the Drug-eluting Stent Revolution: A critical appraisal II", Chicago, IL, March 28<sup>th</sup>, 2003.
809. Problem Solving for Myocardial Infarction Intervention: Management of Intraluminal Thrombus. Presented at the 52<sup>nd</sup> Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 29<sup>th</sup>, 2003.
810. The Drug Eluting Stent Revolution: Status of Paclitaxol. Presented at the 52<sup>nd</sup> Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 29<sup>th</sup>, 2003.
811. The Management of Acute Myocardial Infarction 2003 and Beyond. Presented at the 52<sup>nd</sup> Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 29<sup>th</sup>, 2003.
812. A Prospective, Randomized Trial of Thromboatherectomy During Intervention of Thrombotic Native Coronary Arteries and Saphenous Vein Grafts. The X-TRACT Trial. Presented at the 52<sup>nd</sup> Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 30<sup>th</sup>, 2003.
813. A Prospective Randomized Multicenter Trial Comparing Distal Protection During Saphenous Vein Graft Intervention With a Filter Based Device Compared to Balloon Occlusion and Aspiration: The FIRE Trial. Presented at the 52<sup>nd</sup> Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, March 30<sup>th</sup>, 2003.
814. A Prospective, Randomized Placebo-Controlled Multicenter Trial Evaluating Fenoldopam Mesylate for the Prevention of Contrast Induced Nephropathy: The CONTRAST Trial. Presented at the 52<sup>nd</sup> Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, April 1<sup>st</sup>, 2003.
815. Drug-eluting Stents III: Paclitaxel. Presented at the 9<sup>th</sup> Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 9<sup>th</sup>, 2003.
816. Presented at the 9<sup>th</sup> Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 9<sup>th</sup>, 2003.
817. The Impact of Drug-eluting Stents. Presented at the 9<sup>th</sup> Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 9<sup>th</sup>, 2003.



818. Chronic total occlusions: The last frontier. Presented at the 9<sup>th</sup> Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 9<sup>th</sup>, 2003.
819. Distal protection devices in vein grafts and native coronary arteries. Presented at the 9<sup>th</sup> Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 10<sup>th</sup>, 2003.
820. AMI Intervention II: Beyond primary PTCA. Presented at the 9<sup>th</sup> Annual National Interventional Cardiology Fellow's Course, San Jose, CA, April 11<sup>th</sup>, 2003.
821. Distal Protection Devices in Vascular Intervention. Presented at the course "Hot Topics in Coronary Intervention", April 24<sup>th</sup>, 2003.
822. Primary angioplasty in AMI: State of the Art and Future Approaches. Presented at the course "Hot Topics in Coronary Intervention", April 24<sup>th</sup>, 2003.
823. The ACUTY Trial: background and rationale. Presented at the EuroPCR course, Paris, France, May 20<sup>th</sup>, 2003.
824. Thrombolysis vs. Primary PTCA: The debate is over! Presented at the EuroPCR course, Paris, France, May 22<sup>nd</sup>, 2003.
825. Saphenous vein graft intervention – overview of the problem. Presented at the EuroPCR course, Paris, France, May 22<sup>nd</sup>, 2003.
826. Distal protection devices, thrombectomy and PTFE stent grafts: Use during SVG intervention. Presented at the EuroPCR course, Paris, France, May 22<sup>nd</sup>, 2003.
827. Applying the CREDO and CURE results to thienopyridine use strategies in ACS and PCI. Presented at the EuroPCR course, Paris, France, May 22<sup>nd</sup>, 2003.
828. Acute MI without critical lesions. Presented at the EuroPCR course, Paris, France, May 22<sup>nd</sup>, 2003.
829. Back to Andreas: PCI of diseased SVGs. Presented at the EuroPCR course, Paris, France, May 23<sup>rd</sup>, 2003.
830. Highlights in Interventional Cardiology from EuroPCR. Presented at the course Coronary Intervention 2003, Atlanta, GA, May 28<sup>th</sup>, 2003.
831. Drug-Eluting Stents: overview and strategies for case selection and technique. Presented at the 12<sup>th</sup> annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 16<sup>th</sup>, 2003.
832. New directions for distal protection during saphenous vein graft intervention. Presented at the 12<sup>th</sup> annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 16<sup>th</sup>, 2003.

833. The rising tide of drug-eluting stent therapy: Fully justified and here's why. Presented at the 12<sup>th</sup> annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 17<sup>th</sup>, 2003.
834. Complex drug-eluting stent cases. Presented at the 12<sup>th</sup> annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 17<sup>th</sup>, 2003.
835. TAXUS: The Race for Leadership. Keynote address at the annual Boston Scientific Technology Awards Dinner, Cambridge, MA, June 17<sup>th</sup>, 2003.
836. Complex Drug-eluting Stent Cases. Presented at the Advanced Endovascular Therapies course, New York City, NY, June 19<sup>th</sup>, 2003.
837. The Case for Aggressive Drug-eluting Stent Use. Presented at the Advanced Endovascular Therapies course, New York City, NY, June 19<sup>th</sup>, 2003.
838. TAXUS Update. Presented at the Advanced Endovascular Therapies course, New York City, NY, June 19<sup>th</sup>, 2003.
839. The Enigma of Chronic Total Occlusions: Are we making progress? Presented at the 11<sup>th</sup> Annual New Devices Seminar, Orlando, FL, July 4<sup>th</sup>, 2003.
840. AMI Intervention: Are New Technologies Better than Primary PTCA? Presented at the 11<sup>th</sup> Annual New Devices Seminar, Orlando, FL, July 5<sup>th</sup>, 2003.
841. Primary Angioplasty in AMI: Advancing the State-of-the-Art. Presented at the 3<sup>rd</sup> annual "Summer in Seattle: Interventional Cardiac and Vascular Therapies Conference", in Seattle, WA, July 17<sup>th</sup>, 2003.
842. Primary PCI for ST Segment Elevation Acute Myocardial Infarction. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 23<sup>rd</sup>, 2003.
843. Treatment of patients with Acute MI and large thrombus burden. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 23<sup>rd</sup>, 2003.
844. What is the role of the mechanical approach in the management of intraluminal thrombus? Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 23<sup>rd</sup>, 2003.
845. Paclitaxel: State-of-the-Art. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 24<sup>th</sup>, 2003.
846. TAXUS Program Update: Looking Beneath the Surface. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCI, Sao Paulo, Brazil, July 24<sup>th</sup>, 2003.

847. Distal Protection in Acute Myocardial Infarction: Preliminary EMERALD findings. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCl, Sao Paulo, Brazil, July 24<sup>th</sup>, 2003.
848. In the era of drug-eluting stents, bypass surgery will be of historical interest only (debate). Presented at the IX Congress of SOLACI and XXV Congress of the SBHCl, Sao Paulo, Brazil, July 24<sup>th</sup>, 2003.
849. Treatment of vascular disease with distal protection devices. Presented at the IX Congress of SOLACI and XXV Congress of the SBHCl, Sao Paulo, Brazil, July 25<sup>th</sup>, 2003.
850. New strategies for acute myocardial infarction and acute coronary syndromes. Center of Excellence meeting, Lenox Hill Hospital, New York City, NY, August 1<sup>st</sup>, 2003.
851. Moderator and chair, The Nephrotoxicity Roundtable, Trenton, NJ, August 16<sup>th</sup>, 2003.
852. The Problem of Contrast-Induced Nephrotoxicity. The Nephrotoxicity Roundtable, Trenton, NJ, August 16<sup>th</sup>, 2003.
853. Future Therapies for Acute Myocardial Infarction: Thrombectomy and Distal Protection Devices. Presented at the Annual Scientific Sessions of the European Society of Cardiology, Vienna, Austria, September 1<sup>st</sup>, 2003.
854. Prevention of Restenosis with Paclitaxel-eluting Stents. Presented at the Annual Scientific Sessions of the European Society of Cardiology, Vienna, Austria, September 2<sup>nd</sup>, 2003.
855. TCT 2003: A new venue, a new format, and the new Academy of Transcatheter Cardiovascular Therapeutics. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15<sup>th</sup>, 2003.
856. TAXUS IV – The Pivotal, Prospective, Randomized Trial of the Polymer-based, Slow-rate Release Paclitaxel Eluting Stent. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15<sup>th</sup>, 2003.
857. TAXUS IV - Clinical overview and subset analysis. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15<sup>th</sup>, 2003.
858. Clinical Imperatives of drug-eluting stents. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 15<sup>th</sup>, 2003.
859. The Impact of Embolic Protection Devices on Myocardial Preservation. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16<sup>th</sup>, 2003.

- 860. Is heparin obsolete? The emergence and appropriate use of low molecular weight heparins and direct thrombin inhibitors. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16<sup>th</sup>, 2003.
- 861. TAXUS IV: The pivotal trial in perspective. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 16<sup>th</sup>, 2003.
- 862. Presentation of the 1<sup>st</sup> Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 17<sup>th</sup>, 2003.
- 863. TCT Synthesis: Late Breaking Clinical Trials. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 17<sup>th</sup>, 2003.
- 864. Vulnerable Plaque Tomorrow: The Maturation of a New Subspecialty—Development Requirements and Insightful Speculation. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 17<sup>th</sup>, 2003.
- 865. Thermocore Experiences, and PARACHUTE/TEMPO Directions. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.
- 866. The Mode of Action of Paclitaxel as an Anti-restenosis Therapy: New Mechanistic Insights. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.
- 867. The TAXUS IV "Mega-Trial". Study design, clinical outcomes and angiographic results. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.
- 868. The TAXUS-V Studies: Emphasizing Diffuse Disease and In-Stent Restenosis. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.
- 869. The TAXUS programs: New trials and directions. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.
- 870. The "hot topic". Is bivalirudin poised to "replace" heparin and IIb/IIIa inhibitors in ACS? Design, rationale and status of ACUTY. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.
- 871. Primary mechanical reperfusion in AMI. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.

- 872. Balloon occlusion and aspiration in AMI: First report from the EMERALD Trial. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.
- 873. Case presentations: Embolic protection in acute myocardial infarction. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.
- 874. Clinical debates 1. Are bare stents an acceptable alternative in certain lesion subsets? Global use of DES should be the standard .....rationing is unconscionable! Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 19<sup>th</sup>, 2003.
- 875. GuardWire in AMI—EMERALD Roll-in Results and Randomized Trial Status. Presented at the 15<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, September 18<sup>th</sup>, 2003.
- 876. The TAXUS-IV Trial. Presented at the TEAM course; Endovascular and Myocardial Therapy, Madrid, Spain, October 1<sup>st</sup>, 2003.
- 877. The TAXUS Trials: How do they affect stent choice? Presented at the TEAM course; Endovascular and Myocardial Therapy, Madrid, Spain, October 1<sup>st</sup>, 2003.
- 878. Pharmacologic Facilitation in Acute Myocardial Infarction is Not Necessary. Presented at the TEAM course; Endovascular and Myocardial Therapy, Madrid, Spain, October 2<sup>nd</sup>, 2003.
- 879. Evolving Therapies for Acute Myocardial Infarction: Combining Drugs with Devices. Presented at the course Coronary Interventions 2003, La Jolla, CA, October 8<sup>th</sup>, 2003.
- 880. Drug-Eluting Stents: Late Breaking Paclitaxel Results. Presented at the course Coronary Interventions 2003, La Jolla, CA, October 8<sup>th</sup>, 2003.
- 881. Drug-Eluting Stents: A Real World Perspective. Presented at the course Coronary Interventions 2003, La Jolla, CA, October 8<sup>th</sup>, 2003.
- 882. Late Breaking Drug-eluting Stent Trials: TAXUS-IV, FUTURE-II and ENDEAVOR. Presented at the Guidant Interventional Fellows Program, Napa Valley, CA, October 11<sup>th</sup>, 2003.
- 883. Acute Myocardial Infarction Therapy 2003. Presented at the Guidant Interventional Fellows Program, Napa Valley, CA, October 11<sup>th</sup>, 2003.
- 884. TAXUS-IV – What can be learned from the pivotal trial? Presented at the Boston Scientific National sales meeting, Chicago, IL, November 3<sup>rd</sup>, 2003.
- 885. Downstream Protection During STEMI PCI: The Latest EMERALD Results and Other Experiences. Presented at the 19th International Symposium on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. Orlando, FL, November 8<sup>th</sup>, 2003.

886. Distal Protection Devices and Adjunctive Pharmacologic Therapy for SVG and Thrombus Containing Lesions. Presented at the course Standards in ACS for 2004 from Diagnosis to Discharge, Orlando, FL, November 8<sup>th</sup>, 2003.
887. Ongoing Trials in ACS: ACUITY Presented at the course Standards in ACS for 2004 from Diagnosis to Discharge, Orlando, FL, November 8<sup>th</sup>, 2003.
888. Adjunctive Antiplatelet/Thrombolytic therapy for facilitated PCI. Presented at the Cardiovascular Seminar Immediate PCI for STEMI during the 76<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 9<sup>th</sup>, 2003
889. Primary Angioplasty in Acute Myocardial Infarction with Distal Protection of the Microcirculation: Results from the Roll-in Phase of the EMERALD Trial. Presented during the 76<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 10<sup>th</sup>, 2003.
890. TAXUS IV: The Pivotal Trial in Perspective. Orlando, FL, November 10<sup>th</sup>, 2003.
891. The Pivotal US Study of the Slow-Rate Polymer-Based Paclitaxel-Eluting TAXUS Stent in Patients with DeNovo Coronary Lesions: 1-Year Clinical Results of the TAXUS –IV Trial. Presented during the 76<sup>th</sup> Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 11<sup>th</sup>, 2003.
892. Perspectives from the TAXUS Trials on drug-eluting stents. Presented at the course Current Concepts in Cardiovascular Management, Buffalo, NY, November 21<sup>st</sup>, 2003.
893. Saphenous vein graft attrition and intervention. Presented at the course Current Concepts in Cardiovascular Management, Buffalo, NY, November 21<sup>st</sup>, 2003.
894. Rationale for embolic protection in acute myocardial infarction angioplasty. Presented at the course “Advanced Interventional Approaches”, December 1<sup>st</sup>, 2003, New York, NY.
895. Paclitaxel-eluting stents – the new gold standard? Presented at the course “Advanced Interventional Approaches”, December 2nd, 2003, New York, NY.
896. Drug-eluting stents, 2004 and beyond. Cardiology Grand Rounds. Beth Israel Hospital, New York City, NY, January 12<sup>th</sup>, 2003.
897. Paclitaxel and sirolimus eluting stents: Are there any differences? Presented at the symposium “Drug-eluting Stents Today and Tomorrow. New York City, NY, January 21<sup>st</sup>, 2004.
898. What it means to be a cardiologist. Parkway Elementary School, Greenwich, CT, January 22<sup>nd</sup>, 2004.
899. The Interventional Landscape of Drug-Eluting Stents. Presented at the Guidant National Sales Meeting, Dallas, TX, January 25<sup>th</sup>, 2004.
900. The Present and Future of Drug-eluting Stent Technology. Presented at Guidant Corporation, Santa Clara, CA, January 26<sup>th</sup>, 2004.

901. TAXUS Technology and Promise. Presented at the National Boston Scientific Sales Meeting, New York City, February 1<sup>st</sup>, 2004.
902. Top clinical trials at TCT2003. Presented at the Joint Interventional Meeting (JIM) 2004. Rome, Italy, February 12<sup>th</sup>, 2003.
903. Proper management of diseased saphenous vein grafts. Presented at the Joint Interventional Meeting (JIM) 2004. Rome, Italy, February 12<sup>th</sup>, 2003.
904. TAXUS trials update and subgroup analysis. Presented at the Joint Interventional Meeting (JIM) 2004. Rome, Italy, February 1<sup>st</sup>, 2003.
905. Troubling Issues: In stent Thrombosis and Off-Label Use in the Drug-Eluting Stent Era: Insights and Recommendations. Presented at the Symposium "ENTER THE DRUG-ELUTING STENT REVOLUTION III: CLINICAL IMPACT AND EVOLVING PERSPECTIVES", New Orleans, March 6th, 2004.
906. Vignettes from Important New (Ongoing or Completed) TAXUS Clinical Trials. Presented at the Symposium "ENTER THE DRUG-ELUTING STENT REVOLUTION III: CLINICAL IMPACT AND EVOLVING PERSPECTIVES", New Orleans, LA, March 6th, 2004.
907. Taped Interventional Case Highlights Session. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 7th, 2004.
908. Distal Protection of the Microcirculation in Acute Myocardial Infarction. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 7th, 2004.
909. Primary Angioplasty in Acute Myocardial Infarction with Distal Protection of the Microcirculation: Principal Results from the Prospective, Randomized EMERALD Trial. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 7th, 2004.
910. The TAXUS Program: A Comprehensive Analysis. presented at the symposium "Clinical Insights from the TAXUS Experience", , New Orleans, LA, March 7th, 2004.
911. Preventing Contrast Nephropathy. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 9th, 2004.
912. Reduction in Late Loss and Restenosis in Patients With Small Vessels Treated With the Slow Rate-Release, Polymer-Based Paclitaxel-Eluting Stent: Results from TAXUS-IV. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 9th, 2004.
913. Direct PCI for AMI in 2004: Adjunctive therapies? Stents? Thrombectomy? Pharmacologic Facilitation? Presented at the course "Hot Topics in Coronary Artery Disease Treatment", New York City, NY, March 19<sup>th</sup>, 2004.

914. Drug Coated Stent Overview: Latest Data, Latest Controversies. Presented at the course "Hot Topics in Coronary Artery Disease Treatment", New York City, NY, March 19<sup>th</sup>, 2004.
915. The integrated use of adjunctive pharmacology and device-based therapy to manage thromboembolic coronary artery disease. Presented at the 19<sup>th</sup> Annual Interventional Cardiology Symposium, Snowmass, CO, March 24<sup>th</sup>, 2004.
916. Direct thrombin inhibition in the cath lab. Presented at the 19<sup>th</sup> Annual Interventional Cardiology Symposium, Snowmass, CO, March 24<sup>th</sup>, 2004.
917. Paclitaxel: Clinical trials update. Presented at the 19<sup>th</sup> Annual Interventional Cardiology Symposium, Snowmass, CO, March 25<sup>th</sup>, 2004.
918. The three most important clinical trials in interventional cardiology within the last year. Presented at the 19<sup>th</sup> Annual Interventional Cardiology Symposium, Snowmass, CO, March 26<sup>th</sup>, 2004.
919. The TAXUS Program: The drug, the polymer, the stent, the trials. Presented at the 10<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, March 31<sup>st</sup>, 2004.
920. Drug-eluting stent terminology: What you need to know. Presented at the 10<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, April 1<sup>st</sup>, 2004.
921. Proven drug-eluting Stent Systems I: Polymer –based paclitaxel release. Presented at the 10<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, April 1<sup>st</sup>, 2004.
922. AMI Intervention II: Beyond Primary PTCA. Presented at the 10<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, April 2<sup>nd</sup> 2004.
923. Interventional Pharmacology IV: Bivalirudin in ACS and PCI. Presented at the 10<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, April 2<sup>nd</sup> 2004.
924. The TAXUS Program: Technology and Trial Update. Minneapolis, Minn., April 16<sup>th</sup>, 2004.
925. Drug-eluting Stent Technology: Current Landscape and Future Directions. Grand Rounds and visiting professorship, Mayo Clinic, Rochester, Minn., April 17<sup>th</sup>, 2004.
926. The Drug-eluting Stent Revolution: Implications for patient care. Garfield, NJ, April 22<sup>nd</sup>, 2004.
927. The TAXUS Stent: Technology and Trials. Webcast, May 12<sup>th</sup>, 2004.
928. Direct PCI for acute myocardial infarction. Adjunctive therapies? Stents? Thrombectomy? Distal Protection? Presented at the course "Hot Topics in Coronary Artery Disease Treatment", New York City, NY, May 21<sup>st</sup>, 2004.



929. The EMERALD Trial. Presented at the EuroPCR symposium, Paris, France, May 25<sup>th</sup>, 2004.
930. Distal Protection in AMI-Lessons from EMERALD. Presented at the EuroPCR symposium, Paris, France, May 25<sup>th</sup>, 2004.
931. Optimizing the Care of High-Risk Patients. Presented at the EuroPCR symposium, Paris, France, May 26<sup>th</sup>, 2004.
932. IIb/IIIa inhibitors during acute MI: in which patients, when, abciximab or small molecules. Presented at EuroPCR 2004, Paris, France, May 26<sup>th</sup>, 2004.
933. Chronic total occlusions – the need to revascularize. Presented at EuroPCR 2004, Paris, France, May 26<sup>th</sup>, 2004.
934. Complex vulnerable plaque presentations. Presented at EuroPCR 2004, Paris, France, May 26<sup>th</sup>, 2004.
935. The Great “non-debate”: Why TAXUS is better. Presented at EuroPCR 2004, Paris, France, May 27<sup>th</sup>, 2004.
936. Selected role of distal protection in acute myocardial infarction – case presentations. Presented at EuroPCR 2004, Paris, France, May 27<sup>th</sup>, 2004.
937. Keynote closing symposium. Profiling tomorrow's patient. Presented at EuroPCR 2004, Paris, France, May 28<sup>th</sup>, 2004.
938. Selected cases from EuroPCR 2004 – Did we adhere to, ignore or anticipate guidelines? The verdict and economic implications. Presented at EuroPCR 2004, Paris, France, May 28<sup>th</sup>, 2004.
939. TAXUS Technologies and Trials. Evening symposium, Philadelphia, PA, June 2<sup>nd</sup>, 2004.
940. Innovative approaches to reperfusion therapy in acute myocardial infarction. Cardiology Grand Rounds, Hospital of the University of Pennsylvania, Philadelphia, PA, June 3<sup>rd</sup>, 2004.
941. Distal protection in acute myocardial infarction. Presented at the course “Intervention 2004”, Boston, MA, June 3<sup>rd</sup>, 2004.
942. Design and Rationale of the Prospect Trial. Presented at the 2<sup>nd</sup> Vulnerable Plaque Symposium, Taormina, Sicily, June 8<sup>th</sup>, 2004.
943. Keynote lecture: The Impact of Drug-Eluting Stents Now and in the Future. Presented at the 13<sup>th</sup> annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 15<sup>th</sup>, 2004.
944. Complex drug-eluting stent cases. Presented at the 13<sup>th</sup> annual Advanced Cardiovascular Interventions Symposium, Hilton Head, SC, June 15<sup>th</sup>, 2004.

945. Complications of Coronary Angioplasty – My Worst Case in the Last 12 Months. Presented at the 18<sup>th</sup> Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 19<sup>th</sup>, 2004.
946. Distal Protection in Acute Myocardial Infarction – Is it Necessary? Presented at the 18<sup>th</sup> Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 19<sup>th</sup>, 2004.
947. Highlights from the TAXUS Trials. Presented at the 18<sup>th</sup> Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 20<sup>th</sup>, 2004.
948. Controversial Case of the Day. Presented at the 18<sup>th</sup> Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 20<sup>th</sup>, 2004.
949. Success and Outstanding Results: The Best Case I did in the last 12 months. Presented at the 18<sup>th</sup> Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 21<sup>st</sup>, 2004.
950. Invasive detection of the vulnerable plaque. Presented at the 18<sup>th</sup> Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 21<sup>st</sup>, 2004.
951. First implantation of a new percutaneous aortic valve. Presented at the 18<sup>th</sup> Annual Principles and Perspectives in Interventional Cardiology Course, Hawaii, July 21<sup>st</sup>, 2004.
952. TCT at SOLACI 2004 – A Glimpse At A Future Soon To Be. Presented at the 10<sup>th</sup> Annual SOLACI Conference, Buenos Aires, Argentina, August 4<sup>th</sup>, 2004.
953. Percutaneous Approaches to Diseased Heart Valves. Presented at the 10<sup>th</sup> Annual SOLACI Conference, Buenos Aires, Argentina, August 4<sup>th</sup>, 2004.
954. Current Standards and Future Directions For: Drug-Eluting Stents. Presented at the 10<sup>th</sup> Annual SOLACI Conference, Buenos Aires, Argentina, August 4<sup>th</sup>, 2004.
955. Training and Accreditation in Interventional Cardiology: The Academy of TCT Vision. Presented at the 10<sup>th</sup> Annual SOLACI Conference, Buenos Aires, Argentina, August 4<sup>th</sup>, 2004.
956. Transferring Acute MI Patients: Is it always the best option.? Presented at the 10<sup>th</sup> Annual SOLACI Conference, Buenos Aires, Argentina, August 4<sup>th</sup>, 2004.
957. Is Unfractionated Heparin Obsolete? The Role of Low Molecular Weight Heparin and Direct Thrombin Inhibitors in PCI and ACS. Presented at the 10<sup>th</sup> Annual SOLACI Conference, Buenos Aires, Argentina, August 5<sup>th</sup>, 2004.
958. My Best Dream, My Worst Nightmare. Presented at the 10<sup>th</sup> Annual SOLACI Conference, Buenos Aires, Argentina, August 5<sup>th</sup>, 2004.
959. Drug-eluting stents and stent thrombosis. Presented at the Materials Science in Drug-eluting Stent Summit. Santa Clara, CA, August 9<sup>th</sup>, 2004.

- 960. Direct thrombin inhibitors in ACS, AMI and PCI. Cardiology Grand Rounds, Beth Israel Newark Hospital, August 13<sup>th</sup>, 2004.
- 961. Management of ST-segment elevation acute myocardial infarction. Presented at the ACCF/SCAI Interventional cardiology Board Review Course, Atlanta, GA, August 21<sup>st</sup>, 2004.
- 962. Direct thrombin inhibition in acute coronary syndromes and acute myocardial infarction. Presented at the Annual Scientific Sessions of the European Society of Cardiology, Munich, German, August 28<sup>th</sup>, 2004.
- 963. Perspectives on the seminal events of the last year that have shaped up a subspecialty. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 27<sup>th</sup>, 2004, Washington, DC.
- 964. Drug-eluting stent “euphoria” in the U.S.: An evidence-based medicine analysis and future clinical initiatives. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 27<sup>th</sup>, 2004, Washington, DC.
- 965. Translation of Evidence-Based Medicine Into Clinical Practice Recommendations: An In-Depth Analysis of the “New” ACC/AHA Guidelines for Management of ST-Segment Elevation MI. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 27<sup>th</sup>, 2004, Washington, DC.
- 966. Advantages of direct Thrombin Inhibition in High and Low Risk Patients. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 27<sup>th</sup>, 2004, Washington, DC.
- 967. Paclitaxel-eluting Stents. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 28<sup>th</sup>, 2004, Washington, DC.
- 968. EMERALD (distal protection - GuardWire based): Overview and subgroup analysis. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 28<sup>th</sup>, 2004, Washington, DC.
- 969. Have Drug Eluting Stents Tipped the Scales Toward Percutaneous Intervention In Patients with Diabetes Mellitus? Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 28<sup>th</sup>, 2004, Washington, DC.
- 970. Multimodality Imaging of Vulnerable Plaque. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 28<sup>th</sup>, 2004, Washington, DC.
- 971. The EMERALD Trial – Lessons Learned. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29<sup>th</sup>, 2004, Washington, DC.
- 972. Introduction - The TCT Health and Human Services Town Hall Meeting: Scientific, Regulatory and Reimbursement Outlook from the FDA, NIH and CMS. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29<sup>th</sup>, 2004, Washington, DC.

973. Current standards and proposed directions in pharmacologic and device-based approaches for primary angioplasty. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29<sup>th</sup>, 2004, Washington, DC.
974. TCT Late Breaking Clinical Trials – TCT 2004 Synthesis. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29<sup>th</sup>, 2004, Washington, DC.
975. TAXUS IV – Two year results from the pivotal prospective, randomized trial of the slow-release polymer-based paclitaxel-eluting TAXUS stent. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29<sup>th</sup>, 2004, Washington, DC.
976. Presentation of the 2<sup>nd</sup> Thomas J. Linnemeier Award – Spirit of Interventional Cardiology Young Investigator Award. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29<sup>th</sup>, 2004, Washington, DC.
977. The EMERALD Trial of Distal Protection in AMI: First report of the 6-month Results. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29<sup>th</sup>, 2004, Washington, DC.
978. What Future Clinical Challenges Should Be Addressed with the TAXUS Stent Program? Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 29<sup>th</sup>, 2004, Washington, DC.
979. Sirolimus and Paclitaxel Drug Eluting Stents I: Descriptions, Indication and Clinical Outcomes. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30<sup>th</sup>, 2004, Washington, DC.
980. Evidence-based medicine analysis of current DES clinical use guidelines: A roadmap for clinicians. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30<sup>th</sup>, 2004, Washington, DC.
981. Primary Mechanical Reperfusion in Acute MI. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30<sup>th</sup>, 2004, Washington, DC.
982. The Guidant BVS Bioabsorbable Stent Program. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30<sup>th</sup>, 2004, Washington, DC.
983. Bivalirudin in ACS: Insights from REPLACE-2, and ACUITY Update. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30<sup>th</sup>, 2004, Washington, DC.
984. The impact of elution rates and release kinetics on DES results. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, September 30<sup>th</sup>, 2004, Washington, DC.

985. Zen Philosophy: The Key to CTO Success. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1<sup>st</sup>, 2004, Washington, DC.
986. A synthesis and status update of the TAXUS clinical trial program. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1<sup>st</sup>, 2004, Washington, DC.
987. Optimizing Outcomes of primary PCI: From CADILLAC to HORIZONS. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1<sup>st</sup>, 2004, Washington, DC.
988. A brief status update on HORIZONS (TAXUS vs. bare metal stents and bivalirudin vs. UFH). Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1<sup>st</sup>, 2004, Washington, DC.
989. The PROSPECT Trial: Design and Rationale for a Vulnerable Plaque Natural History Study. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1<sup>st</sup>, 2004, Washington, DC.
990. Distal Protection in AMI I: The EMERALD trial-First presentation and analysis of the 6 month results. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1<sup>st</sup>, 2004, Washington, DC.
991. TAXUS V: 30 day Clinical Outcomes (1<sup>st</sup> presentation). Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1<sup>st</sup>, 2004, Washington, DC.
992. From Syntax to Horizons: Brief Overview and Update of Ongoing and "Next Generation" TAXUS Clinical Trials. Presented at the 16<sup>th</sup> Annual Scientific Sessions of Transcatheter Cardiovascular Therapeutics, October 1<sup>st</sup>, 2004, Washington, DC.
993. Long-term durability of paclitaxel-eluting stents. Webcast on TCTMD.com, October 13<sup>th</sup>, 2004.
994. Highlights from TCT 2004. Webcast to the Charles Rivers Laboratories Cardiovascular Interventional Symposium, October 13<sup>th</sup>, 2004.
995. Post market surveillance for a new drug-eluting stent. Presented at the 2<sup>nd</sup> Dartmouth Device Development Symposium, Woodstock, Vermont, October 14<sup>th</sup>, 2004.
996. Drug-eluting stents: A transforming technology. Presented at the annual meeting of the New York State chapter of the American College of Cardiology, NY, NY, October 16<sup>th</sup>, 2004.
997. Drug-eluting Stent Indications: Are there any differences between Japan and the rest of the world? Presented at the CCT2004 Course, Kobe, Japan, October 20<sup>th</sup>, 2004
998. Directions in Pharmacologic and device-based approaches for primary angioplasty. Presented at the CCT2004 Course, Kobe, Japan, October 21<sup>st</sup>, 2004

999. Final EMERALD Results and future primary angioplasty directions. Presented at the CCT2004 Course, Kobe, Japan, October 21<sup>st</sup>, 2004
1000. New Insights of Polymeric Paclitaxel Eluting Stent- from the latest clinical trials and real world registries. Presented at the CCT2004 Course, Kobe, Japan, October 21<sup>st</sup>, 2004
1001. Advantage of CTO crossing with new generation guidewires. Presented at the CCT2004 Course, Kobe, Japan, October 22<sup>nd</sup>, 2004.
1002. The Future of Interventional Cardiology. Presented t Cardiology Grand Rounds. St. Francis Hospital, Long Island, NY, October 27<sup>th</sup>, 2004.
1003. Protective Devices with STEMI PCI: The prognosis for Success after EMERALD. Presented at the 20th International Symposium on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, New Orleans, LA, November 6<sup>th</sup>, 2004.
1004. Discussant – A Randomized, Double-Blind, placebo-Controlled Trial of Glycoprotein IIb/IIIa Inhibition with Abciximab in Patients with Diabetes Undergoing Percutaneous Coronary Intervention (ISAR-SWEET Trial). Presented at the 77<sup>th</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 7<sup>th</sup>, 2004.
1005. New Applications for Drug Eluting Coronary Artery Stents. Presented at the 77<sup>th</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 8<sup>th</sup>, 2004.
1006. Durability of the Polymer-Based Paclitaxel-eluting TAXUS stent: Two year Results from the TAXUS-IV Trial. Presented at the 77<sup>th</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 8<sup>th</sup>, 2004.
1007. Outcomes of the Polymer-Based Paclitaxel-eluting TAXUS Stent in Complex Lesions: First Report from the TAXUS-V Pivotal Randomized Trial. Presented at the 77<sup>th</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 8<sup>th</sup>, 2004.
1008. Are we preventing or just delaying Restenosis with drug-eluting stents? A data overview of the TAXUS II and TAXUS IV 2-year results and the TAXUS I 3-year results Presented at the 77<sup>th</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 8<sup>th</sup>, 2004.
1009. How to Use PCI to Treat Difficult Subsets of Patients: Saphenous Vein Grafts. Presented at the 77<sup>th</sup> Annual Scientific Sessions of the American Heart Association, New Orleans, LA, November 9<sup>th</sup>, 2004.
1010. Guidewires and the Zen Master Approach to CTO Recanalization. Presented at the Workshop on Highly Stenoses Lesions course, New York City, NY, November 13<sup>th</sup>, 2004.
1011. Drug: Eluting Stents: The Science and Technology Behind the Revolution. Houston, Texas, November 18<sup>th</sup>, 2004.

1012. Drug-eluting Stents: A transforming, revolutionary technology. Cardiology Grand Rounds, Methodist Hospital, Houston, Texas, November 19<sup>th</sup>, 2004.
1013. Clinical Experiences and Insights into Treatment Strategies with Drug-Eluting Stents. Cardiology Grand Rounds, St. Luke's Hospital, Texas Heart Institute, Houston, Texas, November 19<sup>th</sup>, 2004.
1014. Optimal reperfusion in AMI (what have we learned from mechanical reperfusion trials)? Presented at the TEAM course, Madrid, Spain, November 22<sup>nd</sup>, 2004.
1015. Drug Eluting Stents and New Materials – TAXUS program and beyond. Presented at the TEAM course, Madrid, Spain, November 22<sup>nd</sup>, 2004.
1016. Controversy–Thrombectomy and / or distal protection in AMI. Presented at the TEAM course, Madrid, Spain, November 23<sup>rd</sup> 2004.
1017. Drug Eluting Stents - What is beyond the TAXUS program. Presented at the TEAM course, Madrid, Spain, November 23<sup>rd</sup> 2004.
1018. Vulnerable Plaque – New Diagnostic and Treatment Vistas. Presented at the TEAM course, Madrid, Spain, November 23<sup>rd</sup> 2004.
1019. Drug-eluting stents – Data, Devices, Differences. Massachusetts General Hospital Department of Cardiology, Boston, MA, December 7<sup>th</sup>, 2004.
1020. Impact of Drug-eluting Stents on Patients, Physicians and Society. Cardiology Grand Rounds, Massachusetts General Hospital, Boston, MA, December 8<sup>th</sup>, 2004.
1021. Acute Myocardial Infarction: Evidence Based Medicine Update. Center of Excellence Meeting, New York City, NY, December 10<sup>th</sup>, 2004.
1022. The Present and Future Role of Direct Thrombin Inhibitors in PCI, ACS and AMI. Presented at the 15<sup>th</sup> Annual ISET Course, Miami, FL, January 16<sup>th</sup>, 2005.
1023. Current Standards and Future Directions in Pharmacologic and Mechanical Approaches for Primary PCI. Presented at the 15<sup>th</sup> Annual ISET Course, Miami, FL, January 16<sup>th</sup>, 2005.
1024. The present and future of direct thrombin inhibitors. Presented at Advanced Angioplasty 2005, British Interventional Cardiology Society, London, UK, January 26<sup>th</sup>, 2005.
1025. Drug-eluting Stents: The Journey Continues. Keynote lecture. Presented at Advanced Angioplasty 2005, British Interventional Cardiology Society, London, UK, January 26<sup>th</sup>, 2005.
1026. TAXUS consistency over time & Future TAXUS Directions. Broadcast to Malaysia, January 29<sup>th</sup>, 2005.
1027. Chronic total occlusions – what have we learned in the last year? Presented at the 2<sup>nd</sup> International CTO Summit, New York City, NY, February 4<sup>th</sup>, 2004.

1028. Chronic Total Occlusions. The Last Frontier. Milford Hospital, Connecticut, February 10<sup>th</sup>, 2004.
1029. TAXUS V: Complex stenting with the paclitaxel-eluting stent. Presented at the JIM2005 meeting, Rome, Italy, February 17<sup>th</sup>, 2005.
1030. Percutaneous aortic valve replacement: CoreValve. Presented at the JIM2005 meeting, Rome, Italy, February 17<sup>th</sup>, 2005.
1031. An Overview perspectives from the late-braking clinical trials at TCT 2004. Presented at the JIM2005 meeting, Rome, Italy, February 17<sup>th</sup>, 2005.
1032. Contrasts and comparisons of the PCI guidelines from Europe and US. Presented at the JIM2005 meeting, Rome, Italy, February 17<sup>th</sup>, 2005.
1033. Current Status of protection devices. Presented at the JIM2005 meeting, Rome, Italy, February 18<sup>th</sup>, 2005.
1034. TAXUS update. Presented at the course "Enter the Drug-Eluting Stent Revolution IV: Clinical Impact and Evolving Perspectives", Orlando, FL, March 5<sup>th</sup>, 2005.
1035. Clinical Outcomes of PCI in High Risk Patients. Presented at the course "Pharmacologic Efficacy in Interventions: Contributions of Ischemia and Bleeding", Orlando, FL, March 5<sup>th</sup>, 2005.
1036. Outcomes of the Polymer-Based, Paclitaxel-Eluting TAXUS Stent In Complex Lesions: Principal Clinical and Angiographic Results From the TAXUS-V Pivotal Randomized Trial. Presented during the 54<sup>th</sup> Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6<sup>th</sup>, 2005.
1037. Perspectives on the ENDEAVOR-II trial. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.
1038. A Prospective, Randomized U.S. Trial of the PTFE Covered JOSTENT for the Treatment of Diseased Saphenous vein Grafts: The BARRICADE Trial. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.
1039. Effectiveness of Distal Embolic Protection During Primary Angioplasty: Final 6-month Results from the Prospective, Randomized, EMERALD Trial.. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.
1040. Predictors and Clinical Impact of the Procedural ACT level in Patient Receiving Bivalirudin during PCI: A REPLACE II Sub Study. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.
1041. TAXUS Trials Meta Analysis: A critical analysis. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 6th, 2005.



1042. Predictors of Infarct Size by Technetium-99m Sestamibi Imaging After Angioplasty in Acute Myocardial Infarction: Meta-analysis from Four Contemporary Randomized Trials. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 7<sup>th</sup>, 2005.
1043. Primary Percutaneous Coronary Intervention for Myocardial Infarction in Women. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 7<sup>th</sup>, 2005.
1044. Thirty Day and Six Month Outcomes after Saphenous Vein Graft Stenting with Distal Protection in patients Excluded from Randomized Trials: The FilterWire EX High Risk Registry. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 8<sup>th</sup>, 2005.
1045. A Prospective, Multicenter Randomized Trial of the Paclitaxel-Eluting Stent vs. Vascular Brachytherapy in Patients with Coronary In-Stent Restenosis: The TAXUS-V ISR Trial. Presented during the 54th Scientific Sessions of the American College of Cardiology, Orlando, FL, March 8<sup>th</sup>, 2005.
1046. Paclitaxel-eluting stents: From Technology to Trials to Widespread Application. Boston, MA, March 16<sup>th</sup>, 2005.
1047. Drug-eluting stents: Evidence-based Medicine and New Directions. Cardiology Grand Rounds, Tufts-New England Medical Center, Boston, MA, March 17<sup>th</sup>, 2005.
1048. Vulnerable Plaque Natural History Clinical Trials: From PROSPECT to PREVAIL. Presented at the 20th Annual Interventional Cardiology 2005: The International Symposium, March 22<sup>nd</sup>, 2005, Snowmass, CO.
1049. New Data from the TAXUS Stent Clinical Trials. Presented at the 20th Annual Interventional Cardiology 2005: The International Symposium, March 22<sup>nd</sup>, 2005, Snowmass, CO.
1050. An Evidence-Based Medicine Analysis of DES Clinical Trial Results: Defining Practice Standards. Presented at the 20th Annual Interventional Cardiology 2005: The International Symposium, March 23<sup>rd</sup>, 2005, Snowmass, CO.
1051. A comprehensive Assessment of Acute MI Therapies: Primary PCI: Adjunctive Pharmacology, DES, and Infarct Size Reduction. Presented at the 20th Annual Interventional Cardiology 2005: The International Symposium, March 23<sup>rd</sup>, 2005, Snowmass, CO.
1052. An Evidence Based Medicine Examination of the DES Clinical Trial Results. Presented at China Interventional Therapeutics 2005, April 1<sup>st</sup>, 2005, Beijing, China.
1053. The Diagnosis and Treatment o f Vulnerable Plaque. Presented at China Interventional Therapeutics 2005, April 1<sup>st</sup>, 2005, Beijing, China.
1054. Case Reviews from the U.S. CTO Symposium. Presented at China Interventional Therapeutics 2005, April 1<sup>st</sup>, 2005, Beijing, China.

1055. The Future of Interventional Cardiology. Presented at China Interventional Therapeutics 2005, April 2<sup>nd</sup>, 2005, Beijing, China.
1056. Reperfusion therapy in acute myocardial infarction; update 2005. Cardiology Fellow's Rounds, Columbia University Medical Center, NY, NY, April 8<sup>th</sup>, 2005.
1057. Current and evolving status of bivalirudin as the foundation anticoagulant in ACS and PCI. Angiomax consultant's meeting. NY, NY, April 9<sup>th</sup>, 2005.
1058. Drug-eluting stents: Current concepts, future directions. Presented at the 2<sup>nd</sup> annual Cardiac and Vascular Symposium: Innovations 2005, University of Maryland, April 13<sup>th</sup>, 2005.
1059. Putting DES to the Test: Treatment of High Risk Lesions. Presented at the 11<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 13<sup>th</sup>, 2005.
1060. Drug-eluting stents: Components, Trials and Terminology. Presented at the 11<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 14<sup>th</sup>, 2005.
1061. Drug-eluting stent systems I: Polymer-based paclitaxel release. Presented at the 11<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 14<sup>th</sup>, 2005.
1062. Evidence-based medicine guidelines to drug-eluting stent use. Presented at the 11<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 14<sup>th</sup>, 2005.
1063. The Future of PCI in ACS: Adjunctive devices and pharmacologic strategies. Presented at the 11<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 14<sup>th</sup>, 2005.
1064. Angioplasty in AMI I: primary PCI state of the art. Presented at the 11<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 15<sup>th</sup>, 2005.
1065. Chronic total occlusions: lessons from the summit. Presented at the 11<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 15<sup>th</sup>, 2005.
1066. Strengths and Weaknesses of the TAXUS stent. Presented at the 10<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 28<sup>th</sup>, 2005.
1067. Recent updates from the TAXUS Trials. Presented at the 10<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 28, 2005.
1068. Results of the Pivotal TAXUS-V Trial in Complex Patients. Presented at the 10<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 28, 2005.
1069. The Emerald Trial - Lessons learned. Presented at the 10<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 29, 2005.
1070. Optimizing outcomes of Primary PCI: From CADILLAC to HORIZONS. Presented at the 10<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 29, 2005.

1071. Zen Philosophy – the key to CTO successes. Presented at the 10<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 30, 2005.
1072. Evidence-Based Medicine analysis of Current DES clinical Use Guidelines: A roadmap for Clinicians. Presented at the 10<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 30, 2005.
1073. The Future of Interventional Cardiology in Acute Coronary Syndromes. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Ponte Verde beach, FL, May 4<sup>th</sup>, 2005.
1074. Perspectives on the Clinical Outcomes with the TAXUS stent. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Ponte Verde Beach, FL, May 5<sup>th</sup>, 2005.
1075. The invasive approach to non ST-segment elevation myocardial infarction. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Ponte Verde Beach, FL, May 5<sup>th</sup>, 2005.
1076. An evidence-based medicine approach to drug-eluting stent usage. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Ponte Verde Beach, FL, May 6<sup>th</sup>, 2005.
1077. Paclitaxel-eluting Stents. Presented at Medical Grand Rounds, Columbia Presbyterian Medical Center, New York City, May 18<sup>th</sup>, 2005.
1078. The Pivotal TAXUS-V trial: Insights to drug-eluting stents in complex lesions. Presented at the TAXUS Speaker's Bureau, Minneapolis, MN, May 19<sup>th</sup>, 2005.
1079. Perspectives on Paclitaxel-eluting Stent Safety and Efficacy from the TAXUS Trials Meta-Analysis. Presented at the TAXUS Speaker's Bureau, Minneapolis, MN, May 19<sup>th</sup>, 2005.
1080. Interpreting the "Head to Head" Cypher vs. TAXUS Trials. Presented at the TAXUS Speaker's Bureau, Minneapolis, MN, May 19<sup>th</sup>, 2005.
1081. Novel insight from the TAXUS-V trial. Presented at the EuroPCR meeting, May 25<sup>th</sup>, 2005, Paris, France.
1082. New evidence based medicine findings on drug eluting stents: Insights from ACC 2005 randomized clinical trials. Presented at the EuroPCR meeting, May 25<sup>th</sup>, 2005, Paris, France.
1083. The impact of elution rates on DES results. Presented at the EuroPCR meeting, May 25<sup>th</sup>, 2005, Paris, France.
1084. The future of anticoagulation therapy in patients undergoing percutaneous coronary intervention. Presented at the EuroPCR meeting, May 25<sup>th</sup>, 2005, Paris, France.
1085. Chronic Total Occlusions: Latest Guidewire Techniques. Presented at the EuroPCR meeting, May 26<sup>th</sup>, 2005, Paris, France.

1086. DES in complex lesion. A technical case review. Presented at the EuroPCR meeting, May 26<sup>th</sup>, 2005, Paris, France.
1087. Pharmacologic prevention of contrast-induced nephropathy. Presented at the EuroPCR meeting, May 26<sup>th</sup>, 2005, Paris, France.
1088. Contrast optimization techniques-managing risk patients. Presented at the EuroPCR meeting, May 27<sup>th</sup>, 2005, Paris, France.
1089. Intervention of the future and future intervention. Presented at the EuroPCR meeting, May 27<sup>th</sup>, 2005, Paris, France.
1090. Chronic total occlusions: lessons from the summit. Webcast June 1<sup>st</sup>, 2005.
1091. Update on distal protection and thrombectomy devices. Presented at the course Intervention 2005, New York City, NY, June 2<sup>nd</sup>, 2005.
1092. Reperfusion therapy in acute myocardial infarction. Presented at the course Advances in the Treatment of Coronary Artery Disease, June 3rd, 2005, New York City, NY.
1093. Drug-eluting stent update: current results and future directions. Presented at the 6<sup>th</sup> Moscow International Course on Endovascular Surgery of Congenital and Acquired Heart Diseases, Coronary and Vascular Pathology, Moscow, Russia, June 9<sup>th</sup>, 2005.
1094. Optimal treatment of degenerated saphenous vein grafts. Presented at the 6<sup>th</sup> Moscow International Course on Endovascular Surgery of Congenital and Acquired Heart Diseases, Coronary and Vascular Pathology, Moscow, Russia, June 9<sup>th</sup>, 2005.
1095. The Future of Transcatheter Valvular Therapies. Presented at the 6<sup>th</sup> Moscow International Course on Endovascular Surgery of Congenital and Acquired Heart Diseases, Coronary and Vascular Pathology, Moscow, Russia, June 10<sup>th</sup>, 2005.
1096. A Natural History Study: The PROSPECT Trial. Presented at the 3<sup>rd</sup> International Vulnerable Plaque meeting – VPM2005, Capri, Italy, June 13<sup>th</sup>, 2005.
1097. Drug-eluting stents for intermediate lesions: Rationale and results. Presented at the annual SOLACI meeting, Mexico City, Mexico, July 20<sup>th</sup>, 2005
1098. TAXUS vs. Cypher – are there any meaningful differences? Presented at the annual SOLACI meeting, Mexico City, Mexico, July 20<sup>th</sup>, 2005.
1099. Drug-eluting stents for specific angiographic subsets. Presented at the annual SOLACI meeting, Mexico City, Mexico, July 20<sup>th</sup>, 2005.
1100. A day in the life of TCT. Presented at the annual SOLACI meeting, Mexico City, Mexico, July 21<sup>st</sup>, 2005.
1101. The TAXUS program – current status and future directions. Presented at the annual SOLACI meeting, Mexico City, Mexico, July 21<sup>st</sup>, 2005.

1102. Drug-eluting stent update: The evidence is mounting. Presented at the 1<sup>st</sup> Midwest Regional Heart and Vascular Meeting, Boyne Falls, Michigan, July 30<sup>th</sup>, 2005.
1103. TAXUS Current Status and Future Directions. BSC National Sales Meeting, Cleveland, Ohio, August 17<sup>th</sup>, 2005.
1104. Sinoplasty treatment of mitral regurgitation. Presented at Multidisciplinary Rounds, Columbia University Medical Center, New York City, NY, August 25<sup>th</sup>, 2005.
1105. Acute myocardial infarction therapies. Columbia University Medical Center, New York City, NY, August 25<sup>th</sup>, 2005.
1106. New directions in primary angioplasty. Cardiology Grand Rounds, Columbia University Medical Center, New York City, NY, September 8<sup>th</sup>, 2005.
1107. Moderator and edited live case presentations. Mitral valve technologies. At the AATS Postgraduate course "Valvular Heart disorders", Chicago, IL, September 9<sup>th</sup> and 10<sup>th</sup>, 2005.
1108. Role and Perspectives of Bivalirudin in PCI. Presented at the Annual TEAM Course, Madrid, Spain, September 21<sup>st</sup>, 2005.
1109. Lessons learned from TAXUS V. Presented at the Annual TEAM Course, Madrid, Spain, September 21<sup>st</sup>, 2005.
1110. Thrombus containing lesions and stent thrombosis in DES. Presented at the Annual TEAM Course, Madrid, Spain, September 22<sup>nd</sup>, 2005.
1111. The Zomaxx DES Program. Presented at the Annual TEAM Course, Madrid, Spain, September 22<sup>nd</sup>, 2005.
1112. Anticoagulation in PCI Debate: Pro Bivalirudin. Presented at the Annual TEAM Course, Madrid, Spain, September 22<sup>nd</sup>, 2005.
1113. TAXUS V – Complex Intervention. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27<sup>th</sup>, 2005.
1114. Primary Angioplasty – New Approaches. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27<sup>th</sup>, 2005.
1115. A Critical Appraisal of the "Head-to-Head" Cypher vs. TAXUS Trials. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27<sup>th</sup>, 2005.
1116. New Strategies to diagnose and treat vulnerable plaque. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27<sup>th</sup>, 2005.
1117. Drug-eluting stent update: TAXUS and Everolimus stents. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27<sup>th</sup>, 2005.

- 1118. The MPS integrated next-generation cath-lab system. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27<sup>th</sup>, 2005.
- 1119. TAXUS DES Safety and Efficacy. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27<sup>th</sup>, 2005.
- 1120. When to use DES: Evidence-based Medicine Guidance. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 27<sup>th</sup>, 2005.
- 1121. The SPIRIT Trials: Design and Rationale. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 28<sup>th</sup>, 2005.
- 1122. Forthcoming TCT Highlights 2005. Presented at the Complex Catheter Therapeutics (CCT) Symposium, Kobe, Japan, September 28<sup>th</sup>, 2005.
- 1123. Lessons from the first two CTO Summits. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 16<sup>th</sup>, 2005.
- 1124. TCT 2005 Crossfire: Trials, Tribulations, Current Trends and Future Projections. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 17<sup>th</sup>, 2005.
- 1125. Paclitaxel-eluting stents: Update 2005. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 17<sup>th</sup>, 2005.
- 1126. PROSPECTS for the invasive and non-invasive diagnosis of vulnerable plaque: Surveying the landscape and narrowing the field. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 17<sup>th</sup>, 2005.
- 1127. Bivalirudin in PCI: A Risk-Benefit Analysis (and ACUITY Preamble). Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 17<sup>th</sup>, 2005.
- 1128. First presentation of the 3-year TAXUS-IV results. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 18<sup>th</sup>, 2005.
- 1129. Thrombectomy in STEMI - Late breaking trial dynamic commentary. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19<sup>th</sup>, 2005.
- 1130. The Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19<sup>th</sup>, 2005.
- 1131. A Future Vision for Interventional Cardiovascular Medicine: Clinical, Regulatory, Scientific and Socioeconomic Perspectives. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19<sup>th</sup>, 2005.

1132. Overall State of Embolic Protection. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19<sup>th</sup>, 2005.
1133. Vulnerable Plaque: The PROSPECT for Vulnerable Plaque Detection and Treatment. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19<sup>th</sup>, 2005.
1134. BVS – 3rd Generation Stents: Here today, gone tomorrow . Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 19<sup>th</sup>, 2005.
1135. A Radical New Approach to Angiography and Angioplasty Guidance: The MPS-Ready Cath Lab and PCI Applications. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1136. Evidence-based medicine analysis of current DES clinical use guidelines: A roadmap for practicing interventionalists. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1137. Do you want the truth? A CYPHER vs. TAXUS mega-trial is required to resolve comparative safety and efficacy issues! Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1138. Bivalirudin in ACS and high risk patients: ACUITY trial update. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1139. Primary Mechanical Reperfusion in Acute ST-segment MI. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1140. Updated meta-analysis of TAXUS clinical trials: safety and efficacy demonstrated in 3,445 randomized patients. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1141. TAXUS - First presentation of the 3 year TAXUS data. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1142. Drug-eluting stents and bivalirudin in AMI: HORIZONS rationale, design and status. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1143. Everolimus drug-eluting stents: Technical aspects and a comprehensive review of the EU and US Guidant SPIRIT program. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1144. The Corazon aortic valve remodeling concept and procedure. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.

1145. Do Drug Release Kinetics and Dose kinetics Impact DES outcomes II? Final PISCES and COSTAR I Results. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 20<sup>th</sup>, 2005.
1146. Synergistic efficacy from combined zotarolimus and dexamethasone elution: Platform for a next generation DES stent. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 21<sup>st</sup>, 2005.
1147. Multimodality imaging of the coronary tree in patients with acute coronary syndromes: The PROSPECT natural history study. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 21<sup>st</sup>, 2005.
1148. Supersaturated Aqueous Oxygen: AMIHOT I analysis and AMIHOT II status. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 21<sup>st</sup>, 2005.
1149. Induced hypothermia to prevent contrast nephropathy. Presented at the 17<sup>th</sup> annual scientific sessions of Transcatheter Cardiovascular Therapeutics, Washington DC, October 21<sup>st</sup>, 2005.
1150. Conflict of Interest: Device Development Clinical Phase. Understanding the role of the Clinician Investigator. Presented at the 3<sup>rd</sup> Dartmouth Device Development Symposium, October 27<sup>th</sup>, 2005, Woodstock, VT.
1151. Optimizing the results of primary angioplasty in acute myocardial infarction. Medical Grand Rounds, Stamford Hospital, Stamford, CT, November 9<sup>th</sup>, 2005.
1152. Percutaneous coronary intervention in patients with diabetes mellitus. Presented during the webcast "Complex lesion and patient intervention", November 9<sup>th</sup>, 2005.
1153. Should the use of Bivalirudin Extend to the Emergency Room? Presented at the course CRT at AHA, November 12<sup>th</sup>, 2005.
1154. Emerging Developments and Future Directions in the Detection of Vulnerable Patients and Vulnerable Plaques. Presented at the SHAPE Meeting at the 78<sup>th</sup> annual scientific sessions of the American Heart Association, Dallas, TX, November 14<sup>th</sup>, 2005.
1155. Topic: DES: Current Data, Unapproved Indications, Oral antiplatelet Rx and Late Stent Thrombosis. Presented at the 78<sup>th</sup> annual scientific sessions of the American Heart Association, Dallas, TX, November 12<sup>th</sup>, 2005.
1156. How to detect Vulnerable plaque with new imaging methods: CTA, MRI, and IVUS. Presented at the 78<sup>th</sup> annual scientific sessions of the American Heart Association, Dallas, TX, November 14<sup>th</sup>, 2005.
1157. Latest Clinical Trial Results with Drug-eluting stents. Presented at the 78<sup>th</sup> annual scientific sessions of the American Heart Association, Dallas, TX, November 14<sup>th</sup>, 2005.
1158. The ACUTY Trial. Presented at the 78<sup>th</sup> annual scientific sessions of the American Heart Association, Dallas, TX, November 14<sup>th</sup>, 2005.



1159. Beneficial effect of the 2.25mm Paclitaxel-Eluting TAXUS Stent in Patients with Small coronary arteries: Results from the TAXUS V Trial. Presented at the 78<sup>th</sup> annual scientific sessions of the American Heart Association, Dallas, TX, November 15<sup>th</sup>, 2005
1160. Three-Year Safety and Efficacy of the Polymer-Based Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial. Presented at the 78<sup>th</sup> annual scientific sessions of the American Heart Association, Dallas, TX, November 15<sup>th</sup>, 2005.
1161. The approach to complex chronic total coronary occlusions. Columbia University Medical Center, November 30<sup>th</sup>, 2005.
1162. Clinical trial update in acute myocardial infarction – post TCT/AHA synthesis. Presented at the course “Advanced Interventional Therapies”, New York City, NY, December 2<sup>nd</sup>, 2005.
1163. Clinical trial update with drug-eluting stents – post TCT/AHA synthesis. Presented at the course “Advanced Interventional Therapies”, New York City, NY, December 3<sup>rd</sup>, 2005.
1164. Imaging the Vulnerable Patient – the Interventional Approach. Presented at the 38<sup>th</sup> Annual New York Cardiovascular Symposium Major Topics in Cardiology Today, New York, NY, December 9<sup>th</sup>, 2005.
1165. Drug-eluting Stent Update 2006. Cardiology Grand Rounds, St. Vincent’s Hospital, New York City, NY, January 12<sup>th</sup>, 2006.
1166. Current standards and future directions in primary angioplasty for acute myocardial infarction. Cardiology Grand Rounds, Montefiore Medical Center, Bronx, NY, January 17<sup>th</sup>, 2006.
1167. Pre-emptive stenting of vulnerable plaque and moderate lesions. Boston Scientific Corp. Scientific Advisory Board Meeting, Boston, MA, January 18<sup>th</sup>, 2006.
1168. Drug-eluting stents: Where are we, what challenges remain? Boston Scientific Corp. Scientific Advisory Board Meeting, Boston, MA, January 18<sup>th</sup>, 2006.
1169. Current and future therapies to enhance myocardial salvage after acute myocardial infarction. The 2<sup>nd</sup> International Conference on Cell Therapy in Cardiovascular Diseases. New York City, NY, January 20<sup>th</sup>, 2006.
1170. Drug- Eluting Stents: Current Status of Adjunctive Pharmacologic Therapy. Presented at the 16<sup>th</sup> Annual ISET Course, Miami, FL, January 22<sup>nd</sup>, 2006.
1171. Drug- Eluting Stent Randomized Trials: Are There Meaningful Differences Between the Devices? Presented at the 16<sup>th</sup> Annual ISET Course, Miami, FL, January 22<sup>nd</sup>, 2006.
1172. Chronic Total Occlusions: Current Perspectives. Presented at the 16<sup>th</sup> Annual ISET Course, Miami, FL, January 22<sup>nd</sup>, 2006.

1173. ACUITY Trial: A landmark investigation in patients with acute coronary syndromes. Medicine's Advisory Board Meeting, New York City, NY, February 4<sup>th</sup>, 2006.
1174. Chronic Total Occlusions: Penetrating Insights. Keynote address. Abbott Vascular Devices National Sales Meeting, Austin TX, February 7<sup>th</sup>, 2006.
1175. Drug-eluting Stents: Current Insights and a Vision for the Future. Presented at the 28<sup>th</sup> annual Cardiovascular Symposium, Holy Cross Hospital, Ft. Lauderdale, FL, February 10<sup>th</sup>, 2006.
1176. Use of Bivalirudin in Acute Coronary Syndromes: From the emergency room to the cath lab. Presented at the Joint Interventional Meeting (JIM) 2006, Rome, Italy, February 15<sup>th</sup>, 2006.
1177. Perspectives on saphenous vein graft intervention. Presented at the Joint Interventional Meeting (JIM) 2006, Rome, Italy, February 16<sup>th</sup>, 2006.
1178. The Xience Drug-eluting Stent: preclinical and clinical update. Presented at the Joint Interventional Meeting (JIM) 2006, Rome, Italy, February 17<sup>th</sup>, 2006.
1179. Outcomes with the TAXUS stent in complex lesions and patients. Presented at the Joint Interventional Meeting (JIM) 2006, Rome, Italy, February 17<sup>th</sup>, 2006.
1180. Lessons in Recanalizing Chronic Total occlusions from the First Two CTO Summits. Presented at the 3<sup>rd</sup> International CTO Summit, February 23<sup>rd</sup>, 2006.
1181. Contemporary strategies in the Management of Non ST-segment Elevation MI. Presented at medical Grand Rounds, University of San Diego California, March 1<sup>st</sup>, 2006, San Diego, California.
1182. TAXUS RCT meta-analysis and registries: Insights and unsettled issues. Presented at the 5<sup>th</sup> Annual Course "Enter the DES Revolution: A Critical Appraisal", Atlanta, GA, March 11<sup>th</sup>, 2006.
1183. Everolimus Elution from a Durable Polymer: Xience. Presented at the 5<sup>th</sup> Annual Course "Enter the DES Revolution: A Critical Appraisal", Atlanta, GA, March 11<sup>th</sup>, 2006.
1184. Prospective, Randomized Comparison of Heparin Plus IIb/IIIa Inhibition Vs. Bivalirudin With or Without IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes: The ACUITY Trial. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 12<sup>th</sup>, 2006.
1185. Vulnerable Plaque the Future: Devices or Drugs? Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 12<sup>th</sup>, 2006.
1186. A Prospective, Multicenter, Randomized Trial Evaluating the TAXUS Paclitaxel-Eluting Coronary Stent Versus Vascular Brachytherapy for the Treatment of Bare Metal Stent In-Stent Restenosis: The TAXUS-V ISR Trial. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 12<sup>th</sup>, 2006.

1187. Drug eluting Stents in Complex Lesions: An Evidence-Based Medicine Approach. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 12<sup>th</sup>, 2006.
1188. Prospective, Randomized Comparison of Routine Upfront Initiation Versus Selective Use of Glycoprotein IIb/IIIa Inhibitors in Patients with Acute Coronary Syndromes: The ACUTY Timing Trial. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 13<sup>th</sup>, 2006.
1189. Do the Traditional Risk Factors of Vessel Size, Lesion Length and Diabetes Mellitus Predict Restenosis with TAXUS Stents? Insights from a TAXUS Meta-Analysis. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 13<sup>th</sup>, 2006.
1190. Acute Myocardial Infarction and Cardiogenic Shock: Future Directions. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 13<sup>th</sup>, 2006.
1191. Role of Direct Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS. Presented during the course "Optimizing Outcomes in ACS and PCI: Evaluating the Findings from Late-Breaking Clinical Trials in Antithrombin Therapy", Atlanta, GA, March 14<sup>th</sup>, 2006.
1192. Update on TAXUS V ISR. Presented during the 55th Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 14<sup>th</sup>, 2006.
1193. Putting DES to the Test: The TAXUS Clinical Program. Atlanta, GA, March 15<sup>th</sup>, 2006.
1194. New insights into the treatment of patients with acute coronary syndromes. Medical Grand Rounds, Beth Israel Medical Center, New York City, NY, March 27<sup>th</sup>, 2006.
1195. Advances in primary angioplasty for acute myocardial infarction. Presented at the course "Update in Cardiovascular Medicine", Southbury, CT, March 28<sup>th</sup>, 2006.
1196. CTO Angioplasty II: Basic and advanced techniques. Presented at the 12<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, CA, March 29<sup>th</sup>, 2006.
1197. Drug Eluting Stents – Current Landscape. Presented at the 12<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, CA, March 29<sup>th</sup>, 2006.
1198. Proven Drug-Eluting Stent Systems II: Polymer-based paclitaxel release. Presented at the 12<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, CA, March 30<sup>th</sup>, 2006.
1199. Emerging Drug-Eluting Stent Systems II: Xience V and Zomaxx. Presented at the 12<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, CA, March 30<sup>th</sup>, 2006.

1200. Evidence-based medicine guidelines to drug-eluting stent use. Presented at the 12<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, CA, March 31<sup>st</sup>, 2006.
1201. Cypher vs. Taxus – A critical review of the evidence. Presented at the 12<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, CA, March 31<sup>st</sup>, 2006.
1202. Angioplasty in AMI: Primary PCI state of the art. Presented at the 12<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, CA, April 1<sup>st</sup>, 2006.
1203. Interventional Pharmacology IV: Bivalirudin in ACS and PCI. Presented at the 12<sup>th</sup> Annual North American Interventional Cardiology Fellow's Course, San Jose, CA, April 1<sup>st</sup>, 2006.
1204. Expanding Use of Bivalirudin Beyond PCI: Lessons from ACUTY to EVOLUTION. Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 3<sup>rd</sup>, 2006.
1205. Superior Strategies for AMI Management – No need for facilitated pharmacology. Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 3<sup>rd</sup>, 2006.
1206. The PROSPECT Trial: Design and Rationale for a Vulnerable Plaque Natural History Study. Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 3<sup>rd</sup>, 2006.
1207. Should Non-obstructive Lesions be Treated with DES? Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 3<sup>rd</sup>, 2006.
1208. The ACUTY Trial. Presented at the annual Cardiovascular Revascularization Therapy course, Washington DC, April 4<sup>th</sup>, 2006.
1209. CIT Crossfire – Current status and future direction in interventional vascular therapies. Satellite transmission to the annual China Interventional Therapies course, April 6<sup>th</sup>, 2006.
1210. Invasive and non-invasive vulnerable plaque detection. Presented at the 11<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 25, 2006.
1211. The TAXUS Clinical Trial Program. Presented at the 11<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 26, 2006.
1212. The XIENCE Clinical Trial Program. Presented at the 11<sup>th</sup> Asia Pacific Interventional Cardiology Summit, Seoul, South Korea, April 26, 2006.
1213. Defending percutaneous aortic valve replacement. Presented at the 3<sup>rd</sup> Transcatheter Valve Symposium, San Francisco, CA, April 28<sup>th</sup>, 2006.
1214. Detection of Vulnerable Plaque: Invasive and Non-invasive Imaging Approaches. Bristol-Myers Squibb, Boston, Mass, May 3<sup>rd</sup>, 2006.

1215. Basic CTO techniques: Wires, Guides, Patient Issues. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Chicago, IL, May 12<sup>th</sup>, 2006.
1216. Prospects for the Invasive and Non-Invasive Identification of Vulnerable Plaque. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Chicago, IL, May 12<sup>th</sup>, 2006.
1217. Mechanical Thrombectomy for AMI: Its Day is Done. Presented at the annual scientific sessions of the Society for Cardiac Angiography and Interventions, Chicago, IL, May 12<sup>th</sup>, 2006.
1218. Dedicated devices for CTO treatment. Presented at EuroPCR, Paris, France, May 16<sup>th</sup>, 2006.
1219. Perspective: an evidence-based medicine review of new DES clinical trials. Presented at EuroPCR, Paris, France, May 17<sup>th</sup>, 2006.
1220. Xience V - A Next Generation DES. Presented at EuroPCR, Paris, France, May 17<sup>th</sup>, 2006.
1221. Upstream Treatment of ACS Patients- Insights from ACUITY. Presented at EuroPCR, Paris, France, May 18<sup>th</sup>, 2006.
1222. Drug-Eluting stents of the future: combining and antiproliferative and an anti-inflammatory agent for enhanced efficacy. Presented at EuroPCR, Paris, France, May 19<sup>th</sup>, 2006.
1223. Replacement of Unfractionated Heparin. Presented at the course Advances in Interventional Cardiology, Munich, Germany, May 20<sup>th</sup>, 2006.
1224. The PROSPECT Trial. Presented at the 4<sup>th</sup> Vulnerable Plaque Meeting (VPM), Capri, Italy, May 21<sup>st</sup>, 2006.
1225. The VIP Program. Presented at the 4<sup>th</sup> Vulnerable Plaque Meeting (VPM), Capri, Italy, May 21<sup>st</sup>, 2006.
1226. Late Breaking Trials from EuroPCR. Webcast. [Clinicaltrials.duke.org](http://Clinicaltrials.duke.org), May 5<sup>th</sup>, 2006.
1227. Vulnerable Plaque – The Next Five Years. Presented at the course VIP 2006: A Vulnerable Plaque Summit. Houston, Texas, June 10<sup>th</sup>, 2006.
1228. Keynote address: Optimizing the Results of Upstream Pharmacologic Therapy in Acute Coronary Syndromes: Insights from ACUITY. Presented at the 15<sup>th</sup> Advanced Cardiovascular Interventions Symposium, June 15<sup>th</sup>, 2006.
1229. Drug-eluting stents and direct thrombin inhibitors in STEMI: Update of HORIZONS. Presented at the 15<sup>th</sup> Advanced Cardiovascular Interventions Symposium, June 16<sup>th</sup>, 2006.

1230. Basic and advanced techniques in CTO recanalization. CTO preceptorship course, Ciolumbia University Medical Center, June 19<sup>th</sup>, 2006.
1231. Optimizing upstream treatment of patients with acute coronary syndromes – the ACUTY Trial. Presented at Cardiac Catheterizataion Conference, Columbia University Medical Center, June 20<sup>th</sup>, 2006.
1232. Update in Acute Myocardial Infarction Therapies. Presented at the course “Clinical Advances in Cardiology”, Naples Florida, June 24<sup>th</sup>, 2006.
1233. Coronary Artery Disease and Atherosclerosis NHLBI Level 1 Working Group. June 27<sup>th</sup> and 28<sup>th</sup>, Bethesda, Md.
1234. DES Guideline Update. Presented at the course TOPIC 2006, Tokyo, Japan, July 21<sup>st</sup>, 2006.
1235. Current Consensus and future direction of PCI for chronic total occlusions. Presented at the course TOPIC 2006, Tokyo, Japan, July 21<sup>st</sup>, 2006.
1236. Detection and treatment of vulnerable plaque. Presented at the course TOPIC 2006, Tokyo, Japan, July 21<sup>st</sup>, 2006.
1237. Primary Angioplasty in Acute Myocardial Infarction: A Primer for Inerventional Cardiology Fellows. Fellows Conference. NewYork Presbyterian Hospital, Columbia University Medical Center, July 31<sup>st</sup>, 2006.
1238. Bivalirudin – a new player in primary percutaneous coronary intervention. Presented at the annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 4<sup>th</sup>, 2006.
1239. Role of new devices in CTO angioplasty. Presented at the annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 4<sup>th</sup>, 2006.
1240. Upstream treatment of ACS patients – Insights and Conclusions from ACUTY. Presented at the annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 4<sup>th</sup>, 2006.
1241. XIENCE V: Components review of a drug-eluting stent. Presented at the annual Scientific Sessions of the European Society of Cardiology, Barcelona, Spain, September 5<sup>th</sup>, 2006.
1242. CoreValve Revalving Percutaneous Aortic Valve Replacement: Update 2006. Presented at the PICS annual meeting, Las Vegas, NV, September 12<sup>th</sup>, 2006.
1243. Debate: All patients with stroke and PFO should be entered in randomized trials: Pro. Presented at the PICS annual meeting, Las Vegas, NV, September 12<sup>th</sup>, 2006.
1244. Challenges and Pitfalls in Designing Meaningful Clinical Trials Using New Percutaneous Therapies in patients with Mitral Regurgitation. Presented at the PICS annual meeting, Las Vegas, NV, September 13<sup>th</sup>, 2006.

1245. Anticoagulation in the ACS Patient from Presentation to PCI. Beth Israel Deaconess Cardiology Grand Rounds, Boston, Mass, September 15<sup>th</sup>, 2006.
1246. Basic and advanced techniques in CTO recanalization. CTO preceptorship course, Columbia University Medical Center, September 25<sup>th</sup>, 2006.
1247. The ACUITY Trial: Insights beneath the surface. Boston, MA, September 30, 2006.
1248. Are drug-eluting stents over-used? Are they safe and effective? Presented at the 6<sup>th</sup> Controversies and Advances in the Treatment of Cardiovascular Diseases course, Los Angeles, CA, October 6<sup>th</sup>, 2006.
1249. Are heparin and glycoprotein IIb/IIIa inhibitors on their way out? New antithrombotic and antiplatelet agents. Presented at the 6<sup>th</sup> Controversies and Advances in the Treatment of Cardiovascular Diseases course, Los Angeles, CA, Washington DC, October 6<sup>th</sup>, 2006.
1250. PCI Pharmacology – What’s Really Important. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 22<sup>nd</sup>, 2006.
1251. Lessons from the CTO Summit: Highlights from Three Years of Unadulterated Live Cases. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 22<sup>nd</sup>, 2006.
1252. CTO Recanalization: Core Concepts. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 22<sup>nd</sup>, 2006.
1253. TCT Crossfire: Recasting the Landscape of Interventional Cardiovascular Medicine. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 23<sup>rd</sup>, 2006.
1254. DES Evidenced-Based Medicine: Perspectives on Emerging Safety Concerns, Real World Outcomes and Use Recommendations. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 23<sup>rd</sup>, 2006.
1255. PROSPECTS for the Prevention of Death and Myocardial Infarction: From Natural History Studies to Novel Therapeutic approaches. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 23<sup>rd</sup>, 2006.
1256. Drug-eluting Stents: What we’ve learned so far. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 23<sup>rd</sup>, 2006.
1257. ACUITY PCI: A prospective trial of patients with acute coronary syndromes undergoing PCI after randomization to heparin plus glycoprotein IIb/IIIa inhibitors vs. bivalirudin with or without glycoprotein IIb/IIIa inhibitors: Thirty day clinical and angiographic core

- laboratory results. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24<sup>th</sup>, 2006.
1258. Independent patient level Independent Physician-Assessed Patient Level Meta-Analyses: Randomized Trials. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24<sup>th</sup>, 2006.
  1259. Shifting Paradigms in Pharmacologic and Interventional Therapies for Acute Coronary Syndromes and Acute Myocardial Infarction. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24<sup>th</sup>, 2006.
  1260. Primary Angioplasty in AMI: Current Standards and Future Directions. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24<sup>th</sup>, 2006.
  1261. CTO angioplasty is difficult: Why bother? Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24<sup>th</sup>, 2006.
  1262. The TCT 2006 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 24<sup>th</sup>, 2006.
  1263. Taking the Evidence-Based Approach to ACS: Examination of New Trial Data. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 25<sup>th</sup>, 2006.
  1264. Xience and ZoMaxx in Perspective. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 25<sup>th</sup>, 2006.
  1265. Evidence-Based Medicine Update on DES Use Guidelines: Highlighting the Meaningful Changes in 2006. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26<sup>th</sup>, 2006.
  1266. Antithrombotic alternatives for patients with ACS managed invasively: Making the case for: Bivalirudin for the best overall outcomes (and most cath lab compatible). Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26<sup>th</sup>, 2006.
  1267. Virtual histology II: First presentation of the baseline clinical features and plaque characteristics from the PROSPECT Trial. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26<sup>th</sup>, 2006.
  1268. An Updated Meta-Analysis of the TAXUS Randomized Controlled Trials. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26<sup>th</sup>, 2006.
  1269. Primary Mechanical Reperfusion in Acute MI. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26<sup>th</sup>, 2006.



1270. Systemic Hypothermia to Prevent Contrast Nephropathy: The COOL-RCN Pilot and Randomized Trials. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26<sup>th</sup>, 2006.
1271. The Abbott ZODIAC and Clever Combination Drug-Eluting Stent Program: Device, Description, Experimental Results and Future Directions. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, October 26<sup>th</sup>, 2006.
1272. DES and Bivalirudin in AMI: Clinical trial perspectives and HORIZONS update. Presented at the 18<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 26<sup>th</sup>, 2006.
1273. Acute Antithrombotic therapy post ACUITY and ISAR-REACT 2 Debate: GP IIb/IIIa inhibitors: Do they Remain a Critical Component of Care in High-Risk ACS Patients? Presented at the Global Cardiovascular Summit, Chicago, IL, November 10<sup>th</sup>, 2006.
1274. Comparison of Heparin Plus IIb/IIIa Inhibition Versus Bivalirudin With or Without IIb/IIIa Inhibition in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUITY Trial. Presented at the 79<sup>th</sup> annual scientific sessions of the American Heart Association, Chicago, IL, November 14<sup>th</sup>, 2006.
1275. Long-Term Outcomes Following Treatment of In-Stent Restenosis with Drug-Eluting Stents: Insights from the TAXUS Meta-Analysis. Presented at the 79<sup>th</sup> annual scientific sessions of the American Heart Association, Chicago, IL, November 14<sup>th</sup>, 2006.
1276. Systemic Hypothermia to Prevent Contrast Nephropathy: The COOL RCN Pilot Trial. Presented at the 79<sup>th</sup> annual scientific sessions of the American Heart Association, Chicago, IL, November 15<sup>th</sup>, 2006.
1277. Reperfusion in acute myocardial infarction – Evidence-based medicine. Presented at the 7<sup>th</sup> New Frontiers in Interventional Cardiology Course, Krakov, Poland, December 1<sup>st</sup>, 2006.
1278. Drug-eluting stent controversies and future directions. Presented at the 7<sup>th</sup> New Frontiers in Interventional Cardiology Course, Krakov, Poland, December 1<sup>st</sup>, 2006.
1279. Pharmacologic therapies in the high risk patient with acute coronary syndromes. Presented at the 7<sup>th</sup> New Frontiers in Interventional Cardiology Course, Krakov, Poland, December 1<sup>st</sup>, 2006.
1280. Perspectives on the safety and efficacy of drug-eluting stents, and regulatory recommendations. FDA advisory panel presentation. Gaithersburg, MD, December 7<sup>th</sup>, 2006.
1281. Perspectives on the safety and efficacy of drug-eluting stents, and evidence-based medicine recommendations. Presented at the course “Advanced Interventional Strategies”, New York City, NY, December 15<sup>th</sup>, 2006.
1282. Basic and advanced techniques for CTO recanalization. CTO preceptorship course, Columbia University Medical Center, New York City, NY, December 18<sup>th</sup>, 2006.

1283. Safety and efficacy of drug-eluting stents – the whole story. Foundation for Cardiovascular Medicine, San Diego, CA, December 20<sup>th</sup>, 2006.
1284. Basic and advanced techniques for CTO recanalization. CTO preceptorship course, Columbia University Medical Center, New York City, NY, January 8<sup>th</sup>, 2006.
1285. Reperfusion strategies to improve ventricular function in acute myocardial infarction. Presented at the Third International Conference on Cell Therapy for Cardiovascular Disease. New York City, NY, January 18<sup>th</sup>, 2007.
1286. Drug-eluting Stents: Current Status, Evidence Based and New Developments. Presented at the International Symposium on Endovascular Therapy 2007 course, Hollywood, FL, January 28<sup>th</sup>, 2007.
1287. Drug-eluting Stents and Late or Very Late Stent Thrombosis - What are the Facts? Presented at the International Symposium on Endovascular Therapy 2007 course, Hollywood, FL, January 28<sup>th</sup>, 2007.
1288. The Current Status of Adjunctive Pharmacological Therapy: Antiplatelet Therapy. Presented at the International Symposium on Endovascular Therapy 2007 course, Hollywood, FL, January 28<sup>th</sup>, 2007.
1289. Technical Lessons from the CTO Summit: Highlights from 3 Years of Unadulterated Live Cases. Presented at the 4th International Chronic Total Occlusion Summit, New York City, NY, February 22<sup>nd</sup>, 2007.
1290. The Drug-eluting Stent Controversy: Risks and Benefits of Widespread use. Cardiology Grand Rounds. Columbia University Medical Center, NY, NY, March 6<sup>th</sup>, 2007.
1291. Insights into Drug-eluting Stent Usage. Presented at the Thought Leaders Summit, Miami, FL, March 9<sup>th</sup>, 2007.
1292. Diagnosing vulnerable plaques and vulnerable patients. Presented at the Thought Leaders Summit, Miami, FL, March 9<sup>th</sup>, 2007.
1293. Future Technologic Developments to Reduce Stent Thrombosis: Bioabsorbable Stent; Non-Polymer Stents; Stents which promote Rapid Re-endothelialization. Presented at the CVI SES Symposium, Philadelphia, PA, March 13<sup>th</sup>, 2007.
1294. Evidence Based Medicine Indications for DES Usage: US Recommendations. Presented at the 6<sup>th</sup> annual “Enter the Drug-eluting Stent Revolution: A Critical Appraisal” course, New Orleans, LA, March 23<sup>rd</sup>, 2007.
1295. The Next Wave of DES in the US: The Abbott Xience V DES Program. Presented at the 6<sup>th</sup> annual “Enter the Drug-eluting Stent Revolution: A Critical Appraisal” course, New Orleans, LA, March 23<sup>rd</sup>, 2007.
1296. Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT -III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients with Coronary Artery Disease. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 24<sup>th</sup>, 2007.

1297. Are Paclitaxel-eluting stents safe and effective compared to Bare Metal Stents? Long-term Results from the TAXUS Meta-analysis. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 25<sup>th</sup>, 2007.
1298. Update on Evolving Drug-Eluting Stent Programs: The XIENCE V Stent and the SPIRIT Trials. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 25<sup>th</sup>, 2007.
1299. What will 2007 unveil for DES – understanding the clinical data landscape. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 25<sup>th</sup>, 2007.
1300. Stent Selection for the Management of ST Segment Elevation Myocardial Infarction. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 26<sup>th</sup>, 2007.
1301. A Prospective, Natural History Study of Multimodality Invasive Imaging to Characterize Vulnerable Plaque: First Report of the Baseline Findings from the PROSPECT Trial. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 26<sup>th</sup>, 2007.
1302. A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes: Final One-Year Results From the ACUTY Trial. Presented at the 56th Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 26<sup>th</sup>, 2007.
1303. Pharmacologic therapies in acute coronary syndromes. Cardiology grand rounds, Yale New Haven Medical Center, New Haven, CT, March 28<sup>th</sup>, 2007.
1304. Lessons Learned from the US 2007 CTO Summit. Presented at the course China Interventional Therapies, Beijing, China, March 30<sup>th</sup>, 2007.
1305. Drug-eluting stents: Delivering What We have Learned So Far. Presented at the course China Interventional Therapies, Beijing, China, March 30<sup>th</sup>, 2007.
1306. Drug-Eluting Stent Thrombosis: Facts and Perspectives – U.S. Insights. Presented at the course China Interventional Therapies, Beijing, China, March 31<sup>st</sup>, 2007.
1307. SPIRIT III: 9-Month Results of the US Pivotal Trial. Presented at the course China Interventional Therapies, Beijing, China, March 31<sup>st</sup>, 2007.
1308. Proven Drug-Eluting Stent Systems II: TAXUS. Presented at the 13<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 12<sup>th</sup>, 2007.
1309. Emerging Drug-Eluting Stent Systems II: Xience and Costar. Presented at the 13<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 12<sup>th</sup>, 2007.
1310. Evidence-Based Medicine Guidelines to Drug-Eluting Stent Use. Presented at the 13<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 13<sup>th</sup>, 2007.

1311. Interventional Pharmacology IV: Bivalirudin in ACS and PCI. Presented at the 13<sup>th</sup> annual Interventional Cardiology Fellow's Course, Boston, MA, April 14<sup>th</sup>, 2007.
1312. Drug-eluting stents: Controversies and Unsettled Issues. Great Neck, NY, April 19<sup>th</sup>, 2007.
1313. Landmark Trials in Acute Coronary Syndromes. Presented at the course "EDICT for ACS", New York City, NY, April 21<sup>st</sup>, 2007.
1314. 2007 Guidelines Update for DES: An Evidence Based Medicine Critical Analysis. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25<sup>th</sup>, 2007.
1315. Should DES use be reduced due to safety concerns? Important Messages from the Randomized DES Trials. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25<sup>th</sup>, 2007.
1316. Debate: Adjunct Pharmacology in ACS and PCI: Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25<sup>th</sup>, 2007.
1317. Clinical Features and Plaque Characteristics from the PROSPECT Trial. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25<sup>th</sup>, 2007.
1318. SPIRIT III (US Pivotal Study Results for Xience V Everolimus Eluting Coronary Stent). Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25<sup>th</sup>, 2007.
1319. Taking the Evidence Based approach to ACS: Examination of New Antithrombin Trial Data. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 25<sup>th</sup>, 2007.
1320. ACUTY PCI: A prospective trial of patients with Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30- Day clinical and Angiographic Core lab Results. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 26<sup>th</sup>, 2007.
1321. SPIRIT-III: Clinical Angiographic & IVUS Results from the Pivotal US Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients with Coronary Artery Disease. Presented at the Angioplasty Summit, TCT Asia Pacific, Seoul, South Korea, April 26<sup>th</sup>, 2007.
1322. Current Status of Percutaneous Mitral Valve Annuloplasty Performed Through the Coronary Sinus. Presented at the 6<sup>th</sup> ACTS course, New York City, NY, May 2<sup>nd</sup>, 2007.
1323. The Drug-eluting Stent Controversy: Laying out the facts. Presented at the Big Ten Cardiovascular Summit, Columbus, Ohio, May 5<sup>th</sup>, 2007.
1324. Primary angioplasty in acute myocardial infarction; Update 2007. Presented at the new Milford Cardiovascular Summit, New Milford, CT, May 8<sup>th</sup>, 2007.

1325. Late stent thrombosis. Presented at the annual scientific session of the Society of Cardiac Angiography and Interventions, Orlando, FL, May 10<sup>th</sup>, 2007.
1326. The Xience V stent and the SPIRIT III trial. Presented at the annual scientific session of the Society of Cardiac Angiography and Interventions, Orlando, FL, May 11<sup>th</sup>, 2007.
1327. Stents vs. Statins: An Academic Debate. Presented at the Midwest Fellows Forum, Chicago, IL, May 17<sup>th</sup>, 2007.
1328. Spirit First 3-Year Update, and SPIRIT II+III Meta-analysis. Presented at EuroPCR, Barcelona, Spain, May 22<sup>nd</sup>, 2007.
1329. Drug-eluting stent safety and efficacy: On-label and off-label perspectives. Presented at EuroPCR, Barcelona, Spain, May 24<sup>th</sup>, 2007.
1330. The Prospect Trial Presented at the 4<sup>th</sup> Symposium on the Burden of Atherothrombotic Disease: Diagnosis and Therapy. New York City, NY, July 10<sup>th</sup>, 2007.
1331. Drug-eluting stent late thrombosis: What are the data and how should we respond? Presented at the 16<sup>th</sup> annual Advanced Cardiovascular Interventions course, Hilton Head, SC, July 12<sup>th</sup>, 2007.
1332. Vulnerable Plaque – Should we stent it? Presented at the 5<sup>th</sup> Vulnerable Plaque meeting, Santorini Greece, June 18<sup>th</sup>, 2007.
1333. The PROSPECT Trial – Baseline findings. Presented at the 5<sup>th</sup> Vulnerable Plaque meeting, Santorini Greece, June 18<sup>th</sup>, 2007.
1334. The long and winding road of interventional cardiology: A personal perspective. Presented at the 7th International Congress on Complications During Coronary interventions: Management and Prevention. Lausanne, Switzerland, June 20<sup>th</sup>, 2007.
1335. The technique of PCI. CTO: Too much hype? Presented at the 7th International Congress on Complications During Coronary interventions: Management and Prevention. Lausanne, Switzerland, June 20<sup>th</sup>, 2007.
1336. Bivalirudin in low and high risk patients undergoing PCI. Presented at the 7th International Congress on Complications During Coronary interventions: Management and Prevention. Lausanne, Switzerland, June 20<sup>th</sup>, 2007.
1337. Basic and advanced angioplasty techniques for CTO intervention. CTO preceptorship, New York City, NY, June 25<sup>th</sup>, 2007.
1338. Update on everolimus-eluting stents. Clinical cardiology research conference. Columbia University Medical Center, NYC, NY, June 28<sup>th</sup>, 2007.
1339. CYPHER: Safety and Efficacy. Presented at the SOLACI '07 meeting, Buenos Aires, Argentina, July 4<sup>th</sup>.

1340. The paclitaxel family of stents. Presented at the SOLACI '07 meeting, Buenos Aires, Argentina, July 4<sup>th</sup>.
1341. Antithrombin update – Role in PCI, ACS and AMI. Presented at the SOLACI '07 meeting, Buenos Aires, Argentina, July 6<sup>th</sup>.
1342. Late DES Events: Do They Modify the Indications? Presented at the SOLACI '07 meeting, Buenos Aires, Argentina, July 6<sup>th</sup>.
1343. DES in the Daily Practice: The importance of the Technique. Presented at the SOLACI '07 meeting, Buenos Aires, Argentina, July 6<sup>th</sup>.
1344. The COURAGE trial in perspective. . Presented at the SOLACI '07 meeting, Buenos Aires, Argentina, July 6<sup>th</sup>.
1345. Valvular Heart Disease: The year in Review: Progress Made – We still have a long way to go. Presented at the SOLACI '07 meeting, Buenos Aires, Argentina, July 6<sup>th</sup>.
1346. Keynote address: TAXUS Stent Experiences. Presented at the annual TOPIC course, Tokyo, Japan, July 19<sup>th</sup>, 2007.
1347. DES thrombosis: Is it real or over-exaggerated? Presented at the annual TOPIC course, Tokyo, Japan, July 19<sup>th</sup>, 2007.
1348. CTO: Where are we now? Where are we going? Insights from the cases done in the past NY CTO summits. Presented at the annual TOPIC course, Tokyo, Japan, July 20<sup>th</sup>, 2007.
1349. Angioplasty strategies in acute myocardial infarction: Update 2007. Cardiology fellows conference, Columbia University Medical Center, New York City, NY, July 23<sup>rd</sup>, 2007.
1350. Challenges in Clinical Trial Design for Transcatheter Mitral Valve Therapies. Presented at the PICS 2007 course, Las Vegas, NV, July 24<sup>th</sup>, 2007.
1351. Angioplasty under Fire: An Interventionalist's Perspective. Presented at the Summer in Seattle meeting, Seattle, WA August 1<sup>st</sup>, 2007.
1352. DES: Real World Outcomes. Presented at the Summer in Seattle meeting, Seattle, WA August 2<sup>nd</sup>, 2007.
1353. Safety and efficacy of everolimus-eluting stents. Presented at ANZET Interventional Cardiology, August 9<sup>th</sup>, 2007, Christchurch, New Zealand.
1354. My Worst Nightmare and Greatest Triumphs. Presented at ANZET Interventional Cardiology, August 9<sup>th</sup>, 2007, Christchurch, New Zealand
1355. Just how important is time to reperfusion in primary angioplasty for AMI? Presented at ANZET Interventional Cardiology, August 9<sup>th</sup>, 2007, Christchurch, New Zealand.
1356. Chronic total occlusion angioplasty: Update 2007. Columbia University Medical Center, New York, NY, August 27<sup>th</sup>, 2007.

1357. Myocardial and Microcirculatory Protection in Acute Coronary Syndromes. Presented at the course "Coroanry Artery Disease: Prevention, Detection, and Treatment. Las vegas, NV, September 10<sup>th</sup>, 2007.
1358. COURAGE: Interventional Perspectives. Presented at the course "Coroanry Artery Disease: Prevention, Detection, and Treatment. Las vegas, NV, September 11<sup>th</sup>, 2007.
1359. Future Directions: Can we Build Better Drug Eluting Stents? Presented at the course "Coroanry Artery Disease: Prevention, Detection, and Treatment. Las vegas, NV, September 11<sup>th</sup>, 2007.
1360. Chronic Total Occlusions: Rationale and Technique. Transmitted to the 1<sup>st</sup> Indian Cardiology Fellow's Course, New Dehli, India, October 1<sup>st</sup>, 2009.
1361. Management of Stable CAD: Should the Courage Trial Change Our Practice? Presented at the course Controversies and Advances in the Treatment of Cardiovascular Disease, Los Angeles, CA, October 5<sup>th</sup>, 2007.
1362. Drug-Eluting Stents: Do the Risks Outweigh the Benefits? Presented at the course Controversies and Advances in the Treatment of Cardiovascular Disease, Los Angeles, CA, October 5<sup>th</sup>, 2007.
1363. The Future of Interventional Cardiology: Stat eo fhte Art lecture. Presented at the course Controversies and Advances in the Treatment of Cardiovascular Disease, Los Angeles, CA, October 5<sup>th</sup>, 2007.
1364. Diagnostic technique to identify and charcterize vulnerable plaques. Transmitted to Padua, Italy, October 9<sup>th</sup>, 2007.
1365. The Drug-eluting Stent Coantrolvery: Implications for Widespread Use. Presetnted at the annual meeting of the New York Cardiologic Society, New York City, NY, October 13<sup>th</sup>, 2007.
1366. PCI Pharmacology – Everything you need to know. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 19<sup>th</sup>, 2007.
1367. The Updated CRF Evidence-Based Medicine Guidelines for DES use. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 20<sup>th</sup>, 2007.
1368. Optimizing the Management of UA/NSTEMI: What the New Guidelines Tell Us". Spotlight for theheart.org. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21<sup>st</sup>, 2007.
1369. The Drug Eluting Stent Controversy: Evidence Bases Medicine or Medicine by Media? Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21<sup>st</sup>, 2007.

1370. Virtual Histology II: Multimodality Imaging of the Coronary Tree in patients with Acute Coronary Syndromes: Final baseline PROSPECT Results. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21<sup>st</sup>, 2007.
1371. The “Live Case” approach to CTO Angioplasty: Lessons from 4 years of the CTO Summit. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21<sup>st</sup>, 2007.
1372. Safety and Efficacy of DES in AMI: perspectives from the randomized trials and registries and HORIZONS update. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21<sup>st</sup>, 2007.
1373. The Xience V DES System: Technical Review and Clinical Trial Updates (SPIRIT 1-4 and Registries). Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21<sup>st</sup>, 2007.
1374. Drug-Eluting Stents in Acute Myocardial Infarction. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 21<sup>st</sup>, 2007.
1375. The Journey of Percutaneous Cardiovascular Intervention: From Empiricism to Evidence-based Medicine; From Balloons to Innovative Biotech Devices; the Next Challenges? Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22<sup>nd</sup>, 2007.
1376. A Celebration of 30 years of PCI; Featuring Dolph Bachmann, who underwent the World’s First Coronary Angioplasty by Andreas Gruentzig on September 16, 1977. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22<sup>nd</sup>, 2007.
1377. An Evidence-Based Medicine Assessment of Drug-Eluting Stents: Safety and Efficacy for “On-Label” and “Off-Label” Clinical Indications. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22<sup>nd</sup>, 2007.
1378. SPIRIT III: A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in patients with Coronary artery disease: 1-Year Follow-Up and Subgroup Analysis. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22<sup>nd</sup>, 2007.
1379. The Evolving Antithrombotic landscape for patients with ST-Elevation myocardial infarction – what’s on the HORIZON? Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 22<sup>nd</sup>, 2007.
1380. AMIHOT II: A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Primary Angioplasty in Anterior Myocardial Infarction. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 23<sup>rd</sup>, 2007.



1381. TAXUS Landmark analysis: Impact of Long-Term Clopidogrel Usage of Death, Myocardial Infarction and Stent Thrombosis. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 23<sup>rd</sup>, 2007.
1382. Characterization of non-flowing limiting coronary lesions: PROSPECT and Beyond. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 24<sup>th</sup>, 2007.
1383. HORIZONS AMI: A Prospective, randomized Comparison of Bivalirudin vs Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction: 30 Day Results. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 25<sup>th</sup>, 2007.
1384. TCT 2007 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 24<sup>th</sup>, 2007.
1385. Embolic protection in SVGs and AMI: From theory to evidence. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 25<sup>th</sup>, 2007.
1386. The Best TCT 2007 Late Breaking Trials Revisited: A Critical Reappraisal of their Likely Impact. Presented at the 19<sup>th</sup> annual Transcatheter Cardiovascular Therapeutics Scientific Sessions, Washington DC, October 25<sup>th</sup>, 2007.
1387. Bivalirudin in the STEMI PCI Patient: New Findings from Horizons. Presented at the 23<sup>rd</sup> Annual International Symposium on Interventional and Pharmacologic Reperfusion for ST-Elevation MI. Orlando, FL, November 3<sup>rd</sup>, 2007.
1388. Drug-Eluting Stents: Do the Outcomes Justify Their Use? Presented at the 80<sup>th</sup> annual scientific sessions of the American Heart Association, Orlando, FL, November 4<sup>th</sup>, 2007.
1389. Effect of Prolonged Thienopyridine Use on Long-term Clinical Outcomes After Drug-eluting Stents: Landmark Analysis from the TAXUS Trials. Presented at the 80<sup>th</sup> annual scientific sessions of the American Heart Association, Orlando, FL, November 5<sup>th</sup>, 2007.
1390. Best of Sessions: Clinical and Research Highlights from Recent Cardiology Programs – Transcatheter Cardiovascular Therapeutics 2007. Presented at the 80<sup>th</sup> annual scientific sessions of the American Heart Association, Orlando, FL, November 5<sup>th</sup>, 2007.
1391. HORIZONS AMI. Presented at the 80<sup>th</sup> annual scientific sessions of the American Heart Association, Orlando, FL, November 6<sup>th</sup>, 2007.
1392. Use of virtual histology to detect vulnerable plaque: The PROSPECT Trial. Presented at the VH Summit, Miami, FL, November 10<sup>th</sup>, 2007.v
1393. Potential directions for treatment of vulnerable plaque. Presented at the VH Summit, Miami, FL, November 11<sup>th</sup>, 2007.

1394. Mitral Valve Technologies for Percutaneous Repair of Mitral Regurgitation (Overview of Edwards MONARC). Presented at the Innovations in Cardiovascular Innovations (ICI 2007) Meeting, Tel Aviv Israel, December 1<sup>st</sup>, 2007.
1395. Direct Thrombin Inhibitors. Presented at the Innovations in Cardiovascular Innovations (ICI 2007) Meeting, Tel Aviv Israel, December 1<sup>st</sup>, 2007.
1396. Invasive Imaging Modalities for Vulnerable Plaque – The PROSPECT STUDY. Presented at the Innovations in Cardiovascular Innovations (ICI 2007) Meeting, Tel Aviv Israel, December 2<sup>nd</sup>, 2007.
1397. Overview of the Edwards MONARC mitral valve annuloplasty device. Presented at the Innovations in Cardiovascular Innovations (ICI 2007) Meeting, Tel Aviv Israel, December 2<sup>nd</sup>, 2007.
1398. Chronic total occlusions: basic and advanced techniques. Columbia University Medical Center, New York City, NY, December 17<sup>th</sup>, 2007.
1399. Bilvairudin in ACS, PCI and STEMI. Cirital Care Grand Rounds, Columbia University Medical Center, December 20<sup>th</sup>, 2007, New York City, NY.
1400. Clinical trial design: The bivalirudin example. Columbia University Medical Center Cardiology journal club, January 4<sup>th</sup>, 2008, New York City, NY.,
1401. New insights into the safety and efficacy of current generation DES. Boradcast to India for the ICER course. January 12<sup>th</sup>, 2008.
1402. Update on PCI Pharmaoclogy: Antithrombins. Presented at the 20<sup>th</sup> annual ISET course, Hollywood, FL, January 18<sup>th</sup>, 2008.
1403. Drug-eluting stents: Controversies and unsettled issues. Presented at the 20<sup>th</sup> annual ISET course, Hollywood, FL, January 18<sup>th</sup>, 2008.
1404. PCI should be the choice for most patients with stable coronary rtery disease. Presented at the 20<sup>th</sup> annual ISET course, Hollywood, FL, January 18<sup>th</sup>, 2008.
1405. Primary angioplasty in AMI: New Horizons. Presented to the 3rd AMI symposium via videolink, New Delhi, India, January 25<sup>th</sup>, 2008.
1406. New Insights into the future of PCI. Presented at the CCT2008 Course, Kobe, Japan, January 31<sup>st</sup>, 2008.
1407. The SPIRIT Trial Updates. Presented at the CCT2008 Course, Kobe, Japan, January 31<sup>st</sup>, 2008.
1408. The PROSPECT for Vulnerable Plaque Detection. Presented at the CCT2008 Course, Kobe, Japan, January 31<sup>st</sup>, 2008.
1409. Safety and Efficacy of DES: Present and Future. Presented at the CCT2008 Course, Kobe, Japan, February 2<sup>nd</sup>, 2008.

1410. What Should the Impact of the COURAGE Trial Be on Interventional Cardiology? - Intervention for Everyone. Presented at the CRT 2008 course, Washington DC, February 11<sup>th</sup>, 2008.
1411. The PROSPECT Trial: First Glimpse into the Study. Presented at the CRT 2008 course, Washington DC, February 11<sup>th</sup>, 2008.
1412. How long should we prescribe Clopidogrel? Presented at the CRT 2008 course, Washington DC, February 11<sup>th</sup>, 2008.
1413. How to Anticoagulate Your Patient in 2008: Insights for ACUITY and HORIZONS Trials. Presented at the CRT 2008 course, Washington DC, February 12<sup>th</sup>, 2008.
1414. Is Viability Assessment Necessary Prior to CTO Angioplasty? Should the COURAGE Nuclear Substudy Impact our Thinking? Presented at the 5th INTERNATIONAL CHRONIC TOTAL OCCLUSION SUMMIT, New York, NY, February 21<sup>st</sup>, 2008.
1415. Angioplasty or Medications for Coronary Artery Disease. Medical Grand Rounds, UMDNJ, Newark, NJ, February 26<sup>th</sup>, 2008.
1416. The role of Bivalirudin in patients with acute coronary syndromes and myocardial infarction: New Horizons. Cardioogy Grand Rounds, St. Francis Hospital, Long Island, NY, March 5<sup>th</sup>, 2008.
1417. PCI in the Modern Era: Indications and accomplishments – a COURAGE Rebuttal. Presented at the 2008 China Interventional Therapeutics Course, Beijing, China, March 20<sup>th</sup>, 2008.
1418. Xience V: Update on the SPIRIT Trials. Presented at the 2008 China Interventional Therapeutics Course, Beijing, China, March 20<sup>th</sup>, 2008.
1419. Vulnerable Plaque Identification is Problematic but Transcatheter treatment is realistic. Presented at the 2008 China Interventional Therapeutics Course, Beijing, China, March 21<sup>st</sup>, 2008.
1420. DES Safety: What have we learned in 2007? Presented at the 2008 China Interventional Therapeutics Course, Beijing, China, March 21<sup>st</sup>, 2008.
1421. What's Next: XIENCE/PROMUS. Presented at the 5th annual "The Drug-Eluting Stent Revolution" meeting, Chicago, IL, March 28<sup>th</sup>, 2008.
1422. Safety and effectiveness of Bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI Trial. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sesions, Chicago, IL, March 29<sup>th</sup>, 2008.
1423. Shifting the paradigm: The concept of net adverse clinical events. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sesions, Chicago, IL, March 29<sup>th</sup>, 2008.
1424. Reducing Infarct Size in Acute Myocardial Infarction with Supersaturated Oxygen Therapy: From Theory to Practice Presented at the 57th Scientific Sessions of the

- American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 29<sup>th</sup>, 2008.
1425. New Treatment Options for STEMI: Role of Direct Thrombin Inhibitors and Drug-eluting Stents: A view to the HORIZON. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 30<sup>th</sup>, 2008.
  1426. Critical Commentary: Pretreatment With a High Loading Dose of Clopidogrel and Value of Abciximab During Primary Coronary Intervention in Patients With Acute Myocardial Infarction. Results of the Randomized BRAVE-3 Trial. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 30<sup>th</sup>, 2008.
  1427. Comprehensive Analysis of Drug-eluting Stent Safety and Efficacy. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 30<sup>th</sup>, 2008.
  1428. COURAGE: Has the Dust Settled? Protagonist View. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 31<sup>st</sup>, 2008.
  1429. A New Era in STEMI Care- Everything is Illuminated: NACE and MACE shed light on the CASE. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, March 31<sup>st</sup>, 2008.
  1430. Is Diabetes a Risk Factor for Restenosis and Adverse Clinical Outcomes After Paclitaxel-Eluting Stent Implantation? Pooled Analysis of the TAXUS IV and TAXUS V Trials. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, April 1<sup>st</sup>, 2008.
  1431. Registry Data on Stent Thrombosis, MI and Death. Presented at the 57th Scientific Sessions of the American College of Cardiology and the SCAI Annual Scientific Sessions, Chicago, IL, April 1<sup>st</sup>, 2008.
  1432. Drug-Eluting Stent Systems II: TAXUS. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 3<sup>rd</sup>, 2008.
  1433. Drug-Eluting Stent Systems IV: Xience/Promus. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 3<sup>rd</sup>, 2008.
  1434. Evidence Based Medicine Guidelines to Drug-Eluting Stent Use (On label and Off Label). Infarct size reduction with supersaturated oxygen: AMIHOT I and II results. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 4<sup>th</sup>, 2008.
  1435. Angioplasty in AMI I: Primary PCI State of the Art. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 4<sup>th</sup>, 2008.
  1436. Interventional Pharmacology IV: Bivalirudin in ACS and PCI. Presented at the 14th annual National Interventional Fellow's Course, San Jose, CA, April 4<sup>th</sup>, 2008.

1437. Clinical strategies in acute myocardial infarction. Presented at the course "State of the Heart", Los Angeles, CA, April 25<sup>th</sup>, 2008.
1438. Outcomes with bivalirudin in patients with NSTEMI and STEMI. Jersey Shore Medical Center, April 30<sup>th</sup>, 2008.
1439. Relacing heparin in patients with coronary artery disease: It's about time! Cardiology grand rounds, UMDNJ, Newark, NY, May 7, 2008.
1440. Acute MI Management 2008. Presented at the Brooklyn Cardiovascular Symposium, SUNY Downstate, Brooklyn, NY, May 10<sup>th</sup>, 2008.
1441. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 13<sup>th</sup>, 2008.
1442. DES should be used in most patients undergoing PCI. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 14<sup>th</sup>, 2008.
1443. Stenting of vulnerable plaque: will we do it? – Yes!. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 14<sup>th</sup>, 2008.
1444. Optimizing upstream management of STEMI and NSTEMI - the case for a consistent strategy for patients undergoing PCI. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 15<sup>th</sup>, 2008.
1445. Infarct size reduction with SSO<sub>2</sub>: AMIHOT I and AMIHOT II. SPIRIT III - 2 Year Clinical Results. Presented at the EuroPCR meeting, Barcelona, Spain, May 15<sup>th</sup>, 2008.
1446. Comprehensive analysis of drug-eluting stent safety and efficacy. Dartmouth Hitchcock Medical Center Cardiology Grand Rounds, Lebanon, NH May 22, 2008.
1447. Vulnerable Plaque: Pathophysiology, Diagnosis and therapy. Columbia University Medical Center, New York, NY, June 5<sup>th</sup>, 2008.
1448. CoreValve Technique and Complications. Presented at the course Transcatheter Valve Therapies, June 6<sup>th</sup>, 2008, Seattle, WA.
1449. Emerging Device-based Therapies for Mitral Regurgitation. Presented at the course Transcatheter Valve Therapies, June 7<sup>th</sup>, 2008, Seattle, WA.
1450. Clinical Trial Basics: Study Design Methodology, Endpoints, Bio-Statistics, and Assessment of Outcomes. Presented at the course Transcatheter Valve Therapies, June 8<sup>th</sup>, 2008, Seattle, WA.
1451. Invasive Detection of Vulnerable Plaque: Preliminary Results from Prospect and Beyond. Presented at the annual C3 course, Baltimore, MD, June 10<sup>th</sup>, 2008.
1452. Should PCI Be the Treatment of Choice for Chronic Stable Angina? Presented at the annual C3 course, Baltimore, MD, June 10<sup>th</sup>, 2008.

- 1453. Optimal antithrombotic and antiplatelet strategies in patients undergoing PCI. Cariology conference, Cornell - New York Hospital, June 12<sup>th</sup>, 2008.
- 1454. The SPIRIT Family of Trials. Video presentation to the New Dehli Interventional Cardiology course, India, June 12<sup>th</sup>, 2008.
- 1455. The Impact of Interventional Cardiology on Acute MI Outcomes: Do Catheters Save Lives? Presented at the Columbia University Cardiovascular Research Initiative Symposium, Columbia University Medical Center, New York, NY, June 17<sup>th</sup>, 2008.
- 1456. The HORIZONS-AMI Trial. Brigham and Women's Hospital eJournal club, July 1<sup>st</sup>, 2008.